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 The development of new chemical methods to generate novel and diverse 
structures to probe chemical space is an important aspect of early phase drug 
discovery.  Diversity-Oriented Synthesis (DOS) is a powerful strategy that seeks to 
generate chemical methods capable of delivering an array of molecular scaffolds with 
structural and functional diversity.  Ultimately, these methods can be adapted to 
produce molecular libraries.  It is the purpose of this thesis to highlight a series of 
new chemical methods that deliver an array of drug-like sultam scaffolds to be 
screened for broad biological activity in the molecular library program run by the 
National Institutes of Health.  
The first project described in chapter one of this dissertation includes the 
synthesis of a collection of diverse bi- and tricyclic sultams in an overall DOS 
approach utilizing a ring-opening metathesis / ring-closing metathesis / cross 
metathesis (ROM–RCM–CM) cascade strategy.  A variety of functionalized, tricyclic 
sultams were generated as precursors derived from a diastereoselective IMDA 
reaction in good yields and selectivity.  The ROM–RCM–CM strategy to produce 
skeletal and appendage-based diverse sultams is presented.  
The second project is the generation of diverse sultams utilizing α,β-
 iv 
unsaturated γ- and δ-sultams.  These 5- and 6-membered sultams were prepared and 
applied to further diversifications using aza-Michael reactions, cycloadditions, 
alkylation/benzylations and propargylation-[3+2]-cycloadditions.  Utilizing the aza-
Michael reaction, we have developed an efficient protocol for the synthesis of a 141-
member library collection of isothiazolidine 1,1-dioxide derivatives.   
The last project outlined in chapter four is the synthesis of novel 7- and 8-
membered tricyclic, biaryl sultams using an intramolecular Pd-catalyzed C-arylation 
reaction.  Namely, in the amino ester-derived sultams, remote 1,5- and 1,6-
asymmetric induction emanating from the external stereogenic center is operative, 
whereby a favorable Cα–H/S=O syn pentane interaction, is the source of asymmetric 
induction for a highly atropdiastereoselective thermodynamic equilibration process 
yielding a low energy conformer of “like” configuration (S,Sa). 
In the course of X-ray crystallographic analysis, as well as detailed NMR 
studies, we uncovered a number of notable and interesting structural features of the  
7-membered amino ester-derived sultams in both solid and solution phases that 
confirm a structure as a single conformer (>95:5) containing biaryl axial chirality of 
“like” configuration (S,Sa) with respect to the stereogenic center in the external side 
chain.  Moreover, variable temperature NMR analysis has indicated that the axis of 
chirality at the biaryl bond has a relatively small interconversion barrier that allows 
for this rapid thermodynamic equilibration of the “like” and “unlike” 
atropdiastereomers.  Detailed variable NMR analyses on a number of analogs, vide 
infra, point to rotamer dynamics (about the N–C bond in the external side chain) and 
 v 
ring size of the corresponding benzothiazepine (n = 1)/benzothiazocine (n = 2) 1,1-
dioxides as governing factors in this notable thermodynamic equilibration of 
atropdiastereomers.  Current efforts are focused on the computational calculation for 
the energy barrier between two atropdiastereomers interconversion, as well as the 
further development of an “atropdiastereoselective” C-arylation process.  In addition, 
future studies will continue to probe the dynamic factors involved in the origins of 
atropselectivity.  Utilizing this methodology, we are also generating additional 
libraries of diverse tricyclic, biaryl sultams for high throughput screening of 
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Sultams (cyclic sulfonamides) represent a class of non-natural amide 
surrogates that have emerged as viable medicinal chemotypes due to their wide 
chemical and biological profiles.1  Historically, sultams have found widespread use 
with utility ranging from chiral auxiliaries in asymmetric synthesis,2 , 3  artificial 
sweeteners (saccharin) in the food industry,4 and ionic liquids serving as novel 
reaction media,5 to a growing number of medicinal agents.  To date, there are several 
sultam-containing drugs for use in the treatment of a variety of disease states, 
including acquired immune deficiency syndrome (AIDS), diabetes, arthritis, hepatitis 
C virus (HCV), respiratory syncytial virus (RSV) and human leukocyte elastase 
(HLE) to name a few.  The rapid rise of sultams in drug discovery and development, 
beacons the call for a review covering their impressive biological activities.  In this 
regard, it is the goal of this introductory chapter to highlight recent investigations on 
biologically active compounds containing the sultam moiety.  After a brief 
introductory paragraph on the unique properties of sulfonamides that affect the 
syntheses of their cyclic counterparts, the chapter will be organized according to the 
nature of the biologically active, heterocyclic sultam motif. 
 
1.1.1  Properties of Sulfonamides 
The aforementioned biological activity of sultams has prompted several 
efforts towards their synthesis.  In 2011, Majumdar and coworker published an 
extensive work in ACS Chemical Reviews that highlights recent developments of 
 3 
synthetic methods to access condensed (fused) sultams, including ring-closing 
metathesis (RCM), Diels-Alder, and [3+2]-cycloaddition reactions.6  In addition this 
body of work, our group has recently reported a number of methodologies for 
generation of various sultams.7   
Although some methodologies for sultam synthesis are comparable to those of 
lactam synthesis, there is significant difference embedded in the physical properties 
of sulfonamides, when compared to their amide counterparts, that open reaction 
pathways to sulfonamides that are unavailable to amides.  Among several parameters, 
the presence of two electronegative oxygen atoms within the SO2 moiety impart 
greater inductive effect within sulfonamide 1.1 than amide 1.2.  Computational 
calculations show a more electron deficient sulfur atom within the SO2 than the 
carbon atom of the lactam.8  Furthermore, this trend affects the electrophilic behavior 
at the β-carbon of vinyl sulfonamides when compared to the  
β-carbon of vinyl amides.  Ultimately, this imparts prominent Michel accepting 
ability for vinyl sulfonamides that have been exploited in our laboratories.7a,b,7g-i   In 
particular, intramolecular oxa-Michael reactions of vinyl sulfonamides occur 
smoothly to obtain 7- and 8-membered sultams, the later in a unique “contra Baldwin 
Rules”, 8-endo-trig pathway that is most likely aided by additional differences of 





 The enhanced electron deficiency of SO2 over the C=O group also affects 
general pKa properties, which for benzenesulfonamides and benzamides, are 16.1 and 
23.3 (in DMSO), respectively.9  This enhanced acidity enables mild alkylation 
conditions for secondary benzenesulfonamides such as 1.7 (Cs2CO3, RX, rt) when 
compared to benzamides 1.9, which require strong bases and thermal conditions to 
produce tertiary benzamides (Figure 1.2).  Moreover, fluoro-substituted 
benzenesulfonamides undergo facile nucleophilic aromatic substitution (SNAr) 
reactions under mild reaction conditions (1.11 to 1.12), while the corresponding 
benzamides (1.13) fail to undergo SNAr reactions even under forcing conditions.  This 
enhanced behavior has been exploited by Fukuyama and coworkers, who, in 2004, 
reported an innovative approach for secondary amine synthesis using the pKa 
properties nitrobenzenesulfonamides.10  This method has been widely utilized in both 












































































Additionally, sulfamide derivatives can undergo ring-closing metathesis 
(RCM) to provide the corresponding cyclic sulfamide compounds.11  However, RCM 
of the corresponding urea analogues did not produce any cyclized products.  The 
















































































1.1.2 Sultam Bioactivities 
In the early 1900’s, sulfonamide chemistry advanced at a rapid pace, due to 
widespread use in azo dyes, which were highly employed in the production of fibers 
and textiles.  Efforts to improve dye properties, found that introduction of a 
sulfonamide group (-SO2NH-) generated dyes with superior stability to light, greater 
water solubility during application, and greater fixation to fibers.13   
In 1932, the investigation about the action of various dyes in streptococcal 
infections in mice was conducted by the research group of Bayer laboratory in 
Germany.  The red dye called prontosil (1.18) exhibited antibacterial properties,14 and 
three years later it was discovered that prontosil is metabolized to active 
sulfanilamide (1.19) in the body (Figure 1.4).  This important discovery led to its 
clinical use for the treatment of bacterial infections.  In addition, sulfonamides have 
shown several interesting biological activities including, inhibition of carbonic 
anhydrase (acetazolamide),15 anticancer activity (agent E7070)16 and antibacterial 
activity (sulfathiazole).17  
 
Figure 1.4 
Ensuing chemical studies involving pKa measurements also revealed that this 
versatile entity is comparable to the carboxyl group and therefore, it has been utilized 













Prontosil (1.18) Sulfanilamide (1.19)
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surrogates and several studies have shown the utility of sulfonamides as ideal 
functional groups in the synthesis of peptidomimetics.18  In 1999, Liskamp and 
coworkers reported that replacement of an amide by a sulfonamide in peptides 
provided more stability towards protease-catalyzed degradation.19  Based on this 
observation, they have been used as transition-state analogues for amide bond 
hydrolysis and have been found applications as potential HIV protease inhibitors.18c 
Furthermore, sulfonamides now represent an important class of drugs with several 
types of pharmacological agents having antibacterial, antitumor, anti-carbonic 
anhydrase, diuretic, hypoglycemic, anti-thyroid, or protease inhibitory activity.20 
Similar to sulfonamides, the bioactivities of sultams bear resemblance to 
lactams.  However, in addition to the aforementioned differences between 
sulfonamides and amides, the presence of an extra H-bond acceptor within the SO2 
moiety, a more acidic sulfonamide N–H, and the geometric layout of SO2, may 
provide supplementary benefits for sultams to interact with proteins.  In this regard, 
sultams have surfaced as a non-natural class of biologically active compounds with a 
wide array of activities.  In this chapter, we will give a brief historical account of 
FDA approved sultam-containing drugs and then provide a preliminary review of the 




1.2 Sultam-Containing Drugs 
The rich history of antibacterial sulfonamides, vide supra, laid the foundation 
for the development of acetazolamide (1.20) in 195021 as a carbonic anhydrase 
inhibitor that is used to treat glaucoma and seizures.22  Brinzolamide [trade name: 
Azopt (1.21)] is also a carbonic anhydrase inhibitor and is introduced for the 
treatment of glaucoma.23  Further investigations to improve diuretic activity led to the 
seridenpidous discovery of a number of ring-closed, benzene disulfonamide 
derivatives (Figure 1.5).  These unexpected, cyclized, benzothiadiazine products 
exhibited enhanced diuretic activity.  
In 1957, Chlorothiazide [trade name: Diuril (1.22)] was introduced as a 
thiazide diuretic by Novello and coworkers from Merck Sharp and Dohme Research 
laboratories.24  Two years later, benzthiazide [trade name: Exna (1.23)] was also 
synthesized by McLamore and coworkers from Pfizer laboratory and used for high 
blood pressure as well as edema.25  However, benzthiazide (1.23) is no longer 
available in the United States.  In Switzerland, it is still available in combination with 
the potassium-sparing diuretic triamterene.  Bendroflumethiazide [trade name: 
Naturetin (1.24)] was synthesized in 195926 and is used for treatment of hypertension 
as well as heart failure.  Methyclothiazide [trade name: Aquatensen, Enduron (1.25)] 
was developed by Vernsten and coworkers in 1960, and is used to treat high blood 
pressure and fluid retention. 27   Hydrochlorothiazide [trade name: HydroDiuril, 
Esidrix (1.26)] has been used for the treatment of hypertension for more than 50 
 9 
years.28  Trichlormethiazide [trade name: Achletin (1.27)] has similar properties to 
hydrichlorothiazide.  Polythiazide [trade name: Aquatensen, Renese (1.28)] are used 
 
Figure 1.5 
in the treatment of hypertension, congestive heart failure, edema, diabetes insipidus, 
renal tubular acidosis, and the prevention of kidney stones.29  Cyclothiazide [trade 
name: Anhydron (1.29)] was introduced in the United States in 1963 by Eli Lilly and 
in 1993, it was discovered as a positive allosteric modulator of AMPA receptor.30  
Ten years later, cyclothiazide was also found acting as a GABAA receptor negative 
allosteric modulator.31  Cyclothiazide is used as adjunctive therapy in edema and is 
also used for treatment of hypertension.  Hydroflumethiazide [trade name: Saluron, 
Diucardin (1.30)] is a drug for acute or chronic vascular hypertension.32  Diazoxide 
[trade name: Proglycem (1.31)] is potassium channel activator and inhibits the 

































































































































A second family of sultam drugs is a class of medications called non-steroidal 
anti-inflammatory drugs (NSAIDs), including piroxicam [trade name: Feldene 
(1.32)],34 meloxicam [trade name: Mobic (1.33)]35 lornoxicam [trade name: Xefo 
(1.34)] 36  and tenoxicam [trade name: Mobiflex (1.35)] 37  (Figure 1.6).  These 
medicines work via non-selective inhibition of cyclooxygenase (COX) imparting both 
analgesic and antipyretic properties. 
 
Figure 1.6 
Piroxicam (1.32) was synthesized by Lombardino and coworkers from Pfizer 
Laboratory in early 197034 and is available in the United Kingdom, Spain, Portugal, 
Australia, Italy, Brazil and the United States and is manufactured by Pfizer.  
Meloxicam (1.33) was introduced by Boehringer-Ingelheim and inhibits selectively 
COX-2 over COX-1.35  Meloxicam (1.33) is usually used for pain relief and is 
available in many countries including the Middle East, Europe, Paraguay, Australia, 
Canada and Latin America.  Lornoxicam (1.34)36 and tenoxicam (1.35)37 are used for 
the treatment of various types of pain resulting from inflammatory diseases of the 
joints, osteoarthritis, surgery, sciatica, and other inflammations.  In particular, 












































1.3 Bioactive Compounds containing 5-Membered Sultam Moiety 
1.3.1  Naphthoisothiazole 1,1-Dioxide Derivatives 
In 2008, Pérez-Pérez and coworkers discovered the first acyclic thymine-base 
derivatives as a Mycobacterium tuberculosis thymidine monophosphate kinase 
(TMPKmt) inhibitor.38  Based on the lead compound 1.36, analogues that differ on 
thymine base, the spacer that connects the thymine base, the distal 1,8-naphthalimide, 
and the 1,8-naphthalimide have been synthesized and examined (Figure 1.7).  Several 
compounds in the naphthalimide derivatives show Ki values in the low µM range.  
Furthermore, a naphtholactam or naphthosultam (compounds 1.37, 1.38, and 1.39) 
instead of the naphthalimide ring showed Ki values in the submicromolar range. 
 
Figure 1.7 
In 2012, Kamal and coworkers reported a series of benzo[c,d]indol-2(1H)one-
pyrrolobenzodiazepine (PBD) conjugates as potential anticancer agents.39  The DNA 
binding ability of these compounds was examined by thermal denaturation studies.  
Among them, sultam 1.40 exhibited significant DNA binding ability compared to its 
lactam and alkene analogues.  Compound 1.40 displayed better anti-cancer activity 




































SubG1 phase was observed upon treatment of A549 cells with 1 and 2 µM (IC50) 
concentrations of compound 1.40. 
 
Figure 1.8 
2-(Aminoalkyl)naphth[1,8-cd]isothiazole 1,1-dioxide derivatives were 
synthesized by Malleron and coworkers in 1991 as a serotonin subtype (5-HT2) 
receptor.40  All compounds were tested in vitro for their binding affinity to rat 5-HT2, 
α1 and D2 receptors.  Most compounds of this series exhibited high affinity for the 
5-HT2 receptor, with good selectivity.  In particular, compound 1.41 (RP 62203) 










X = CO, C=C(CN)2, SO2

















1.3.2  1,2-Benzisothiazol-3-one 1,1-Dioxide (Saccharin) Derivatives 
1,2-Benzisothiazol-3-one 1,1-dioxide (saccharin) was discovered by Remsen 
and Fahlberg in 1879.41  Saccharin with sodium salt is about 500 times sweeter than 
sugar, therefore has been used as a no calorie sweetener and food additive42 in the 
1970’s, but was later banned as a food additive when preliminary studies reported that 
high doses caused urinary bladder carcinoma in mice.43  Later saccharin has been 
found as an important molecular component in a variety of classes of 5HT1A 
antagonists,44 human leukocyte elastase (HLE) inhibitors,45 analgetics,46 human mast 
cell tryptase inhibitors, 47  and aldehyde dehydrogenase inhibitors. 48   
N-Alkylarylpiperazine of benzo[d]isothiazole 49  and a series of heterocyclic 
isothiazoles ring were also synthesized and found to display anti-mycobacterium and 
central nervous system activity.50,51 
In 2011, a series of N-basic side chains was derived from 2,3-dihydro-2H-3-
oxobenzo[d]isothiazole and aliphatic or aromatic aldehydes by Hamama and 
coworkers (Figure 1.10).52  Compounds 1.42, 1.43c and 1.44 revealed remarkable 
anti-microbial activity, and compounds 1.43a, 1.43b, 1.45a, 1.45b and 1.46 displayed 
high anti-oxidant activity.  These compounds also appeared to impart a high degree of 




Saccharin derivatives have been widely used as human leukocyte elastase 
(HLE) inhibitors.45  Mechanistic studies suggest elastase inhibition involving an SN2’ 
displacement step in which Ser-195 of the enzyme attacks the carbonyl group of 
saccharin and with subsequent departure of the sulfonamide leaving group (Figure 
1.11).  In this regard, the Groutas group discovered that the activities of compounds 
1.47–1.49 were related to their leaving group ability in the system.53  In 1995, Desai 
and coworkers synthesized saccharin derivatives including alkyl and aryl 
phosphonates and phosphinates as an acid-based leaving group.54  Compound 1.50, a 

















1.43a, R = OMe, R1 = OMe
1.43b, R = NMe2, R1 = OMe




















1.45a, R = OMe















In 2006, Otto et al. prepared pseudosaccharinamine derivatives as potential 
elastase inhibitors (Figure 1.12).55  Several pseudosaccharinamine derivatives were 
found to be reversible inhibitors of porcine pancreatic elastase (PPE) and HLE.  
Diversification of the most potent compounds, 1.51 and 1.52, should lead to improve 
activities of HLE inhibitors. 
 
Figure 1.12 
In 2006, Güzel and coworkers synthesized a series of saccharin derivatives 
containing dithiocarbamate and dithiocarbonate side chains.  Dithiocarbamates and 
dithiocarbonates have been reported to possess a variety of biological activities 
including fungicidal, antibacterial and anticancer effects.56  Saccharin was treated 










































































N,N-disubstituted dithiocarbamate and O-alkyldithiocarbonate saccharin derivatives 
(1.53 and 1.54 in Figure 1.13).57  Several compounds of the derivatives exhibited in 




In 2011, Zwanenburg and coworker prepared a series of strigolactone (SL) 
analogues derived from phthalimide, saccharin, p-tolylmalondialdehyde, benzoic and 
salicylic acid.58  These SL derivatives are highly active as germination stimulants of 
seeds of Striga hermonthica and Orobanche cernua.  The authors also observed that 
the compound from a direct coupling of saccharin with the chlorobutenolide exhibited 
a high germination activity towards O. cernua seeds.  The compound 1.55 was a very 
active germinating agent (Figure1.13), prompting belief that these SL mimics appear 
to be new types of potential germination stimulants.   
 
Figure 1.14 
Repinotan (BAYx3702, 1.56) is a high-affinity 5-HT1A receptor agonist 



























ischemic stroke and traumatic brain injury and was trialed up to phase II, however, it 
did not go further in clinical trials because of insufficient efficacy of repinotan.60 
 
Figure 1.15 
In 2010, Zakharova and coworkers prepared N,N'-linked benzo-annulated 
isothiazol-3(2H)-one 1,1-dioxide analogues as inhibitors toward human leukocyte 
elastase (HLE) and acetylcholinesterase (AChE).61  Two compounds, 1.52a and 1.52b 
were found to be inhibitors of HLE and AChE (Figure 1.16).  The derivatives were 
also examined as potential precursors of nitrogen-centered radicals using 266 nm 
laser flash photolysis. 
 
Figure 1.16 
In 2002, benzenesulfonamide derivatives containing the pyrazole and 
oxadiazole moieties were synthesized by El-Sanbbagh and coworkers.62   These 
derivatives are structurally similar to the COX-2 inhibitor celecoxib (Celebrex®).  A 
pharmacological study of the pyrazole analogues showed that several compounds 
exhibited higher analgesic and anti-inflammatory activities than celecoxib, 





























In 2005, La Motta and coworkers introduced a series of 1,1-dioxide-
benzo[d]isothiazol-3-one alkanoic acid (BiT, 1.61) derivatives as aldose reductase 
(ALR2) inhibitors.63  These compounds appeared to be relatively potent inhibitors, 
with IC50 values in the µM range.  Among them, the 4-NO2 acetic acid derivative 
showed the highest activity (IC50 = 5.5 µM).  It is known that the in vitro ALR2 
inhibitory effectiveness of a compound is a function both of its acidic group ionized 
at the anion-binding site and of its lipophilic part interacting with the enzyme 
hydrophobic catalytic site, which terminate the inhibitory potency and the selectivity 
of an inhibitor.  Therefore, increasing the overall lipophilicity of BiT (1.61) inhibitors 
may improve the in vitro activity and, possibly, in ALR2 selectivity (Figure 1.18).  
Based on this rationale, La Motta and coworkers decided to introduce a 
benzoisothiazole backbone generating the acetic acid derivatives of 3,3-dioxide-1,2-





















1.3.3  Benzo[d]isothiazole 1,1-Dioxide Derivatives 
In 2006, Evans and coworkers from GlaxoSmithKline Pharmaceuticals 
synthesized benzothiadiazine analogues 1.63 as potential HCV polymerase inhibitors 
(Figure 1.19).64  Two years later, Zhou and coworkers from Anadys laboratories 
reported a related series of pyridazinone-containing NS5B inhibitors (1.64), which 
also interact to the same region of the enzyme.65   
In 2008, Kim and coworkers from Anadys laboratories synthesized a series of 
benzo[d]isothiazole-1,1-dioxides, which essentially introduced the 1,1-
dioxoisothiazole fragment instead of the benzothiazine moiety of compound 1.64.66  
Among them, compound 1.65 displayed the most potent activities against the 
genotype 1b HCV polymerase (IC50 < 10 nM) and against a genotype 1b replicon 
(EC50 = 70 nM) in cell culture.  However, DMPK properties results for selected 
compounds revealed that the incorporation of polar substituents on the C4 position 
was important for enhancing the biological potencies of these molecules and their oral 
pharmacokinetic (PK) properties.  Although compounds 1.63 and 1.64 derivatives 
were potent inhibitors of HCV polymerase both in enzymatic and replicon assays, 
they revealed low oral bioavailability and high clearance because of metabolic 














In 2009, Vicente and coworkers prepared a series of inhibitors of HCV 
polymerase.  The authors reported sultam 1.66 as the most potent analogue in their 
HCV replicon assay with moderate pharmacokinetic properties.67  However, it turned 
out that the reduced potency in the presence of 40% human serum limited the 




1.3.4  Isothiazole 1,1-Dioxide Derivatives 
In 2002, Clerici and coworkers synthesized a series of isothiazole dioxides 
and tested them as inhibitors of Trypanosoma brucei protein farnesyltransferase 
(PFTase) from the parasite that causes African sleeping sickness.68,69  Among these 
derivatives (1.67–1.70), compound 1.71 exhibited the most potent activity against 
protein farnesyltransferase and smooth muscle cell (SMC) proliferation by interfering 
























































1.3.5 2,3-Dihydroisothiazole 1,1-Dioxide Derivatives 
Based on the commercially available antibiotic thiolutin (1.72), an agent that 
suppresses tumor-induced angiogenesis, the sulfonyl analogues (so called 
“sulfothiolutin”, 1.73) were prepared by Stachel and coworkers in 2005 (Figure 
1.21).70  The sultams 1.73a, 1.73b, 1.73c, and 1.73d displayed anti-mycobacterial 




amino-1”,2”-oxathiole-2”,2”-dioxide)thymine (TSAO-T) derivatives were 
synthesized as a specific anti-HIV agent by Postel and coworkers in 2005.71  As one 
of the SAR studies, the cyclic sulfonate fragment of compound 1.74 was replaced 
with a sultam to produce a family of aza analogues of TSAO (ATSAO, 1.75).  Some 
of compounds displayed HIV-1 specific reverse transcriptase inhibitory activities.  

















































1.73a, R1 = R2 = CO2Me
1.73b, R1 = NHAc, R2 = CO2Me
1.73c, R1 = H, R2 = CO2Me
1.73d, R1 = NHAc, R2 = H
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only 2- to 7-fold less active against HIV-1 replication in MT-4 and CEM cells than 




1.4 Bioactive Compounds Containing 6-Membered Sultam Moiety 
1.4.1 1,2-Thiazinane 1,1-Dioxide Derivatives 
In 2004, sultam hydroxamates have been introduced as a new template for 
matrix metalloproteinase (MMP) inhibition by Cherney and coworkers.72  Compound 
1.76 displayed the most active inhibitor (MMP-2 IC50 =1 nM) with excellent 
selectivity over MMP-1 and with good oral bioavailability (F = 43%) in mouse 
(Figure 1.23).  Based on the X-ray crystal structure of 1.76 in MMP-13, the authors 
demonstrated that the hydrogen bonds (between the pro-(S) sultam sulfonyl and the 
Leu-185) and major side binding in the active site (S1 pocket of the MMPs) are 
essential.  The authors also examined these sultam analogues for potent TNF-α 
converting enzyme (TACE) inhibitors.73  They studied on structural differences 
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TSAO-T, R = H











             1.75
ATSAO-T derivatives
R = H, Boc, CH3
R1 = H, CH3
R1
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methyl-4-quinolinylmethoxyphenyl group into this region.  Based on these studies, 
compound 1.77 was identified as a potent TACE inhibitor (IC50 = 3.7 nM) that lacked 




1.4.2 Benzodithiazine 1,1-Dioxide Derivatives 
Saczewski and coworker reported cyclic analogues of  
2-mercaptobenzenesulfonamides 1.78 and 1.79 that possessed anti-HIV and 
anticancer properties (Figure 1.24).  Based on these biological activities the authors 
extended their work to explore a new series of 8-chloro-5,5-dioxoimidazo[1,2-
b][1,4,2]benzodithiazine derivatives with heteroaryloxycarbonyl or 
heteroarylcarbamoyl substituents at position 7 as potential antitumor agents.74  All 
synthesized compounds were tested at the National Cancer Institute (NCI) for their 
activities against a panel of 60 tumor cell lines.  Compounds 1.80, 1.81 and 1.82 
displayed the most potent of all derivatives tested.  Compound 1.80 exhibited 
activities against lung cancer cell lines and compound 1.82 was shown to be a 































In 2003, Saczewski research group also synthesized a series 4-
dimethylaminopyridinium (6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)methanides 
and examined them for in vitro antitumor activities.75  Among the aminium salts, 4-
dimethylaminopyridinium 4-chlorobenzoyl cyano (6-chloro-7-methyl-1,1-dioxo-
1,4,2-benzodithiazin-3-yl)methanide (1.83) exhibited significant activity (log GI50 
and log TGI < –8.00) and high selectivity for the lung HOP-92 and melanoma 
UACC-257 cell lines.  Furthermore, the authors noticed that the benzodithiazines 
containing carbon atom at the C3 position displayed antitumor and/or anti-HIV 
activities.  Therefore, they performed further investigations for a series of 
benzodithiazines fragments bearing a carbon atom at position 3.76  Compound 1.84 
displayed potent activities (GI50 = 6.9–49.4 µM) against 49 tumor cell lines, and also 









































































Previously, Saczewski et al. reported dithiazine-carboxylic acid derivatives 
with remarkable anti-cancer activity.  Because these type of compounds displayed 
several biological activities, they also synthesized 8-chloro-5,5-dioxoimidazo[1,2-
b][1,4,2]benzodithiazine 5,5-dioxide derivatives as potential antitumor or anti-HIV 
agents.77  The in vitro antitumor and anti-HIV-1 activities of the compounds were 
examined across a panel of cell lines.  The benzodithiazine-dioxide 1.86 exhibited 
low µM activity in several cell lines including leukemia, lung, melanoma, ovarian, 
and renal cancer cells (GI50 = 1–2 µM) (Figure 1.25).  Furthermore, benzodithiazine-
dioxide 1.87 also showed anti-HIV-1 activity (EC50 = 0.94 µM) without any 
significant cytotoxicity at 200.0 µM.  These investigations indicated that the 
substitution of the methyl group at the 7-position by a nitrile is crucial for affecting 
selectivity.  
The previous studies with N-(azolyl or azinyl)-2-
mercaptobenzenesulfonamides (MBSAs type I, 1.85) showed promising anticancer 
activities and potent HIV-1 integrase inhibition.  In 2003, Pomarnacka and coworker 
noticed that cyclic sulfonamide derivatives of 8-chloro-5,5-dioxoimidazo[1,2-
b][1,4,2]benzodithiazine of type II, 1.79 displayed anti-cancer properties (Figure 
1.25).78  The authors designed a novel tricyclic ring system as a lead structure to 
improve anti-cancer activity.  Among them, compounds 1.88 and 1.89 were the most 
potent.  In 2006, Pomarnacka’s research group also designed compounds bearing 
electron-withdrawing substituents at both positions 2 and 7.  Two series of 1-(6-
chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)-4-arylsemicarbazides and 2-arylamino-8-
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chloro-5,5-dioxo[1,2,4]triazolo[2,3-b][1,4,2]benzodithiazines were synthesized and 
tested for their in vitro cytotoxic potency against 12 human cancer cell lines.79  
Compounds 1.90a and 1.90b were the most potent among examined derivatives and 
displayed inhibitory activity against cancer cell lines generally better than cisplatin.  
The authors observed that compounds containing electron-withdrawing substituents at 
both positions 2 and 7 of the triazolobenzodithiazine scaffold exhibited activity. 
 
Figure 1.25 
In 2006, Saczewski et al. reported a series of benzodithiazines-dioxide 
derivatives with both antiviral and anticancer activities.  In order to obtain 
compounds with significant antiviral properties, they replaced the imidazole rings 
with pyrimidine rings (Figure 1.26).80  The authors successfully determined a lead 
compound with representative anti-HIV-1 activity (EC50 = 0.09 µM) in cell-based 
assays by NCI.  The most active compounds were 4-chloro-2,3,4-
trihydropyrimido[1,2-b][1,4,2]benzodithiazines 1.91a, 1.91b, and 1.91c (EC50 = 














































1.90a, R1 = Cl


















bears an electron-donating methyl group at position 7 displayed the most potent anti-
HIV activity (EC50  = 0.09 µM).  
In 2007, Saczewski and coworkers also synthesized a series of N-(6-chloro-
1,1-dioxo-1,4,2-benzodithiazin-3-yl)arylsulfonamides as potential anticancer agents.81  
Several sultam compounds depending on their structure displayed high (GI50 = 0.03–
5.0 µM) activities against most of the tumor cell lines.  In particular, compounds 
1.92a, 1.92b, 1.92c, and 1.92d were the most potent among them (Figure 1.26). 
Compound 1.92d, with a 5-Br-thienyl group at the Ar position, showed remarkably 
improved potency against melanoma UACC-257 cell line; and thus may serve as a 
lead compound for selective antineoplastic agents. 
 
Figure 1.26 
In 2009, Saczewski et al. synthesized 3-aroyl-2,3-dihydro-1,1-dioxo-1,4,2-
benzodithiazine derivatives as potential HIV-1 integrase (IN) inhibitors.82  Several of 
the generated compounds showed inhibitions of IN-mediated strand transfer reaction, 
with IC50 values ranging from 3 to 30 µM.  The 3-(4-bromobenzoyl)-6-chloro-7-
methyl-2,3-dihydro-1,1-dioxo-1,4,2-benzodithiazine 1.93 was the most potent (Figure 
1.27). 
1.91a, R1 = H, R2 = H
1.91b, R1 = Me, R2 = H








1.92a, R1 = Me, R2 = 4-ClPh, Ar = Ph 
1.92b, R1 = EtOCO, R2 = Ph, Ar = 4-O2NPh
1.92c, R1 = NC, R2 = Ph, Ar = 4-ClPh

















1.4.3 Benzothiazine 1,1-Dioxide Derivatives 
In 2001, a series of peptide mimetic aldehyde inhibitors of calpain I was 
produced by Bihovsky and coworkers.83  The effect of 2, 6, and 7-benzothiazine 
substituents and the amino acid was also tested against human recombinant calpain I.  
Compound 1.94 is a selective inhibitor of calpain I versus cathepsin B probably due 
to rigidity of the compound 1.94 (Figure 1.28). 
 
Figure 1.28 
In 2002, 6-methyl-3-isopropyl-2H-1,2-benzothiazin-4(3H)-one 1,1-dioxides 
derivatives were derived from L-valine as anti-inflammatory agents by Bouraoui and 
coworkers. 84   Compounds 1.95a–f were active anti-inflammatory agents in 
carrageenan-induced rat paw oedema assay in albino rats, and effects of the 
derivatives were comparable to that of piroxicam as a reference drug (Figure 1.29).  























revealed a significant effect on the anti-inflammatory activity.  Studies of structure–
activity relationships led to a lead compound 2,6-dimethyl-3-isopropyl-1,2-
benzothiazin-3,4-diol 1,1-dioxide 1.89f, which displayed the most potent activity.  
 
Figure 1.29 
In 2010, Siddiqui et al. synthesized N’-arylmethylidene-2-(3,4-dimethyl-5,5-
dioxidopyrazolo[4,3-c][1,2]benzothiazin-2(4H)-yl)acetohydrazides derivatives 
starting from saccharine as potential anti-oxidant and anti-bacterial agents.  A 
dihydroxy derivative 1.96 showed the most potent activities against B. subtillis and 
Escherichia coli (MIC = 5.0 µg ml-1, Figure 1.30).85  The lone pairs on oxygen atoms 
of hydroxyl and methoxy groups of compound 1.96 probably attributed to the 
activity.  Furthermore, compounds containing heteroatoms (nitrogen and sulfur) on 




In 2010, Goldberg and coworkers reported two related series of selective 
norepinephrine reuptake inhibitors based on 3,4-dihydro-1H-2,1,3-benzothiadiazine 
1.95a, R1 = H, R2 = H
1.95b, R1 = Me, R2 = H
1.95c, R1 = Me R2 =OH
1.95d, R1 = H, R2 = H
1.95e, R1 = Me, R2 = H




















2,2-dioxide or 3,4-dihydrosulfostyril cores, and evaluated them for monoamine 
reuptake inhibition.86  The authors identified that the series’ in vitro potency and 
selectivity versus serotonin or dopamine transporter inhibition, and analogues based 
on both cores were found to be potent and selective norepinephrine reuptake 
inhibitors (NRIs) from structure–activity relationships.  Compound 1.97 was further 
optimized for both potency and stability, and displayed efficacy in an in vivo model 




1.4.4 Benzothiadiazine 1,1-Dioxide Derivatives 
In 1993, Pirotte and coworkers synthesized a series of pyrido[4,3-e]-1,2,4-
thiadiazine 1,l-dioxide derivatives involving different aminoalkyl side chains in the  
3-position.87  The pyridine ring was introduced as a bioisostere of a benzene ring 
containing an electron-withdrawing substituent (halogeno, nitro, cyano).  The three 
best compounds, 1.98a, 1.98b and 1.99, which showed a maximal inhibition of 
insulin release at 50 µM, were also investigated at the same concentration for their 
vasorelaxant activity on K+-depolarized rat aorta (Figure 1.32).   
In 2000, Vega and coworkers noticed that several compounds belonging to the 












different pharmacological assays during an investigation focused on the discovery of 
novel potassium channel openers.88  These results led them to synthesize new 
compounds as potassium channel openers in which the benzene ring of known 
benzothiadiazines was substituted by thiophene (Figure 1.32).  From in vivo studies, 




Two years later, Hansen et al. prepared 6-chloro-3-alkylamino-4H-thieno[3,2-
e]-1,2,4-thiadiazine 1,1-dioxide derivatives as activators of adenosine 5’-triphosphate 
(ATP) sensitive potassium (KATP) channels in the β-cells by measuring effects on 
membrane potential and insulin release in vitro.89  The authors observed that 6-
chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide 
(1.103) binds as well as activates the SUR1/Kir6.2 KATP channels in the low nM 
range and was at least 1000 times more potent than the reference compound 
diazoxide with respect to inhibition of insulin release from rat islets (Figure 1.33).  
The compounds 3-propylamino- (1.101a), 3-isopropylamino- (1.101b), 3-(S)-sec-
butylamino- (1.101c), and 3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-










1.98a, R = CH(CH3)CH2CH3

















1.100a, R = Bn









minimal effects on blood pressure and exhibited good oral pharmacokinetic 
properties. 
In 2006, Hansen and coworkers observed that compound 1.102 (NN414) was 
a potent opener of Kir6.2/SUR1 KATP channels, inhibited insulin release in vitro and 
in vivo, and preserved beta cell function in preclinical animal models suggesting that 
such a compound could find use in treatment or prevention of type 1 and type 2 
diabetes (Figure 1.33).90  Compound 6-chloro-3-(1-methyl-1-phenylethyl)amino-4H-
thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (1.104), were potent openers of 
Kir6.2/SUR1 KATP channels and were suppressed glucose-stimulated insulin release 
from rat islets in vitro (EC50 = 0.04 ± 0.01 µM) and in vivo (ED50 = 4.0 mg/kg) after 
intravenous or parenteral administration to hyperinsulinemic obese Zucker rats. 
Structural diversifications of this series of analogues provided compounds with 
promising pharmacokinetic properties, indicating that brief periods of beta cell rest 
can be achieved. 
 
Figure 1.33 
Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are 
a major subdivision of the glutamate receptor family that mediates excitatory synaptic 






1.101a, R = (CH2)2CH3
1.101b, R = CH(CH3)2







































(1.105) which has been reported to enhance synaptic transmission and be effective in 
behavioral tests, but typically requires threshold concentrations of at least 100 µM to 
be active in vitro (Figure 1.34).91  In 2002, Chamberlin and coworkers reported the 
synthesis a series of 5’-alkyl-benzothiadiazide derivatives with IDRA-21 (1.105) as 
lead compound of AMPA receptor modulator and examined them for their potency in 
modulating AMPA receptor kinetics (Figure 1.34).92  A significant increase in drug 
affinity was obtained by alkyl substitution at the 5’-position of IDRA-21.  The 5’-
ethyl derivative exhibited an EC50 value in the order of 22 µM, which was about 30-
fold better in affinity than that of IDRA-21.  Based on these biological testing results, 
the authors assumed that the constrained structure of 1.107a and 1.107b might be 
similar to the binding conformation of 1.106a.  
In 2007, Francotte and coworkers synthesized and evaluated biological 
activities of a series of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides analogues 
as a positive allosteric modular of the AMPA receptors.  The authors observed that 
analogue 1.108a containing a fluorine and an ethyl group at C7 and N4 positions 
exhibited better biological activity among them (Figure 1.34).93   
In 2010, Francott and coworkers extended their investigations in order to 
improve biological activity and they observed that compounds 1.108b and 1.108c 
showed a remarkable dose dependent activity after oral administration.94   
In 2011, Cannazza and coworkers performed more detailed investigations 
about compound 1.107b bearing two stereogenic centers (Figure 1.34).95  The authors 
prepared all stereoisomers of compound 1.107b, however, single stereoisomers of 
 34 
1.107b underwent epimerization of the C3 position in saline solution.  Therefore, the 
epimeric mixtures of 1.107b were used for biological testing for positive AMPA 
receptor modulators and the epimeric mixture (3*,6S)-1.107b was more active than 
the epimeric mixture (3*,6R)-1.107b. 
 
Figure 1.34 
In 2003, Pirotte et al. synthesized a series of 3-(alkylamino)-7-halo-4H-1,2,4-
benzothiadiazine 1,1-dioxides as potential tissue-selective pancreatic β-cells KATP 
channel openers.96  From structure-activity relationship studies, introductions of a 
fluorine atom in the 7-position, and a short linear or cyclic hydrocarbon chain on the 
nitrogen atom in the 3-position were improved both potency and selectivity for the 
pancreatic tissue.  In addition, strong myorelaxant activity was obtained by 
introducing a chlorine atom in the 7-position, and a bulky branched alkylamino chain 
in the 3-position.  Compound 3-(ethylamino)-7-fluoro-4H-1,2,4-benzothiadiazine 1,1-
dioxide (1.109a) displayed a remarkable inhibitory activity on pancreatic β-cells (IC50 
= 1 µM) associated with a weak vasorelaxant effect (ED50 > 300 µM), whereas 7-
1.106a, R1 = CH2CH3, R2 = Cl
1.106b, R = CH2CH3,  R2 = F
























1.107a, R1 = H, R2 = F



























chloro-3-(1,1-dimethylpropyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide (1.109b) 
was very potent on vascular smooth muscle cells (ED50 = 0.29 µM) (Figure 1.35).  
 
Figure 1.35 
In 2010, Pirotte and coworkers synthesized 5-chloro-, 6-chloro-, and 8-chloro-
substituted 3-alkylamino/cycloalkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides to 
understand biological activity depending on the position of the substituent.  Of these 
derivatives, compounds 1.110, 1.111, and 1.112 showed improvement of biological 
activities and were further identified as KATP channel openers by radioisotopic 
measurements conducted on insulin-secreting cells (Figure 1.36).97  Pirotte and 
coworkers also explored their work to synthesize 3-alkylamino-4H-1,2,4-
benzothiadiazine 1,1-dioxides diversely substituted in the 7-position. 98   These 
compounds are structurally related to the previously reported 7-chloro-3-
alkylamino/cycloalkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide derivatives as 
potassium channel openers.  The natures of the substituent introduced in the  
7-position, and the alkylamino side chain in the 3-position were essential for both 
potency and tissue selectivity of 4H-1,2,4-benzothiadiazine 1,1-dioxides.  
Compounds containing in the 7-position a methyl or a methoxy group or devoid of a 
substituent in this position and bearing an ethyl, an isopropyl, or a cyclobutylamino 
group in the 3-position exhibited more potent and selective inhibitors of insulin 
1.109a, R1 = F, R2 = CH3











release from rat pancreatic β-cells (1.113a,b, 1.113e,f, and 1.114d).  Compounds 3-
alkylamino-7-trifluoromethyl- (1.114a–c),98 compounds, 3-alkylamino-7-pentyl-4H-
1,2,4-benzothiadiazine 1,1-dioxides (1.113c, d) showed a significant myorelaxant 
activity on the rat aorta ring.  In particular, the 3-alkylamino-7-pentyl derivative 
1.111c showed a notable selectivity for the vascular smooth muscle tissue.  
 
Figure 1.36 
In 2005, Tait and coworkers synthesized a series of 1,2,4-benzothiadiazine 
derivatives with an arylpiperazine moiety linked at position 3 of the heterocyclic ring 
as α1-adrenoceptor subtypes (α1A, α1B and α1D) and human cloned 5-HT1A receptor 
ligands.99  Compound 1.115 was determined as a novel α1D antagonist with high 
selectivity over the 5-HT1A receptor (Figure 1.37).  Compound 1.116 also displayed 
better affinity as well as selectivity for the 5-HT1A receptor.99  
 
Figure 1.37 
1.113a, R1 = CH3, R2 = CH2CH3
1.113b, R1 = CH3, R2 = CH(CH3)2
1.113c, R1 = C5H11, R2 = CH2CH3
1.113d, R1 = C5H11, R2 = CH(CH2)3
1.113e, R1 = OCH3, R2 = CH(CH3)2







































1.114a, R1 = CF3, R2 = CH2CH2CH3
1.114b, R1 = CF3, R2 = CH(CH3)2
1.114c, R1 = CF3, R2 = CH(CH3)CH2CH3




















A series of 6,7-disubstituted 4H-1,2,4-benzothiadiazine 1,1-dioxides involving 
a short alkylamino side chain in the 3-position were synthesized by de Tullio and 
coworkers in 2005.  All derivatives were examined on rat pancreatic islets and on rat 
aorta rings. 100   In vitro data revealed that, in most substitutions, in the  
6-and the 7-positions increased compound activity as inhibitors of insulin secretion, 
while the myorelaxant potency of the drugs was maintained or enhanced depending 
on the nature of the substituent in the 7-position.  However, compounds with one or 
two fluorine atoms and a methoxy group in the 7-position, appeared potent and 
selective inhibitors of insulin release. Radio isotopic and fluorometric experiments 
with the most potent compound inhibiting insulin release (1.117, BPDZ 259,  
6-chloro-7-fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide) 
confirmed that the drug activated KATP channels (Figure 1.38).  Among them, 
compound 1.117 was the most potent and selective pancreatic potassium channel 
opener.   
In 2011, de Tullio and coworkers also introduced a hydroxyl group onto the 3-
alkylaminoside chain to improve physicochemical and pharmacological properties 
based on previous observation. 101   The authors evaluated both (R) and (S) 
enantiomers for biological activities and (R)-7-chloro-3-(1-hydroxy-2-propyl)amino-
4H-1,2,4-benzothiadiazine 1,1-dioxide 1.118 to be the most potent.  Compound 1.118 





In 2005, Fitch and coworkers synthesized a series of benzothiadiazine-
substituted tetramic acid derivatives as potent inhibitors of hepatitis C virus RNA-
dependent RNA polymerase.102  The authors observed that compound 1.119 showed 
modest but encouraging activity against HCV NS5B polymerase (~3.5 µM), 
prompting further investigation (Figure 1.39). 
 
Figure 1.39 
In 2011, Kamal and coworkers synthesized a series of [1,2,4]triazolo [1,5-
b]benzothiadiazine conjugates and evaluated them for their anti-proliferative 
activities.103  The compound 1.120 displayed potent cytotoxicity against human 
leukemia HL-60 cell lines with IC50 values in the range of 0.08–0.70 µM (Figure 
1.40).  The authors also reported the synthesis of a class of arylsulfonamido-
conjugated oxazolidinones.104  Compounds 1.121a and 1.121b exhibited good in vitro 
activity against Mycobacterium tuberculosis H37Rv.  Furthermore, the compound 





































In 2008, Francotte and coworkers designed a series of pyrido-[2,3-e]-[1,2,4]-
thiadiazines (‘5-aza’ compounds) substituted at the 7-position in order to improve 
lipophilicity for new positive allosteric modulators of the AMPA receptors based on 
SAR studies.105  Among them, compound 1.122, containing a 7-chloro and N4-ethyl 
group, showed the most interesting in vitro activity with the proper lipophilicity to 
bind the central nervous system (CNS) (Figure 1.41).  
In 2010, Ma and coworkers extended to benzothiadiazine 1,1-dioxide 
analogues bearing different substituent groups at N2, N4 and 7 positions of the 
system.106  The compounds with an N4-acetic acid group and an N2-benzyl group 
exhibited significant and selective in vitro inhibition on aldose reductase (ALR2).  In 
particular 1.123a, 1.123b, and 1.123c showed more pronounced ALR2 inhibitory 
activities (Figure 1.41).  The authors identified that the N4-acetic acid group and N2-
benzyl group were recommended for ALR2 inhibitory activity from SAR analysis.   
In 2011, Ma and coworkers also synthesized a series of pyrido[2,3-e]-[1,2,4]-
thiadiazine 1,1-dioxide acetic acid derivatives and tested for inhibitory activities 
against ALR2.107  These compounds were identified to be potent aldose reductase 

















1.121a, R = Me








derivatives, compound 1.124 exhibited the highest inhibition activity (Figure 1.41). 
Structure-activity relationship studies demonstrated that the N2-benzyl group with 




Cannazza and coworkers synthesized a series of 5-arylbenzothiadiazine 
derivatives as positive allosteric modulators of AMPA/Kainate receptors in 2012.108  
During the investigation compounds 1.125 and 1.126 displayed higher activity, 
plausibly due to H-bond ability within the 5-membered heterocycles (Figure 1.42).  
The authors also observed that compound 1.125 was more active than compound 
1.126 because of the electronegativity difference between the oxygen atom and sulfur 






















1.123a, R1 = F, R2 = 2,4,5-F3
1.123b, R1 = Cl, R2 = 2-F, 4-Br




























1.4.5 4-Hydroxy-2H-benzo[e][1,2]thiazine 1,1-Dioxide Derivatives 
3,4-Dihydro-1,2-benzothiazine-3-carboxylate 1,1-dioxide α-ketomide 
compounds are well known as potent calpain I inhibitors.  In this regard, 1,2-
benzothiazin-3-yl-quinazolin-4(3H)-one derivatives were synthesized and evaluated 
by Zia-ur-Rehman and coworkers in 2006.109  Among the series of compounds, 1.127 
displayed better activity against Escherichia coli (Figure 1.43).  In 2009, the authors 
also prepared 4-hydroxy-N’-(benzylidene)-2H-benzo[e][1,2]thiazine-3-
carbohydrazide 1,1-dioxides derivatives and examined them for several antibacterial 
activities.110  Compounds 1.128a and 1.128c showed significant activities against S. 
typhi.  Compound 1.128b revealed remarkable activity against S. aureus. 
In 2010, Ahn and coworkers synthesized cyclic sulfonamide derivatives as 
new 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors (Figure 
1.43).111  Of derivatives tested, compound 1.129 was obtained with good in vitro 
activity and selectivity toward human 11β-HSD1.  Interestingly, the same core 
scaffolds bearing two different ketone moieties at N2 and C3 positions also exhibited 
a good in vitro inhibitory activity. 
A series of benzo-thiopyran S-dioxides, as exemplified by 1.131, were 
discovered from high throughput screening of the Pfizer chemical file against the 
human mPGES-1 enzyme (Figure 1.43).112  Based on this bioactivity, in 2010, Wang 
and coworkers synthesized compound 1.132.  The authors also found potency both in 
the enzyme and cell-based assays furthermore compound 1.132 exhibited selectivity 
for mPGES-1 over COX-2.  In order to improve biological activity, several analogues 
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were prepared based on SAR analysis.  Compounds with no linker between the C and 
D rings showed less potency both in the enzyme and cell assay compared with 
compound 1.132, and compounds with a single heteroatom linker also displayed 
decrease enzyme inhibition.  Among them, compound 1.130b showed excellent 
mPGES-1 inhibition and selectivity over COX-2 in the human fetal fibroblast cell 
assay.  The authors noticed that the acidic proton within the dioxobenzothiazinone is 
very significant for achieving potent mPGES-1 inhibition.  Compound 1.130 also 
displayed the activity against PGE2 production in the LPS/human whole blood assay 
with an IC50 around 5 µM.  The authors explained that this low inhibition in the 

























1.128a, R1, R3 = OH,  R2, R4, R5 = H
1.128b, R1, R2 = H,  R3, R4, R5 = OMe











1.130a, R1, R2 = H

























1.4.6 Benzothiadiazine-hydroxyquinolin-2(1H)-one Derivatives 
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease 
and the leading cause of death from liver disease in the United States.113  The Centers 
for Disease Control and Prevention estimate that more than 4.1 million individuals in 
the United States have ongoing HCV infection.113  The preliminary SAR of the N-1-
alkyl benzothiadiazines showed equivalent polymerase activity for the quinolone core 
1.133 and 1,8-naphthyridone core 1.134 by Pratt and coworkers from Abbott 
laboratory in 2005 (Figure 1.44).114  Pratt and coworkers also performed a series of 
investigations to obtain new inhibitors of HCV NS5B polymerase.  During the study, 
the authors found that the nature of the hydrophobic fragment at the N1 position of 
the quinolone ring significantly effected potency of biological activity.  With this 
information, the authors designed several types of molecules to improve activities.  
Among the series of analogues, compounds 1.134 displayed better activity.  
Introduction of an oxygen or nitrogen atom as a linker (X) in the system could allow 
the attached alkyl groups to reach to hydrophobic binding via lightly different bond 
angles and conformations.  However none of these analogues showed pronounced 
improved activity over compounds 1.134.  
In 2006, Rockway and coworkers carried out more detailed investigations on 
1,8-naphthyridone core derivatives in order to improve activities.115  The authors 
found that a methyl sulfonamide group to the position 7 of the D-ring in substituted  
N-1-3-methylbutyl-4-hydroxy-1,8-naphthyridone benzothiadiazine 1.133, displayed 
enhanced enzyme inhibition potency as well as cell culture activity (Figure 1.44). 
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Furthermore, Rockway and coworkers introduced a sulfamide group to extend more 
functionality away from the methyl sulfonamide based on the SAR analysis.116  
Compounds 1.139 and 1.140 containing the methyl and unsubstituted 
benzothiadiazine sulfamides displayed the most potent biochemical and cell culture 
activities.  However, these compounds showed poor solubility.  
In 2008, Huchinson and coworkers focused on modifications at C1 of the  
B ring in the hydroxyquinolon-3-yl-benzothiadiazine series, whereby they substituted 
a dialkyl naphthalene unit to increase potency.117  Upon generation of a small set of 1-
hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene analogs, the SAR analysis 
suggested that the most potent analogues bear an unsymmetrical dialkyl groups in the 
B ring.  In addition, Huchinson and coworkers also found that the compounds 
containing a more polar ester and diol group were less potency.  This suggested that 
the binding pocket in this region is hydrophobic in nature.  In general, the saturated 
alkane analogues were more active than the corresponding unsaturated alkene 
derivatives.  Compound 1.141 showed the most potent activity in the assay as well as 
better solubility properties than compounds 1.139 and 1.140 (Figure 1.44).  
Because compound 1.141 was a racemic mixture, in 2009, Wagner and 
coworkers synthesized all enantiomerically pure compounds. 118   (R)-Configured 
isomers 1.142a and 1.142b were more active stereoisomers than (S)-configured 
compounds from in vitro studies.  Both compounds 1.142a and 1.142b inhibited 
genotypes 1a and 1b polymerase activity and HCV replicon replication at low nM 
concentrations.  The (R)-configured isoamyl and neo-hexyl substituted compounds 
 45 
1.142a and 1.142b showed promise as drug candidates for the treatment of HCV 
infection.   
In 2009, Randolph and coworkers reported that the B-ring dialkylthiadiazine 
inhibitors, containing a variety of substitutions on this site, exhibited low nM 
inhibitors of genotypes 1a and 1b polymerase.119  The methyl group of the B-ring was 
replaced with an amino functionality to improve inhibition ability.  The analogue 
1.143 bearing neohexyl and benzylamine moieties displayed good pharmacokinetic 
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In 2008, Donner and coworkers noticed that the tetracyclic benzothiadiazine 
system has a major drawback due to its high degree of protein binding.  In order to 
solve this problem, Donner and coworkers studied the possibility of replacement of 
this four-ring system to the minimum core required for activity.120  Donner and 
coworkers found that when the A-ring was removed, the potency of compound 
decreased and substitutions from the B-ring into the space previously occupied by the 
A-ring produced analogues that retained nM enzyme inhibitory potency.  Several 
three-ring systems, namely 1.144a, 1.144b and 1.144c, bearing small substituents to 
the 5-position of the B-ring displayed more active in 1b replicon than the original 
tetracyclic analogues. 
 
1.5 Bioactive Compounds Containing 7-Membered Sultam Moiety 
1.5.1 Benzothiazepine 1,1-dioxide Derivatives 
In 2010, Dodd and coworker synthesized several benzofused sultam 
compounds as potential calcium sensing receptor agonists.121  The corresponding 
compounds were examined for agonist activity on human CaSR (hCaSR) expressed 
in HEK293 cells. Among them, the six- and seven-membered cyclic sulfonamide 
derivatives 1.145 and 1.146 were the most potent calcimimetics.  Even though the 
calcimimetic activities of both compounds were less active than that of calindol, these 
lead candidates allow achieving diverse structural modifications for better activities. 
In 2003, 5-aryl-3,3-dibutyl-7-(dimethylamino)-1,2-benzothiazepin-4-ol 1,1-
dioxide derivatives were prepared by Tollefson and coworkers as potential apical 
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sodium co-dependent bile acid transporter (ASBT) inhibitors.122  The authors found 
that compounds 1.147a, 1.147c and 1.147d revealed low nM in vitro activity and 
inhibited ASBT for the potential treatment for hyperlipidemia (Figure 1.45).  In 
particular, compound 1.147b exhibited the most potent activity. 
 
Figure 1.45 
In 2007, Millet and coworkers synthesized a series of tricyclic-containing 
dioxodibenzothiazepine or dibenzocycloheptane derivatives as farnesyltransferase 
(FTase) inhibitors.123  These compounds were evaluated for their in vitro inhibitory 
activity against FTase using the continuous fluorescence spectrometry technique.  
Among the series of compounds, dioxodibenzothiazepine 1.148 revealed pronounced 
inhibitory FTase activity (IC50 = 17.3 nM) and antiproliferative properties (Figure 
1.46).  The authors observed that the compound containing an additional morpholine 
moiety as a hydrogen bond acceptor resulted in improved binding to the enzyme. 
In 2005, Depreux and coworkers prepared a series of 
benzoindolinothiazepines involving a piperazine fragment with interesting cytostatic 



































1.5.2 Benzothiadiazepine 1,1-Dioxide Derivatives 
Several compounds including nevirapine, efavirenz (Sustiva), and delavirdine 
(Rescriptor) have been approved for clinical use as AIDS therapeutics125 prompting 
Di Santo and coworkers in 2006 to report the first example of 1-[(2-
hydroxyethoxy)methyl]-6-phenylsulfanyl)thymine (HEPT) and 4,5,6,7-
tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) 
derivatives within the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of 
chemotherapeutic agents for the treatment of AIDS.  The novel TIBO- and TBO-like 
derivatives were prepared and evaluated for their cytotoxicity and anti-HIV-1 activity 
in MT-4 cells.  These compounds revealed activities against the HIV-1 replication 
cycle in cell-based assays.  In particular, compound 1.150 was the most potent in cell-
based assays (EC50= 0.07 mm, CC50>200 mm, SI>2857) and also showed more 




















In 1991, Giannotti and coworkers synthesized a family of 11-
[(aminoalkyl)carbonyl] derivatives of 6,11-dihydrodibenzo[c,f][1,2,5]thiadiazepine 
5,5-dioxide for potential antidepressant activity in the apomorphine-induced  
hypothermia (Apo 16).126  Compound 1.151 showed not only structural similarities 
with classical antidepressant tricyclic compounds, but was also the most potent and 
least toxic in this series, by assessing physostigmine lethality (Figure 1.47). 
Pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (PBTD) derivatives were 
introduced for apoptosis in human breakpoint cluster region (BCR)-Abelson murine 
leukemia (ABL) expressing leukemia cells, by Silvestri and coworkers in 2006.127  
Based on the apoptotic mechanism studies, the authors found that compounds 1.152 
and 1.153 activated caspase activity and induced apoptosis before the BCR-ABL 
protein expression (Figure 1.47).  Silvestri and coworkers obtained PBTD derivatives 




In 2005, a series of benzopyridothiadiazepine derivatives were synthesized 
and tested for their anti-proliferative activity toward the murine L1210 leukemia cell 






























cytotoxicity.  In particular compounds 1.154 and 1.155, were the most potent 
inhibitors of tubulin polymerization with IC50 of 3.8 and 2.4 µM respectively, 
compared to 2.4 µM for desoxypodophyllotoxin (Figure 1.48).  The  
4-methoxyphenylethyl group on the pyridinyl nitrogen of the 
benzopyridothiadiazepine was required for the antiproliferative activity.  
Benzopyridothiadiazepine dioxides were considered as a promising new class of 




1.5.3 Thiadiazepinoindole 2,2-Dioxide Derivatives 
In 2009, Demont and coworkers synthesized a series of hydroxyethylamines 
derivatives, as beta-secretase 1 (BACE-1) inhibitors, with µM potency in cell-based 
assays. 129   Among them, GSK188909 (compound 1.156) possessed appropriate 
pharmacokinetics and was the first orally bioavailable inhibitor reported to 
demonstrate brain amyloid lowering in an animal model (Figure 1.49). 
In 2008 Demont and coworkers, reported another type of sultam compounds 












assay as well as enhanced oral bioavailability in rat and good bioavailability in dogs.  
The authors extended their work to synthesize 6-membered sultam as well as tricyclic 
sultam compounds based on previous observations of the first generation of 
hydroxyethylamine BACE-1 inhibitors. 131  Several compounds displayed having 
good oral exposure from in vivo pharmacokinetics profile in rat as well as dog.  
Generally, compounds in the tricyclic series need to contain a basic nitrogen in order 
to obtain good correlation of activities.  The α-amino ketone derivative 1.158 was the 
first tricyclic BACE-1 inhibitor without hydroxyethylamine transition state mimetic 
that displayed excellent potency in cell-based assays.  During the investigation, 
inhibitors containing [8.6.5]-tricyclic system were also prepared, however, these 
inhibitors decreased potency and selectivity when compared to their [7.6.5] 





There are several commercially available drugs containing sultam moiety in 





























size and connectivity have been reported possessing a variety of biologically 
activities such as anti-HIV, HCV-NS5B polymerase and HIV-1 integrase activities.  
In this regard, developments of new chemical methodologies to generate more 
skeletally diverse sultam derivatives are important to survey more biologically active 
sultam-containing compounds.  
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Metathesis Cascade Strategies (ROM–RCM–CM):  














2.1.1 Metathesis Reaction in Diversity-Oriented Synthesis 
The development of new chemical methods to generate novel small molecules 
with diverse structures to probe chemical space is an important aspect of early phase 
drug discovery.  Diversity-oriented synthesis (DOS) is one of the most powerful 
methods to produce structurally complex and skeletally diverse small molecules.1  As 
collections of small molecules can represent a wide range of physical and biological 
properties, and they are ideal synthetic target to aspire in order to probe chemical 
space for the identification of novel lead compounds in early stage drug discovery.2  
Towards this goal, the development of simple methods that, allow for the production 
of an array of structurally complex scaffolds is one of several challenging facets of 
DOS.  A number of accomplished strategies have reported employing skeletal 
rearrangement utilizing both functional-group-pairing (FGP)1d,3 strategies and tandem 
metathesis (TM) strategies.4   
In 1996, Grubbs and coworkers reported a tandem ring opening-ring closing 
metathesis (RO–RCM) strategy, that allowed access to a number of bi- and tricyclic 
compounds from their strained mono- and bicyclic precursors in good to excellent 
yields [Scheme 2.1 (a) and (b)].5a  In 2004, Aubé and coworkers also reported an  
RO–RCM reaction protocol, mediated by Grubbs first generation catalyst, en route to 
the total synthesis of dendrobatid alkaloids [Scheme 2.1 (c)].5b 
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Scheme 2.1 Representative ROM–RCM reaction strategy. 
Recently, a number of strategies employing ROM–CM strategies with 
norbornene, oxa-norbornene, and aza-norbornene derivatives have been reported.6  In 
particular, a number of key metathesis cascades and strategies have surfaced, some in 
the context of DOS.7  For example, Schreiber and coworkers reported the efficient 
synthesis of structurally complex compounds.7k  A 4-component Ugi reaction and 
subsequent intramolecular Diels–Alder (IMDA) reaction afforded corresponding 
tricyclic compound 2.9 via intermediate 2.8.  When treated with Grubbs 2nd 
generation catalyst {[(IMesH2)(PCy3)(Cl)2Ru]CHPh, (cat-B)}8 allylation product 2.10 
readily underwent ROM–RCM (69%), and successive TIPS-deprotection with HF-
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Scheme 2.2  
In 2011, Kotha and coworker reported the synthesis of various biaryl 
compounds using a cross-enyne metathesis strategy in DOS (Scheme 2.3).9  In the 
presence of cat-B, Substituted phenylacetylene 2.12 underwent cross-enyne 
metathesis with ethylene to furnish diene 2.13.  Diene 2.13 was then subjected to 
Diels-Alder reaction conditions to afford the corresponding adduct 2.14.  Finally, 
aromatization using DDQ provided biaryl compound 2.15 in excellent overall yield 
(Scheme 2.3).  
With the goal of aspiring to the aforementioned attributes of scaffold 
production, we envisioned a DOS approach, whereby skeletally diverse sultam 
scaffolds could be generated using a domino ring-opening metathesis/ring-closing 
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derived oxa-norbornenyl sultam. 
 
Scheme 2.3 
Sulfonamides and unnatural sultams (cyclic sulfonamides) have been reported 
as privileged structures in drug discovery due to their diverse biological properties.  A 
number of reports have highlighted an assortment of sultams that display potent 
activity against a variety of targets, including inhibition of COX-2 
(Ampiroxicam),10,11 HIV integrase,12 and cysteine protease involved in the 
progression of malaria,13 and inhibition of matrix metalloproteinase (MMP)14 and 
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.15 
In this investigation, we explored the application of an ROM–RCM–CM 
strategy for the generation of a collection of skeletally diverse sultams via a 
diastereoselective intramolecular Diels–Alder (IMDA) reaction with a central 
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Scheme 2.4  ROM–RCM–CM strategy. 
A number of transition metal-catalyzed approaches to sultams have come to 
light, including ring-closing metathesis (RCM).16  Our continued interest in the 
development of new synthetic routes toward structurally diverse sulfur-containing 
small molecules for library production16,17 has prompted the following investigation 
on the application of metathesis cascade processes for their construction. 
 
2.2 Results and Discussion 
2.2.1 Intramolecular Diels-Alder Reaction 
  As developed by Metz and coworkers in 1989, the IMDA reaction of both 
vinyl sulfonates18 and vinyl sulfonamides19 with substituted furans has provided an 
efficient route to highly versatile intermediates rich in stereochemistry and 
functionality.  In their seminal paper, Metz et al. report furan-containing vinyl 
sulfonamide 2.16 was derived from commercially available starting material in  
3 steps.  Vinyl sulfonamide 2.16 underwent IMDA reaction to produce readily 
separable exo-γ-sultam compounds 2.17 and 2.18 [Scheme 2.5 (a)].  Production of the 
exo-δ-homologues 2.21 and 2.22 occurred via furan derivative 2.19 in 3 steps 





























Norbornene systems of this type possess a strained internal double bond, and 
thus are attractive scaffolds for application of the aforementioned metathesis cascade 
process.  Utilizing a similar IMDA method, the IMDA-derived sultams 2.23 and 2.24 
were synthesized from commercially available starting materials.19 
 
Scheme 2.6 
2-Chloroethanesulfonyl chloride was coupled with furfurylamine under standard 
conditions to obtain the corresponding sulfonamide in 86% yield.  
Allylation/propargylation of the resulting sulfonamide, followed by in situ IMDA 
O CHO
1. (S)-(–)-1-Phenyl
   ethylamine, MgSO4
   Et2O, 0 ºC to rt
   15 h, 98%
2. LiAlH4, Et2O
   0 ºC to rt, 6 h, 95%
3. Vinylsulfonyl chloride
   Et3N, CH2Cl2, 0 ºC
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or
B. CH2Cl2, rt
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   ethylamine, 80 ºC
  12 h, 79%
2. Vinylsulfonyl chloride
   Et3N, CH2Cl2, 0 ºC
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2.23, R = Allyl, 55% (over 2 steps)







reaction in reflux conditions, furnished the corresponding tricyclic sultams 2.23 and 
2.24, in 55% and 58% yields, respectively (Scheme 2.6), as single diastereomers.  
 
2.2.2 ROM–RCM–CM Strategy to a  
Tetrahydro-2H-3a,6-epoxybenzo[d]isothiazole 1,1-Dioxide Sultams 
 
Application of the proposed ROM–RCM–CM cascade protocol was explored 
with scaffold 2.23. Sultam 2.23 was subjected to 5 mol % of cat-B, at 0.005 M in 
CH2Cl2 at 40 ºC under argon atmosphere for 3 hours, to provide ROM–RCM–
dimerization product 2.25 in 84% yield (Scheme 2.7).  In order to prevent 
homodimerization process, a cross-metathesis partner was used to afford the desired 
product.  Additionally, the utilization of ethylene gas has been well reported in the 
application of ROM–RCM–CM, whereby a terminal olefin is ultimately produced.7   
 
Scheme 2.7 
Thus, sultam 2.23 was subjected to standard cascade conditions under 
ethylene atmosphere, in ethylene-degassed CH2Cl2 solvent.  The corresponding 
tricyclic sultam 2.26 containing a terminal olefin was obtained, in 74% yield with 
ethylene acting as the final cross-metathesis partner.  Based on this result, studies 
were directed toward the addition of a cross-metathesis partner to circumvent 





















subjected in the presence of ethyl acrylate [10 equiv], cat-B [10 mol%], in 0.005 M 
CH2Cl2 at 40 ºC, the desired bridged tricyclic sultam 2.27 derived from ROM–RCM–
CM process was isolated in 65% yield (Scheme 2.8).  
 
Scheme 2.8 
With the successful application of an ROM–RCM–CM protocol, the scope of 
possible cross-metathesis partners was studied.  When exposed to the aforementioned 
protocol, a variety of acrylate, including ethyl acrylate, methyl acrylate and tert-butyl 
acrylate, were converted to the desired products with good yield (Entries 1–3, Table 
2.1).  Interestingly, the application of methyl vinyl ketone (MVK) did not provide the 
desired product.  In addition to acrylates, acrylonitrile and styrene were applied as the 
cross-metathesis partners.  Under standard cascade reaction conditions, the protocol 
provided the desired tricyclic sultam products as the sole product in good isolated 












































































































cascade reaction strategy for the propargyl-substituted sultam 2.24.  In this case, a 
ring-opening metathesis/ring-closing enyne metathesis/cross metathesis (ROM–
RCEM–CM) sequence was envisioned as a method of generating skeletally diverse 
sultams.  Additionally, reaction of sultam 2.24 containing propargyl group in the 
presence of ethylene would provide the desired product 2.33 bearing a diene 
fragment, allowing for additional incorporation of diversity via [4+2]-cycloaddition 
with activated dienophiles under standard reaction condition.  However, when sultam 
2.24 was subjected to the ROM–RCEM–CM conditions, none of the desired product 
was observed, instead bicyclic, tetraene-containing sultam 2.34 was obtained in 75% 
isolated yield.  This result showed that sultam 2.24 undergoes an intermolecular 
enyne metathesis with ethylene instead of the corresponding intramolecular process.  
Sultam 2.34 bearing tetraene, treated with N-phenylmaleimide in toluene at heating 
condition to provide the corresponding [4+2] cis-cycloadduct 2.35 in 83% yield as an 









































We also investigated the synthesis of a modified sultam scaffold with the 
simple relocation of the allyl group in 2.23 by adding one carbon that would allow for 
the generation of new tricyclic sultams 2.37–2.39.  This sultam homologue, 
possessing a tethered allyl group, also enhances overall structural diversity by 
yielding a different type fused-ring system.  4-Methoxybenzylamine was condensed 
with 2-furaldehyde to produce the corresponding imine, which was subsequently 
converted to the furfuryl-substituted allylamine upon the addition of allyl magnesium 
bromide.  Vinyl sulfonylation with 2-chloroethanesulfonyl chloride generated, the 
corresponding vinyl sulfonamide intermediate 2.36, which when refluxed in toluene 
for 12 hours furnished the desired IMDA-derived sultam scaffold (2.37) as a mixture 
of diastereomers (~1:1) in 95% isolated yield (Scheme 2.10).21   
 
Scheme 2.10 
The diastereomeric mixture of sultam 2.37 was subjected to the ROM–RCM–
CM reaction conditions, in the presence of ethylene, to produce two different sultam 
products, 2.38 and 2.39 (Scheme 2.11).  Structures of sultams 2.38 and 2.39 were 
confirmed by spectroscopic analysis including 1H NMR NOESY studies.  These 
results indicated that diastereomer sultam 2.37a selectively underwent cyclization to 
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was also derived from ROM–CM of diastereomer 2.37b with ethylene.   
 
Scheme 2.11 
This result demonstrated that in the case of diastereomer 2.37b, an unfavorable 
interaction between the allyl substituent and the oxo-bridge prevents proper alignment 
between the ruthenium alkylidene and the norbornenyl olefin, thus preventing 
metathesis reaction (Figure 2.1).  
 
Figure 2.1 
Based on this steric effects, the corresponding ROM–RCM–CM product of 2.39 
would have a trans ring junction in a bicyclo[3.3.0] ring system, which, under the 




































(±)-2.40, R = CO2Et, 52%  
































RCM–CM process with diastereomeric mixture of sultam 2.37, in the presence of 
ethyl acrylate or tert-butyl acrylate as cross-metathesis partners, provided the desired 
bridged tricyclic sultams 2.40 and 2.41 in 52% and 49% isolated yields, respectively 
(Scheme 2.11).   
Furthermore, we decided to investigate the rationalization for obtaining one 
regioisomer product from the ROM–RCM–CM reaction protocol.  Boc-protected 
IMDA sultam 2.42 was subjected to standard reaction conditions with ethyl acrylate 
as a cross-metathesis partner (Scheme 2.11).  This reaction provided only bicyclic 
sultam 2.43 that was derived from the ROM–CM process and neither 2.44a nor 2.44b 
was observed ultimately.  Based on this result, we hypothesized that, upon initiation 
with ruthenium catalyst, two possible transition states are formed: TS-I and TS-II, 
where, the TS-I is more favored than the TS-II due to an unfavorable steric 
interaction between the ligand of the ruthenium catalyst and the carbon backbone of 






2.2.3 ROM–RCM–CM Strategy to a  
Hexahydro-4a,7-epoxybenzo[e][1,2]thiazine 1,1-Dioxide Sultams 
 
In conjuction with the previously described 5-membered systems, we were 
also developing the synthesis of an IMDA-derived 6-membered sultam 2.47 
involving additional functional handles and therefore proving its utility in the 
metathesis cascade protocol.  In this regard, N-Boc-phenylalanine was converted to 
the corresponding Weinreb amide and reacted with lithiated furan.  The furyl ketone 
treated with NaBH4 to obtain corresponding N-Boc-amino alcohol 2.45 as a mixture 
of diastereoisomers (~2:1) in 64% yield over three steps.22  An amino alcohol 2.46 as 






















































sulfonylation/diastereoselective IMDA sequence to afford tricyclic sultam 2.47, as a 
single diastereoisomer, in 52% yield over three steps (Scheme 2.11).19  
 
Scheme 2.13 
Ticyclic sultam 2.47 is a useful scaffold because of a number of characters in 
a DOS aspect, including (i) stereochemistry (ii) the presence of both free hydroxy 
(OH) and free sulfonamide (NH) groups, (iii) peripheral functionality and, (iv) 
structural rigidity.  These features allow for the production of focused libraries to 
probe chemical space via two approaches.  The first is via simple peripheral 
diversification and the second achieves skeletal diversity utilizing the aforementioned 
ROM–RCM–CM cascade protocol.  Sultam 2.48 derived from chemoselective  
O-allylation reaction of sultam 2.47,23 underwent ROM–RCM–CM process to 
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After acryloylation of sultam 2.47, the sultam intermediate 2.50 was also 
converted to bicyclic sultam 2.51 via ROM–CM reaction (Scheme 2.15).  Both 
pathways for IMDA sultam 2.47, possess another functional handle (SO2NH) for late 
stage peripheral diversification.  Depending on the property of the olefin appendage 
in sultam 2.47 it allows us to generate skeletally diverse sultams either tricyclic 
sultam 2.49 or bicyclic sultam 2.51, presumably due to variable olefin reactivity types 
(I, II, II or IV), as defined by Grubbs affecting the site of the initial metathesis event. 
24  Overall, the three starting material sultams 2.23, 2.37, and 2.47 are tricyclic, 
IMDA-derived scaffolds that, upon submission to the metathesis cascade protocol 




2.2.4 ROM–RCM–CM Strategy to a Functionalized  
Tetrahydro-2H-3a,6-epoxybenzo[d]isothiazole 1,1-Dioxide Sultam 
 
In the final example, we investigated that the synthesis of a sultam scaffold 
bearing an ester functional handle as an alternative strategy toward the synthesis of 
functionalized derivatives of 2.23.  This goal could be achieved via incorporation of 



































Overman and coworkers in 1999.25  To this study, furfurylamine was coupled with 
methanesulfonyl chloride to obtain secondary sulfonamide, then subsequently 
allylated to yield tertiary sulfonamide 2.52 in 82% over two steps.  Generation of the 
phosphonate 2.53, followed by Horner–Wadsworth–Emmons reaction with ethyl 
glyoxalate, provided a mixture of uncyclized sulfonamide 2.54 and IMDA-derived 
sultam 2.55 after purification to remove any remaining starting material.  Addition of 
hexane to the crude mixture resulted in the sole precipitation of 2.55 as X-ray quality 
crystals (Scheme 2.16).  
 
Scheme 2.16 
It is important to mention that it was observed that in NMR solvents including 
CDCl3 and MeOH-d4, sultam 2.55 undergoes retro-IMDA to generate sultam 2.54 
over time.26  The acidic nature of the solvent catalyzed the retro-IMDA reaction 
indicates the increased reactivity of the bridged tricyclic system in comparison to 
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in the presence of ethylene and cat-B in CH2Cl2 to produce the desired tricyclic 
sultam 2.56 bearing an ester group (Scheme 2.17).  
 
Scheme 2.17 
Formation of an additional lactone ring was also carried out using 
iodolactonization reaction between the carboxylate resulting from saponification of 
the ester with LiOH and the terminal olefin in the presence of iodine to afford 
tetracyclic, iodo-product 2.57 as a single isomer, albeit in low yield (Scheme 2.18).  
 
Scheme 2.18 
The iodo-lactone product 2.57 was treated with different nucleophiles such as 
4-chlorobenzylamine and morpholine to obtain substituted products. The secondary 
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isolated yield. Interestingly, the reaction with morpholine provided the tricyclic 
compound 2.59 instead of tetracyclic sultam 2.60 resulting from inherent basicity of 
the nucleophile (Scheme 2.18).  
 
Figure 2.2 
Iodo-compound 2.57 underwent elimination reaction with morpholine to provide an 
exo double bond containing γ-lactone intermediate.  The compound 2.59 was derived 
from nucleophilic addition to carbonyl carbon followed by enol-keto tautomerization 
(Figure 2.2).  
 
2.3  Conclusions 
In conclusion, the generation of a small collection of several bi-, tri-, and 
tetracyclic sultams has been obtained in an overall DOS-based approach utilizing an 
ROM–RCM–CM cascade strategy.  Several tricyclic sultams bearing various 
functional groups were derived from a diastereoselective IMDA reaction in good 
yields and selectivity as precursors for the metathesis cascade strategy.  The ROM–
RCM–CM proceeded in good to excellent yields, generating sultams possessing 
skeletally diverse that was controlled by elements incorporated into the sultam 
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Vinyl Sulfonamides in Diversity-Oriented Synthesis: 













3.1  Introduction 
3.1.1 Aza-Michael Reaction 
The conjugate addition reaction is one of the most useful methods to form 
new C–X (X = C, N and O) bonds.1  The synthetic versatility of this reaction depends 
mainly on a variety of nucleophiles, as well as acceptors.  Usually α,β-unsaturated 
carbonyl compounds are known as acceptors, and the nucleophiles can be either 
carbon- or heteroatom-centered moieties.  However, different types of activating 
groups such as nitro, sulfonate, sulfoxide and phosphate have also been used as 
acceptors.  Among a broad range of nucleophiles and activated olefins that can be 
employed in diverse transformations, the conjugate addition of nitrogen nucleophiles, 
formally known as the aza-Michael reaction, has been extensively studied.  The aza-
Michael reaction represents one of the most powerful strategies for the C–N bond 
formation present in a variety of biologically active β-amino compounds or related 
derivatives.2  As such, it has been widely used for the synthesis of natural products as 
well as nitrogen-containing heterocyclic small molecules. 3   Recently, several 
conjugate addition reactions have been applied to small library productions.4  In 
particular, Schreiber and coworkers reported the diastereoselective intramolecular 
aza-Michael reaction to produce nitrogen-containing heterocyclic compounds using 
chiral, non-racemic substrates in a diversity-oriented synthesis (DOS) approach. 5  
Ring-closing metathesis (RCM) remains a widely used and powerful approach 
for the synthesis of complex molecules of various ring size.  Our group has 
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previously utilized RCM for the generation of simple 5-, 6- and 7-membered sultam 
derivatives from the corresponding allyl and vinyl sulfonamides (Figure 3.1).6  In 
addition to sultams, we have reported the utilization of RCM for the synthesis of  
P-heterocycles,7 phosphonosugars,8 and sulfamide peptidomimetics.9  
 
Figure 3.1 RCM approaches to S-heterocycles. 
An inherent feature of using an RCM approach with vinyl sulfonamides to 
construct sultams, is that the corresponding sultam retains the α,β-unsaturated 
functionality incorporated within the generated cycle.  The resulting α,β-unsaturated 
γ-sultam is an ideal synthon with several functional handles that can be applied to 
different types of reactions such as aza-Michael, cycloaddition and 
alkylation/arylation reactions to achieve diverse sultams (Figure 3.2).  Our group has 
already reported the application of efficient oxa- and aza-Michael reaction protocols 
for the generation of sultams via intermolecular Michael cyclizations.10  In the study 
discussed below, we investigate several reactions of α,β-unsaturated sultams to 






























Figure 3.2  Representative general strategy utilizing α,β-unsaturated sultam. 
 
3.2 Results and Discussion 
3.2.1  Diversifications of 2,3-Dihydroisothiazole 1,1-Dioxide Sultams 
α,β-Unsaturated γ-sultam (R)-3.3 was derived from commercially available 
starting material (S)-benzyl glycidyl ether in five steps (Scheme 3.1).  The glycidyl 
ether underwent epoxide ring opening with trimethylsulfonium iodide in the presence 
of nBuLi at -30 ºC to provide allylic alcohol 3.1.  The resultant allylic alcohol was 
reacted under Gabriel primary amine synthesis conditions to yield allylamine 
derivative 3.2 in 2 steps.6b  The primary amine 3.2 was coupled with  
2-chloroethanesulfonyl chloride to afford corresponding vinyl sulfonamide in 46% 
isolated yield.  The desired (R)-α,β-unsaturated γ-sultam product 3.3 was obtained in 
92% isolated yield from the RCM reaction.  In addition, with the same protocol, the 

















Having successfully synthesized sultam 3.3, the first position manipulated for 
diversification was the nitrogen atom of sultam 3.3.  Simple alkylation was applied to 
generate tertiary sultams.  Sultam 3.3 was reacted with an alkyl halide, including 
methyl iodide and allyl bromide, in the presence of Cs2CO3 in CH3CN at 60 ºC, to 
furnish 3.4 and 3.5 in 79% and 87% isolated yields, respectively (Scheme 3.2).  
Utilizing the similar reaction conditions, sultams 3.6–3.9 were derived from various 
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    DIAD (1.3 eq)
    CH2Cl2, rt, 77%
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X = I or Br
R2
3.6, R2 = H, 98%
3.7, R2 = 4-Br, 71%
3.8, R2 = 4-NO2, 36%
3.9, R2 = 3-Me, 47%
(R)-3.3
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Sultam 3.3 was next subjected to acylation reactions with acyl chloride (1.1 
eq), Et3N (1.3 eq) in the presence of DMAP in CH2Cl2 at room temperature to afford 
desired products 3.10–3.16 in 18–98% yields.  In particular, the reactions with  
4-morpholinecarbonyl chloride as well as acryloyl chloride provided the 
corresponding products with good yields (98% and 86%, respectively) (Scheme 3.3). 
 
Scheme 3.3 
These studies were further extended with the application of the aza-Michael 
reaction onto sultam 3.3 to obtain a series of saturated 5-membered sultams.  In this 
method, only secondary cyclic amines were used as nucleophiles for the aza-Michael 
reaction since the purification with primary amines was problematic.  We are 
currently working to rectify this problem.  Therefore, we began the reaction with 
sultam 3.3 being subjected to the aza-Michael reaction with 2 equivalents of 































































reaction furnished the desired product 3.17 in 88% yield after purification.  Both 5- 
and 6-membered secondary cyclic amines underwent aza-Michael reaction with 
moderate yields, and the reaction provided a single isomer of product for each 
reaction due to the C3-stereogenic center of sultam 3.3 (Scheme 3.4).  
 
Scheme 3.4 
In addition to these results, sultam 3.17 derived from the aza-Michael reaction 
was further diversified via alkylation of the sultam nitrogen (Scheme 3.5).  N-Allyl 
sultam 3.25 was derived from the reaction with allyl bromide in the presence of 
Cs2CO3 in CH3CN at 60 ºC with 29% yield.  Benzyl derivatives 3.26–3.28 were 
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The free N–H of sultam 3.17 also underwent the acylation reaction with acyl 
chlorides, including benzoyl chloride and 4-nitrobenzoyl chloride, to afford the 




In addition to these earlier results, another application was developed utilizing 
γ-sultams 3.3 and 3.17 (Scheme 3.7).  The sultams were subjected to the 
propargylation under standard alkylation reaction conditions.  The alkynyl group 

































R1 Br (1.5 eq)
Cs2CO3 (1.5 eq)
CH3CN (0.1 M)
60 ºC, 12 h

































1,2,3-triazole compounds 3.32 and 3.34 in good isolated yields. 
 
Scheme 3.7 
Additionally, N-allylated α,β-unsaturated γ-sultam 3.5 was also subjected to 
the aza-Michael reaction with L-prolinol under standard reaction conditions, to 
generate the corresponding sultam 3.35 in 26% yield.  Because sultam 3.35 possesses 
a free alcohol, the allylation reaction was carried out to afford sultam 3.36 in 73% 
isolated yield (Scheme 3.8). 
 
Scheme 3.8 
Removal of the benzyl group provided a primary alcohol.  However, the 
product with free N–H could not be recovered from the reaction due to the 
compound’s increased solubility in water, we are currently trying to circumvent this 
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60 ºC, 12 h
Allyl-Br (1.5 eq)
10 mol% DBU
MeOH (1 M) 
60 ºC, 12 h
sealed tube
L-Prolinol (2 eq)
3.35, 26% 3.36, 73%3.5
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strategy.  Benzylated sultams 3.7 and 3.9 were treated with 2 equivalents of BCl3 at  
-78 ºC to obtain the primary alcohol-containing products 3.37 and 3.38 in moderate 
yields.  The reaction between an alcohol and phenyl isocyanate to obtain cyclized 
product was previously reported.6b  Based on this precedence each alcohol compound 
was subjected to reaction with phenyl isocyanate (1.1 eq) in the presence of Et3N (0.2 
eq) in CH2Cl2.  After 3.5 hours, none of the desired cyclized products were obtained; 
instead the corresponding uncyclized carbamate products 3.39 and 3.40 were isolated 
with good yields.  The propargylated sultam 3.31 was also treated with BCl3 to obtain 
 
Scheme 3.9 
primary alcohol 3.41 in 59% yield.  After [3+2]-cycloaddition with benzyl azide, 
sultam 3.42 containing a triazole moiety as well as a primary alcohol, was obtained in 
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Building upon these results, we next investigated the cyclization reaction 
including Diels-Alder and 1,3-dipolar cycloaddition with α,β-unsaturated γ-sultam to 
produce bi- and tricyclic sultams.  The Diels-Alder reaction provided bridged tricyclic 
sultams, while the 1,3-dipolar cycloaddition reaction furnished bicyclic sultams 
(Scheme 3.10).11  The cyclization began with cyclopentadiene (7 eq) in the presence 
of Et2AlCl (2 eq) in toluene at -78 ºC to yield bridged tricyclic sultam 3.43 in 36% 
yield (Scheme 3.10a).  Bicyclic sultam 3.44 was derived from cycloaddition reaction 
of sultam 3.3 with sarcosine (5 eq) and paraformaldehyde (12 eq) in the presence of 









































–78ºC to rt, 36%
a) Diels-Alder Route to Bridged Tricyclic Sultams






3.2.2  Diversification of 3,4-Dihydro-2H-1,2-thiazine 1,1-Dioxide Sultams 
During this investigation, α,β-unsaturated δ-sultams 3.51 and 3.52 were also 
prepared.  (S)-Trityl glycidyl ether underwent the epoxide ring opening reaction with 
trimethylsulfonium iodide (2.5 eq) in the presence of nBuLi (2.5 eq) at -30 ºC to 
provide the corresponding allylic alcohol.  The secondary alcohol was protected with 
either benzyl or p-methoxybenzyl group followed by deprotection of trityl group in 
the presence of pTsOH•H2O in methanol, to produce the primary alcohol 3.45 and 
3.46 in 21% and 48% yields, respectively.  The primary amine resulting from Gabriel 
amine synthesis was coupled with 2-chloroethanesulfonyl chloride under standard 
condition to generate vinyl sulfonamides 3.49 and 3.50 in moderate yields.  RCM in 
the presence of cat-B provided desired δ-sultams 3.51 and 3.52 in 63% and 73% 
yield, respectively (Scheme 3.11).  
 
Scheme 3.11 























i) Me3SI (2.5 eq)
   nBuLi (2.4 eq)
   THF, –30 ºC to rt
OR1
OH
ii) R1-Br (1.5 eq)
    NaH (3 eq), THF
iii) pTsOH•H2O 
    (0.1 eq), MeOH
i) Phthalimide (1 eq)
    PPh3 (1.3 eq)
    DIAD (1.3 eq)
    CH2Cl2, rt
ii) Hydrazine (1.5 eq)
    EtOH, 60 ºC, 0.5 h
3.45, R1 = Bn, 21% (3 steps)
3.46, R1 = PMB, 48% (3 steps)
3.47, R1 = Bn, 50% (2 steps)
3.48, R1 = PMB, 79% (2 steps)
3.49, R1 = Bn, 49%
3.50, R1 = PMB, 50%
3.51, R1 = Bn, 63% 




standard reaction conditions, to furnish sultam 3.53.  After propargylation, the 
alkynyl group underwent a simple [3+2]-cycloaddition reaction with benzyl azide to 
produce α,β-unsaturated δ-sultam 3.55 in 99% yield.  On the other hand, the δ-sultam 
3.54 was reacted with pyrrolidine followed by [3+2]-cycloaddition reaction under 




Furthermore, the α,β-unsaturated δ-sultam 3.52 was also subjected to 
alkylation and benzylation reactions. Allyl bromide, 2-fluoro and 3-fluorobenzyl 
bromides were used as coupling partners to afford the corresponding sultams (3.58–
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3.2.3  141-Member Library Production 
Based on the aforementioned aza-Michael reactions, we were able to produce 
a library of isothiazolidine 1,1-dioxides utilizing an RCM-aza-Michael protocol.  
 
Figure 3.3 Proposed diversification of core RCM-derived dihydroisothiazole 1,1-
dioxide scaffolds via intermolecular aza-Michael reaction. 
 
The ten core scaffolds of dihydroisothiazole 1,1-dioxides were synthesized from 
commercially available 2-chloroethane sulfonyl chloride (Table 3.1).  Key RCM 
precursors 3.61a–h were generated via a 2-step procedure where a variety of amines 
were sulfonylated followed by allylation to generate vinyl sulfonamides 3.61a–h in 
good yield and on multi-gram scale.  Cyclization of the precursors 3.61a–h via RCM 
utilizing metathesis catalyst [cat-B], 12 , 13  was successfully achieved yielding the 
desired cyclized dihydroisothiazole 1,1-dioxide derivatives 3.62–3.69 in excellent 
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CH3CN (0.1 M)



























R1 = H, Alkyl, Aryl, Cyclic
R2 = H, CH2OBn
R3 =  H, Alkyl, Aryl, Cyclic
Amines
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derivatives (R)-3.3 and (S)-3.3 possessing a chiral center alpha to the Michael 
acceptor were also used. 




Entry R1 Product Yield 
1 cyclopentyl 3.62 93 % 
2 nBu 3.63 98 % 
3 Bn 3.64 96 % 
4 4-F-Bn 3.65 95 % 
5 4-NO2-Bn 3.66 98 % 
6 (CH2)2Ph 3.67 96 % 
7 4-Me-Bn 3.68 93 % 
8 cyclohexyl 3.69  92 % 
 
With these scaffolds readily synthesized on gram-scale, the diversification of 
the dihydroisothiazole 1,1-dioxide cores was investigated.  Utilizing previously 
reported conditions developed within our group for intermolecular oxa- and aza-
Michael cyclizations,10 the diversification of 3.62 via an intermolecular aza-Michael 
with piperidine {11} and pyrrolidine {16} was investigated (Scheme 3.14).  This 
study initially focused on the screening of a range of conditions varying amine 

















 CH2Cl2, 0 ºC to rt
  ii. Allyl-Br
     K2CO3, CH3CN
     60 ºC, 2 – 4 h
80 - 91% over 2 steps
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DMF), concentration (0.5–2 M), temperature (rt–100 ºC), and heating platforms 
(thermal vs. microwave).  
 
 
Scheme 3.14 Optimization of aza-Michael conditions with amines {11} and {16} 
utilizing scaffold 3.62. 
 
A prototype library was investigated for the diversification of 
dihydroisothiazole 1,1-dioxide 3.66 with a variety of secondary amine nucleophiles 
under the optimized condition (Table 3.2).  Reactions were carried out in 1 dram vials 
on reaction blocks, whereby crude reaction mixtures were diluted in EtOAc, filtered 
through a silica SPE to remove excess amine and QC/purified by an automated 
preparative reverse phase HPLC (detected by mass spectroscopy).  The prototype 
library successfully generated all the desired products in good yield and excellent 
final purity after automated preparative reverse phase HPLC, with good crude purities 





    MeOH (1 M)
    60 ºC, 6 h
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i. {11} or {16} (1.5 eq)












Table 3.2  Prototype library utilizing dihydroisothiazole 1,1-dioxide 3.66. 
 
Entry Product Crude purity Yield 
Final 
purity 
1 3.66 {1} 94% 40% 100% 
2 3.66 {2} 89% 45% 100% 
3 3.66 {7} 89% 52% 100% 
4 3.66 {8} 71% 40% 96% 
5 3.66 {9} 84% 51% 96% 
6 3.66 {10} 91% 46% 99% 
7 3.66 {12} 99% 50% 100% 
8 3.66 {15} 83% 33% 96% 
9 3.66 {16} 93% 48% 100% 
aReaction conditions: Dihydroisothiazole 1,1-dioxide 3.66 (75 mg, 1 eq.), amine (1.5 
eq), DBU (10 mol%), dry MeOH (1 M), 60 ºC, 6h.  bPurified by an automated 
preparative reverse phase HPLC (detected by mass spectroscopy).  cPurity was 
determined by HPLC with peak area (UV) at 214 nm and % rounded up to nearest 
1%.   
 
With the successful synthesis of the 9-member prototype library, two libraries 
A and B were proposed for the synthesis of 144-isothiazolidine 1,1-dioxide 
derivatives utilizing scaffolds (R)- and (S)-3.3, as well as 3.62–3.69 and two sets of 
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Figure 3.4 Set of secondary amine nucleophiles for library synthesis. 
 
Utilizing the optimized conditions, library A (116-member) was generated 
utilizing scaffolds 3.62–3.69 and amine set A, followed by QC and purification using 
automated preparative reverse phase HPLC (detected by mass spectroscopy).  A total 
of 113 out of 116 compounds were prepared,14 with good overall yield and mass 
recovery with all compounds with final purity >90% after automated purification 
(Graph 3.1).15  
 
 

































A: Standard Nucleophile Set























Graph 3.1  Library A: aza-Michael of scaffolds 3.62–3.69.  
 
 
Upon completion of library A (116-member), library B (28-member) was 
generated utilizing scaffolds (R)-3.3 and (S)-3.3 with both amine set A and amine set 
B, followed by QC and purification using automated preparative reverse phase HPLC 
(detected by mass spectroscopy).  A total of 28 out of 28 compounds were prepared, 
with good overall yield with all compounds with final purity >90% after automated 
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3.3  Conclusions 
In conclusion, we have reported several reaction pathways to generate diverse 
sultam compounds using α,β-unsaturated sultams generated from RCM.  Utilizing 
aza-Michael reaction, we have developed an efficient protocol for synthesis of a 141-
member collection of isothiazolidine 1,1-dioxide derivatives.  Utilizing RCM of vinyl 
sulfonamides, ten dihydroisothiazole 1,1-dioxide core scaffolds were generated on 
gram-scale followed by efficient diversification utilizing an aza-Michael protocol 
with a variety of secondary amines.  A 144-member was undertaken with 141/144 
successfully yielding the desired products after automated preparative reverse phase 
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have been submitted to a number of biological collaborators within the NIH 
Molecular Libraries Probe Center Network (MLPCN) for evaluation of their 
biological activity in high-throughput screening. 
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Intramolecular C-Arylation to Tricyclic, Biaryl Sultams:  
Long-range Asymmetric Induction in an Atropdiastereoselective, 












4.1  Introduction 
4.1.1 Biaryl, Axially Chiral Compounds and Atropselectivity 
Biaryl small molecules displaying axial chirality have surfaced as key 
scaffolds in early phase drug discovery.1  The presence of axial chirality in biaryl 
systems is the consequence of hindered rotation around the biaryl bond when ortho 
substituents are present in both ring systems.  Recently, LaPlante and coworkers 
addressed the importance of atropisomers and provided a practical computational 
guideline for them in drug discovery and development that is dependent on rotation 
energy barriers and interconversion half-lives.1  A number of prominent examples 
have emerged in recent years, including: acyclic biaryl compounds such as 
quinoxalinedione (4.1, Figure 4.1), korupensamine A (4.2), BMS-207940 (4.3),  
 


















































































the cyclic biaryl compounds HIV integrase inhibitor (4.4), LY-411575 (4.5), 
benzomalvin (4.6), steganacin (4.7), and telenzepine (4.8).2  In response to this 
impressive biological activity, a number of elegant methods have been reported for 
atropselective synthesis of axially chiral biaryl compounds.  In general, three 
strategies have been utilized in the field to produce atropisomeric biaryl compounds: 
(i) resolution of stereochemically undefined (racemic/diastereomeric) biaryls, 3  
(ii) direct asymmetric biaryl coupling,4 and (iii) atropselective biaryl synthesis by 
construction of the second aromatic ring.5 
We now report a remarkable intramolecular C-arylation process of the 
triazole-containing tertiary sulfonamide 4.9a (Scheme 4.1) leading to a novel class of 
tricyclic, biaryl sultam 4.9b possessing benzothiazepine (n = 1)/benzothiazocine (n = 
2) 1,1-dioxides and triazole subunits.  These unique structures were designed with 
hopes of bringing the synergies between bioactive benzothiazepine/benzothiazocine 
1,1-dioxides, 1,2,3-triazoles, and biaryl compounds which all have received much 
attention over the past decade and found wide application in medicinal chemistry 

























1,4-Benzodiazepines fused to five-membered heterocycles are well-known 
drugs for the treatment of central nervous system (CNS) disorders.6  Alprazolam 
(4.10) is common anxiolytic agent,7 flumazenil (4.11) belongs to the family of 
cognition enhancers,8 while G-7453 (4.12) has been reported as a potential fibrinogen 
antagonist.9  
 
Figure 4.2 Representative 1,4-benzodiazepine compounds. 
1,2,3-Triazole compounds exhibited various biological activities including 
anti-HIV activity10,11 and antimicrobial activity against Gram-positive bacteria.12  The 
cycloaddition reaction between azides and alkynes is one of the most widely used 
approaches to 1,2,3-triazoles.  More specifically, the Huisgen’s 1,3-dipolar [3+2]-
cycloaddition of azide and alkynes is undoubtedly the most widely used method to 
synthesize 1,2,3-triazoles, whereby Cu(I)-catalyst,13 and Ru(II)-catalyst14 can now be 
utilized to regioselective generate 1,4- or 1,5-disubstituted triazoles, respectively.  A 
unique class of triazole-containing benzodiazepines were produced by Thomas who 
reported a one-pot alkyne-azide cycloaddition reaction starting from readily available 
anthranilic acids to derive 4.13 in an overall C–N bond forming process [Scheme 4.2 



























diazotization/azidation followed by cycloaddition reaction to afford the unique 
triazole-containing benzodiazepine compounds 4.14 [Scheme 4.2 (b)].15  Previously 
we reported the generation of a triazole-containing sultam using SNAr, followed by a 
[3+2]-cycloaddition between the alkyne and azide, to construct the tricyclic, biaryl 
sultam 4.15 [Scheme 4.2 (c)].16   
 
Scheme 4.2  (a) and (b) Representative examples for preparation of 
benzodiazepines.  (c) Generation of thiadiazepine 6,6-dioxide.   










1. i) NaNO2, HCl
    ii) NaN3, toluene
2. Propargylamine










































































(d) In this work
4.15
4.9bR3




C-Arylation is a well-known alternative method for functionalization of 1,2,3-
triazole compounds.  In 2007, Gevorgyan and coworkers reported a method to 
synthesize multi-substituted 1,2,3-triazoles via Pd-catalyzed C-5 arylation between 
1,2,3-triazoles and aryl bromides in an overall C–C bond forming process.17  In 
contrast, Potukuchi and coworker showed examples using Pd-catalyzed 
intramolecular oxidative arylation for synthesis of hetero-annulated triazoles using a 
C–C bond forming process.18   
The work presented herein utilizes C-arylation of a substituted triazole as a 
strategy to generate a novel class of tricyclic, biaryl sultams [Scheme 4.2 (d)].  In the 
course of X-ray crystallographic analysis of product sultams within a series of 
analogs, as well as detailed NMR studies, vide infra, we have uncovered a number of 
notable and interesting structural features in both solid and solution phases that will 
be described throughout the chapter.  Namely, in the amino ester-derived sultams, 
remote 1,5- and 1,6-asymmetric induction emanating from the external stereogenic 
center is operative, whereby a favorable Cα–H/S=O syn pentane interaction, is  
 
Figure 4.3 
believed to be the source of asymmetric induction for a highly atropdiastereoselective 































configuration (S,Sa).  This chapter will initially describe the synthesis of all analogs 
before discussing the X-ray and NMR studies that have led to these conclusions. 
 
4.2  Result and Discussion 
4.2.1 Synthesis of 7-Membered Tricyclic, Biaryl Sultams Derived from  
tert-Butylamine 
  Initial investigations focused on the generation of the  
7-membered benzofused tricyclic, biaryl sultam using a simple alkylamine starting 
material.  For each reaction, two different 2-bromobenzenesulfonyl chlorides, as well 
as three azides [benzyl azide, 4-methylbenzyl azide and cyclohexylmethyl azide], 
were employed to generate the desired triazole-containing benzenesulfonamides.  
Commercially available 2-bromobenzenesulfonyl chloride was coupled with tert-
butylamine under standard conditions (Et3N and CH2Cl2 at rt) to provide the 
corresponding secondary benzenesulfonamides. 
 
Scheme 4.3   
 After propargylation (propargyl bromide, Cs2CO3 in CH3CN at 60 ºC), the 







CH2Cl2, rt, 12 h
b) Propargyl-Br 
    (1.2 eq)
    Cs2CO3 (1.2 eq)
    CH3CN (0.1 M)















4.16, R1 = H, R2 = Ph, 66% (3 steps)
4.17, R1 = H, R2 = 4-CH3-Ph, 68% (3 steps)
4.18, R1 = H, R2 = Cy, 71% (3 steps)
4.19, R1 = F, R2 = Ph, 77% (3 steps)
4.20, R1 = F, R2 = 4-CH3-Ph, 87% (3 steps)







reaction in the presence of CuSO4•5H2O (0.2 eq) and (+)-sodium L-ascorbate (0.3 eq) 
in tBuOH/CH2Cl2/H2O (1:1:1, 0.2 M) at rt.  Under these reaction conditions, a single 
regioisomer of 4.16–4.18 was obtained in good yields (66–71%).  Using the same 
pathway, 2-bromo-4-fluorobenzenesulfonyl chloride was also converted to tertiary 
benzenesulfonamides 4.19–4.21 in good yields (77–87% overall yields for 3 steps, 
Scheme 4.3). 
With triazole-containing, tertiary sulfonamides 4.16–4.21 in hand, C-arylation 
was carried out using catalytic Pd(OAc)2 (10 mol%) and Bu4NOAc (2 eq) as a base,  
in N-methylpyrrolidone (NMP) (0.5 M) at 110 ºC for 17 hours, to furnish the 
corresponding 7-membered sultams (Scheme 4.4).  C-Arylation of 
benzenesulfonamides 4.16–4.18 provided 7-membered tricyclic, biaryl sultam 
compounds 4.22–4.24 in 78–99% isolated yields.  4-Fluoro-substituted, benzofused 
7-membered sultams 4.25–4.27 were produced from benzenesulfonamide precursors 
4.19–4.21.  The exchange of catalytic Pd(OAc)2 with Pd(PPh3)4 or Pd(PPh3)2Cl2 also 
provided similar isolated yields.  
 
Scheme 4.4   
 
4.22, R1 = H, R2 = Ph, 99% 
4.23, R1 = H, R2  = 4-CH3-Ph, 78% 
4.24, R1 = H, R2 = Cy, 84%
4.25, R1 = F, R2  = Ph, 99% 
4.26, R1 = F, R2  = 4-CH3-Ph, 83% 






















4.2.2 Synthesis of 7-Membered Tricyclic, Biaryl Sultams Derived from Chiral, 
Non-racemic Amino Esters 
The effect of an amino ester-derived external chiral center on the C-arylation 
process was next investigated.  Using the same reaction sequence, a series of  
2-bromobenzenesulfonamides were produced using L-valine methyl ester 
hydrochloride, as well as L-leucine methyl ester hydrochloride. 
Table 4.1   
 
Entry R1 R2 R3 Product Yield  
1 H iPr Ph 4.28 99% 
2 H iPr 4-CH3-Ph 4.29 99% 
3 H iPr Cy 4.30 72% 
4 H iBu Ph 4.31 85% 
5 H iBu 4-CH3-Ph 4.32 85% 
6 H iBu Cy 4.33 69% 
7 F iPr Ph 4.34 99% 
8 F iPr 4-CH3-Ph 4.35 77% 
9 F iPr Cy 4.36 70% 
10 F iBu Ph 4.37 94% 
11 F iBu 4-CH3-Ph 4.38 97% 





BrR1 Et3N (2 eq)CH2Cl2, rt, 12 h
b) Propargyl-Br (1.2 eq)
    Cs2CO3 (1.2 eq)
    CH3CN (0.1 M)

























2-Bromobenzenesulfonyl chloride was coupled with L-valine methyl ester 
hydrochloride, followed by propargylation and [3+2]-cycloaddition reaction, under 
standard reaction conditions, to obtain the desired tertiary benzenesulfonamides 4.28–
4.33 in good isolated yields (69–99%).  2-Bromo-4-fluorobenzenesulfonyl chloride 
was also converted to the corresponding secondary benzenesulfonamides and then 
treated with propargyl bromide.  After Huisgen [3+2]-cycloaddition reaction with 
three azides, the reactions furnished the tertiary 2-bromobenzenesulfonamides (4.34–
4.39) (Entries 7–12, Table 4.1). 
Each benzenesulfonamide was subjected to the C-arylation reaction in the 
presence of Pd(OAc)2.  The results are summarized in Table 4.2.  Both triazole 
containing valine (R2 = iPr) and leucine (R2 = iBu) methyl ester benzenesulfonamide 
analogues underwent C-arylation reaction with Pd(OAc)2 and Bu4NOAc in NMP at 
110 ºC to furnish 7-membered tricyclic sultams 4.40–4.45 with moderate to good 
yields (Entries 1–6, Table 4.2).  2-Bromo-4-fluorobenzenesulfonamides (4.46–4.51) 
were converted to the corresponding tricyclic sultams under the Pd-catalyzed  
C-arylation reaction conditions in 25–86% yields (Entries 7–12, Table 4.2).  
Surprisingly, the glycine ethyl ester derivative did not undergo C-arylation and the  
L-alanine methyl ester analogues did not reach completion under the same reaction 




Table 4.2  
 
Entry R1 R2 R3 Product Yield  
1 H iPr Ph 4.40 67% 
2 H iPr 4-CH3-Ph 4.41 54% 
3 H iPr Cy 4.42 66% 
4 H iBu Ph 4.43 60% 
5 H iBu 4-CH3-Ph 4.44 33% 
6 H iBu Cy 4.45 48% 
7 F iPr Ph 4.46 34% 
8 F iPr 4-CH3-Ph 4.47 31% 
9 F iPr Cy 4.48 36% 
10 F iBu Ph 4.49 25% 
11 F iBu 4-CH3-Ph 4.50 86% 
12 F iBu Cy 4.51 51% 
 
4.2.3 Synthesis of 8-Membered Tricyclic, Biaryl Sultams Derived from Chiral, 
Non-racemic Amino Esters 
With the previous results in hand, we extended the C-arylation reaction to 
access tricyclic, biaryl sultams of larger ring size.  3-Butyn-1-ol was used to introduce 
a distal homopropargyl group for ring extension.  After sulfonylation with the 
























110 ºC, 17 h
sealed tube
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2-bromobenzenesulfonamide was subjected to Mitsunobu reaction conditions  
[3-butyn-1-ol, DIAD, Ph3P, CH2Cl2, rt] to achieve homopropargyl 
benzenesulfonamides (4.52–4.54).  Huisgen [3+2]-cycloaddition with three different  
Table 4.3  
 
 
Entry R1 R2 R3 Product Yield   
1 H iPr Ph 4.55 78% 
2 H iPr 4-CH3-Ph 4.56 82% 
3 H iPr Cy 4.57 81% 
4 H iBu Ph 4.58 98% 
5 H iBu 4-CH3-Ph 4.59 98% 
6 H iBu Cy 4.60 86% 
7 F iPr Ph 4.61 99% 
8 F iPr 4-CH3-Ph 4.62 88% 
9 F iPr Cy 4.63 98% 
 
Et3N (2 eq)

















b) 3-butyn-1-ol (2 eq)


















4.52, R1 = H, R2 = iPr, 84%
4.53, R1 = F, R2 = iPr, 91%
4.54, R1 = H, R2 = iBu, 52%
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azides provided corresponding 1,2,3-triazole-containing benzenesulfonamides  
4.55– 4.60 in good isolated yields (Entries 1–6, Table 4.3).  
With the successful generation of scaffolds, the C-arylation reactions were 
carried out with 4.55–4.63 to produce 8-membered sultams in the presence of  
Pd-catalyst.  The results for C-arylation of L-valine (R2 = iPr) methyl ester analogues 
were summarized in Table 4.4.  The 2-bromobenzenesulfonamides 4.55–4.57 and 
4.61–4.63 were subjected to C-arylation reaction under standard reaction condition.  
8-Membered tricyclic sultams 4.64–4.66 were produced in 54–67% isolated yields.  
The 4-fluoro substituted benzenesulfonamides 4.61–4.63 were also converted to  
8-membered sultams in 31–36% isolated yields.  The 1H NMR spectra of these 
isolated products showed the mixture of two inseparable compounds with ~10:1 ratio. 
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Table 4.4  
 
 
Entry R1 R2 Product Yield  Ratio
a 
major:minor 
1 H Ph 4.64 67% ~10:1 
2 H 4-CH3-Ph 4.65 54% ~10:1 
3 H Cy 4.66 66% ~10:1 
4 F Ph 4.67 34% ~10:1 
5 F 4-CH3-Ph 4.68 31% ~10:1 
6 F Cy 4.69 36% ~10:1 
a Ratio was determined from 1H NMR spectra. 
 
The C-arylation reactions to obtain 8-membered tricyclic, biaryl sultams 
derived from L-leucine methyl ester were next performed.  Interestingly, all three 
reactions provided a 2:1 mixture of cyclized, inseparable products as evident by 1H 
NMR (Table 4.5).  The nature of this 2:1 mixture will be discussed at the end of this 
























Table 4.5   
 
Entry R1 Product Yield 
Ratioa 
major:minor 
1 Ph 4.70 60% ~2:1 
2 4-CH3-Ph 4.71 33% ~2:1 
3 Cy 4.72 48% ~2:1 
 a Ratio was determined from 1H NMR spectra. 
 
4.2.4 Further Synthetic Applications of C-Arylation  
Based on previous results, several N-alkyl substituted 7-membered sultam 
compounds were also obtained from this C-arylation reaction process.  The tertiary  
2-bromobenzenesulfonamides 4.73–4.76 were prepared with methyl, ethyl, isopropyl 
and cyclopropyl groups in good isolated yields (82–98% over 3 steps).  The triazole-
containing, tertiary benzenesulfonamides were converted to the 7-membered tricyclic 
sultams 4.77–4.80, in the presence of Pd(PPh3)4 catalyst, in 72–88% isolated yields 
(Scheme 4.5).  Because Mitsunobu alkylation, as well as homopropargylation, did not 





















110 ºC, 17 h
sealed tube
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8-membered sultams was not possible via this particular reaction sequence.  The 
origins of these failed reactions are not clear at this time. 
 
Scheme 4.5 
A 7-membered tricyclic sultam (4.82) derived from a chiral, non-racemic 
amino alcohol was also synthesized.  TBS-protected L-valinol was synthesized from 
L-valine over 2 steps.  TBS-protected 2-bromobenzenesulfonamide 4.81 was 
subjected to cyclization reaction in the presence of Pd(OAc)2 to obtain the desired 
sultam 4.82 in 47% yield as a primary alcohol resulting from deprotection of TBS 
group during the reaction (Scheme 4.6). 
H2Na)
b) R-I (3 eq)
    Cs2CO3 (1.2 eq)
    CH3CN (0.1 M) 




























a) RNH2 (1.2 eq)
    Et3N (2 eq)
    CH2Cl2, rt, 12 h
Cs2CO3 (1.2 eq)
CH3CN (0.1 M) 
60 ºC, 12 h
(±)
4.77, R = Me, 78% 
4.78, R = Et, 80%
4.79, R = iPr, 88%
4.80, R = Cyclopropyl, 72%
4.73, R = Me, 98% (3 steps)
4.74, R = Et, 86%  (3 steps)
4.75, R = iPr, 98%  (3 steps)
4.76, R = Cyclopropyl, 82% (3 steps)
R = iPr, Cyclopropyl















The 7- and 8-membered tricyclic sultams containing a phenyl-substituted 
triazole were also produced using this C-arylation pathway.  The secondary  
2-bromobenzenesulfonamides were prepared using the same reaction sequences from 
the previous reaction.  The phenyl azide was prepared freshly starting from aniline in 
3 steps.19  Huisgen [3+2]-cycloaddition reactions were performed under standard 
reaction condition as mentioned earlier to provide the corresponding 








CH2Cl2, rt, 12 h
CH3CN (0.1 M)



































(1:1:1, 0.2 M), rt, 12 h
30% (over 5 steps)
v) (2 eq)












Entry R1 n Product Yielda 
1 iPr 1 4.87 60% 
2 iBu 1 4.88 46% 
3 iPr 2 4.89 44% (~ 10:1)b 
4 iBu 2 4.90 49% (~ 2:1)b 
a based on recovered starting material; bRatio (major:minor) was determined 
from 1H NMR. 
 
7-Membered tricyclic compounds 4.87 and 4.88 were obtained from  
Pd-catalyzed C-arylation in 60% and 46% yields based on recovered starting 
materials, respectively (Entries 1 and 2, Table 4.6).  In contrast, cyclization reactions 
to 8-membered 4.89 and 4.90 gave a mixture of inseparable products in a similar ratio 
to that seen in the benzyl-substituted triazoles, vide supra.  The ratio between major 






























4.83, R1 = iPr, n = 1, 21% (3 steps)
4.84, R1 = iBu, n = 1, 78% (3 steps)
4.85, R1 = iPr, n = 2, 90%  
4.86, R1 = iBu, n = 2, 95%
Et3N (2 eq)








(1:1:1, 0.2 M), rt, 12 h
b) Propargyl-Br (1.2 eq)
    Cs2CO3 (1.2 eq)
    CH3CN (0.1 M)
    60 ºC, 12 h
b) 3-butyn-1-ol (2 eq)
    DIAD (2 eq)
    Ph3P (2 eq)
    CH2Cl2 (0.1 M)




ratio for L-leucine methyl ester, respectively, as observed by 1H NMR.  It is worth 
noting that the similarity in the ratio of products (10:1 and 2:1) in the benzyl- and 
phenyl-substituted triazoles was the same for 4.64 and 4.70. 
Study on the C-arylation of regioisomeric, 1,5-triazole benzenesulfonamide 
4.91 was also performed.  1,5-Triazole benzenesulfonamide 4.91 was prepared in the 
presence of CpRuCl(PPh)3 catalyst.14b  The 1,5-triazole benzenesulfonamide 4.91 was 
obtained in 31% isolated yield as a minor product and the reaction still provided the 
1,4-triazole benzenesulfonamide 4.28 as a major product (44% isolated yield).  The 
1,5-triazole benzenesulfonamide 4.91 was subjected to standard cyclization reaction 
generating the corresponding 7-membered tricyclic sultam 4.91 in 13% yield.  We 











































4.2.5 X-ray and NMR Studies on Tricyclic, Biaryl Sultam Compounds 
4.2.5.1 X-ray Structures 
Among the series of tricyclic sultam compounds, several X-ray structures 
were obtained, with six of them presented in Figure 4.4.  Several interesting structural 
characteristics were noted from these X-ray structures.  Firstly, all six X-ray 
structures show the aforementioned axis of chirality between the benzene ring and the 
triazole ring in the solid phase.  In addition, all amino ester-derived systems displayed 






















































angle 29.7 º dihedral 
angle 33.9 º
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of chirality [and not “unlike” (S,Ra)].  Based on these structures, we also noticed the 
methyl group of the ester functionality (CO2Me) was consistently positioned in a 
rotamer which placed it underneath the sultam benzene ring in all structures.  This 
position is in agreement with anisotropic shielding by the phenyl group resulting in a 
notable upfield chemical shift of the methyl ester resonance (3.1–3.2 ppm) in its 
NMR spectrum, vide infra.  Additionally, dihedral angles between two aryl rings are 
different depending on ring size as well as the triazole substituent.  The dihedral angle 
of the 7-membered tricyclic sultam derived from L-leucine methyl ester was observed 
to be 34º.  However, the dihedral angle for the 8-membered sultam 4.64 is 
approximately 60º.  The dihedral angles for sultams with the phenyl group on the 
triazole (4.87 and 4.89) are bigger than the benzyl derivatives for both 7- and 8-
membered sultams (Figure 4.4).  
 
4.2.5.2 NMR Studies 
 The chemical shifts of the methyl ester, the α-proton of the ester, and the two 
methyl groups within R1 for the L-valine- and L-leucine-derived 7-membered sultams 
4.40–4.45, 4.87 and 4.88 at room temperature are displayed in Table 4.7 (spectra are 
contained in the experimental section).   
 From this table, it can be seen that the average chemical shift of the α-proton 
of the ester is approximately 3.9 ppm and 4.5 ppm for the L-valine (R1 = iPr) and  
L-leucine (R1 = iBu) derivatives, respectively.  Of notable importance, the chemical 
shift of the L-valine methyl esters (R1 = iPr) occurs at approximately 3.1 ppm, while 
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the corresponding L-leucine methyl esters (R1 = iBu) occurs at approximately 3.3 ppm.  
These values are consistent with the aforementioned anisotropic shielding by the 
phenyl group, and when combined with the X-ray data, substantiates the existence of 
a preferred rotamer about the N–C bond in solution phase. 
Detailed 1H NMR studies at room temperature were next carried out on the  
8-membered sultams 4.64 and 4.70 since the C-arylation reaction leading to both 
provided inseparable mixtures of products for which no X-rays could be obtained in 
the L-leucine-derived sultams (2:1 mixtures).  We initially noticed a difference in the 
chemical shifts of the methyl ester resonance of the compound mixture for the L-
valine- and L-leucine-derived sultams, 4.64 and 4.70, respectively.  The minor isomer 
occurs at 3.73 ppm in 4.64 and 3.76 ppm in 4.70, while the major isomer displays 
upfield chemical shifts of 3.19 ppm and 3.25 ppm for 4.64 and 4.70, respectively.  
For comparison purposes, detailed chemical shifts of particular protons from 




Table 4.7 1H NMR chemical shift data for the L-valine- (R1= iPr) and L-leucine-
derived (R1= iBu), 7-membered sultams (single isomers, CDCl3). 
 
 









iPr Bn 4.40 5.82, 5.54 5.07, 5.02 3.92 3.10 1.05 0.91 
iPr 4-Me-Bn 4.41 5.78, 5.48 5.06, 5.01 3.92 3.10 1.05 0.91 
iPr Cy-CH2- 
4.42 4.41, 4.29 5.02, 4.94 3.94 3.16 1.04 0.91 
iPr Ph 4.87 n/a 5.15, 5.10 3.93 3.11 1.08 0.92 
iBu Bn 4.43 5.82, 5.60 4.93, 4.83 4.57 3.32 0.95 0.93 
iBu 4-Me-Bn 4.44 5.75, 5.53 4.91, 4.81 4.56 3.30 0.93 0.91 
iBu Cy-CH2- 
4.45 4.40, 4.32 4.84, 4.74 4.58 3.34 0.94 0.92 
iBu Ph 4.88 n/a 5.01, 4.94 4.55 3.32 0.94 0.93 
 
The representative chemical shifts of the 8-membered, L-valine-derived 
sultams 4.64–4.66 and 4.89 (which were all ~10:1 mixtures) are also summarized in 
Table 4.8.  From Table 4.8, we noticed the aforementioned, significant chemical shift 
















The chemical shifts of the methyl ester for each major isomer occur around ~3.2 ppm, 
while the minor isomers appear near ~3.7 ppm.  This notable 0.5 ppm difference in 
methyl ester chemical shifts between major and minor isomers is augmented in an 
additional significant, but opposite, chemical shift trend for the two methyl groups in 
the alkyl side-chain (R1 = iPr) of 4.64, whereby the major isomer occur further 
downfield (1.02/0.92 ppm) and the minor compound further upfield (0.85/0.41 ppm).  
These opposing trends continue for compounds 4.65, 4.66 and 4.89 as well as for the 
2:1 mixtures seen in all of the L-leucine-derived, 8-membered, tricyclic sultams 
(4.70–4.72 and 4.90) outlined in Table 4.9.  Based on these chemical shift trends, we 
propose a major anisotropic shielding effect by the sultam benzene ring on both the 
methyl ester of the major isomer and the two diastereotopic methyl groups within 
each alkyl side chain of the minor isomer.  
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Table 4.8  1H NMR chemical shift data for the L-valine-derived, 8-membered 
sultams (major:minor = 10:1, CDCl3). 
 
  α-H CO2CH3 2(CH3) 











Bn 4.64 4.00 4.07 3.19 3.73 1.02 0.92 0.85 0.41 
4-Me-Bn 4.65 4.00 4.07 3.18 3.73 1.02 0.92 0.85 0.41 
Cy-CH2- 4.66 4.06 4.13 3.22 3.74 1.04 0.93 0.87 0.45 

















Table 4.9  1H NMR chemical shift data for the L-leucine-derived, 8-membered 
sultams (major:minor = 2:1, CDCl3). 
 
 
  α-H CO2CH3 2(CH3) 











Bn 4.70 4.60 4.52 3.25 3.76 0.99 0.98 0.70 0.69 
4-Me-
Bn 4.71 4.60 4.53 3.24 3.76 0.99 0.98 0.71 0.69 
Cy-
CH2- 
4.72 4.66 4.58 3.28 3.76 1.01 0.99 0.73 0.72 
Ph 4.90 4.72 4.65 3.29 3.80 1.03 1.01 0.75 0.74 
 
The aforementioned opposing chemical trends in the major and minor isomers 
of the 2:1 inseparable mixtures, contained in Table 4.9, led us to perform a detailed 
1D selective NOESY (Nuclear Overhauser Effect Spectroscopy) and ROESY 
(Rotating frame Overhauser Effect Spectroscopy) experiments on sultam 4.70 in 
order to uncover the identity of the major/minor isomers produced in the cyclization 
reactions leading to the L-leucine-derived, 8-membered sultams.   
Given the molecular mass of these molecules, the NOESY and ROESY 
should be equivalent, though, in our hands, the signal-to-noise ratio is higher in the 















recorded with various mixing times (50-500 ms) and offset of the selective pulse are 
summarized in Figure 4.5.  The arrow indicates a signal enhancement of the 
resonance at the tip of the arrow upon selective inversion of the resonance at the end 
of the arrow.  As shown below, selective inversion of the aromatic proton at C7 
results in enhancement of the methyl ester of the major product, the amino ester  
δ-proton residing in the alkyl side chain of the minor product, and the amino ester  
α-proton in both observed isomers. This result is consistent with the opposing 
anisotropic effects seen in the 1H NMR trends outlined above, as well as the X-ray 
data highlighted in Figure 4.4.  Taken collectively, these experimental findings 
identify the 2:1 mixture in the L-leucine-derived 8-membered sultam systems as a 
distribution of rotamers about the exocyclic N–Cα bond.  
 
Figure 4.5   ROESY results for sultam 4.70. 
Though the X-ray structures show an axis of chirality between the benzene 
and triazole moieties of each sultam, data obtained from the previously described 
room temperature 1H NMR studies were insufficient to confirm or deny the existence 
of a single atropdiastereomer or the rapid interconversion between two conformers of 







































both the L-valine-derived and L-leucine-derived 7-membered sultams, both 
extremes—high energy barrier or low energy barrier—could be operative.  Thus, 
several temperature-variable NMR experiments, involving a variety of sultam 
substrates, were conducted to quantitate the energy barrier associated with this 
interconversion of atropdiastereomers. 
The first assumption was that the energy barrier is very low and thus lowering 
the temperature will affect the rate of atropdiastereomer interconversion with a 
chance to observe resonance splitting corresponding to the “unlike” conformer (S,Ra).  
The first low temperature NMR study was carried out using L-valine-derived,  
7-membered sultam 4.40 in acetone-d6 as a NMR solvent and overlay spectrum 






Figure 4.6 Overlay from low temperature NMR study (4.40, Acetone-d6). 
  
 The representative chemical shifts from low temperature NMR studies are 
summarized in Tables 4.10A and 4.10B.  As shown below, while temperatures were 
lowered to -85 ºC, no peak splitting or significant peak broadening was observed 



































Table 4.10A  1H NMR chemical shift data from low temperature NMR studies for 
















25 ºC 5.96 5.81 5.05 4.91 3.82 3.10 1.03 0.89 
10 ºC 5.98 5.82 5.07 4.92 3.76 3.05 1.03 0.86 
0 ºC 6.00 5.83 5.09 4.92 3.73 3.02 1.03 0.85 
-10 ºC 6.00 5.83 5.10 4.92 3.71 3.01 1.03 0.84 
-20 ºC 6.01 5.83 5.11 4.93 3.69 2.95 1.02 0.83 
-30 ºC 6.02 5.84 5.12 4.93 3.66 2.98 1.02 0.82 
-40 ºC 6.03 5.84 5.13 4.93 3.64 2.95 1.03 0.81 
-50 ºC 6.03 5.84 5.15 4.93 3.64 2.93 1.04 0.81 
-60 ºC 6.05 5.85 5.17 4.94 3.60 2.90 1.04 0.80 
-75 ºC 6.05 5.84 5.18 4.94 3.59 2.89 1.04 0.78 
















Table 4.10B 1H NMR chemical shift data from low temperature NMR studies for 











25 ºC 7.97 7.57 7.71 7.79 
10 ºC 7.97 7.58 7.72 7.79 
0 ºC 7.97 7.60 7.74 7.80 
-10 ºC 7.97 7.60 7.74 7.80 
-20 ºC 7.97 7.60 7.75 7.80 
-30 ºC 7.97 7.61 7.75 7.80 
-40 ºC 7.97 7.61 7.76 7.80 
-50 ºC 7.98 7.62 7.76 7.80 
-60 ºC 7.98 7.62 7.76 7.79 
-75 ºC 7.98 7.62 7.76 7.78 
-85 ºC 7.99 7.63 7.78 7.79 
 
Since no absolute conclusions could be drawn from the low temperature NMR 
studies discussed above, we moved onto the high temperature NMR studies with 
sultam 4.40.  In order to verify that thermodynamic equilibration had been fully 
achieved, the sample was heated for 24 hours at 210 ºC in benzene-d6, cooled to room 














change in the spectrum indicating that thermodynamic equilibration had fully 
proceeded.  In addition, detailed chemical shift trends for temperatures up to 125 ºC 
are highlighted in Tables 4.10A and 4.10B.  From this experiment we noted peak 
shifting as a function of temperature.  The difference of chemical shift for the methyl 
group is 0.23 ppm between room temperature and 125 ºC.  In addition, the resonance 
of the α-proton shifted downfield at 125 ºC. 
 
Table 4.11A 1H NMR chemical shift data from high temperature NMR studies for 

















25 ºC 5.94 5.84 5.00 4.86 3.73 3.05 0.93 0.82 
35 ºC 5.93 5.83 4.98 4.85 3.76 3.08 0.94 0.83 
45 ºC 5.92 5.82 4.97 4.85 3.80 3.11 0.94 0.85 
55 ºC 5.91 5.82 4.95 4.84 3.83 3.14 0.95 0.87 
65 ºC 5.90 5.81 4.95 4.84 3.86 3.18 0.95 0.88 














85 ºC 5.88 5.80 4.93 4.83 3.91 3.21 0.96 0.90 
95 ºC 5.88 5.80 4.92 4.83 3.94 3.23 0.96 0.91 
115 ºC 5.86 5.79 4.92 4.82 3.98 3.26 0.97 0.93 
125 ºC 5.85 5.79 4.91 4.82 4.01 3.28 0.94 0.98 
 
The distances between the AB quartet corresponding to each benzylic CH2, as well as 
the C3-CH2, also slightly decreased with increasing temperature (Table 4.11A) 
indicating no coalescence up to a temperature of 125 ºC.  The chemical shifts for the 
four aromatic methine protons residing on C6–C9 are highlighted in Table 4.11B.  As 
noted, only small variations of chemical shift were observed between rt and 125 ºC.   
 
Table 4.11B 1H NMR chemical shift data from high temperature NMR studies for 












25 ºC 7.90 7.56 7.71 7.85 
35 ºC 7.90 7.56 7.71 7.84 














55 ºC 7.91 7.56 7.70 7.82 
65 ºC 7.92 7.56 7.70 7.81 
75 ºC 7.92 7.56 7.69 7.80 
85 ºC 7.93 7.56 7.69 7.80 
95 ºC 7.93 7.55 7.69 7.79 
115 ºC 7.94 7.55 7.68 7.78 
125 ºC 7.94 7.55 7.68 7.77 
 
Taken collectively, with the aforementioned low temperature studies, only 
minor variations of chemical shift were observed between temperatures ranging from 
-85 ºC to 125 ºC, and thus we postulate that the energy barrier of interconversion lies 
below 10 kcal/mol.20 
 With these studies in hand, we next performed high temperature NMR studies 
using the 2:1 mixture of rotamers in the 8-membered sultam 4.70.  Several 1H NMR 
spectra were obtained between room temperature and 95 ºC (Table 4.12).  While the 
diastereotopic benzylic CH2 protons of the major compound coalesced at 65 ºC, no 
other coalescence was observed (Table 4.12). 
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Table 4.12 1H NMR chemical shift data from high temperature NMR studies for 






















25 ºC 5.51, 5.46 5.75, 5.50 4.51 4.38 3.20 3.69 0.93 0.66, 0.63 
45 ºC 5.51, 5.46 5.73, 5.50 4.52 4.39 3.21 3.69 0.94 0.67, 0.64 
55 ºC 5.50, 5.46 5.72, 5.49 4.52 4.39 3.22 3.69 0.95 0.68, 0.65 
65 ºC 5.47 (s) 5.70, 5.49 4.52 4.39 3.23 3.70 0.95 0.68, 0.66 
75 ºC 5.47 (s) 5.69, 5.49 4.52 4.40 3.24 3.70 0.95 0.70, 0.67 
85 ºC 5.47 (s) 5.68, 5.48 4.52 4.41 3.24 3.70 0.96 0.70, 0.68 
95 ºC 5.47 (s) 5.67, 5.47 4.53 4.42 3.25 3.70 0.96 0.70 
 
In order to ascertain the effect of steric bias in the external side chain on the 
interconversion barrier, we performed additional low temperature NMR studies with 
sultam 4.79 containing the N-isopropyl group.  In theory, the achiral nature of the  
N-alkyl side chain renders any peak coalescence or splitting in this system to be a 















atropisomer interconversion barrier.  Thus, several 1H NMR spectra were obtained at 
various temperatures in acetone-d6 as an NMR solvent.  The overlay spectra is shown 
in Figure 4.7. 
At 25 ºC, the spectra showed two singlets corresponding to the C3–CH2 and 
benzylic CH2 at 5.64 ppm and 4.80 ppm, respectively, while the isopropyl methyl 
resonance appeared as a doublet at 0.97 ppm.  At -55ºC, all three peaks are broad 
singlets for each proton.  At -75 ºC and -82 ºC, the benzylic CH2 resonance divides 
into two broad singlets at 6.10 and 5.91 ppm, C3–CH2 divides into two broad singlets 
at 5.00 and 4.80 ppm, and the isopropyl CH3 also divides into two broad singlets at 
1.23 and 0.51 ppm.  Thus, at -82 ºC all signals are in slow-exchange on the NMR 
timescale.  At low temperature, rotation about the N–Cα bond slows, causing the two 
methyl groups in the isopropyl side chain to have inequivalent chemical shifts, as 
only one methyl group is influenced by the aforementioned anisotropic shielding of 
the benzene ring which leads to an upfield chemical shift.  Likewise, the benzylic 
CH2 signal splits into two singlets as low temperature renders the methylene protons 
diastereotopic.  These resonances divide into two separate broad singlets at low 
temperature because of a temperature-dependent decrease in the first order rate 





Figure 4.7  Overlay from low temperature NMR study (4.79, Acetone-d6). 
 
Moreover, as noted below, the rate constant and energy barrier could be calculated as 
outlined in Table 4.13.  A value of ~ 10 kcal per mole in this isopropyl system is most 
likely similar to that in the valine-derived sultam 4.40 which substantiates the 






























Figure 4.8   
Table 4.13 Rate constants and energy barriers. 




ΔG = 2.303!"[10.32+ !"# !!] 








-55 ºC 1410.47 9.48 199.86 10.32 333.18 10.10 
-65 ºC 344.29 9.60 433.13 9.51 510.88 9.44 
-75 ºC 755.22 8.82 144.39 9.47 166.59 9.41 
-85 ºC 777.43 8.34 222.13 8.81 222.13 8.81 
 
 To test this hypothesis one more time, non-chiral tricyclic sultam 4.77 
containing an N-methyl group was used for an additional low temperature NMR 
study, whereby diastereotopicity among the external side-chain is non-existent 













































NMR probe low enough to divide the C3-CH2 or benzylic CH2 singlets into two 
separate singlets.  Thus, for this system, the rate constants for rotation about the 
triazole N-benzylic–C bond and the rate constants for atropisomer inversion are such 
that, even at -90 ºC, these signals are still in fast exchange on the NMR time scale.  
Nevertheless, both signals broaden significantly, indicating a trend towards the 
intermediate exchange regime.  Efforts towards studying the conformational 
dynamics of the more sterically hindered, and symmetrical, N-tBu system, are in order 






Figure 4.9 Overlay from low temperature NMR study (4.77, Acetone-d6). 
 
4.3  Conclusions 
The synthesis of a collection of 7- and 8-membered tricyclic, biaryl sultams 
has been achieved using an intramolecular Pd-catalyzed C-arylation reaction of a 































racemic amino ester-based tertiary sulfonamides furnished the corresponding 7-
memberd tricyclic, biaryl sultams as a single conformer in a highly 
atropdiastereoselective thermodynamic equilibration process yielding a low energy 
conformer of “like” configuration (S,Sa).  Furthermore, this Pd-catalyzed C-arylation 
reaction provided different conformational mixtures of 8-membered sultam products 
(10:1 and 2:1 for valine- and leucine-based systems, respectively).   
In the course of X-ray crystallographic analysis, as well as detailed NMR 
studies, we uncovered a number of notable and interesting structural features of the  
7-membered amino ester-derived sultams in both solid and solution phases that 
confirm a structure as a single conformer (>95:5) containing biaryl axial chirality of 
“like” configuration (S,Sa) with respect to the stereogenic center in the external side 
chain.  Moreover, variable temperature NMR analysis has indicated that the axis of 
chirality at the biaryl bond has a relatively small interconversion barrier that allows 
for this rapid thermodynamic equilibration of the “like” and “unlike” 
atropdiastereomers.  Detailed variable NMR analyses on a number of analogs, vide 
infra, point to rotamer dynamics (about the N–C bond in the external side chain) and 
ring size of the corresponding benzothiazepine (n = 1)/benzothiazocine (n = 2) 1,1-
dioxides as governing factors in this notable thermodynamic equilibration of 
atropdiastereomers.  Current efforts are focused on the computational calculation for 
the energy barrier between two atropdiastereomers interconversion, as well as the 
further development of an “atropdiastereoselective” C-arylation process.  In addition, 
future studies will continue to probe the dynamic factors involved in the origins of 
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atropselectivity.  Utilizing this methodology, we are also generating additional 
libraries of diverse tricyclic, biaryl sultams for high throughput screening of 
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5.1  General Experimental Methods 
All air and moisture sensitive reactions were carried out in flame- or oven-
dried glassware under argon atmosphere using standard gas tight syringes, cannulas 
and septa.  Stirring was achieved with oven-dried, magnetic stir bars. CH3CN, 
CH2Cl2, THF and toluene were purified by passage through the Solv-Tek purification 
system employing activated Al2O3 (Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. 
Organometallics 1996, 15, 1518-1520).  Et3N was purified by passage over basic 
alumina and stored over KOH.  Flash column chromatography was performed with 
SiO2 obtained from Sorbent Technologies (30930M-25, Silica Gel 60 Å, 40-63 µm).  
Metathesis catalysts were provided by Materia, Inc. and used without further 
purification.  All protected glycidol compounds were provided from Daiso Co., Ltd., 
Fine Chemical Department.  Thin layer chromatography was performed on silica gel 
60F254 plates (EM-5717, Merck).  Deuterated solvents were purchased from 
Cambridge Isotope laboratories.  1H and 13C NMR spectra were recorded on a Bruker 
DRX-400 spectrometer operating at 400 MHz and 100 MHz respectively; or a Bruker 
Avance operating at 500 MHz and 125 MHz respectively.  High-resolution mass 
spectrometry (HRMS) were obtained on a VG Instrument ZAB double-focusing mass 
spectrometer.  Melting points were obtained on a Thomas Hoover capillary melting 
point apparatus.  Optical rotations were carried out on a Rudolph Automatic 




5.2  Experimental Data for Chapter 2 







Into a flame dried flask under argon was added furfurylamine (1.05 mL, 11.9 mmol), 
Et3N (1.66 mL, 11.9 mmol), and dry CH2Cl2 (20 mL).  After stirring at 0 ºC for 10 
min, 2-chloroethanesulfonyl chloride (0.96 mL, 9.2 mmol) was added and the 
reaction flask stirred at rt for 2 h.  The crude reaction mixture was filtered and the 
filtrate was concentrated under reduced pressure.  The crude material was dissolved 
in dry CH3CN (50 mL, 0.2 M) to which K2CO3 (3.9 g, 32.0 mmol) was added.  After 
stirring for 5 mins, allyl bromide (2.8 mL, 32.0 mmol) was added and the reaction 
mixture was stirred at 60 ºC, until SM disappeared as monitored by TLC analysis.  
After such time, the crude reaction mixture was filtered through a pad of celite, 
concentrated under reduced pressure and purified by flash chromatography (1:1 
hexane:EtOAc) to yield 2.23 (1.15 g, 5.0 mmol, 55%) as a white solid.   
Mp 98 ºC;  
FTIR (neat): 1442, 1301, 1068, 1137 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.53 (dd, J = 5.7, 1.7 Hz, 1H), 6.37 (d, J = 5.7 
Hz, 1H), 5.88 (ddt, J = 16.6, 10.1, 6.4 Hz, 1H), 5.30 (ddq, J = 24.7, 10.1, 1.3 Hz, 2H), 
5.23 (dd, J = 4.5, 1.7 Hz, 1H), 3.84 (d, J = 11.3 Hz, 1H), 3.80 – 3.75 (m, 2H), 3.62 (d, 
J = 11.3 Hz, 1H), 3.18 (dd, J = 7.9, 3.6 Hz, 1H), 2.61 – 2.55 (m, 1H), 1.81 (dd, J = 
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12.3, 7.9 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 139.5, 134.1, 132.4, 119.7, 90.5, 79.7, 60.5, 48.9, 
47.6, 29.2;  
HRMS calculated for C10H13NO3SNa (M+Na)+ 250.0514, found 250.0518. 
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Using the same procedure as that used to produce sultam 2.12, N-(2-
furanylmethyl)ethanesulfonamide (1.0 g, 5.28 mmol), propargyl bromide (2.8 ml, 
32.0 mmol) yielded 2.13 (68.9 mg, 3.0 mmol, 58%) as a white solid.  
Mp 150 ºC;  
FTIR (neat): 3226, 1304, 1282, 1140 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.55 (dd, J = 1.7, 5.7 Hz, 1H), 6.42 (d, J = 5.7 
Hz, 1H), 5.26 (dd, J = 4.5, 1.6 Hz, 1H), 4.10 – 4.02 (m, 2H), 3.93 (dd, J = 17.7, 2.5 
Hz, 1H), 3.81 (d, J = 11.4 Hz, 1H), 3.18 (dd, J = 7.9, 3.6 Hz, 1H), 2.61 – 2.55 (m, 
1H), 2.37 (t, J = 2.5 Hz, 1H), 1.81 (dd, J = 12.4, 7.9 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 139.5, 134.1, 90.7, 79.8, 76.8, 74.1, 60.5, 48.8, 
34.7, 29.1;  














To a flame dried flask was added dry CH2Cl2 (95 mL, 0.005 M), which was degassed 
for 30 min with argon.  After such time, sultam 2.23 (0.1 g, 0.44 mmol) and cat-B 
(0.04 g, 0.044 mmol) were added and the reaction mixture was refluxed at 45 ºC for 3 
h. The crude reaction mixture concentrated under reduced pressure and purified by 
flash chromatography (1:1 hexane:EtOAc) to provide 2.25 (15.7 mg, 0.36 mmol, 84% 
yield) as a white solid.  
Mp 227 ºC;  
FTIR (neat): 1336, 1164, 1112 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.28 (ddd, J = 10.1, 5.1, 2.1 Hz, 1H), 5.76 (ddd, J 
= 6.7, 3.4, 1.7 Hz, 1H), 5.55 (dt, J = 10.1, 2.5 Hz, 1H), 4.84 (d, J = 6.0 Hz, 1H), 4.19 
(dt, J = 19.5, 2.5 Hz, 1H), 3.79 (dt, J = 19.6, 2.2 Hz, 1H), 3.71 (dd, J = 11.0, 5.7 Hz, 
1H), 3.59 (dd, J = 12.2, 1.9 Hz, 1H), 3.24 (dd, J = 12.2, 1.8 Hz, 1H), 2.71 (dddd, J = 
14.0, 8.1, 5.8, 2.1 Hz, 1H), 2.14 – 2.06 (m, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 134.2, 134.2, 131.2, 130.9, 124.1, 124.1, 87.6, 
80.9, 80.7, 71.0, 71.0, 51.9, 50.9, 34.1, 34.1;  




General Procedure A for ROM-RCM-CM Cascade: To a flame dried flask was 
added dry CH2Cl2 (0.005 M), which was degassed for 30 min with argon.  To this 
was added, sultam (1 eq.), cat-B (10 mol%) and CM partner (10 eq.).  The reaction 
mixture was refluxed at 45 ºC for 3 h.  The crude reaction mixture was concentrated 
under reduced pressure and purified by flash chromatography (1:1 hexane: EtOAc) to 
afford the desired compound. 
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(5aR,8aR)-7-Vinyl-3,7,8,8a-tetrahydro-2,5a-methanofuro[2,3-f][1,2]thiazepine 






According to general procedure A, 2.23 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
was added to ethylene degassed, dry CH2Cl2 (85 mL, 0.005 M) to yield 2.26 (50 mg, 
0.22 mmol, 74%) as a yellow solid.  
Mp 91 ºC;  
FTIR (neat): 2925, 1350, 1338, 1166 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.28 (dq, J = 10.1, 2.1 Hz, 1H), 5.80 (ddd, J = 
17.0, 10.4, 6.4 Hz, 1H), 5.57 – 5.48 (m, 1H), 5.33 – 5.25 (m, 1H), 5.19 (dt, J = 10.4, 
1.1 Hz, 1H), 4.82 (dd, J = 14.6, 6.9 Hz, 1H), 4.18 (dt, J = 19.5, 2.4 Hz, 1H), 3.76 (dt, 
J = 19.5, 2.2 Hz, 1H), 3.70 (ddd, J = 10.9, 6.0, 1.9 Hz, 1H), 3.59 (dd, J = 12.2, 2.0 
Hz, 1H), 3.23 (dd, J = 12.2, 2.0 Hz, 1H), 2.68 (ddd, J = 14.0, 8.0, 6.0 Hz, 1H), 2.09 
(ddd, J = 14.1, 10.9, 7.1 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 135.6, 133.5, 123.0, 116.4, 86.6, 81.4, 70.2, 51.1, 
50.0, 33.0;  













According to general procedure A, 2.23 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
and ethyl acrylate (3.2 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 (85 
mL, 0.005 M) to yield 2.27 (58 mg, 0.19 mmol, 65%) as a pale yellow solid.   
Mp 232 ºC;  
FTIR (neat): 1716, 1350, 1269, 1167 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.85 (dd, J = 15.6, 5.0 Hz, 1H), 6.30 (d, J = 10.1 
Hz, 1H), 6.04 (d, J = 15.6 Hz, 1H), 5.57 (d, J = 10.1 Hz, 1H), 5.02 (dd, J = 13.4, 6.7 
Hz, 1H), 4.24 – 4.16 (m, 3H), 3.82 – 3.75 (m, 1H), 3.75 – 3.69 (m, 1H), 3.62 – 3.56 
(m, 1H), 3.30 – 3.25 (m, 1H), 2.83 – 2.74 (m, 1H), 2.21 – 2.12 (m, 1H), 1.32 – 1.27 
(m, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 165.9, 144.7, 134.0, 124.2, 121.7, 88.0, 80.0, 
70.5, 60.8, 52.1, 51.0, 33.5, 14.2;  













According to general procedure A, 2.23 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
and methyl acrylate (2.7 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 (85 
mL, 0.005 M) to yield 2.28 (48 mg, 0.16 mmol, 56%) as a pale yellow solid.  
Mp 144 ºC;  
FTIR (neat): 1722, 1350, 1340, 1167 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.86 (d, J = 13.8 Hz, 1H), 6.30 (d, J = 8.0 Hz, 
1H), 6.05 (d, J = 15.3 Hz, 1H), 5.56 (d, J = 7.9 Hz, 1H), 5.02 (s, 1H), 4.19 (d, J = 
19.2 Hz, 1H), 3.85 – 3.53 (m, 6H), 3.28 (d, J = 11.6 Hz, 1H), 2.78 (s, 1H), 2.16 (s, 
1H);  
13C NMR (125 MHz, CDCl3) δ ppm 166.3, 145.0, 133.9, 124.2, 121.2, 88.0, 80.0, 
70.5, 52.1, 51.9, 50.9, 33.5;  














According to general procedure A, 2.23 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
and t-butyl acrylate (4.3 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 (85 
mL, 0.005 M) to yield 2.29 (76 mg, 0.23 mmol, 78%) as a yellow oil.  
FTIR (neat): 2978, 1711, 1352, 1314, 1165 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 6.77 (dd, J = 15.6, 5.0 Hz, 1H), 6.34 (d, J = 10.2 
Hz, 1H), 5.99 (d, J = 15.6 Hz, 1H), 5.59 (d, J = 10.3 Hz, 1H), 5.03 (s, 1H), 4.23 (d, J 
= 19.6 Hz, 1H), 3.87 – 3.71 (m, 2H), 3.62 (d, J = 12.5 Hz, 1H), 3.30 (d, J = 12.2 Hz, 
1H), 2.80 (s, 1H), 2.19 (ddd, J = 14.0, 10.8, 6.6 Hz, 1H), 1.51 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 165.1, 143.4, 134.1, 124.2, 123.6, 88.0, 81.0, 
80.1, 76.8, 70.6, 52.1, 50.9, 33.5, 31.0, 28.1;  













According to general procedure A, 2.23 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
and acrylonitrile (1.9 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 (85 
mL, 0.005 M) to yield 2.30 (50 mg, 0.20 mmol, 67%) as a white solid.  
Mp 170 ºC;  
FTIR (neat): 1338, 1164, 1114 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.67 (dd, J = 16.2, 4.3 Hz, 1H), 6.28 (dq, J = 
10.1, 2.1 Hz, 1H), 5.67 (dd, J = 16.2, 1.9 Hz, 1H), 5.60 (dt, J = 10.1, 2.5 Hz, 1H), 
5.03 – 4.96 (m, 1H), 4.21 (dt, J = 19.6, 2.5 Hz, 1H), 3.80 (dt, J = 19.6, 2.2 Hz, 1H), 
3.72 (ddd, J = 10.8, 6.4, 1.9 Hz, 1H), 3.58 (dd, J = 12.3, 2.0 Hz, 1H), 3.29 (dd, J = 
12.3, 2.0 Hz, 1H), 2.86 – 2.79 (m, 1H), 2.16 (ddd, J = 14.1, 10.9, 6.9 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 149.9, 132.3, 123.5, 115.4, 99.4, 87.1, 78.4, 69.1, 
50.9, 49.9, 32.2;  













According to general procedure A, 2.23 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
and styrene (3.4 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 (85 mL, 
0.005 M) to yield 2.31 (73 mg, 0.24 mmol, 81%) as a brown liquid.  
FTIR (neat): 1348, 1338, 1164, 1132, 968, 750 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.39 (dd, J = 5.0, 3.4 Hz, 2H), 7.35 – 7.31 (m, 
2H), 7.28 (dt, J = 4.7, 1.9 Hz, 1H), 6.64 (d, J = 15.8 Hz, 1H), 6.34 (dq, J = 10.1, 2.1 
Hz, 1H), 6.15 (dd, J = 15.8, 7.0 Hz, 1H), 5.56 (dt, J = 10.1, 2.5 Hz, 1H), 5.01 (q, J = 
7.2 Hz, 1H), 4.22 (dt, J = 19.5, 2.5 Hz, 1H), 3.84 – 3.74 (m, 2H), 3.66 (dd, J = 12.2, 
2.0 Hz, 1H), 3.28 (dd, J = 12.2, 2.0 Hz, 1H), 2.78 (ddd, J = 13.9, 8.0, 5.7 Hz, 1H), 
2.21 (ddd, J = 14.2, 11.1, 7.3 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 135.9, 134.4, 132.8, 128.9, 128.3, 127.3, 126.7, 
124.0, 87.5, 82.2, 71.3, 51.9, 51.0, 34.4;  












According to general procedure, 2.23 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
and 4-bromostyrene (3.9 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 (85 
mL, 0.005 M) to yield 2.32 (87 mg, 0.23 mmol, 80%) as a white solid.  
Mp 140 ºC;  
FTIR (neat): 1487, 1350, 1338, 1164, 744 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.48 – 7.43 (m, 2H), 7.25 (dt, J = 9.0, 2.2 Hz, 
2H), 6.58 (d, J = 15.8 Hz, 1H), 6.33 (dq, J = 10.1, 2.1 Hz, 1H), 6.14 (dd, J = 15.8, 6.9 
Hz, 1H), 5.57 (dt, J = 10.1, 2.5 Hz, 1H), 4.99 (q, J = 7.1 Hz, 1H), 4.22 (dt, J = 19.5, 
2.5 Hz, 1H), 3.84 – 3.73 (m, 2H), 3.65 (dd, J =12.2, 2.0 Hz, 1H), 3.28 (dd, J = 12.2, 
2.0 Hz, 1H), 2.77 (ddd, J = 13.9, 8.0, 5.7 Hz, 1H), 2.19 (ddd, J = 14.2, 11.1, 7.4 Hz, 
1H);  
13C NMR (125 MHz, CDCl3) δ ppm 134.8, 134.3, 131.8, 131.5, 128.2, 128.1, 124.1, 
122.1, 87.6, 81.9, 71.2, 51.9, 51.0, 34.3;  












According to general procedure A, 2.24 (80 mg, 0.3 mmol, cat-B (30 mg, 0.03 mmol) 
was added to argon degassed, dry CH2Cl2 (85 mL, 0.005 M) to yield 2.34 (63 mg, 
0.23 mmol, 75%) as a brown liquid.  
FTIR (neat): 2927, 1597, 1311, 1150, 931 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.36 (dd, J = 17.7, 11.1 Hz, 1H), 5.99 (dd, J = 
17.0, 10.6 Hz, 1H), 5.81 (ddd, J = 17.2, 10.3, 6.9 Hz, 1H), 5.57 – 5.44 (m, 2H), 5.33 
(dd, J = 17.2, 1.1 Hz, 1H), 5.28 – 5.16 (m, 5H), 4.71 – 4.65 (m, 1H), 4.15 (d, J = 13.8 
Hz, 1H), 3.53 (d, J = 8.6 Hz, 1H), 3.47 (d, J = 13.8 Hz, 1H), 3.28 (d, J = 10.9 Hz, 
1H), 3.10 (d, J = 10.9 Hz, 1H), 2.70 (dd, J = 13.7, 5.0 Hz, 1H), 2.00 (ddd, J = 13.7, 
10.8, 8.7 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 139.4, 137.3, 136.2, 136.0, 119.9, 118.1, 116.4, 
115.7, 85.7, 81.8, 66.6, 56.7, 44.7, 35.1;  



















To a flame dried flask containing dry toluene (0.5 mL) was added diene 2.34 (30 mg, 
0.1 mmol) and N-phenylmaleimide (0.23 g, 0.13 mmol).  The reaction was heated at 
85 ºC for 24 h.  The crude reaction mixture was concentrated under reduced pressure 
and purified by flash chromatography (3:2 hexane:EtOAc) to yield 2.35 (38 mg, 8.3 × 
10-5 mol, 83%) as a yellow oil.  
FTIR (neat): 1709, 1498, 1383, 1309, 1147 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.43 (dd, J = 16.5, 8.0 Hz, 2H), 7.36 (dd, J = 
15.2, 7.5 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.22 (d, J = 7.3 Hz, 1H), 5.94 (td, J = 16.7, 
10.8 Hz, 2H), 5.80 (dddd, J = 17.0, 13.4, 10.4, 6.8 Hz, 1H), 5.56 – 5.47 (m, 1H), 5.37 
(dd, J = 22.0, 17.2 Hz, 1H), 5.28 – 5.13 (m, 2H), 4.79 – 4.71 (m, 1H), 3.81 (d, J = 
14.1 Hz, 1H), 3.52 (d, J = 8.0 Hz, 1H), 3.42 – 3.22 (m, 3H), 3.16 (dd, J = 10.8, 5.5,  
Hz, 1H), 3.06 (dd, J = 10.8, 3.0 Hz, 1H), 2.76 – 2.64 (m, 3H), 2.47 – 2.32 (m, 2H), 
2.00 (ddd, J = 17.0, 14.1, 7.7 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 178.8, 178.7, 178.4 (2), 137.3, 137.2, 136.3, 
136.2, 134.4, 134.0, 131.9 (2), 129.1, 129.0, 128.6, 128.5, 126.4 (2), 125.7, 125.6, 
118.2, 117.8, 116.6, 116.5, 86.0, 85.7, 82.2, 81.7, 66.7 (2), 57.9, 57.0, 49.5, 49.2, 
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39.4, 39.0, 38.9 (2), 34.9, 34.8, 25.6 (2), 24.3, 24.1;  











H OMe  
To a flame dried flask under argon was added furfural (1.72 mL, 20.8 mmol), 4-
methoxybenzylamine (2.7 mL, 20.8 mmol), MgSO4 (3.0 g) and dry CH2Cl2 (20 mL). 
After stirring at rt for 6 h, the crude reaction mixture was filtered and the filtrate was 
concentrated under reduced pressure.  The crude was dissolved in THF (20 mL) to 
which was added allyl magnesium bromide (5.57 mL, 11.15 mmol). The reaction 
mixture was stirred for 5 h. after which time NH4Cl (sat. aq., 10 mL) was added.  The 
aqueous layer was extracted with CH2Cl2 (4 × 20 mL) and the combined organic layer 
was dried (MgSO4).  The crude reaction mixture 2.36 (1.2 g) was solvated in dry 
toluene (5 mL) and heated at reflux for 12 h.  After such time the crude reaction 
mixture concentrated under reduced pressure and purified by flash chromatography 
(1:1 hexane:EtOAc) to provide the desired compound 2.37 (95%) as a yellow liquid.  
FTIR (neat): 1612, 1514, 1301, 1247, 1137 cm-1;  
[Mixture of Diastereoisomers (1:1)] 1H NMR (500 MHz, CDCl3) δ ppm 7.37 (d, J = 
8.6 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 6.95 – 6.81 (m, 4H), 6.52 (dd, J = 5.8, 1.7 Hz 
1H), 6.47 – 6.38 (m, 3H), 6.18 (d, J = 5.7 Hz, 1H), 5.93 – 5.78 (m, 1H), 5.74 – 5.58 
(m, 1H), 5.28 (dd, J = 4.5, 1.5 Hz 1H), 5.22 – 5.14 (m, 2H), 5.09 – 4.97 (m, 2H), 4.51 
(d, J = 15.7 Hz, 1H), 4.41 (d, J = 15.3 Hz, 1H), 4.28 (dd, J = 15.5, 8.7 Hz 2H), 3.81 
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(dd, J = 8.9, 5.6 Hz, 6H), 3.72 (t, J = 5.3 Hz, 1H), 3.24 (dd, J = 7.9, 3.2 Hz, 1H), 3.13 
(dd, J = 7.8, 3.3 Hz, 1H), 2.74 – 2.59 (m, 1H), 2.56 – 2.48 (m, 1H), 2.45 (t, J = 7.2 
Hz, 1H), 1.80 (td, J = 12.4, 7.9 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 159.3, 159.2, 139.7, 137.9, 135.3, 132.9, 132.6, 
132.1, 130.0, 129.9, 127.6, 127.3, 119.4, 118.9, 114.1, 114.1, 94.5, 92.2, 79.4, 78.8, 
60.4, 59.7, 58.6, 58.4, 55.3, 55.3, 46.6, 46.0, 34.6, 33.8, 30.1, 29.5;  











According to general procedure A, 2.37 (0.06 g, 0.17 mmol), cat-B (0.015 g, 0.017 
mmol) in ethylene degassed CH2Cl2 (35 mL).  The crude reaction was purified by 
flash chromatography (2:1 hexane:EtOAc) to provide 2.38 (32 mg, 54%) and 2.39 (10 
mg, 16%).  
FTIR (neat): 1612, 1514, 1305, 1249, 1149 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.42 – 7.22 (m, 2H), 7.11 – 6.74 (m, 2H), 6.10 – 
5.87 (m, 1H), 5.80 (ddd, J = 17.1, 10.4, 6.6 Hz, 1H), 5.72 (dt, J = 5.7, 2.2 Hz, 1H), 
5.30 (dt, J = 17.2, 1.2 Hz, 1H), 5.23 – 5.15 (m, 1H), 4.52 – 4.38 (m, 2H), 4.05 (d, J = 
14.4 Hz, 1H), 3.82 (d, J = 5.2 Hz, 3H), 3.64 – 3.54 (m, 2H), 2.75 (ddd, J = 13.8, 5.5, 
2.0 Hz, 1H), 2.64 – 2.43 (m, 2H), 2.12 (dt, J = 13.8, 9.9 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 159.5, 135.9, 135.1, 130.4, 130.2, 126.8, 118.0, 
114.1, 97.3, 80.1, 64.6, 63.8, 55.3, 45.4, 35.5, 35.2;  














FTIR (neat): 1514, 1303, 1247, 1145 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.31 (d, J = 8.7 Hz, 2H), 6.90 – 6.85 (m, 2H), 
5.97 – 5.81 (m, 2H), 5.72 (dddd, J = 11.7, 9.5, 7.5, 6.4 Hz, 1H), 5.56 – 5.48 (m, 1H), 
5.39 (ddd, J = 12.5, 4.3, 3.1 Hz, 2H), 5.27 – 5.20 (m, 1H), 5.00 – 4.92 (m, 2H), 4.76 
(dd, J = 11.0, 5.9 Hz, 1H), 4.42 (d, J = 15.8 Hz, 1H), 4.10 (d, J = 15.8, 1H), 3.84 – 
3.78 (s, 3H), 3.55 (d, J = 8.4 Hz, 1H), 3.38 (dd, J = 7.4, 5.2 Hz 1H), 2.75 (ddd, J = 
13.6, 5.1, 0.9 Hz, 1H), 2.47 – 2.38 (m, 1H), 2.34 – 2.26 (m, 1H), 2.02 (ddd, J = 13.6, 
10.8, 8.5 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 159.5, 139.1, 136.8, 129.8, 118.1, 118.1, 117.1, 
114.3, 88.5, 82.4, 66.9, 66.1, 55.7, 46.0, 35.1, 32.5;  















According to general procedure A, 2.37 (80 mg, 0.3 mmol), cat-B (30 mg, 0.03 
mmol), ethyl acrylate (3.0 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 
(85 mL, 0.005 M) to yield 2.40 (61 mg, 0.147 mmol, 49%) as a yellow oil.  
FTIR (neat): 1718, 1514, 1303, 1149 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.28 – 7.24 (m, 2H), 6.90 – 6.82 (m, 3H), 6.01 
(ddd, J = 9.7, 7.9, 1.9 Hz, 2H), 5.71 (dt, J = 2.2, 5.7 Hz, 1H), 4.65 – 4.60 (m, 1H), 
4.46 (d, J = 14.4 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 4.04 (d, J = 14.4 Hz, 1H), 3.81 (s, 
3H), 3.63 (dd, J = 9.7, 1.9 Hz, 1H), 3.59 (dd, J = 7.2, 3.7 Hz, 1H), 2.63 – 2.44 (m, 
3H), 2.14 (dt, J = 13.8, 9.9 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 165.9, 159.5, 144.1, 135.4, 130.2 130.1, 126.7, 
122.2, 114.2, 97.8, 76.8, 64.6, 63.6, 60.7, 55.3, 45.5, 35.3, 35.2, 14.2;  
















According to general procedure A, 2.37 (80 mg, 0.3 mmol), cat-B (30 mg, 0.03 
mmol), t-butyl acrylate (4.3 mL, 30 mmol) was added to argon degassed, dry CH2Cl2 
(85 mL, 0.005 M) to yield 2.41 (69 mg, 0.156 mmol, 52%) as a yellow oil.   
FTIR (neat): 2978, 1710, 1514, 1308, 1151 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.27 – 7.23 (m, 2H), 6.90 – 6.85 (m, 2H), 6.74 
(dd, J = 15.7, 5.3 Hz, 1H), 6.01 – 5.98 (m, 1H), 5.94 (dd, J = 15.7, 1.4 Hz, 1H), 5.71 
(dt, J = 5.7, 2.2 Hz, 1H), 4.59 (dd, J = 7.3, 2.7 Hz, 1H), 4.46 (d, J = 14.4 Hz, 1H), 
4.03 (d, J = 14.4 Hz, 1H), 3.81 (s, 3H), 3.62 (dd, J = 19.7, 1.9 Hz, 1H), 3.57 (dd, J = 
7.2, 3.8 Hz, 1H), 2.80 (ddd, J = 13.8, 5.8, 2.0 Hz, 1H), 2.60 – 2.46 (m, 1H), 2.13 (dt, 
J = 13.8, 9.9 Hz, 1H), 1.87 – 1.82 (m, 1H), 1.46 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 165.2, 159.5, 142.9, 135.4, 130.2, 130.1, 126.7, 
124.1, 114.2, 97.7, 80.8, 76.8, 64.6, 63.6, 55.3, 45.4, 35.2, 35.2, 28.1;  












Mp 129 ºC;  
FTIR (neat): 2981, 2935, 1720, 1458, 1334, 1137 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.40 (dd, J = 5.7, 1.7 Hz, 1H), 6.11 (t, J = 5.2 Hz, 
1H), 5.04 (dd, J = 4.6, 1.7 Hz, 1H), 4.12 – 3.98 (m, 2H), 3.14 (dd, J = 7.8, 3.1 Hz, 
1H), 2.50 (ddd, J = 12.5, 4.6, 3.2 Hz, 1H), 1.65 (dd, J = 12.5, 7.8 Hz, 1H), 1.32 (s, 
9H);  
13C NMR (125 MHz, CDCl3) δ 149.8, 140.6, 132.8, 88.2, 84.4, 79.6, 62.3, 47.1, 30.2, 




















FTIR (neat): 2982, 2935, 1724, 1514, 1313, 1134 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.86 (dd, J = 15.6, 6.0 Hz, 1H), 6.12 – 6.05 (m, 
1H), 5.97 – 5.89 (m, 1H), 5.60 (dd, J = 17.0, 0.6 Hz, 1H), 5.38 (ddd, J = 10.6, 4.6, 0.6 
Hz, 1H), 5.02 – 4.94 (m, 1H), 4.25 – 4.17 (m, 2H), 4.01 – 3.94 (m, 1H), 3.78 (t, J = 
6.6 Hz, 1H), 3.70 – 3.64 (m, 1H), 2.87 (dd, J = 13.9, 5.8 Hz, 1H), 2.19 – 2.08 (m, 
1H), 1.54 (d, J = 2.6 Hz, 10H), 1.32 – 1.27 (m, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 165.9, 149.5, 144.6, 136.1, 122.8, 118.4, 85.2, 
85.0, 79.5, 68.5, 60.8, 53.1, 34.1, 28.0, 14.2;  
HRMS calculated for C17H25NO7SNa (M+Na)+ 410.1249, found 410.1243. 
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To a stirring suspension of imidazole (12.8 g, 188 mmol) in CH2Cl2 (40 mL) was 
added a solution of PhOP(O)Cl2 (5.61 mL, 37.7 mmol) in CH2Cl2 (40 mL).  After 
stirring for 1 h, the reaction was cooled to 0 °C and a solution of Boc-phenylalanine 
(10.0 g, 37.7 mmol) in CH2Cl2 (28 mL) was added and the reaction mixture stirred for 
1 h.  After such time, Weinreb amine (3.68 g, 37.7 mmol) was added and the reaction 
stirred at rt for 14 h.  The reaction was quenched with citric acid (2 M aq., 80 mL), 
the organic layer washed with NaHCO3 (1 M aq., 80 mL) and brine (80 mL). The 
organic layer was dried (MgSO4), filtered and concentrated under reduced pressure to 
generate the desired intermediate as a clear oil (crude NMR analysis).   
A portion of the crude (6.59 g, 25.3 mmol) in THF (84.5 mL) was cooled to -40 °C 
was stirred for 30 min.  In a separate round bottom flask, a solution of furan (4.6 mL, 
63.3 mmol) in THF (110 mL) was cooled to -78 °C to which nBuLi (26.3 mL) was 
added slowly and upon completion, was stirred for 30 min.  After such time, this 
solution was added slowly to the crude mixture at -40 °C and the reaction mixture 
was subsequently stirred for an additional 6 h.  After such time the reaction was 
quenched with NH4Cl (sat. aq., 80 mL) and the reaction mixture warmed to rt.  The 
aqueous layer was extracted with EtOAc (3 x 120 mL) and the combined organic 
layers were dried (MgSO4), filtered and concentrated under reduced pressure to give 
the desired intermediate as a clear oil (crude NMR analysis). A portion of the crude 
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(1.0 g) in THF (12 mL)/MeOH (1.5 mL) was cooled to 0 °C and after stirring for 15 
min, NaBH4 (0.14 g, 3.8 mmol) was added and reaction stirred for 2 h at 0 °C.  After 
such time the reaction was warmed to rt, diluted with EtOAc (10 mL) followed by 
HCl (10% aq., 10 mL).  After stirring for 15 min, the organic layer was washed with 
HCl (10% aq., 10 mL), H2O (10 mL), NaHCO3 (sat. aq., 10 mL) and brine (10 mL).  
The combined organic layers were dried (MgSO4), filtered and concentrated under 
reduced pressure to yield the desired intermediate as a white solid.  
Mp 144–146 °C;  
FTIR (neat): 1716, 1454, 1292, 1172, 1132 cm-1;  
[Major Isomer] 1H NMR (500 MHz, CDCl3) δ ppm 7.48 – 7.43 (m, 1H), 7.34 – 7.17 
(m, 5H), 6.38 – 6.29 (m, 2H), 4.80 (d, J = 19.2 Hz, 1H), 4.70 – 4.78 (m, 1H), 4.27 (br 
s, 1H), 3.55 (br s, 1H), 2.80 (d, J = 6.3 Hz, 2H), 1.35 (s, 9H);  
[Minor Isomer] 1H NMR (500 MHz, CDCl3) δ ppm 7.39 (s, 1H), 7.16 – 7.35 (m, 5H), 
6.43 – 6.38 (m, 2H), 4.89 (s, 1H), 4.75 (s, 1H), 4.14 (s, 1H), 3.08 (s, 1H), 2.88 – 2.99 
(m, 2H), 1.41 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 156.6, 154.6, 154.0, 142.3, 142.0, 137.9, 137.6, 
129.3, 129.3, 128.5, 128.5, 126.5, 126.5, 110.3, 107.8, 106.8, 80.0, 79.7, 77.3, 77.0, 
76.7, 70.1, 68.7, 56.5, 55.4, 37.6, 36.6, 28.3;  












Carbamate 2.45  (2.0 g, 6.3 mmol) was dissolved in CH2Cl2 (32 mL), cooled to 0 °C 
and after stirring for 15 min TFA (1.95 mL, 25.2 mmol) was added cautiously. After 
stirring at rt for 3 h, the reaction was cooled to 0 °C and NaOH (10% aq., 35 mL) was 
added.  The reaction was diluted with CH2Cl2 (32 mL), the aqueous layer extracted 
with CH2Cl2 (2 x 30 mL) and the combined organic dried (MgSO4), filtered and 
concentrated under reduced pressure to afford the desired carbamate intermediate as a 
white solid.  The crude product (1.78 g) was dissolved in EtOH (40 mL) and NaOH 
(1 M aq., 40 mL) was added.  After stirring at reflux for 14 h, the organic solvent was 
removed under reduced pressure.  The resulting aqueous layer was extracted with 
CH2Cl2 (3 × 30 mL) and the combined organic layers were dried (MgSO4), filtered 
and concentrated under reduced pressure to produce the desired amino alcohol 
intermediate as a yellow oil.  The crude material was dissolved in CH2Cl2 (11.7 mL), 
to which was added Et3N (1.58 mL, 91 mmol) and the reaction was cooled to 0 ºC.  
After stirring for 10 min, 2-chloroethanesulfonyl chloride (0.52 mL, 4.89 mmol) was 
added drop wise over 5 min.  The reaction mixture was warmed to rt and stirred for 
12 h.  After which time the crude mixture was concentrated and purified by flash 
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chromatography (1:2 hexane:EtOAc) to yield (1.0 g, 3.2 mmol, 52%) of 2.47 as a 
white solid.   
FTIR (neat): 3480, 3350, 2358, 1448, 1305, 1139 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.35 – 7.28 (m, 2H), 7.28 – 7.19 (m, 3H), 6.55 
(dd, J = 5.7, 1.5 Hz, 1H), 6.34 (d, J = 5.7 Hz, 1H), 5.19 (dd, J = 4.7, 1.5 Hz, 1H), 4.64 
(d, J = 10.6 Hz, 1H), 4.07 (dd, J = 16.4, 9.7 Hz 1H), 3.90 (s, 1H), 3.21 (dd, J = 7.9, 
3.2 Hz 1H), 3.10 (dd, J = 13.9, 6.6 Hz, 1H), 2.92 (dd, J = 13.8, 8.9 Hz, 1H), 2.61 – 
2.52 (m, 1H), 2.35 (s, 1H), 1.77 (dd, J = 12.2, 7.9 Hz 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 140.1, 136.1, 133.4, 129.1, 129.0, 127.2, 91.2, 
79.5, 64.2, 56.2, 55.6, 37.0, 28.8;  





















Into a 1 dram vial was added 2.47 (85 mg, 0.27 mmol), DMF (0.6 mL, 0.46 M), 
Cs2CO3 (0.18 g, 0.55 mmol) and allyl bromide (25 µL, 0.30 mmol).  The reaction was 
heated at 50 ºC and stirred for 4 h after which time the crude mixture was filtered and 
concentrated under reduced pressure.  The resulting crude oil was purified by flash 
chromatography (1:2 hexane:EtOAc) to yield (86 mg, 2.48 mmol, 92%) of 2.48 as a 
yellow oil.  
FTIR (neat): 3386, 3249, 2358, 1336, 1315, 1152 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.36 – 7.30 (m, 2H), 7.25 (dd, J = 7.2, 5.2 Hz 
3H), 6.57 (dt, J = 5.6, 2.8 Hz 1H), 6.27 (d, J = 5.7, 1H), 6.04 – 5.94 (m, 1H), 5.33 
(ddq, J = 20.2, 10.4, 1.4 Hz 2H), 5.21 (dd, J = 4.7, 1.6 Hz 1H), 4.71 (d, J = 12.1 Hz, 
1H), 4.31 (dt, J = 5.5, 1.4 Hz, 2H), 4.14 (dddd, J = 12.1, 8.3, 7.1, 1.0 Hz, 1H), 3.64 (s, 
1H), 3.20 (dd, J = 7.9, 3.3 Hz, 1H), 3.11 (dd, J = 14.3, 7.1 Hz, 1H), 2.90 (dd, J = 
14.3, 8.5 Hz, 1H), 2.60 (ddd, J = 12.2, 4.6, 3.4 Hz, 1H), 1.78 (dd, J = 12.1, 7.9 Hz, 
1H);  
13C NMR (125 MHz, CDCl3) δ ppm 140.3, 136.5, 133.6, 133.4, 129.1, 129.0, 127.1, 
118.2, 91.0, 79.5, 74.9, 72.5, 56.7, 56.1, 37.4, 29.0;  
HRMS calculated for C18H21NO5SNa (M+Na)+ 370.1089, found 370.1087. 
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(3aS,6S,6aR,10aS)-6-Benzyl-2-vinyl-3,3a,5,6,6a,8-hexahydro-2H-furo[2,3-









According to general procedure A, sultam 2.48 (20 mg) underwent ROM-RCM-CM 
with ethylene to yield 2.49 (18 mg, 90%) as a clear oil.   
FTIR (neat): 3481, 2975, 1724 1445, 1308, 1139 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.25 – 7.17 (m, 3H), 7.14 (ddd, J = 9.5, 6.6, 3.4 
Hz, 2H), 6.46 (d, J = 5.7 Hz, 1H), 6.37 (dd, J = 5.7, 1.6 Hz, 1H), 5.75 (dddd, J = 17.2, 
10.0, 7.6, 5.7 Hz, 1H), 5.16 (ddd, J = 13.6, 11.0, 1.1 Hz, 2H), 5.02 (dd, J = 4.6, 1.6 
Hz, 1H), 4.03 – 3.90 (m, 3H), 3.80 – 3.70 (m, 2H), 3.25 – 3.16 (m, 2H), 3.01 (dd, J = 
13.4, 5.1 Hz 1H), 2.18 (dt, J = 12.7, 4.4 Hz, 1H), 1.87 (dd, J = 12.7, 8.5 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 137.9, 137.3, 135.3, 134.9, 129.4, 128.6, 126.7, 
118.6, 91.6, 78.4, 64.2, 62.9, 57.3, 53.6, 37.1, 30.8;  

















To a stirring solution of sultam 2.47 (50 mg, 0.16 mmol), Et3N (45 µL, 0.32 mmol), 
and CH2Cl2 (0.35 mL) in a 1 dram vial was added was added acryloyl chloride (17 
µL, 0.21 mmol).  After stirring for 4 h at rt, the reaction mixture was concentrated 
under reduced pressure and purified by flash chromatography (1:1 hexane:EtOAc) to 
yield (53 mg, 0.14 mmol, 92%) of 2.50 as a yellow oil.  
FTIR (neat): 3470, 2980, 1726 1452, 1300, 1140 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.32 – 7.22 (m, 3H), 7.17 (dd, J = 6.6, 5.0 Hz, 
2H), 6.62 (dd, J = 17.3, 1.0 Hz 1H), 6.54 (dd, J = 5.8, 1.6 Hz, 1H), 6.27 (dd, J = 17.3, 
10.4 Hz, 1H), 6.06 (dd, J = 10.4, 1.0 Hz, 1H), 5.95 (d, J = 5.8 Hz, 1H), 5.48 (d, J = 
19.2 Hz, 1H), 5.22 (dd, J = 4.7, 1.6 Hz 1H), 4.64 (d, J = 11.6 Hz, 1H), 4.21 (dtd, J = 
11.6, 7.3, 1.0 Hz, 1H), 3.19 (dd, J = 7.9, 3.2 Hz, 1H), 2.84 (qd, J = 14.3, 7.3 Hz, 2H), 
2.67 – 2.57 (m, 1H), 1.79 (dd, J = 12.2, 7.9 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 137.9, 137.2, 135.3, 134.9, 129.4, 128.6, 126.7, 
118.6, 91.6, 78.4, 64.2, 62.9, 57.3, 53.6, 37.1, 30.8;  
HRMS calculated for C18H19NO5SNa (M+Na)+ 384.0882, found 384.0886. 
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(3S,4R,4aS,7aS)-3-Benzyl-1,1-dioxido-4a,6-divinylhexahydro-2H-furo[2,3-











According to general procedure A, sultam 2.50 (18 mg) underwent ROM-RCM-CM 
with ethylene to yield 2.51 (16 mg, 85%) as a clear oil.  
FTIR (neat): 3480, 2982, 1726 1448, 1305, 1139 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.23 (t, J = 7.3 Hz, 2H), 7.16 (dd, J = 15.3, 7.9 
Hz, 1H), 7.11 (d, J = 7.1 Hz, 2H), 6.43 (dd, J = 17.2, 0.9 Hz, 1H), 6.08 (dd, J = 17.2, 
10.4 Hz 1H), 5.91 (dd, J = 10.4, 0.9 Hz, 1H), 5.77 – 5.69 (m, 1H), 5.66 (dd, J = 17.4, 
10.8 Hz, 1H), 5.26 (d, J = 17.4 Hz, 1H), 5.19 (dd, J = 13.9, 7.4 Hz, 2H), 5.09 (d, J = 
10.2 Hz, 1H), 5.07 (s, 1H), 4.93 (dd, J = 16.2, 7.8 Hz, 1H), 4.36 (d, J = 12.1 Hz, 1H), 
4.27 – 4.19 (m, 1H), 3.63 (d, J = 6.6 Hz, 1H), 2.73 – 2.60 (m, 3H), 2.03 (ddd, J = 
14.0, 9.5, 6.7 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 164.2, 138.9, 138.3, 135.6, 133.2, 129.1, 128.7, 
127.0, 127.0, 118.2, 118.1, 87.1, 81.4, 77.3, 61.8, 54.7, 37.5, 32.8;  












Into a flame dried flask under argon was added methanesulfonyl chloride (2.03 mL, 
26.2 mmol), Et3N (4.4 mL, 31.6 mmol) and dry CH2Cl2 (70 mL).  After cooling down 
to 0 ºC, furfurylamine (2.32 mL, 26.1 mmol) was added and the reaction flask stirred 
at room temperature for 5 h.  After such time, the crude reaction mixture was washed 
with water and the organic layer dried (MgSO4), filtered and concentrated under 
reduced pressure to yield yellow oil.  The crude material was subsequently dissolved 
in CH3CN (100 mL), to which K2CO3 (7.27 g, 52.6 mmol) and allyl bromide (3.0 mL, 
34.6 mmol) was added.  After stirring at 60 ºC for 12 h, the crude reaction mixture 
was filtered through a pad of celite and washed with CH2Cl2.  The crude mixture was 
concentrated under reduced pressure and purified by flash chromatography (4:1 
hexane:EtOAc) to provide desired product 2.52 (5.35 g, 24.8 mmol, 95 % yield) as a 
yellow oil.  
FTIR (neat): 2980,2934, 1733, 1504, 1328, 1147, 925 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.43 – 7.40 (m, 1H), 6.36 (dd, J = 3.1, 1.9 Hz, 
1H), 6.31 (d, J = 3.2 Hz, 1H), 5.78 (ddt, J = 16.4, 10.1, 6.3 Hz, 1H), 5.30 (ddd, J = 
10.9, 8.7, 1.3 Hz 2H), 4.42 (s, 2H), 3.82 (d, J = 6.2 Hz, 2H), 2.79 (s, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 149.7, 142.9, 132.6, 119.4, 110.5, 110.0, 49.3, 
42.5, 39.4;  
HRMS calculated for C9H13NO3SNa (M+Na)+ 238.051, found 238.0510. 
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(3aR,6R,7R,7aR)-Ethyl 2-allyl-3,6,7,7a-tetrahydro-2H-3a,6-









To a flame dried flask was added, 2.52 (2 g, 9.29 mmol), diethyl chlorophosphate (1.6 
mL, 11.1 mmol) and THF (40 mL).  The reaction mixture was cooled to -78 ºC and 
after stirring for 15 mins, LHMDS (1.0 M solution in THF) was added.  The resulting 
solution was warmed to 0 ºC and maintained for 2 h. To another flame dried flask, 
ethyl glyoxalate (3.7 mL, 18.7 mmol) and THF (40 mL) were added at -78 ºC.  After 
stirring for 15 min, this solution was added to the anionic solution containing 2.52 via 
cannula.  The resulting solution was stirred at -78 ºC for 7 h and then warmed to rt 
and stirred for an additional for 18 h.  After such time, NH4Cl (sat. aq., 25 mL) was 
added and the mixture was extracted with CH2Cl2 (4 × 25 mL).  The organic layer 
was dried (MgSO4), filtrated, concentrated under reduced pressure and purified by 
flash chromatography (7:1 hexane:EtOAc) to provide the mixture of Diels-Alder 
product 2.55 and precursor 2.54 product.  Addition of hexane and Et2O followed by 
cooling at 0 ºC, resulted in crystallization of the desired product 2.55 as a white solid 
(1.55g, 5.2 mmol, 56%).  
FTIR (neat): 2983, 1736, 1301, 1141, 1020 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.51 (d, J = 5.7 Hz, 1H), 6.48 (dd, J = 5.7, 1.5 
Hz, 1H), 5.88 (ddt, J = 16.6, 10.1, 6.4 Hz, 1H), 5.40 (dd, J = 4.7, 1.4 Hz 1H), 5.34 
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(dd, J = 17.1, 1.3 Hz, 1H), 5.29 (dd, J = 10.1, 1.0 Hz, 1H), 4.20 – 4.12 (m, 2H), 3.84 
(dd, J = 9.9, 5.9 Hz, 2H), 3.81 – 3.77 (m, 2H), 3.62 (d, J = 11.5 Hz, 1H), 3.55 (d, J = 
3.7 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 168.8, 137.4, 135.6, 132.2, 119.9, 91.8, 81.0, 
63.4, 61.8, 48.8, 48.3, 47.7, 14.2;  













To a flame dried flask was added dry CH2Cl2 (50 mL, 0.005 M), which was degassed 
with ethylene 30 min. After such time, sultam 2.55 (0.1 g, 0.33 mmol) and cat-B 
(0.03 g, 0.033 mmol) were added and the reaction was refluxed at 40 ºC for 1 h under 
ethylene (1 atm).  After cooling to rt, the crude reaction mixture concentrated under 
reduced pressure and purified flash chromatography (6:1 hexane:EtOAc) to yield 2.56 
(58 mg, 1.94 mmol, 59% yield) as a grey solid.   
Mp 155 ºC;  
FTIR (neat): 2978, 1732, 1340, 1194, 999 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.34 (dq, J = 10.1, 2.1 Hz, 1H), 5.73 (ddd, J = 
17.2, 10.4, 6.8 Hz, 1H), 5.58 (dt, J = 2.5, 10.1 Hz, 1H), 5.39 (dt, J = 17.1, 1.2 Hz, 
1H), 5.27 (dt, J = 10.4, 1.1 Hz 1H), 5.08 (dd, J = 8.2, 7.4 Hz, 1H), 4.21 (ddd, J = 6.7, 
5.7, 1.9 Hz 1H), 4.18 – 4.12 (m, 3H), 3.82 – 3.75 (m, 2H), 3.57 (dd, J = 12.3, 2.0 Hz, 
1H), 3.31 (dd, J = 12.3, 2.0 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 168.9, 134.3, 132.7, 124.1, 119.3, 87.2, 84.2, 
72.2, 61.8, 52.7, 51.0, 50.9, 14.1;  
HRMS calculated for C13H17NO5SNa (M+Na)+ 322.0725, found 322.0716. 
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(5aR,6aR,7S,9aR,9bR)-7-(Iodomethyl)-6a,7,9a,9b-tetrahydro-2,5a-












Into a flame dried flask under argon sultam 2.56 (862 mg, 2.88 mmol), CH3CN (11.5 
mL, 0.25 M), and I2 (730 mg, 2.88 mmol) were added.  The resulting solution was 
stirred at rt for 24 h.  The reaction was quenched with aqueous NaHCO3 and the 
aqueous layer was extracted with EtOAc (3 × 10 mL).  The organic layer was dried 
(MgSO4) and was filtered. The filtrate was concentrated under reduced pressure and 
purified by flash chromatography (6:1 hexane:EtOAc) to provide 78 mg (25%) of the 
desired compound.   
FTIR (neat): 2961, 1778, 1354, 1159, 1111 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.26 (dq, J = 10.1, 2.1 Hz, 1H), 5.61 (dt, J = 10.1, 
2.5 Hz, 1H), 4.85 (d, J = 6.6 Hz, 1H), 4.66 (dd, J = 6.9, 3.4 Hz, 1H), 4.24 (dt, J = 
19.7, 2.5 Hz, 1H), 3.99 (dd, J = 6.6, 3.5 Hz, 1H), 3.87 – 3.82 (m, 2H), 3.59 (dd, J = 
12.4, 2.1 Hz, 1H), 3.43(dd, J = 11.1, 3.5 Hz, 1H), 3.30 (dd, J = 11.1, 6.9 Hz, 1H), 
3.29 (dd, J = 12.5, 1.9 Hz, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 173.5, 132.0, 125.0, 89.4, 85.0, 81.2, 73.1, 50.9, 
50.9, 49.0, 3.6;  


















Into an oven dried flask under argon sultam 2.57 (50 mg, 0.13 mmol), 4-
chlorobenzylamine (20 µL, 0.16 mmol), CH3CN (2 mL), and K2CO3 (35 mg, 0.25 
mmol) were added.  The resulting solution was stirred at 65 ºC for 24 h.  The reaction 
was filtered through Celite pad. The filtrate was concentrated under reduced pressure 
and purified by flash chromatography (1:1 hexane:EtOAc) to provide 6 mg (12%) of 
the desired compound.   
FTIR (neat): 3353, 2959, 2924, 1778, 1658, 1650, 1537, 1492, 1337, 1161, 750 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.38 – 7.32 (m, 2H), 7.24 – 7.19 (m, 2H), 6.52 (t, 
J = 5.5 Hz, 1H), 6.44 (ddd, J = 10.1, 4.0, 2.0 Hz, 1H), 5.54 (dt, J = 10.2, 2.5 Hz, 1H), 
5.01 (dd, J = 8.6, 0.9 Hz, 1H), 4.45 (d, J = 5.8 Hz, 2H), 4.34 (dd, J = 8.0, 3.0 Hz, 1H), 
4.17 (dt, J = 19.4, 2.5 Hz, 1H), 3.88 – 3.83 (m, 1H), 3.77 (dt, J = 19.4, 2.2 Hz, 1H), 
3.63 (dd, J = 10.9, 8.7 Hz, 1H), 3.43 (qd, J = 12.4, 1.7 Hz, 2H), 3.27 (dq, J = 5.9, 2.8 
Hz, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 168.4, 135.1, 134.9, 133.8, 129.1, 128.9, 123.3, 
87.8, 87.0, 73.6, 72.5, 54.5, 50.9, 49.6, 43.6, 5.0;  
















Into an oven-dried flask under argon sultam 2.57 (35 mg, 0.09 mmol), morpholine 
(10 µl, 0.11 mmol), CH3CN (2 mL), and K2CO3 (24 mg, 0.17 mmol) were added.  
The resulting solution was stirred at 65 ºC for 18 h.  The reaction was filtered through 
Celite pad. The filtrate was concentrated under reduced pressure and purified by flash 
chromatography (EtOAc) to provide 11 mg (38%) of the desired compound.   
FTIR (neat): 3353, 2959, 2924, 1725, 1685, 1537, 1492, 1337, 1161, 1110, 750 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.44 (dq, J = 10.1, 2.1 Hz, 1H), 5.64 (dt, J = 10.1, 
2.5 Hz, 1H), 4.73 (d, J = 9.0 Hz, 1H), 4.24 (dd, J = 9.0, 5.6, 2.7 Hz, 1H), 4.23 (dt, J = 
19.4, 2.5 Hz, 1H), 4.02 (dd, J = 5.7, 1.9 Hz, 1H), 3.84 (dt, J = 19.5, 2.2 Hz, 1H), 3.82 
– 3.77 (m, 1H), 3.72 – 3.66 (m, 3H), 3.64 – 3.51 (m, 5H), 3.35 (dd, J = 12.4, 2.0 Hz, 
1H), 2.32 (s, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 207.6, 167.6, 133.2, 124.4, 88.1, 86.4, 73.7, 66.6, 
66.4, 51.7, 51.0, 47.9, 46.7, 42.7, 27.5;  
HRMS calculated for C15H20N2O6SNa (M+Na)+ 379.0940, found 379.0930. 
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5.3 Experimental Data for Chapter 3 
General procedure A: Aza-Michael reaction 
Into a 1-dram vial was added a solution of dihydroisothiazole 1,1-dioxide in dry 
MeOH (1 M), DBU (10 mol %) and amine (1.5 eq).  The vial was placed in oil bath 
and heated at 60 ºC for 12 h.  After such time the reaction was diluted in 
CH2Cl2:MeOH (9:1), purified by column chromatography (1:2 hexane:EtOAc) to 
yield the desired product.  
General procedure B: Alkylation/arylation reaction 
Into an r. b. flask was added sulfonamide (1 eq) in dry CH2Cl2 (0.1 M), Cs2CO3 (1.3 
eq) and alkyl bromide (aryl bromide) (1.3 eq).  The resulting mixture was stirrer at 60 
ºC in oil bath for 12 h. The reaction was filtered through Celite plug, concentrated and 
purified by column chromatography (1:1 hexane:EtOAc) to yield the desired sultam 
product. 
General procedure C: Carbonylation reaction 
Into an r. b. flask was added sulfonamide (1 eq) in dry CH3CN (0.1 M). DMAP (0.1 
eq), acyl chloride (1.1 eq) and Et3N (1.3 eq) were added at 0 ºC. The resulting 
mixture was stirrer at rt for 1 h. The reaction was quenched with water, the solution 
extracted with CH2Cl2 (3 × 15 mL). The combined organic layer was dried over 
Na2SO4, filtered and solvent removed under reduced pressure. Flash chromatography 




General procedure D: Sulfonylation followed by allylation to yield 3.61a–h: 
An r. b. flask was containing amine (7 mmol, 1 eq) in dry CH2Cl2 (0.5 M) was cooled 
to 0º C and the reaction mixture was stirred for 10 min. After such time, 2-
chloroethanesulfonyl chloride (7 mmol, 1 eq) and the reaction mixture was warmed to 
rt and stirred for 2 h.  The crude reaction mixture was quenched with 10% HCl. aq, 
the organic layer separated and washed with water, brine, dried over MgSO4.  Simple 
filtration and subsequent concentration yielded the desire sulfonamide in excellent 
crude purity. The crude was taken forward where was solvated in dry CH3CN (0.2 
M), followed by addition of K2CO3 (21 mmol, 3 eq) and allyl bromide (10.5 mmol, 
1.5 eq).  The reaction mixture was heated at 60 ºC for 2–4 h (TLC monitoring), 
filtered through a Celite plug, concentrated and purified by column chromatography 
(3:1 hexane:EtOAc) to yield the desired sulfonamides 3.61a–h. 
General procedure E: RCM of vinylsulfonamide to yield dihydroisothiazole 1,1-
dioxide 3.62–3.69: 
 Into an r. b. flask fitted with reflux condenser was added vinylsulfonamide 3.61a–h 
(9.0 mmol, 1 eq), cat-B (8 mol%), and Ar degassed DCE (0.02 M).  The reaction was 
heated at 45 ºC for 1–2 h (TLC monitoring) under Ar atmosphere.  After such time, 
the reaction was cooled to rt, quenched with ethyl vinyl ether (EVE) [0.5 ml) and 
after stirring for an additional 10 min, the crude mixture was concentrated and 
purified by flash chromatography (7:3 hexane:EtOAc) to yield the desired 
dihydroisothiazole 1,1-dioxide 3.61a–h. 
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General procedure F: Aza-Michael Library protocol: 
Into a 1-dram vial was added a solution of dihydroisothiazole 1,1-dioxide (R)- and 
(S)-3.33 as well as 3.62– 3.69 (75 mg, 1 eq) in dry MeOH (1 M), DBU (10 mol %) 
and amine (1.5 eq).  The vial was placed on a reaction block and heated at 60 ºC for 
12 h.  After such time the reaction was diluted in CH2Cl2:MeOH (9:1), filtered 
through a silica SPE (vacuum box) and flushed with CH2Cl2:MeOH (9:1) [10 ml].  
The crude reaction was concentrated and QC/purified by an automated preparative 









To a solution of amine (0.809 g, 4.56 mmol), DMAP (56 mg, 0.458 mmol) and 
CH2Cl2 (15 mL) were added. 1,2-dichloroethanesulfonyl chloride (0.53 mL, 5.07 
mmol) and Et3N (1.6 mL, 11.48 mmol) was added slowly. The resulting solution was 
stirred at rt for overnight. The organic layer was washed with water and dried with 
anhydrous Na2SO4. The solvent was removed under reduced pressure. Flash 
chromatography (SiO2, 6:1 Hexane/EtOAc) afforded 0.60 g (50%) of desired product 
as yellow oil.  
IR (neat): 3282, 1328, 1147, 1110, 736 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.41 – 7.29 (m, 5H), 6.49 (dd, J = 16.5, 9.9 Hz 
1H), 6.22 (d, J = 16.5 Hz, 1H), 5.90 – 5.77 (m, 2H), 5.32 (dt, J = 17.2, 1.1 Hz, 1H), 
5.24 (dt, J = 10.4, 1.1 Hz, 1H), 4.76 (d, J = 7.3, 1H), 4.59 – 4.48 (m, 2H), 4.09 – 3.99 
(m, 1H), 3.63 – 3.45 (m, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 137.4, 136.9, 135.3, 128.1, 128.0, 127.8, 126.0, 
117.7, 73.4, 72.1, 55.9;  











To a solution of diene sulfonamide (1.54 g, 5.746 mmol) in degassed 1,2-
chloroethane (350 mL, 0.016 M) was added Grubbs 2nd-generation catalyst  (487 mg, 
0.574 mmol) in one portion and the reaction was refluxed for 6 h. The solvent was 
removed under reduced pressure. Flash chromatography (SiO2, 3:1 Hexane/EtOAc) 
afforded 1.20 g (88 % yield) of sultam as brownish liquid.  
 [α]D25 = +68.83 (c = 3.10, CH2Cl2); 
IR (neat): 3259, 3087, 2864, 1286, 1157, 1105 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.42 – 7.30 (m, 5H), 6.80 (dd, J = 6.5, 1.8 Hz, 
1H), 6.77 (dd, J = 6.6, 1.9 Hz, 1H), 4.69 (s, 1H), 4.62 – 4.53 (m, 2H), 4.45 (dt, J = 
6.4, 4.9 Hz, 1H), 3.61 (qd, J = 9.6, 5.9 Hz, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 137.9, 136.6, 128.7, 128.3, 127.9, 127.5, 73.2, 
70.2, 58.6;  













[α]D25 = +20.40 (c = 2.10, CH2Cl2); 
IR (neat): 3280, 1328, 1145, 1110, 968, 736 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.32 – 7.27 (m, 2H), 7.27 – 7.21 (m, 3H), 6.41 
(dd, J = 20.0, 10.4 Hz, 1H), 6.14 (d, J = 16.5 Hz, 1H), 5.78 (d, J = 5.0 Hz, 1H), 5.75 
(ddd, J = 16.5, 10.4, 5.0 Hz, 1H), 5.24 (dt, J = 15.0, 1.1 Hz, 1H), 5.16 (dt, J = 10.4, 
1.1 Hz, 1H), 4.68 (d, J = 7.1 Hz, 1H), 4.46 (dd, J = 15.5, 11.9 Hz, 2H), 4.00 – 3.92 
(m, 1H), 3.52 (dd, J = 9.5, 4.2 Hz, 1H), 3.44 – 3.38 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.4, 136.9, 135.3, 128.6, 128.0, 127.8, 126.0, 
117.7, 73.4, 72.1, 55.9;  















Yield 92%;  
[α]D25 = –68.83 (c = 3.10, CH2Cl2); 
IR (neat): 3255, 2862, 1315, 1279, 1160, 1103 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.42 – 7.30 (m, 5H), 6.80 (dd, J = 6.5, 1.8 Hz, 
1H), 6.77 (dd, J = 6.6, 1.9 Hz, 1H), 4.67 (s, 1H) 4.57 (dd, J = 14.4, 12.0 Hz, 2H), 4.47 
– 4.42 (m, 1H), 3.61 (ddd, J = 16.1, 9.6, 5.9 Hz, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 138.2, 136.9, 129.1, 128.7, 128.2, 127.9, 73.6, 
70.5, 58.9;  

















Procedure B; Yield 79%;  
[α]D25 = +38.03 (c = 1.27, CH2Cl2); 
IR (neat): 3205, 3085, 2927, 2864, 1608, 1454, 1290, 1153, 1097 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.41 – 7.30 (m, 5H), 6.85 (dd, J = 7.0, 2.0 Hz, 
1H), 6.71 (dd, J = 7.0, 2.1 Hz, 1H), 4.62 – 4.51 (m, 2H), 4.05 (tt, J = 6.1, 2.1 Hz, 1H), 
3.69 (dd, J = 9.5, 6.1 Hz, 1H), 3.55 (dd, J = 9.5, 6.1 Hz, 1H), 2.88 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.1, 137.0, 128.5, 128.0, 127.7, 127.5, 73.6, 
70.4, 64.3, 29.8; 
















Procedure B; Yield 87%; 
[α]D25 = +31.57 (c = 0.70, CH2Cl2); 
IR (neat): 3086, 2901, 2864, 1610, 1363, 1294, 1153, 1105, 738 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.35 (m, 2H), 7.33 (td, J = 6.4, 1.4 Hz, 
3H), 6.89 (dd, J = 6.9, 2.2 Hz, 1H), 6.71 (dd, J = 6.9, 2.0 Hz, 1H), 5.91 (dddd, J = 
17.2, 10.1, 7.2, 5.8 Hz, 1H), 5.30 (ddd, J = 17.1, 2.8, 1.4 Hz, 1H), 5.26 (ddd, J = 10.1, 
2.4, 1.1 Hz, 1H), 4.55 (s, 2H), 4.21 (ddt, J = 6.9, 5.7, 2.1 Hz, 1H), 3.94 – 3.83 (m, 
2H), 3.70 (dd, J = 9.4, 5.6 Hz, 1H), 3.50 (dd, J = 9.4, 6.8 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.3, 137.2, 132.6, 128.6, 128.1, 127.7, 127.5, 
120.0, 73.6, 70.5, 61.8, 46.8; 














Procedure B; Yield 98%;  
[α]D25 = +42.13 (c = 2.15, CH2Cl2); 
IR (neat): 3087, 2862, 1609, 1497, 1454, 1288, 1153, 1107, 738, 698 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.40 – 7.29 (m, 8H), 7.26 – 7.22 (m, 2H), 6.87 
(dd, J = 7.0, 2.3 Hz, 1H), 6.75 (dd, J = 7.0, 2.0 Hz, 1H), 4.47 (d, J = 15.3 Hz, 1H), 
4.40 (s, 2H), 4.38 (d, J = 13.7 Hz, 1H), 4.10 (ddt, J = 7.5, 5.3, 2.1 Hz, 1H), 3.46 (dd, J 
= 9.5, 5.4 Hz, 1H), 3.36 (dd, J = 9.5, 6.7 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.3, 137.2, 135.6, 128.8, 128.7, 128.6, 128.5, 
128.0, 127.8, 127.3, 73.5, 70.1, 62.0, 47.2; 













BnO Br  
Procedure B; Yield 71%;  
[α]D25 = +32.00 (c = 1.50, CH2Cl2); 
IR (neat): 3263, 2860, 1452, 1286, 1153, 1103, 746 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.44 (d, J = 8.4 Hz, 2H), 7.39 – 7.30 (m, 4H), 
7.24 (d, J = 8.5 Hz, 4H), 6.84 (dd, J = 7.0, 2.2 Hz, 1H), 6.75 (dd, J = 7.0, 1.9 Hz, 1H), 
4.44 (d, J = 14.0 Hz, 1H), 4.42 (s, 2H), 4.33 (d, J = 15.5 Hz, 1H), 4.09 (tt, J = 6.0, 2.4 
Hz, 1H), 3.47 (dd, J = 9.5, 5.8 Hz, 1H), 3.40 (dd, J = 9.5, 6.2 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.0, 136.9, 134.8, 131.8, 130.3, 128.6, 128.1, 
127.8, 127.4, 122.0, 73.6, 70.3, 62.2, 46.7; 












BnO NO2  
Procedure B; Yield 36%;  
[α]D25 = +80.00 (c = 0.50, CH2Cl2); 
IR (neat): 3082, 2864, 1609, 1518, 1346, 1288, 1153, 748 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 8.15 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.5 Hz, 2H), 
7.34 (dd, J = 5.1, 1.6 Hz, 3H), 7.23 – 7.17 (m, 2H), 6.84 (dd, J = 7.0, 1.9 Hz, 1H), 
6.79 (dd, J = 7.2, 1.6 Hz, 1H), 4.66 (d, J = 16.1 Hz, 1H), 4.44 (d, J = 16.0 Hz, 1H), 
4.41 (d, J = 1.9 Hz, 2H), 4.16 (t, J = 5.8 Hz, 1H), 3.49 (d, J = 5.6 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 147.6, 143.7, 136.7, 136.5, 129.1, 128.6, 128.3, 
127.9, 127.6, 123.8, 73.6, 70.7, 63.1, 47.0; 















Procedure B; Yield 47%;  
[α]D25 = +54.29 (c = 1.05, CH2Cl2); 
IR (neat): 3088, 2920, 2864, 1285, 1155, 1105, 1094, 750 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.38 – 7.30 (m, 3H), 7.24 (dd, J = 7.6, 1.2 Hz, 
2H), 7.21 (d, J = 8.3 Hz, 1H), 7.16 (d, J = 7.3 Hz, 2H), 7.11 (d, J = 7.6 Hz, 1H), 6.87 
(dd, J = 7.0, 2.3 Hz, 1H), 6.75 (dd, J = 7.0, 2.0 Hz, 1H), 4.41 (d, J = 15.2 Hz, 1H), 
4.40 (s, 2H), 4.35 (d, J = 15.2 Hz, 1H), 4.10 (ddt, J = 7.4, 5.2, 2.1 Hz, 1H), 3.46 (dd, J 
= 9.5, 5.3 Hz, 1H), 3.35 (dd, J = 9.5, 6.7 Hz, 1H), 2.33 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 138.4, 137.4, 137.2, 135.5, 129.3, 128.8, 128.6, 
128.5, 128.0, 127.8, 127.2, 125.7, 73.5, 70.0, 61.9, 47.1, 21.4;  














Procedure C; Yield 74%;  
[α]D25 = +247.64 (c = 0.55, CH2Cl2); 
IR (neat): 3088, 2864, 1678, 1448, 1330, 1278, 1166, 1114, 723, 696 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.88 (dt, J = 8.4, 1.5 Hz, 2H), 7.64 61 (tt, J = 7.5, 
1.3 Hz, 1H), 7.50 (t, J = 8.0 Hz, 2H), 7.40 – 7.34 (m, 4H), 7.34 – 7.29 (m, 1H), 7.04 
(dd, J = 7.1, 2.8 Hz, 1H), 6.68 (dd, J = 7.1, 2.0 Hz, 1H), 5.52 (ddd, J = 9.0, 4.6, 2.7 
Hz, 1H), 4.66 – 4.58 (m, 2H), 3.91 (dd, J = 9.7, 4.2 Hz, 1H), 3.70 (dd, J = 9.7, 6.6 Hz, 
1H); 
13C NMR (125 MHz, CDCl3) δ ppm 168.2, 137.3, 136.9, 133.9, 132.9, 128.6, 128.6, 
128.4, 128.0, 127.7, 126.5, 73.7, 69.2, 59.7; 














Procedure C; Yield 18%;  
[α]D25 = +182.66 (c = 3.13, CH2Cl2); 
IR (neat): 30888, 2864, 1681, 1589, 1331, 1167, 1111, 1012, 750 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.77 – 7.72 (m, 2H), 7.66 – 7.62 (m, 2H), 7.39 – 
7.29 (m, 5H), 7.04 (dd, J = 7.1, 2.8 Hz, 1H), 6.68 (dd, J = 7.1, 2.0 Hz, 1H), 5.50 (ddd, 
J = 6.4, 4.3, 2.6 Hz, 1H), 4.61 (s, 2H), 3.89 (dd, J = 9.7, 4.2 Hz, 1H), 3.68 (dd, J = 
9.7, 6.4 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 167.3, 137.2, 137.0, 132.7, 131.8, 130.2, 128.6, 
128.1, 128.0, 127.7, 126.4, 73.7, 69.0, 59.7; 














Procedure C; Yield 75%;  
[α]D25 = +189.46 (c = 3.96, CH2Cl2); 
IR (neat): 3086, 2866, 1684, 1525, 1335, 1315, 1169, 1124, 1111, 734 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 8.37 – 8.32 (m, 2H), 8.01 – 7.96 (m, 2H), 7.41 – 
7.30 (m, 5H), 7.06 (dd, J = 7.2, 2.8 Hz, 1H), 6.71 (dd, J = 7.2, 2.0 Hz, 1H), 5.47 
(dddd, J = 8.9, 4.1, 2.7, 2.1 Hz, 1H), 4.61 (d, J = 5.7 Hz, 2H), 3.93 (dd, J = 9.7, 4.1 
Hz, 1H), 3.74 (dd, J = 9.7, 6.2 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 166.3, 150.1, 139.2, 137.2, 137.1, 129.7, 128.6, 
128.2, 127.7, 126.4, 123.6, 73.7, 68.7, 59.8; 















Procedure C; Yield 54%;  
[α]D25 = +214.73 (c = 1.60, CH2Cl2); 
IR (neat): 3086, 2866, 1682, 1583, 1328, 1159, 1114, 1041, 746 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.49 (dt, J = 7.6, 1.1 Hz, 1H), 7.44 – 7.34 (m, 
6H), 7.34 – 7.28 (m, 1H), 7.15 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 7.03 (dd, J = 7.1, 2.8 
Hz, 1H), 6.67 (dd, J = 7.1, 2.0 Hz, 1H), 5.52 (ddd, J = 9.0, 4.3, 2.6 Hz, 1H), 4.62 (d, J 
= 1.5 Hz, 2H), 3.90 (dd, J = 8.0, 4.0 Hz, 1H), 3.87 (s, 3H), 3.69 (dd, J = 9.7, 6.6 Hz, 
1H); 
13C NMR (125 MHz, CDCl3) δ ppm 168.0, 159.4, 137.3, 136.9, 135.0, 129.5, 128.5, 
128.0, 127.7, 126.5, 121.1, 119.7, 113.1, 73.7, 69.2, 59.7, 55.4; 














Procedure C; Yield 58%;  
[α]D25 = +211.92 (c = 1.09, CH2Cl2); 
IR (neat): 3090, 2962, 2868, 1680, 1606, 1332, 1278, 1168, 1116, 736 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.88 – 7.84 (m, 2H), 7.54 – 7.49 (m, 2H), 7.39 – 
7.34 (m, 4H), 7.31 (m, 1H), 7.03 (dd, J = 7.1, 2.7 Hz, 1H), 6.67 (dd, J = 7.1, 2.0 Hz, 
1H), 5.55 (ddd, J = 9.0, 4.3, 2.6 Hz, 1H), 4.61 (d, J = 4.2 Hz, 2H), 3.89 (dd, J = 9.7, 
4.2 Hz, 1H), 3.67 (dd, J = 9.7, 6.6 Hz, 1H), 1.36 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ ppm 168.1, 156.6, 137.3, 136.9, 131.0, 128.7, 128.5, 
128.0, 127.7, 126.5, 125.5, 73.7, 69.3, 59.7, 35.1, 31.1; 

















Procedure C; Yield 98%;  
[α]D25 = +83.10 (c = 3.39, CH2Cl2); 
IR (neat): 3086, 2964, 2924, 2860, 1682, 1614, 1427, 1317, 1244, 1159, 1115, 740 
cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.39 – 7.34 (m, 2H), 7.34 – 7.29 (m, 3H), 6.93 
(dd, J = 6.8, 2.6 Hz, 1H), 6.64 (dd, J = 6.8, 2.2 Hz, 1H), 5.54 – 5.49 (m, 1H), 4.56 (t, 
J = 3.6 Hz, 2H), 3.84 – 3.73 (m, 4H), 3.71 – 3.55 (m, 6H); 
13C NMR (125 MHz, CDCl3) δ ppm 152.3, 137.5, 137.2, 128.5, 128.0, 127.6, 126.2, 
73.3, 70.6, 66.5, 60.5, 46.8; 












Procedure C; Yield 86%;  
[α]D25 = +92.26 (c = 2.28, CH2Cl2); 
IR (neat): 2923, 2866, 1688, 1622, 1454, 1407, 1323, 1247, 1137, 1047, 977, 792, 
738, 698 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.38 – 7.33 (m, 2H), 7.33 – 7.29 (m, 3H), 7.04 
(dd, J = 7.2, 2.7 Hz, 1H), 6.95 (dd, J = 16.6, 10.4 Hz, 1H), 6.72 (dd, J = 7.2, 1.9 Hz, 
1H), 6.58 (dd, J = 16.6, 1.4 Hz, 1H), 5.96 (dd, J = 10.4, 1.4 Hz, 1H), 5.12 (dddd, J = 
5.6, 3.6, 2.6, 2.0 Hz, 1H), 4.55 (s, 2H), 3.98 (dd, J = 9.6, 3.6 Hz, 1H), 3.68 (dd, J = 
9.6, 6.6 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 162.4, 137.7, 137.2, 132.2, 128.5, 128.0, 127.7, 
127.5, 126.3, 73.7, 68.4, 59.5; 













Procedure A; Yield 88%;  Mp 98 ºC; 
[α]D25 = –56.08 (c = 5.27, CH2Cl2); 
IR (neat): 3260, 2825, 1598, 1310, 1234, 1137, 1012 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm δ 7.41 – 7.35 (m, 2H), 7.35 – 7.30 (m, 3H), 4.71 
(d, J = 7.5 Hz, 1H), 4.57 (s, 2H), 3.78 (dd, J = 7.7, 1.4 Hz, 1H), 3.71 (m, 2H), 3.65 – 
3.56 (m, 1H), 3.22 (qd, J = 13.2, 8.0 Hz, 2H), 2.66 – 2.49 (m, 4H), 1.82 – 1.73 (m, 
4H);  
13C NMR (125 MHz, CDCl3) δ ppm 137.3, 128.6, 128.1, 127.8, 73.5, 68.4, 61.8, 58.0, 
49.8, 47.1, 23.5;  














Procedure A; Yield 30%;  
[α]D25 = –62.37 (c = 1.95, CH2Cl2); 
IR (neat): 3260, 2924, 1299, 1132, 1027 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.31 (ddd, J = 7.4, 4.4, 1.4 Hz, 2H), 7.26 (ddd, J 
= 12.7, 5.6, 4.1 Hz, 3H), 4.58 (s, 1H), 4.49 (dd, J = 11.9, 21.6 Hz, 2H), 3.89 (dt, J = 
9.1, 7.2 Hz, 1H), 3.67 – 3.58 (m, 2H), 3.30 (ddd, J = 30.1, 10.9, 4.8 Hz, 2H), 3.13 
(ddd, J = 37.9, 13.4, 7.0 Hz, 2H), 3.06 – 2.97 (m, 2H), 2.55 (dd, J = 15.9, 8.3 Hz, 
1H), 1.82 – 1.57 (m, 4H);  
13C NMR (125 MHz, CDCl3) δ ppm 137.1, 128.6, 128.2, 128.0, 73.5, 68.1, 65.0, 61.8, 
59.5, 57.6, 52.5, 49.3, 29.1, 24.3;  














Procedure A; Yield 30%;  
[α]D25 = –83.43 (c = 1.58, CH2Cl2); 
IR (neat): 3247, 2932, 2871, 1454, 1328, 1303, 1137, 1112 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.41 – 7.30 (m, 5H), 4.66 – 4.52 (m, 3H), 4.28 
(dd, J = 16.4, 9.3 Hz, 1H), 3.74 (d, J = 3.5 Hz, 2H), 3.57 – 3.47 (m, 1H), 3.31 (s, 3H), 
3.26 – 3.15 (m, 4H), 2.90 (ddd, J = 10.5, 6.2, 4.5 Hz, 1H), 2.80 – 2.72 (m, 1H), 2.62 
(dd, J = 16.7, 7.8 Hz, 1H), 1.88 – 1.69 (m, 3H), 1.55 – 1.46 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.3, 128.6, 128.1, 127.8, 76.8, 73.6, 67.2, 61.5, 
60.9, 59.1, 58.0, 46.1, 45.5, 28.4, 23.3; 













Procedure A; Yield 72%;  
[α]D25 = –96.35 (c = 3.43, CH2Cl2); 
IR (neat): 3265, 2945, 2864, 1328, 1299, 1139, 1101, 700 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.36 (m, 2H), 7.35 – 7.30 (m, 3H), 4.82 
(dd, J = 35.1, 7.8 Hz, 1H), 4.59 (d, J = 11.5 Hz, 1H), 4.55 (d, J = 11.8 Hz, 1H), 4.34 
(s, 1H), 3.81 (tt, J = 16.6, 8.3 Hz, 1H), 3.75 – 3.65 (m, 2H), 3.57 (dq, J = 12.2, 4.2 
Hz, 1H), 3.29 (dd, J = 13.4, 6.5 Hz, 1H), 3.20 (dd, J = 13.3, 9.2 Hz, 1H), 2.82 (dd, J = 
16.1, 7.5 Hz, 1H), 2.77 – 2.67 (m, 2H), 2.58 (m, 1H), 2.13 – 2.00 (m, 1H), 1.95 – 1.84 
(m, 1H), 1.80 – 1.70 (m, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 137.2, 128.6, 128.1, 127.9, 73.4, 70.8, 68.2, 68.0, 
61.8, 61.7, 58.6, 57.8, 53.7, 48.1, 48.0, 47.5, 47.4, 34.3, 31.7, 29.2;  












Procedure A; Yield 74%;  
[α]D25 = –95.66 (c = 4.27, CH2Cl2); 
IR (neat): 3261, 2935, 2854, 1454, 1328, 1311, 1145, 1107, 912 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.42 – 7.29 (m, 5H), 4.60 (d, J = 11.9 Hz, 1H), 
4.58 – 4.55 (m, 1H), 4.54 (d, J = 11.9 Hz, 1H), 3.71 (d, J = 3.7 Hz, 2H), 3.68 – 3.57 
(m, 1H), 3.57 – 3.50 (m, 1H), 3.30 (dd, J = 13.2, 7.2 Hz, 1H), 3.08 (dd, J = 13.2, 9.5 
Hz, 1H), 2.50 (ddd, J = 10.6, 7.0, 3.5 Hz, 2H), 2.38 (ddd, J = 10.2, 6.1, 3.4 Hz, 2H), 
1.62 – 1.48 (m, 5H), 1.44 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.3, 128.6, 128.1, 127.9, 73.4 68.0 65.5, 56.6, 
51.0, 45.0, 26.1, 24.3; 












Procedure A; Yield 44%;  
[α]D25 = –110.81 (c = 2.84, CH2Cl2); 
IR (neat): 3254, 2956, 2858, 1496, 1454,1336, 1296, 1134, 1117, 914 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.42 – 7.29 (m, 5H), 4.63 – 4.61 (m, 1H), 4.61 
(dt, J = 11.9 Hz, 3H), 4.54 (d, J = 11.9 Hz, 1H), 3.73 (d, J = 3.3 Hz, 2H), 3.70 – 3.59 
(m, 5H), 3.52 (ddd, J = 12.1, 8.4, 3.6 Hz, 1H), 3.31 (dd, J = 13.4, 6.7 Hz, 1H), 3.11 
(dd, J = 13.4, 9.7 Hz, 1H), 2.55 (ddd, J = 10.9, 5.7, 3.3 Hz, 2H), 2.46 (ddd, J = 11.1, 
5.2, 3.8 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.1, 128.6, 128.2, 128.0, 73.4, 67.5, 66.8, 65.0, 
56.1, 50.0, 45.2; 













Procedure A; Yield 35%;  
[α]D25 = –81.83 (c = 2.80, CH2Cl2); 
IR (neat): 3263, 3026, 2918, 2850, 1452, 1330, 1303, 1151, 1130 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.41 – 7.34 (m, 3H), 7.34 – 7.28 (m, 4H), 7.20 (t, 
J = 7.3 Hz, 1H), 7.13 (d, J = 6.9 Hz, 2H), 4.59 (d, J = 11.9 Hz, 1H), 4.58 – 4.56 (m, 
1H), 4.54 (d, J = 11.9 Hz, 1H), 3.70 (d, J = 3.7 Hz, 2H), 3.64 (dd, J = 16.5, 8.9 Hz, 
1H), 3.56 – 3.47 (m, 1H), 3.26 (dd, J = 13.2, 7.2 Hz, 1H), 3.07 (dd, J = 13.2, 9.5 Hz, 
1H), 2.80 – 2.72 (m, 2H), 2.58 – 2.46 (m, 2H), 2.20 (td, J = 11.4, 2.5 Hz, 1H), 2.04 
(td, J = 11.4, 9.1 Hz, 1H), 1.69 – 1.60 (m, 2H), 1.51 (ddd, J = 11.3, 7.5, 3.9 Hz, 1H), 
1.31 – 1.11 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 140.3, 137.3, 129.0, 128.6, 128.2, 128.1, 127.8, 
125.9, 73.4, 68.0, 65.0, 56.7, 53.9, 46.7, 45.1, 43.0, 37.9, 32.5, 32.0; 












Procedure A; Yield 35%;  
[α]D25 = –95.33 (c = 0.60, CH2Cl2); 
IR (neat): 3261, 2825, 1598, 1496, 1332, 1234, 1137, 1012, 696 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.42 – 7.36 (m, 2H), 7.36 – 7.31 (m, 3H), 7.31 – 
7.24 (m, 3H), 6.94 – 6.87 (m, 3H), 4.65 (d, J = 8.6 Hz, 1H), 4.57 (dd, J = 19.0, 11.8 
Hz, 2H), 3.79 – 3.69 (m, 3H), 3.55 (tdd, J = 9.5, 7.7, 3.9 Hz, 1H), 3.40 – 3.29 (m, 
1H), 3.24 – 3.07 (m, 5H), 2.77 – 2.57 (m, 4H);  
13C NMR (125 MHz, CDCl3) δ ppm 151.0, 137.2, 129.2, 128.6, 128.2, 128.0, 120.2, 
116.3, 73.5, 67.6, 64.7, 56.5, 49.6, 49.4, 45.3;  













Procedure B; Yield 29%;  
[α]D25 = –110.59 (c = 0.85, CH2Cl2); 
IR (neat): 2961, 2916, 2858, 1456, 1307, 1136, 750 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.39 – 7.29 (m, 5H), 5.88 (dddd, J = 17.6, 10.1, 
7.6, 5.2 Hz, 1H), 5.22 (ddd, J = 13.6, 11.4, 1.2 Hz, 2H), 4.55 (s, 2H), 3.94 (ddt, J = 
15.5, 5.2, 1.4 Hz, 1H), 3.77 (dd, J = 15.5, 7.7 Hz, 1H), 3.69 – 3.62 (m, 2H), 3.61 – 
3.51 (m, 2H), 3.29 (dd, J = 12.6, 7.4 Hz, 1H), 3.13 (dd, J = 12.6, 6.8 Hz, 1H), 2.60 
(m, 2H), 2.54 (m, 2H), 1.81 – 1.75 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.7, 133.0, 128.4, 127.8, 127.7, 119.2, 73.3, 
70.2, 60.3, 57.7, 50.0, 47.1, 46.5, 23.4; 












Procedure B; Yield 35%;  
[α]D25 = –35.20 (c = 2.00, CH2Cl2); 
IR (neat): 2961, 2871, 1456, 1306, 1136, 1027, 736, 698 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.38 – 7.25 (m, 10H), 4.47 (d, J = 15.2 Hz, 1H), 
4.39 (s, 2H), 4.34 (d, J = 15.3 Hz, 1H), 3.64 – 3.53 (m, 3H), 3.45 (dt, J = 9.2, 4.6 Hz, 
1H), 3.34 (dd, J = 12.6, 7.7 Hz, 1H), 3.17 (dd, J = 12.6, 7.3 Hz, 1H), 2.55 – 2.47 (m, 
2H), 2.46 – 2.38 (m, 2H), 1.76 – 1.68 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.7, 136.2, 128.6, 128.5, 128.4, 127.8, 127.7, 
127.6, 73.2, 70.3, 60.1, 57.5, 49.8, 46.9, 23.4(2); 














Procedure B; Yield 37%;  
[α]D25 = –75.00 (c = 0.88, CH2Cl2); 
IR (neat): 2920, 2864, 1452, 1303, 1134, 748 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.28 (m, 5H), 7.20 (t, J = 7.4 Hz, 1H), 7.14 (d, J 
= 9.0 Hz, 2H), 7.08 (d, J = 7.3 Hz, 1H), 4.44 (d, J = 15.1 Hz, 1H), 4.39 (d, J = 1.2 Hz, 
2H), 4.29 (d, J = 15.2 Hz, 1H), 3.65 – 3.53 (m, 3H), 3.45 (td, J = 5.5, 3.7 Hz, 1H), 
3.34 (dd, J = 12.6, 7.7 Hz, 1H), 3.18 (dd, J = 12.6, 7.2 Hz, 1H), 2.53 – 2.51 (m, 2H), 
2.47 – 2.41 (m, 2H), 2.29 (s, 3H), 1.73 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 138.1, 137.8, 136.0, 129.3, 128.4, 128.4, 128.3, 
127.7, 127.6, 125.6, 73.2, 70.2, 60.0, 57.5, 49.8, 46.9, 46.7, 23.4, 21.3; 












Procedure B; Yield 87%;  
[α]D25 = –46.03 (c = 2.44, CH2Cl2); 
IR (neat): 2960, 2910, 2806, 1601, 1517, 1346, 1346, 1306, 1136, 860, 734 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 8.14 – 8.07 (m, 2H), 7.47 (d, J = 8.8 Hz, 2H), 
7.36 – 7.29 (m, 3H), 7.21 – 7.16 (m, 2H), 4.57 (d, J = 16.1 Hz, 1H), 4.43 (d, J = 16.1 
Hz, 1H), 4.34 (s, 2H), 3.61 (m, 2H), 3.55 (dd, J = 14.0, 7.5 Hz, 1H), 3.46 (td, J = 5.8, 
3.9 Hz, 1H), 3.36 (dd, J = 12.5, 7.6 Hz, 1H), 3.20 (dd, J = 12.5, 7.8 Hz, 1H), 2.61 – 
2.44 (m, 4H), 1.77 (dd, J = 6.1, 3.2 Hz, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 147.3, 144.5, 137.2, 128.9, 128.4, 128.0, 127.7, 
123.6, 73.4, 71.1, 61.6, 57.5, 50.0, 46.9, 46.5, 23.4; 














Procedure C; Yield 56%;  
[α]D25 = +15.88 (c = 2.02, CH2Cl2); 
IR (neat): 2962, 2872, 1678, 1450, 1339, 1290, 1124, 1026, 734, 696 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.85 – 7.80 (m, 2H), 7.57 (tt, J = 7.6, 1.2 Hz, 
1H), 7.50 – 7.44 (m, 2H), 7.38 – 7.28 (m, 5H), 4.87 (dt, J = 6.4, 3.9 Hz, 1H), 4.65 (d, 
J = 12.2 Hz, 1H), 4.56 (d, J = 12.2 Hz, 1H), 3.90 (dt, J = 8.8, 6.5 Hz, 1H), 3.84 – 3.76 
(m, 2H), 3.57 (dd, J = 12.6, 6.6 Hz, 1H), 3.37 (dd, J = 12.6, 8.7 Hz, 1H), 2.73 – 2.60 
(m, 4H), 1.81 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 168.8, 137.8, 134.7, 132.6, 128.6, 128.4, 128.3, 
127.7, 127.5, 73.3, 68.2, 59.6, 55.7, 50.0, 49.8, 23.5; 













Procedure C; Yield 96%;  
[α]D25 = +8.82 (c = 1.23, CH2Cl2); 
IR (neat): 2961, 2871, 1678, 1521, 1344, 1308, 1128, 736 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 8.35 – 8.28 (m, 2H), 7.95 – 7.89 (m, 2H), 7.37 – 
7.31 (m, 5H), 4.85 (dt, J = 5.7, 3.7 Hz, 1H), 4.64 (d, J = 12.1 Hz, 1H), 4.59 (d, J = 
12.1 Hz, 1H), 3.90 – 3.78 (m, 3H), 3.64 (dd, J = 12.8, 6.5 Hz, 1H), 3.41 (dd, J = 12.8, 
8.0 Hz, 1H), 2.73 – 2.59 (m, 4H), 1.86 – 1.83 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 166.9, 149.9, 140.1, 137.6, 129.5, 128.5, 127.9, 
127.6, 123.5, 73.4, 68.0, 59.8, 56.3, 50.2, 30.94, 23.5; 










Procedure B; Yield 84%;  
[α]D25 = +69.33 (c = 2.25, CH2Cl2); 
IR (neat): 3271, 2864, 1296, 1157, 1107 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.36 (m, 2H), 7.35 – 7.30 (m, 3H), 6.89 
(dd, J = 6.9, 2.2 Hz, 1H), 6.74 (dd, J = 6.9, 2.0 Hz, 1H), 4.58 (d, J = 1.8 Hz, 2H), 4.48 
(tt, J = 6.2, 2.2 Hz, 1H), 4.17 (dd, J = 18.0, 2.4 Hz, 1H), 4.04 (dd, J = 18.0, 2.2 Hz, 
1H), 3.76 (dd, J = 9.5, 6.3 Hz, 1H), 3.60 (dd, J = 9.5, 6.1 Hz, 1H), 2.33 (t, J = 2.5 Hz, 
1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.3, 137.2, 128.6, 128.1, 127.7, 127.5, 77.1, 
73.9, 73.7, 70.7, 61.8, 33.9; 













Into an r. b. flask was added sulfonamide 3.31 (200 mg, 0.72 mmol) and benzyl azide 
(191 mg, 1.440 mmol) in CH2Cl2/tBuOH (1.25 mL/1.25 mL). The aq. solution 
mixture of CuSO4•5H2O (36 mg, 0.14 mmol) and (+)-sodim L-ascorbate (43 mg, 
0.217 mmol) in water (1.25 mL) was added into the previous flask. The resulting 
mixture was stirred at rt for 12 h. The separated aqueous layer was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Flash chromatography (1:1 hexane:EtOAc) 
afforded the desired product 3.32. 
Yield 97%; 
[α]D25 = +61.68 (c = 2.80, CH2Cl2); 
IR (neat): 3086, 2860, 1454, 1290, 1153, 1105, 741 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.64 (s, 1H), 7.38 – 7.33 (m, 5H), 7.31 (t, J = 6.0 
Hz, 3H), 7.24 (dd, J = 7.1, 2.4 Hz, 2H), 6.85 (dd, J = 6.9, 2.2 Hz, 1H), 6.66 (dd, J = 
6.9, 2.0 Hz, 1H), 5.52 (d, J = 14.8 Hz, 1H), 5.43 (d, J = 14.8 Hz, 1H), 4.62 – 4.51 (m, 
2H), 4.52 – 4.47 (m, 2H), 4.30 (ddd, J = 8.9, 4.9, 2.1 Hz, 1H), 3.73 (dd, J = 9.7, 5.1 
Hz, 1H), 3.52 (dd, J = 9.7, 6.6 Hz, 1H); 
 244 
13C NMR (125 MHz, CDCl3) δ ppm 143.0, 138.0, 137.3, 134.4, 129.1, 128.8, 128.5, 
128.0, 127.9, 127.7, 127.0, 124.0, 73.5, 69.6, 61.6, 54.3, 38.3; 
HRMS calculated for C21H22N4O3SNa (M+Na)+ 433.1310, found 433.1308.  
 245 
(3R,4S)-3-((Benzyloxy)methyl)-2-(prop-2-yn-1-yl)-4-(pyrrolidin-1-







Procedure A; Yield 48%;  
[α]D25 = –34.80 (c = 1.25, CH2Cl2); 
IR (neat): 3333, 2920, 2872, 1132, 1137, 912, 741 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.34 (m, 3H), 7.34 – 7.29 (m, 2H), 4.58 (s, 
2H), 4.23 (dd, J = 18.1, 2.4 Hz, 1H), 3.93 (dd, J = 18.1, 2.4 Hz, 1H), 3.81 (dd, J = 
9.7, 2.6 Hz, 1H), 3.76 (td, J = 7.1, 2.5 Hz, 1H), 3.69 (dd, J = 9.7, 6.8 Hz, 1H), 3.62 
(dt, J = 8.8, 7.3 Hz, 1H), 3.27 (dd, J = 12.2, 7.2 Hz, 1H), 3.11 (dd, J = 12.2, 8.9 Hz, 
1H), 2.66 – 2.56 (m, 4H), 2.32 (t, J = 2.4 Hz, 1H), 1.81 – 1.75 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.8, 128.5, 127.8, 127.6, 77.9, 73.5, 73.4, 71.3, 
60.5, 57.2, 49.8, 45.8, 35.5, 23.5; 

















Into an r. b. flask was added sulfonamide 3.33 (137 mg, 0.39 mmol) and benzyl azide 
(104 mg, 0.780 mmol) in CH2Cl2/tBuOH (0.7 mL/0.7 mL). The aq. solution mixture 
of CuSO4•5H2O (20 mg, 0.08 mmol) and (+)-sodim L-ascorbate (23 mg, 0.12 mmol) 
in water (0.7 mL) was added into the previous flask. The resulting mixture was stirred 
at rt for 12 h. The separated aqueous layer was extracted with CH2Cl2 (3 × 20 mL). 
The combined organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure. Flash chromatography (1:1 hexane:EtOAc) afforded the desired 
product 3.34. 
Yield 84%;  
[α]D25 = –17.95 (c = 2.98, CH2Cl2); 
IR (neat): 2951, 2934, 1454, 1359, 1303, 1135, 1047, 750 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.59 (s, 1H), 7.37 – 7.32 (m, 5H), 7.32 – 7.29 (m, 
3H), 7.24 – 7.20 (m, 2H), 5.47 (d, J = 14.8 Hz, 1H), 5.41 (d, J = 14.8 Hz, 1H), 4.58 
(d, J = 16.2 Hz, 1H), 4.48 (d, J = 15.9 Hz, 1H), 4.46 (d, J = 1.1 Hz, 2H), 3.74 (dd, J = 
10.3, 3.2 Hz, 1H), 3.69 – 3.59 (m, 1H), 3.63 (dd, J = 10.4, 4.9 Hz, 1H), 3.53 (m, 1H), 
3.26 (dd, J = 12.5, 7.7 Hz, 1H), 3.02 (dd, J = 12.5, 7.2 Hz, 1H), 2.43 (m, 4H), 1.68 
(m, 4H); 
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13C NMR (125 MHz, CDCl3) δ ppm 143.7, 137.9, 134.6, 129.1, 128.7, 128.4, 127.9, 
127.7, 127.5, 123.7, 73.1, 69.2, 60.4, 57.2, 54.1, 49.8, 46.6, 38.9, 23.4; 











Procedure B; Yield 26%;  
[α]D25 = –58.00 (c = 1.50, CH2Cl2); 
IR (neat): 3475, 2984, 2867, 1497, 1304, 1134, 912, 742 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.30 (m, 5H), 5.92 – 5.82 (m, 1H), 5.23 
(dd, J = 6.3, 1.4 Hz, 1H), 5.20 (d, J = 1.2 Hz, 1H), 4.55 (d, J = 5.0 Hz, 2H), 3.97 (q, J 
= 7.9 Hz, 1H), 3.88 (ddt, J = 15.7, 5.1, 1.4 Hz, 1H), 3.69 (dd, J = 15.5, 7.8 Hz, 1H), 
3.67 (dd, J = 10.8, 4.7 Hz, 1H), 3.62 – 3.59 (m, 1H), 3.60 (dd, J = 10.2, 4.2 Hz, 1H), 
3.46 (dt, J = 7.7, 4.4 Hz, 1H), 3.37 (d, J = 10.9 Hz, 1H), 3.23 (dd, J = 12.5, 8.2 Hz, 
1H), 3.14 (dd, J = 12.5, 7.9 Hz, 1H), 2.97 – 2.90 (m, 1H), 2.81 (m, 1H), 2.64 (dd, J = 
16.3, 7.4 Hz, 1H), 2.41 (d, J = 15.3 Hz, 1H), 1.84 (tt, J = 9.7, 5.9 Hz, 1H), 1.80 – 1.71 
(m, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.3, 132.8, 128.5, 128.1, 128.0, 119.4, 73.5, 
68.9, 62.6, 62.4, 60.0, 55.3, 46.6, 46.2, 44.0, 27.8, 24.1; 












Procedure B; Yield 73%;  
[α]D25 = –80.85 (c = 1.29, CH2Cl2); 
IR (neat): 2961, 2871, 1678, 1521, 1344, 1308, 1128, 736 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.29 (m, 5H), 5.96 – 5.81 (m, 2H), 5.21 
(m, 4H), 4.58 – 4.49 (m, 2H), 4.10 (dd, J = 16.1, 8.0 Hz, 1H), 3.98 – 3.94 (m, 3H), 
3.76 (dd, J = 15.7, 8.5 Hz, 1H), 3.73 (dd, J = 10.2, 2.6 Hz, 1H), 3.64 (dd, J = 10.2, 5.6 
Hz, 1H), 3.47 (ddd, J = 8.1, 5.6, 2.6 Hz, 1H), 3.33 – 3.29 (m, 2H), 3.24 (dd, J = 12.6, 
8.4 Hz, 1H), 3.13 (dd, J = 12.6, 7.6 Hz, 1H), 2.92 – 2.86 (m, 1H), 2.82 (ddd, J = 11.7, 
8.0, 5.8 Hz, 1H), 2.58 (dd, J = 16.3, 8.2 Hz, 1H), 1.90 – 1.80 (m, 1H), 1.74 (tdd, J = 
20.8, 10.6, 6.3 Hz, 2H), 1.60 – 1.51 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.8, 134.6, 133.2, 128.4, 127.8, 127.7, 119.0, 
117.1, 74.2, 73.3, 72.2, 69.8, 60.9, 60.4, 55.3, 46.4, 46.0, 44.0, 28.5, 23.4; 









HO Br  
Into an r. b. flask was added sulfonamide 3.7 (130 mg, 0.318 mmol) in CH2Cl2 (3.2 
mL). BCl3 solution (6.4 mL, 0.64 mmol) was added slowly at -78 ºC in dry 
ice/acetone bath and the temperature was let to rise slowly to rt. The reaction was 
quenched with sat. aq. NaHCO3. The separated aqueous layer was extracted with 
CH2Cl2 (3 × 15 mL). The combined organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Flash chromatography (1:1 hexane:EtOAc) 
afforded the desired product 3.37. 
Yield 76%;  
[α]D25 = +49.40 (c = 1.00, CH2Cl2); 
IR (neat): 3500, 2871, 1678, 1521, 1348, 1283, 1149, 1070 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.51 (d, J = 6.6 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 
6.83 (dd, J = 7.0, 2.0 Hz, 1H), 6.80 (dd, J = 7.0, 1.7 Hz, 1H), 4.52 (d, J = 15.5 Hz, 
1H), 4.30 (d, J = 15.5 Hz, 1H), 4.09 – 4.06 (m, 1H), 3.69 – 3.54 (m, 2H), 1.71 (s, 
1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.2, 134.7, 132.1, 130.2, 128.0, 122.4, 64.5, 
61.9, 46.8; 










Into an r. b. flask was added sulfonamide 3.9 (25 mg, 0.073 mmol) in CH2Cl2 (2 mL). 
BCl3 solution (1.5 mL, 0.15 mmol) was added slowly at -78 ºC in dry ice/acetone 
bath and the temperature was let to rise slowly to rt. The reaction was quenched with 
sat. aq. NaHCO3. The separated aqueous layer was extracted with CH2Cl2 (3 × 15 
mL). The combined organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure. Flash chromatography (1:2 hexane:EtOAc) afforded the 
desired product 3.38. 
Yield 56%;  
[α]D25 = +18.00 (c = 0.50, CH2Cl2); 
IR (neat): 3500, 2920, 2867, 1279, 1151, 1130, 783 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.30 – 7.25 (m, 1H), 7.25 – 7.21 (m, 2H), 7.17 – 
7.15 (d, J = 7.3 Hz, 1H), 6.83 – 6.79 (m, 2H), 4.55 (d, J = 15.2 Hz, 1H), 4.25 (d, J = 
15.2 Hz, 1H), 4.09 – 4.07 (m, 1H), 3.63 – 3.48 (m, 2H), 2.37 (s, 3H), 1.68 (s, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 138.9, 137.5, 135.5, 129.1, 129.0, 128.9, 128.0, 
125.5, 64.6, 61.7, 47.4, 21.4; 














Into an r. b. flask was added sulfonamide 3.37 (10 mg, 0.031 mmol) in CH2Cl2 (1 
mL). Phenyl isocyanate (3.8 µL, 0.035 mmol) and Et3N (1 µL, 0.007 mmol) were 
added and refluxed for 12 h. The solvent removed under reduced pressure and 
purified by flash chromatography (1:1 hexane:EtOAc) afforded the desired product 
3.39. 
Yield 63%;  
[α]D25 = +172.00 (c = 0.50, CH2Cl2); 
IR (neat): 3335, 2918, 2871, 1732, 1537, 1500, 1445, 1313, 1217, 1153 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.49 (d, J = 8.3 Hz, 2H), 7.38 – 7.30 (m, 6H), 
7.11 (tt, J = 5.2, 3.0 Hz, 1H), 6.83 (dd, J = 7.0, 1.4 Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 
6.64 (s, 1H), 4.44 (d, J = 1.9 Hz, 2H), 4.30 – 4.25 (m, 1H), 4.22 – 4.16 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 152.5, 137.1, 135.9, 134.3, 132.0, 130.2, 129.1, 
128.3, 124.1, 122.3, 118.8, 61.5, 46.0; 















Into an r. b. flask was added sulfonamide 3.38 (10 mg, 0.031 mmol) in CH2Cl2 (1 
mL). Phenyl isocyanate (30 µL, 0.276 mmol) and Et3N (6 µL, 0.043 mmol) were 
added and the reaction mixture was refluxed for 12 h. The solvent removed under 
reduced pressure and purified by flash chromatography (3:1 hexane:EtOAc) afforded 
the desired product 3.40. 
Yield 98%; 
[α]D25 = +101.93 (c = 1.50, CH2Cl2); 
IR (neat): 3335, 2915, 1732, 1601, 1537, 1445, 1289, 1217, 1155, 756 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.37 – 7.30 (m, 4H), 7.27 – 7.21 (m, 3H), 7.13 (d, 
J = 7.1 Hz, 1H), 7.10 (tt, J = 6.7, 1.7 Hz, 1H), 6.82 – 6.79 (m, 2H), 6.70 (s, 1H), 4.49 
(d, J = 15.3 Hz, 1H), 4.41 (d, J = 15.3 Hz, 1H), 4.27 – 4.22 (m, 1H), 4.20 – 4.14 (m, 
2H), 2.34 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 152.6, 138.7, 137.2, 136.1, 135.0, 129.2, 129.1, 
129.0, 128.8, 128.3, 125.5, 123.9, 118.8, 62.0, 61.3, 46.3, 21.4; 









Into an r. b. flask was added sulfonamide 3.31 (239 mg, 0.862 mmol) in CH2Cl2 (15 
mL). BCl3 solution (1.7 mL, 1.7 mmol) was added slowly at -78 ºC in dry ice/acetone 
bath and the temperature was let to rise slowly to rt. The reaction was quenched with 
sat. aq. NaHCO3. The separated aqueous layer was extracted with CH2Cl2 (3 × 20 
mL). The combined organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure. Flash chromatography (1:10 hexane:EtOAc) afforded the 
desired product 3.41. 
Yield 59%; Mp 110 ºC; 
[α]D25 = +13.42 (c = 2.43, CH2Cl2); 
IR (neat): 3320, 3271, 3087, 2926, 2876, 1286, 1155, 1121, 742 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 6.87 (dd, J = 6.9, 2.3 Hz, 1H), 6.78 (dd, J = 6.9, 
2.0 Hz, 1H), 4.39 (tt, J = 4.1, 2.2 Hz, 1H), 4.10 (d, J = 2.5 Hz, 2H), 3.97 (dt, J = 11.7, 
3.9 Hz, 1H), 3.85 (ddd, J = 11.9, 8.3, 4.0 Hz, 1H), 2.38 (t, J = 2.7 Hz, 1H), 2.06 (dd, J 
= 8.5, 4.2 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.6, 128.0, 76.9, 74.1, 64.5, 62.2, 33.9; 












Into an r. b. flask was added sulfonamide 3.41 (134 mg, 0.720 mmol) and benzyl 
azide (191 mg, 1.440 mmol) in CH2Cl2/tBuOH (1.3 mL/1.3 mL). The aq. solution 
mixture of CuSO4•5H2O (36 mg, 0.140 mmol) and (+)-sodim L-ascorbate (43 mg, 
0.220 mmol) in water (1.3 mL) was added into the previous flask. The resulting 
mixture was stirred at rt for 12 h. The separated aqueous layer was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Flash chromatography (1:2 hexane:EtOAc) 
afforded the desired product 3.42. 
Yield 61%; Mp 174 ºC; [α]D25 = +0.99 (c = 2.42, CH2Cl2); 
IR (neat): 3320, 3087, 2926, 2876, 1608, 1456, 1285, 1151, 742 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.59 (s, 1H), 7.42 – 7.35 (m, 3H), 7.29 – 7.25 (m, 
2H), 6.78 (dd, J = 7.0, 2.1 Hz, 1H), 6.68 (dd, J = 7.0, 2.1 Hz, 1H), 5.52 (s, 2H), 4.72 
(d, J = 16.3 Hz, 1H), 4.44 (d, J = 16.3 Hz, 1H), 4.30 (td, J = 5.5, 2.1 Hz, 1H), 3.93 
(dd, J = 12.2, 3.5 Hz, 1H), 3.80 (dd, J = 12.2, 5.0 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 143.6, 137.4, 134.1, 129.2, 128.9, 128.1, 127.6, 
123.2, 65.8, 62.7, 54.4, 37.6; 
HRMS calculated for C14H16N4O3SNa (M+Na)+ 343.0841, found 343.0842. 
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(3S,3aS,4S,7R,7aS)-3-((Benzyloxy)methyl)-2,3,3a,4,7,7a-hexahydro-4,7-









Into an r. b. flask was added sulfonamide (S)-3.3 (22 mg, 0.093 mmol) in anhydrous 
toluene (1 mL). Cyclopentadiene (60 µL, 0.735 mmol) and Et2AlCl (0.1 mL, 0.180 
mmol) were added and the resulting mixture was stirred at 55 ºC for 24 h. The 
reaction was quenched with water and sat. aq. NaHCO3. The separated aqueous layer 
was extracted with CH2Cl2 (3 × 5 mL). The combined organic layer was dried over 
Na2SO4, filtered and concentrated under reduced pressure. Flash chromatography (2:1 
hexane:EtOAc) afforded the desired product 3.43. 
Yield 36%;  
IR (neat): 3273, 2974, 2868, 1452, 1302, 1146, 1092, 751 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.41 – 7.29 (m, 5H), 6.48 (dd, J = 5.7, 3.0 Hz, 
1H), 6.30 (dd, J = 5.8, 3.1 Hz, 1H), 4.59 (d, J = 11.9 Hz, 1H), 4.55 (d, J = 11.9 Hz, 
1H), 4.21 (d, J = 6.9 Hz, 1H), 3.83 (dd, J = 8.6, 4.0 Hz, 1H), 3.61 (dd, J = 9.5, 7.2 Hz, 
1H), 3.57 (dd, J = 9.5, 7.4 Hz, 1H), 3.43 – 3.36 (m, 1H), 3.24 – 3.15 (m, 2H), 3.13 
(m, 1H), 1.65 (dt, J = 8.9, 1.8 Hz, 1H), 1.44 (dt, J = 8.8, 1.5 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.7, 136.4, 134.2, 128.5, 127.9, 127.8, 73.5, 
71.8, 64.2, 56.3, 51.3, 49.1, 47.0, 46.2; 
HRMS calculated for C16H20NO3S (M+H)+ 306.1164, found 306.1159.  
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(3R,3aS,6aR)-3-((Benzyloxy)methyl)-5-methylhexahydro-2H-pyrrolo[3,4-










Into an r. b. flask was added sulfonamide (R)-3.3 (100 mg, 0.418 mmol) in anhydrous 
DMSO (0.8 mL). Sarcosine (190 mg, 2.133 mmol), paraformaldehyde (150 mg, 4.995 
mmol) and anhydrous MgSO4 (200 mg, 1.662 mmol) were added and the reaction 
mixture was kept in microwave at 150 ºC for 1 h. The reaction was quenched with 
water and sat. aq. brine and diethyl ether. The organic layer was washed with water (3 
× 15 mL). The organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure. Flash chromatography (1:3 acetone:EtOAc) afforded the desired 
product 3.44. 
Yield 10%;  
[α]D25 = +0.32 (c = 0.10, CH2Cl2); 
IR (neat): 3232, 2945, 2791, 1452, 1307, 1141, 1093, 746 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.35 (m, 2H), 7.35 – 7.30 (m, 3H), 4.67 (d, 
J = 8.4 Hz, 1H), 4.57 (s, 2H), 3.72 – 3.67 (m, 1H), 3.66 (dd, J = 9.7, 5.2 Hz, 1H), 3.60 
(dd, J = 9.6, 5.1 Hz, 1H), 3.47 (dd, J = 11.0, 2.1 Hz, 1H), 3.45 – 3.40 (m, 1H), 3.16 
(dtd, J = 9.7, 6.1, 1.6 Hz, 1H), 2.77 (d, J = 9.5 Hz, 1H), 2.41 (dd, J = 10.8, 8.0 Hz, 
1H), 2.34 (s, 3H), 2.33 (dd, J = 9.5, 6.1 Hz, 1H); 
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13C NMR (125 MHz, CDCl3) δ ppm 137.3, 128.6, 128.1, 127.8, 73.5, 69.5, 61.9, 61.1, 
58.8, 57.0, 47.2, 41.2; 










Yield 49%;  
[α]D25 = +0.25 (c = 0.50, CH2Cl2); 
IR (neat): 3320, 2935, 2840, 1520, 1336, 1263, 1152 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.35 (m, 2H), 7.32 (td, J = 6.1, 1.3 Hz, 
3H), 6.42 (dd, J = 16.5, 9.9 Hz, 1H), 6.22 (d, J = 16.6 Hz, 1H), 5.89 (d, J = 9.8 Hz, 
1H), 5.74 (ddd, J = 17.1, 10.5, 7.4 Hz, 1H), 5.42 – 5.39 (m, 1H), 5.38 (t, J = 0.6 Hz, 
1H), 4.65 – 4.60 (m, 1H), 4.62 (d, J = 11.4 Hz, 1H), 4.36 (d, J = 11.5 Hz, 1H), 4.02 – 
3.95 (m, 1H), 3.20 (ddd, J = 13.1, 8.1, 3.8 Hz, 1H), 3.06 (ddd, J = 13.0, 8.2, 4.1 Hz, 
1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.6, 135.8, 134.9, 128.6, 128.1, 128.0, 126.6, 
120.1, 78.6, 70.5, 46.9; 












Yield 50%;  
[α]D25 = +28.00 (c = 0.50, CH2Cl2); 
IR (neat): 3315, 2939, 2845, 1513, 1331, 1248, 1148, 739 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.24 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 
6.42 (dd, J = 16.6, 9.9 Hz, 1H), 6.22 (d, J = 16.6 Hz, 1H), 5.89 (d, J = 9.9 Hz, 1H), 
5.73 (ddd, J = 17.0, 10.5, 7.5 Hz, 1H), 5.40 (dt, J = 6.9, 1.2 Hz, 1H), 5.37 (s, 1H), 
4.63 (dd, J = 7.8, 4.0 Hz, 1H), 4.55 (d, J = 11.1 Hz, 1H), 4.29 (d, J = 11.1 Hz, 1H), 
3.97 (dt, J = 8.2, 3.8 Hz, 1H), 3.82 (s, 3H), 3.18 (ddd, J = 12.9, 8.1, 3.8 Hz, 1H), 3.03 
(ddd, J = 12.8, 8.2, 4.1 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 159.4, 135.8, 135.0, 129.7, 129.6, 126.6, 119.96, 
113.9, 78.3, 70.2, 55.3, 46.9; 
HRMS calculated for C14H20NO4SNa (M+Na)+ 298.1113, found 298.1116.  
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Yield 63%;  
[α]D25 = +65.77 (c = 5.88, CH2Cl2); 
IR (neat): 3254, 2926, 1558, 1506, 1317, 1174, 1145, 912 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.43 – 7.31 (m, 5H), 6.70 (dd, J = 11.0, 1.1 Hz, 
1H), 6.45 (ddd, J = 11.0, 4.5, 1.8 Hz, 1H), 4.71 – 4.64 (m, 1H), 4.63 (d, J = 1.0 Hz, 
2H), 3.86 – 3.81 (m, 1H), 3.79 (dtd, J = 4.4, 3.0, 1.3 Hz, 1H), 3.71 – 3.64 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 136.8, 135.0, 131.4, 128.8, 128.5, 127.8, 71.7, 
65.1, 46.3; 













Yield 73%;  
[α]D25 = +30.50 (c = 2.50, CH2Cl2); 
IR (neat): 3250, 2929, 1555, 1285, 1151, 742 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.30 – 7.25 (m, 2H), 6.96 – 6.90 (m, 2H), 6.70 
(dd, J = 11.0, 1.1 Hz, 1H), 6.43 (ddd, J = 11.0, 4.5, 1.8 Hz, 1H), 4.70 – 4.63 (m, 1H), 
4.57 (d, J = 1.2 Hz, 2H), 3.84 (s, 3H), 3.83 – 3.76 (m, 2H), 3.69 – 3.63 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 159.7, 135.2, 131.2, 129.5, 128.8, 114.1, 71.4, 
64.8, 55.3, 46.4; 












Procedure A; Yield 39%;  
[α]D25 = –76.91 (c = 0.75, CH2Cl2); 
IR (neat): 3259, 2964, 2950, 2796, 1406, 1356, 1153, 1099, 742 cm-1; 
1H NMR (400 MHz, CDCl3) δ ppm 7.43 – 7.30 (m, 5H), 4.64 (d, J = 2.5 Hz, 2H), 
4.52 (d, J = 7.9 Hz, 1H), 3.89 (ddd, J = 14.6, 11.0, 1.7 Hz, 1H), 3.53 (td, J = 4.4, 1.6 
Hz, 1H), 3.47 (dd, J = 14.3, 3.9 Hz, 1H), 3.31 (dd, J = 14.4, 4.6 Hz, 1H), 3.25 (dt, J = 
15.6, 3.2 Hz, 1H), 3.04 (d, J = 3.2 Hz, 1H), 2.73 – 2.62 (m, 2H), 2.60 – 2.50 (m, 2H), 
1.85 – 1.74 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.4, 128.7, 128.2, 127.7, 71.8, 70.8, 63.0, 51.7, 
48.4, 43.8, 23.5; 









Procedure B; Yield 87%;  
[α]D25 = +93.33 (c = 1.50, CH2Cl2); 
IR (neat): 3283, 2864, 1342, 1329, 1177, 1148, 912, 744 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.42 – 7.32 (m, 5H), 6.57 (dd, J = 10.9, 1.7 Hz, 
1H), 6.43 (ddd, J = 10.9, 3.7, 1.4 Hz, 1H), 4.74 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.6 
Hz, 1H), 4.27 (ddd, J = 16.7, 2.5, 0.6 Hz, 1H), 4.11 (ddd, J = 15.4, 4.0, 1.5 Hz, 1H), 
4.05 (dd, J = 16.7, 2.5 Hz, 1H), 4.04 – 4.00 (m, 1H), 3.94 (dd, J = 15.4, 4.3 Hz, 1H), 
2.39 (t, J = 2.5 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 136.9, 136.0, 128.8, 128.7, 128.6, 128.3, 127.8, 
74.2, 72.0, 65.8, 47.5, 39.3; 













Into an r. b. flask were added sulfonamide 3.51 (140 mg, 0.505 mmol) and benzyl 
azide (140 mg, 1.051 mmol) in CH2Cl2/tBuOH (0.9 mL/0.9 mL). The aq. solution 
mixture of CuSO4•5H2O (26 mg, 0.104 mmol) and (+)-sodim L-ascorbate (30 mg, 
0.151 mmol) in water (0.9 mL) was added into the previous flask. The resulting 
mixture was stirred at rt for 12 h. The separated aqueous layer was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Flash chromatography (1:1 hexane:EtOAc) 
afforded the desired product 3.55. 
Yield 99%;   
[α]D25 = +35.20 (c = 1.25, CH2Cl2); 
IR (neat): 3138, 3031, 2943, 2866, 1454, 1335, 1146, 1095, 1049, 912 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.53 (s, 1H), 7.42 – 7.30 (m, 8H), 7.30 – 7.25 (m, 
2H), 6.56 (dd, J = 10.9, 1.7 Hz, 1H), 6.36 (dd, J = 11.0, 3.6 Hz, 1H), 5.51 (d, J = 1.8 
Hz, 2H), 4.68 (d, J = 11.7 Hz, 1H), 4.63 (d, J = 15.0 Hz, 1H), 4.58 (d, J = 15.0 Hz, 
1H), 4.53 (d, J = 11.7 Hz, 1H), 3.98 (tdd, J = 4.9, 3.5, 1.8 Hz, 1H), 3.88 (ddd, J = 
15.2, 4.9, 1.2 Hz, 1H), 3.78 (dd, J = 15.3, 4.5 Hz, 1H); 
 266 
13C NMR (125 MHz, CDCl3) δ ppm 143.7, 137.0, 136.4, 134.3, 129.2, 129.1, 128.9, 
128.6, 128.2, 128.1, 127.9, 123.3, 71.9, 66.1, 54.3, 48.3, 44.0; 










Procedure A; Yield 45%;  
[α]D25 = –20.86 (c = 1.75, CH2Cl2); 
IR (neat): 3284, 2962, 2874, 1454, 1337, 1329, 1150, 1103, 899 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 – 7.35 (m, 4H), 7.34 – 7.29 (m, 1H), 4.70 (s, 
2H), 4.16 (dd, J = 17.6, 2.5 Hz, 1H), 3.92 – 3.87 (m, 1H), 3.87 (dd, J = 17.5, 2.4 Hz, 
1H), 3.54 (dd, J = 14.0, 4.3 Hz, 1H), 3.50 – 3.46 (m, 1H), 3.44 (dd, J = 13.9, 9.1 Hz, 
1H), 3.37 (dd, J = 13.4, 3.9 Hz, 1H), 3.15 (dd, J = 13.3, 9.9 Hz, 1H), 2.71 – 2.60 (m, 
4H), 2.36 (t, J = 2.5 Hz, 1H), 1.83 – 1.72 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.8, 128.5, 128.0, 127.9, 78.1, 74.3, 72.4, 72.2, 
61.3, 48.9, 48.7, 47.0, 37.8, 23.6; 














Into an r. b. flask were added sulfonamide 3.54 (31 mg, 0.112 mmol) and benzyl 
azide (31 mg, 0.233 mmol) in CH2Cl2/tBuOH (0.2 mL/0.2 mL). The aq. solution 
mixture of CuSO4•5H2O (4.2 mg, 0.017 mmol) and (+)-sodim L-ascorbate (5 mg, 
0.0.25 mmol) in water (0.2 mL) was added into the previous flask. The resulting 
mixture was stirred at rt for 12 h. The separated aqueous layer was extracted with 
CH2Cl2 (3 × 15 mL). The combined organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Flash chromatography (1:4 hexane:EtOAc) 
afforded the desired product 3.57. 
Yield 72%;  [α]D25 = –28.79 (c = 0.58, CH2Cl2); 
IR (neat): 2938, 2870, 1457, 1335, 1147, 1119, 1115, 1076, 917, 750 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.55 (s, 1H), 7.41 – 7.31 (m, 10H), 5.54 (d, J = 
14.9 Hz, 1H), 5.48 (d, J = 14.8 Hz, 1H), 4.61 (d, J = 11.8 Hz, 1H), 4.56 (d, J = 11.8 
Hz, 1H), 4.50 (d, J = 3.1 Hz, 2H), 3.64 – 3.55 (m, 2H), 3.37 (m, 2H), 3.34 – 3.25 (m, 
1H), 3.02 (dd, J = 14.3, 10.0 Hz, 1H), 2.66 – 2.53 (m, 4H), 1.79 – 1.71 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 143.8, 137.7, 134.3, 129.2, 128.9, 128.4, 128.1, 
127.9, 127.8, 123.1, 72.6, 71.7, 61.6, 54.3, 49.3, 48.0, 47.5, 42.9, 23.6; 










Procedure B; Yield 84%;  
[α]D25 = +74.06 (c = 2.78, CH2Cl2); 
IR (neat): 3055, 2936, 2866, 1612, 1512, 1342, 1323, 1250, 1176, 1144, 1031, 820 
cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.27 – 7.22 (m, 2H), 6.93 – 6.88 (m, 2H), 6.58 
(dd, J = 10.9, 1.8 Hz, 1H), 6.38 (ddt, J = 10.9, 3.5, 1.0 Hz, 1H), 5.90 – 5.77 (m, 1H), 
5.30 (d, J = 1.4 Hz, 1H), 5.27 (dq, J = 8.4, 1.4 Hz, 1H), 4.57 (d, J = 11.5 Hz, 1H), 
4.50 (d, J = 11.5 Hz, 1H), 4.01 (ddt, J = 14.3, 5.4, 1.6 Hz, 1H), 3.90 (tdd, J = 4.4, 3.5, 
1.8 Hz, 1H), 3.83 (s, 3H), 3.80 (dt, J = 7.0, 1.1 Hz, 1H), 3.79  3.75 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 159.6, 136.0, 132.7, 129.4, 129.3, 129.0, 119.9, 
114.0, 71.5, 65.6, 55.3, 51.3, 47.4; 












Procedure B; Yield 71%;  
[α]D25 = +87.13 (c = 2.09, CH2Cl2); 
IR (neat): 3937, 2912, 1612, 1585, 1514, 1493, 1456, 1339, 1303, 1249, 1175, 1146, 
1032, 760 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.45 (td, J = 7.6, 1.8 Hz, 1H), 7.32 (dddd, J = 8.2, 
7.3, 5.3, 1.8 Hz, 1H), 7.23 – 7.19 (m, 2H), 7.15 (td, J = 7.5, 1.2 Hz, 1H), 7.08 (ddd, J 
= 9.6, 8.2, 1.2 Hz, 1H), 6.90 – 6.86 (m, 2H), 6.64 (dd, J = 10.9, 1.8 Hz, 1H), 6.43 – 
6.38 (m, 1H), 4.59 (d, J = 14.7 Hz, 1H), 4.51 (d, J = 14.7 Hz, 1H), 4.53 (d, J = 11.5 
Hz, 1H), 4.46 (d, J = 11.5 Hz, 1H), 3.91 (tdd, J = 4.5, 3.5, 1.8 Hz, 1H), 3.82 (s, 3H), 
3.74 (dd, J = 15.4, 4.5 Hz, 1H), 3.69 (ddd, J = 15.4, 4.6, 1.3 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 161.2 (d, 1JC-F = 245.9 Hz), 159.6, 136.2, 130.9 
(d, 3JC-F = 3.8 Hz), 129.7 (d, 3JC-F = 8.1 Hz), 129.5, 129.4, 128.9, 124.4 (d, 4JC-F = 3.6 
Hz), 122.9 (d, 2JC-F = 13.9 Hz), 115.5 (d, 2JC-F = 21.3 Hz), 114.0, 71.6, 65.5, 55.3, 
48.2, 45.9; 











Procedure B; Yield 98%;  
[α]D25 = +94.30 (c = 2.85, CH2Cl2); 
IR (neat): 2938, 1609, 1595, 1514, 1339, 1252, 1175, 1146, 1096, 1032, 768 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.34 (td, J = 7.9, 5.8 Hz, 1H), 7.22 – 7.18 (m, 
2H), 7.13 (ddd, J = 7.6, 1.6, 0.8 Hz, 1H), 7.08 (dt, J = 9.4, 2.2 Hz, 1H), 7.06 – 7.02 
(m, 1H), 6.92 – 6.87 (m, 2H), 6.66 (dd, J = 10.9, 1.8 Hz, 1H), 6.45 (ddd, J = 11.0, 3.7, 
1.6 Hz, 1H), 4.62 (d, J = 14.1 Hz, 1H), 4.48 (d, J = 11.4 Hz, 1H), 4.44 (d, J = 11.5 
Hz, 1H), 4.30 (d, J = 14.2 Hz, 1H), 3.84 (s, 4H), 3.76 (ddd, J = 15.5, 4.4, 1.0 Hz, 1H), 
3.57 (ddd, J = 15.5, 3.5, 1.7 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 163.0 (d, 1JC-F = 245.1 Hz), 159.7, 138.1 (d, 3JC-F 
= 7.3 Hz), 135.9, 132.0 (d, 3JC-F = 8.0 Hz), 129.5, 129.2, 128.7, 124.3 (d, 4JC-F = 2.9 
Hz), 115.7 (d, 2JC-F = 21.6 Hz), 114.9 (d, 2JC-F = 20.9 Hz), 114.0, 71.7, 65.5, 55.3, 
51.9, 47.5; 








Procedure D; Yield 86%; 
FTIR (neat): 3102, 3069, 1610, 1516, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 6.46 – 6.39 (m, 1H), 6.20 (d, J = 16.5 Hz, 1H), 
5.90 – 5.84 (m, 2H), 5.29 – 5.23 (m, 1H), 5.16 (ddd, J = 10.2, 2.8, 1.4 Hz, 1H), 4.17 – 
4.08 (m, 1H), 3.71 (dt, J = 5.6, 1.5 Hz, 2H), 1.90 – 1.81 (m, 2H), 1.70 – 1.61 (m, 2H), 
1.60 – 1.49 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 135.7, 133.1, 125.8, 116.9, 59.1, 46.00, 29.7, 
23.4; 










Procedure D; Yield 91%; 
FTIR (neat): 3106, 3067, 1608, 1514, 1341, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 6.46 – 6.39 (m, 1H), 6.20 (d, J = 16.5 Hz, 1H), 
5.90 (dd, J = 10.7, 5.3 Hz, 1H), 5.28 – 5.20 (m, 2H), 3.82 – 3.75 (m, 2H), 3.11 (dd, J 
= 15.5, 7.8 Hz, 2H), 1.59 – 1.50 (m, 3H), 1.36 – 1.26 (m, 2H), 0.92 (t, J = 7.3 Hz, 
3H); 
13C NMR (125 MHz, CDCl3) δ ppm 135.5, 133.2, 126.1, 118.9, 49.9, 46.1, 30.4, 19.8, 
13.7; 
















Procedure D; Yield 90%; 
FTIR (neat): 3100, 3069, 1514, 1341, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.37 – 7.27 (m, 5H), 6.47 – 6.41 (m, 1H), 6.27 – 
6.21 (m, 1H), 5.93 – 5.89 (m, 1H), 5.81 – 5.71 (m, 1H), 5.20 (dd, J = 17.1, 1.2 Hz, 
2H), 4.33 (s, 2H), 3.73 (d, J = 6.5 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 135.9, 135.8, 132.2, 128.7, 128.5, 127.9, 126.4, 
119.7, 49.6, 48.9; 
HRMS calculated for C12H15NO2SNa (M+Na)+ 260.0721, found 260.0711. 
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Procedure D; Yield 80%; 
FTIR (neat): 3104, 3066, 1605, 1514, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.33 – 7.28 (m, 2H), 7.06 – 6.99 (m, 2H), 6.46 – 
6.39 (m, 1H), 6.27 – 6.21 (m, 1H), 5.96 – 5.90 (m, 1H), 5.74 (ddq, J = 13.1, 10.1, 6.7 
Hz, 1H), 5.26 – 5.13 (m, 2H), 4.28 (s, 2H), 3.71 (d, J = 6.6 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 162.4 (d, 1JC-F = 245.8 Hz), 135.7, 131.6 (d, 4JC-F 
= 3.3 Hz) 131.6, 130.2, (d, 3JC-F = 8.1 Hz), 126.6, 119.8, 115.5, (d, 2JC-F = 21.4 Hz), 
49.0, 48.9; 













Procedure D; Yield 89%; 
FTIR (neat): 3105, 3069, 1600, 1515, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 8.22 – 8.15 (m, 2H), 7.55 – 7.49 (m, 2H), 6.49 
(dd, J = 16.5, 9.9 Hz, 1H), 6.30 (dd, J = 22.4, 12.3 Hz, 1H), 6.03 – 5.96 (m, 1H), 5.72 
(ddt, J = 16.8, 10.1, 6.6 Hz, 1H), 5.25 – 5.11 (m, 2H), 4.39 (s, 2H), 3.76 (t, J = 9.5 
Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 147.6, 143.8, 135.2, 131.8, 128.9, 127.4, 123.8, 
120.4, 49.9, 49.3; 











Procedure D; Yield 84%; 
FTIR (neat): 3105, 3069, 1608, 1514, 1340, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.33 – 7.29 (m, 2H), 7.26 – 7.18 (m, 3H), 6.28 
(dd, J = 16.5, 9.5 Hz, 1H), 6.22 – 6.16 (m, 1H), 5.86 (d, J = 9.5 Hz, 1H), 5.84 – 5.74 
(m, 1H), 5.29 – 5.23 (m, 2H), 3.79 – 3.77 (m, 2H), 3.37 (dd, J = 8.7, 6.9 Hz, 2H), 
2.92 – 2.88 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 138.4, 135.2, 133.0, 128.9, 128.6, 126.6, 126.2, 
119.2, 50.3, 48.3, 35.4; 









Procedure D; Yield 75%; 
FTIR (neat): 3110, 3070, 1605, 1516, 1347, 1283 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.25 – 7.20 (m, 2H), 7.19 – 7.14 (m, 2H), 6.43 
(dd, J = 16.5, 9.9 Hz, 1H), 6.25 (d, J = 16.6 Hz, 1H), 5.91 (d, J = 9.8 Hz, 1H), 5.77 
(ddt, J = 16.7, 10.1, 6.5 Hz, 1H), 5.29 – 5.14 (m, 2H), 4.30 (s, 2H), 3.72 (dt, J = 6.5, 
1.3 Hz, 2H), 2.36 (s, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.7, 136.0, 132.7, 132.3, 129.3, 128.6, 126.3, 
119.6, 49.4, 48.7, 21.2; 














Procedure D; Yield 88%;  
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 6.35 (dd, J = 16.5, 9.9 Hz, 1H), 6.12 (t, J = 10.0 
Hz, 1H), 5.78 – 5.75 (m, 2H), 5.17 (ddd, J = 17.2, 2.9, 1.5 Hz, 1H), 5.07 (dq, J = 
10.2, 1.3 Hz, 1H), 3.70 (dt, J = 6.1, 1.4 Hz, 2H), 3.51 (tt, J = 12.3, 3.4 Hz, 1H), 1.76 – 
1.68 (m, 4H), 1.58 – 1.52 (m, 1H), 1.46 – 1.35 (m, 2H), 1.29 – 1.16 (m, 2H), 1.04 – 
0.93 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 136.6, 136.1, 125.2, 117.2, 57.9, 46.1, 32.2, 26.0, 
25.3; 









Procedure E; Yield 93%; 
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 6.82 (tt, J = 7.2, 2.1 Hz, 1H), 6.64 – 6.59 (m, 
1H), 3.95 (t, J = 2.4 Hz, 2H), 3.77 – 3.69 (m, 1H), 2.05 – 1.95 (m, 2H), 1.79 – 1.68 
(m, 4H), 1.65 – 1.54 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 134.9, 127.6, 56.3, 50.4, 30.5, 23.4; 
HRMS calculated for C8H17N2O2S (M+NH4)+ 205.1011, found 205.1012. 
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Procedure E; Yield 98%; 
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 6.85 (dt, J = 6.9, 2.4 Hz, 1H), 6.68 – 6.62 (m, 
1H), 3.98 – 3.93 (m, 2H), 3.14 (dd, J = 15.9, 8.4 Hz, 2H), 1.68 – 1.58 (m, 2H), 1.45 – 
1.32 (m, 2H), 0.92 (q, J = 7.4 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 135.1, 127.5, 52.3, 44.0, 30.1, 19.9, 13.6; 










Procedure E; Yield 96%; 
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.39 (m, 2H), 7.38 – 7.35 (m, 1H), 7.34 – 7.30 
(m, 1H), 6.83 (dt, J = 7.0, 2.4 Hz, 1H), 6.73 (dt, J = 7.0, 2.2 Hz, 1H), 4.37 (s, 2H), 
3.83 (t, J = 2.3 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 135.2, 135.1, 128.8, 128.5, 128.2, 127.3, 51.5, 
47.5; 
HRMS calculated for C10H14N2O2S (M+NH4)+ 227.0854, found 227.0846. 
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Procedure E; Yield 95%;  
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1116cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.46 – 7.31 (m, 2H), 7.07 – 6.98 (m, 2H), 6.87 – 
6.81 (m, 1H), 6.73 – 6.68 (m, 1H), 4.34 – 4.29 (m, 2H), 3.84 – 3.79 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 162.5 (d, 1JC-F = 245.6 Hz) 135.1, 130.9 (d, 4JC-F 
= 3.3 Hz), 130.2, (d, 3JC-F = 8.1 Hz), 127.2, 115.7, (d, 2JC-F = 18.8 Hz), 51.5, 46.9; 
HRMS calculated for C10H14FN2O2S (M+NH4)+ 245.0760, found 245.0753. 
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Procedure E; Yield 98%; 
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 8.24 – 8.19 (m, 2H), 7.63 – 7.56 (m, 2H), 6.92 – 
6.87 (m, 1H), 6.78 (dt, J = 7.0, 2.3 Hz, 1H), 4.46 (d, J = 12.9 Hz, 2H), 3.95 – 3.88 (s, 
2H); 
13C NMR (125 MHz, CDCl3) δ ppm 147.8, 142.9, 134.9, 129.1, 127.2, 124.1, 51.9, 
47; 










Procedure E; Yield 96%; 
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.31 (dd, J = 10.3, 5.0 Hz, 2H), 7.24 (dd, J = 
13.0, 7.0 Hz, 3H), 6.82 – 6.78 (m, 1H), 6.64 (dt, J = 14.0, 7.1 Hz, 1H), 3.91 – 3.84 
(m, 2H), 3.49 – 3.42 (m, 2H), 2.99 (dd, J = 15.6, 8.4 Hz, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 138.4, 135.3, 128.8, 128.7, 127.3, 126.7, 52.9, 
45.8, 35.1; 










Procedure E; Yield 93%; 
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.19 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 7.8 Hz, 2H), 
6.75 (dt, J = 7.0, 2.4 Hz, 1H), 6.63 (dt, J = 7.0, 2.2 Hz, 1H), 4.23 (s, 2H), 3.73 (t, J = 
2.3 Hz, 2H), 2.27 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.9, 135.1, 131.9, 129.5, 128.5, 127.3, 51.4, 
47.3, 21.2; 









Procedure E; Yield 92%; 
FTIR (neat): 3105, 3078, 1606, 1517, 1344, 1286, 1161 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 6.87 – 6.82 (m, 1H), 6.62 (dt, J = 7.0, 2.3 Hz, 
1H), 3.99 (t, J = 2.3 Hz, 2H), 3.52 (tt, J = 11.4, 3.7 Hz, 1H), 2.04 – 1.96 (m, 2H), 1.81 
(ddd, J = 6.1, 3.4, 1.0 Hz, 2H), 1.68 – 1.60 (m, 1H), 1.49 (ddd, J = 23.8, 12.3, 3.3 Hz, 
2H), 1.41 – 1.29 (m, 2H), 1.19 – 1.06 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 134.6, 127.5, 52.9, 47.5, 31.3, 25.4, 25.4; 
















Procedure F;  
FTIR (neat): 2962, 2806, 1454, 1305, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.37 – 7.30 (m, 5H), 7.19 (t, J = 7.5 Hz, 1H), 7.07 
(dd, J = 14.9, 7.3 Hz, 3H), 4.16 (q, J = 14.1 Hz, 2H), 3.55 – 3.47 (m, 1H), 3.44 (s, 
2H), 3.35 (dd, J = 12.8, 8.3 Hz, 1H), 3.25 – 3.17 (m, 2H), 2.98 (dd, J = 9.5, 7.2 Hz, 
1H), 2.45 (s, 8H), 2.33 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.9, 137.6, 135.1, 129.7, 128.7, 128.6, 128.2, 
128.1, 127.9, 126.3, 62.9, 56.9, 52.7, 49.6, 49.1, 48.2, 47.6, 21.4; 










Procedure F;  
FTIR (neat): 2962, 2805, 1450, 1305, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.32 – 7.22 (m, 5H), 4.20 (d, J = 14.3 Hz, 1H), 
4.05 (t, J = 14.3 Hz, 1H), 3.38 – 3.29 (m, 2H), 3.19 – 3.09 (m, 2H), 2.96 – 2.90 (m, 
1H), 2.46 – 2.35 (m, 4H), 1.73 – 1.64 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 135.3, 128.7, 128.5, 128.0, 56.1, 51.3, 50.9, 50.8, 
47.7, 23.2; 















Procedure F;  
FTIR (neat): 2943, 2813, 1510, 1307, 1222, 1139 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.32 – 7.28 (m, 2H), 7.19 (dd, J = 13.1, 5.5 Hz, 
1H), 7.07 (dd, J = 13.2, 5.7 Hz, 3H), 7.05 – 7.01 (m, 2H), 4.13 (q, J = 14.2 Hz, 2H), 
3.51 (p, J = 8.0 Hz, 1H), 3.44 (s, 2H), 3.34 (dd, J = 12.8, 8.3 Hz, 1H), 3.20 (ddd, J = 
15.4, 11.1, 7.9 Hz, 2H), 2.97 (dd, J = 9.5, 7.2 Hz, 1H), 2.45 (s, 8H), 2.33 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 162.4 (d, 1JC-F = 246.7 Hz), 137.9, 137.5, 130.8 
(d, 3JC-F = 3.4 Hz), 130.3 (d, 2JC-F = 9.2 Hz), 129.8, 128.1, 127.9, 126.3, 115.7 (d, 2JC-
F = 25.0 Hz), 62.9, 56.9, 52.7, 49.6, 49.0, 48.2, 46.9, 21.4; 
HRMS calculated for C22H29FN3O2S (M+H)+ 418.1965, found 418.1968. 
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Procedure F;  
FTIR (neat): 2966, 2806, 1510, 1307, 1220, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.32 – 7.28 (m, 2H), 7.05 – 7.01 (m, 2H), 4.19 – 
4.07 (m, 2H), 3.50 (p, J = 8.0 Hz, 1H), 3.35 (dd, J = 12.8, 8.3 Hz, 1H), 3.19 (ddd, J = 
13.9, 11.1, 7.9 Hz, 2H), 2.97 (dd, J = 9.5, 7.2 Hz, 1H), 2.45 (s, 8H), 2.28 (dd, J = 8.9, 
6.7 Hz, 2H), 1.48 – 1.38 (m, 2H), 1.31 – 1.22 (m, 6H), 0.86 (t, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 162.5 (d, 1JC-F = 249.9 Hz), 130.8 (d, 4JC-F = 1.8 
Hz), 130.3 (d, 3JC-F = 9.6 Hz), 115.7 (d, 2JC-F = 21.6 Hz), 58.6, 56.9, 52.8, 49.7, 48.9, 
48.3, 46.9, 31.7, 27.2, 26.8, 22.6, 14.0; 
HRMS calculated for C20H33FN3O2S (M+H)+ 398.2278, found 398.2284. 
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Procedure F;  
FTIR (neat): 2964, 2806, 1510, 1307, 1222, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.34 – 7.30 (m, 2H), 7.06 – 7.01 (m, 2H), 4.23 (d, 
J = 14.3 Hz, 1H), 4.08 (d, J = 14.3 Hz, 1H), 3.44 – 3.35 (m, 2H), 3.23 – 3.17 (m, 2H), 
3.01 – 2.95 (m, 1H), 2.52 – 2.42 (m, 4H), 1.79 – 1.74 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 162.5 (d, 1JC-F = 243.5 Hz), 131.0 (d, 4JC-F = 3.0 
Hz), 130.3 (d, 3JC-F = 10.2 Hz), 115.7 (d, 1JC-F = 21.7 Hz), 56.1, 51.3, 50.9, 50.9, 47.1, 
23.2; 












Procedure F;  
FTIR (neat): 2964, 2808, 1510, 1304, 1222, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.34 – 7.30 (m, 2H), 7.06 – 7.01 (m, 2H), 5.77 – 
5.74 (m, 2H), 4.22 (d, J = 14.3 Hz, 1H), 4.12 – 4.06 (m, 1H), 3.74 (p, J = 7.6 Hz, 1H), 
3.53 – 3.38 (m, 5H), 3.21 (ddd, J = 17.5, 11.1, 7.5 Hz, 2H), 2.98 (dd, J = 9.4, 7.3 Hz, 
1H); 
13C NMR (125 MHz, CDCl3) δ ppm 162.5 (d, 1JC-F = 258.6 Hz), 131.0 (d, 4JC-F = 2.97 
Hz), 130.3 (d, 2JC-F = 9.52 Hz), 127.2, 115.7 (d, 1JC-F = 22.0 Hz), 56.8, 55.4, 50.5, 
50.3, 47.0; 
HRMS calculated for C14H18FN2O2S (M+H)+ 297.1073, found 297.1072. 
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Procedure F;  
FTIR (neat): 2962, 2358, 1519, 1346, 1305, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 8.24 – 8.19 (m, 2H), 7.54 (d, J = 8.7 Hz, 2H), 
4.38 (d, J = 15.3 Hz, 1H), 4.20 (d, J = 15.3 Hz, 1H), 3.48 – 3.40 (m, 2H), 3.29 – 3.20 
(m, 2H), 3.05 (dt, J = 8.9, 6.2 Hz, 1H), 2.49 (dt, J = 9.2, 6.7 Hz, 4H), 1.81 – 1.74 (m, 
4H); 
13C NMR (125 MHz, CDCl3) δ ppm 147.7, 143.0, 129.1, 124.0, 56.2, 51.5, 51.4, 50.8, 
47.4, 23.2; 
HRMS calculated for C14H20N3O4S (M+H)+ 326.1175, found 326.1178. 
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Procedure F;  
FTIR (neat): 2962, 1305, 1236, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.16 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 7.8 Hz, 2H), 
4.14 (t, J = 12.5 Hz, 1H), 3.99 (d, J = 14.1 Hz, 1H), 3.32 (tdd, J = 21.2, 13.4, 7.7 Hz, 
2H), 3.17 – 3.09 (m, 2H), 2.91 (ddd, J = 13.1, 6.5, 3.5 Hz, 1H), 2.45 – 2.34 (m, 4H), 
2.27 (s, 3H), 1.74 – 1.64 (m, 4H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.7, 132.2, 129.4, 128.5, 56.1, 51.3, 50.9, 50.8, 
47.4, 23.2, 21.2; 













Procedure F;  
FTIR (neat): 2968, 1305, 1236, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.23 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 7.8 Hz, 2H), 
5.75 (d, J = 7.2 Hz, 2H), 4.24 – 4.19 (m, 1H), 4.10 – 4.05 (m, 1H), 3.77 – 3.69 (m, 
1H), 3.51 – 3.38 (m, 5H), 3.25 – 3.16 (m, 2H), 2.98 (dd, J = 9.5, 7.3 Hz, 1H), 2.35 (s, 
3H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.8, 132.1, 129.4, 128.5, 127.2, 56.8, 55.4, 
50.4, 50.3, 47.4, 21.2; 













Procedure F;  
FTIR (neat): 2930, 2856, 1450, 1297, 1236, 1134 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.20 (t, J = 7.5 Hz, 1H), 7.09 (dd, J = 18.1, 9.0 
Hz, 3H), 3.53 – 3.42 (m, 4H), 3.39 (dd, J = 9.0, 7.4 Hz, 1H), 3.27 (dd, J = 12.6, 8.1 
Hz, 1H), 3.13 (dt, J = 12.4, 7.8 Hz, 2H), 2.49 (d, J = 30.0 Hz, 8H), 2.34 (s, 3H), 1.95 
– 1.87 (m, 2H), 1.78 (d, J = 13.0 Hz, 2H), 1.66 – 1.59 (m, 1H), 1.36 (m, 4H), 1.13 – 
1.02 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 137.9, 129.9, 128.2, 127.9, 126.3, 62.9, 57.2, 
52.8, 52.7, 49.7, 49.2, 44.7, 31.2, 30.9, 25.5, 25.4, 21.4; 
HRMS calculated for C21H34N3O2S (M+H)+ 392.2372, found 392.2408 
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Procedure F;  
FTIR (neat): 2933, 2856, 1450, 1296, 1236, 1132 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 3.47 – 3.36 (m, 3H), 3.36 – 3.29 (m, 1H), 3.16 – 
3.07 (m, 2H), 2.59 – 2.47 (m, 4H), 1.91 (dd, J = 20.3, 9.2 Hz, 2H), 1.82 – 1.74 (m, 
6H), 1.66 – 1.59 (m, 1H), 1.48 – 1.26 (m, 4H), 1.08 (q, J = 12.7, 3.6 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 56.4, 52.9, 51.6, 51.4, 46.6, 31.3, 30.8, 25.5, 
25.4, 23.3; 










Procedure F;  
FTIR (neat): 2930, 2852, 1451, 1296, 1236, 1131 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 5.79 (s, 2H), 3.76 – 3.68 (m, 1H), 3.58 – 3.46 (m, 
4H), 3.43 (ddd, J = 16.2, 8.4, 5.4 Hz, 2H), 3.32 (dd, J = 12.6, 7.9 Hz, 1H), 3.11 (ddd, 
J = 19.8, 10.8, 8.0 Hz, 2H), 1.91 (ddd, J = 12.3, 10.6, 3.3 Hz, 2H), 1.81 – 1.75 (m, 
2H), 1.66 – 1.59 (m, 1H), 1.48 – 1.27 (m, 4H), 1.08 (qt, J = 12.7, 3.6 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 127.3, 56.9, 55.7, 52.9, 50.9, 46.3, 31.3, 30.8, 
25.5, 25.4, 25.3; 
HRMS calculated for C13H22N2O2SNa (M+Na)+ 293.1323, found 293.1327. 
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 Purification results of 144 member library 







3.62{1} 288.1745 288.1775 8 100 
3.62{2} 318.1851 318.1887 40 100 
3.62{3} 345.2323 345.2335 37 100 
3.62{4} 378.2215 378.2242 48 100 
3.62{8} 368.1635 368.1660 35 100 
3.62{9} 371.2480 371.2491 20 100 
3.62{10} 328.2058 328.2077 46 100 
3.62{12} 363.2105 363.2111 45 100 
3.62{15} 290.1901 290.1902 28 100 
3.62{16} 259.1479 259.1484 44 100 
3.63{1} 276.1745 276.1758 39 100 
3.63{2} 306.1851 306.1864 37 100 
3.63{3} 333.2323 333.2353 36 100 
3.63{4} 366.2214 366.2218 45 100 
3.63{7} 346.2527 346.2542 36 100 
3.63{8} 356.1644 356.1652 20 100 
3.63{9} 359.2480 359.2484 22 100 




3.63{11} 261.1636 261.1649 19 100 
3.63{12} 351.2106 351.2155 15 100 
3.63{15} 278.1901 278.1906 26 100 
3.63{16} 247.1479 247.1492 37 100 
3.63{17} 245.1323 245.1339 31 87 
3.64{1} 310.1589 310.1603 38 100 
3.64{2} 340.1694 340.1711 40 100 
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3.64{3} 367.2167 367.2186 28 100 
3.64{4} 400.2058 400.2070 47 100 
3.64{5} 373.1697 373.1700 22 99 




3.64{7} 380.2371 380.2405 37 98 
3.64{8} 390.1487 390.1512 35 100 
3.64{9} 393.2323 393.2333 14 100 
3.64{10} 350.1901 350.1905 45 100 
3.64{11} 295.1479 295.1499 55 99 
3.64{12} 385.1949 385.1961 49 96 
3.64{13} 371.1792 371.1812 43 98 
3.64{14} 353.1534 353.1546 43 100 
3.64{15} 312.1745 312.1697 33 98 
3.64{16} 281.1132 281.1281 44 100 
3.64{17} 279.1166 279.1126 52 91 
3.65{1} 328.1494 328.1497 36 100 
3.65{2} 358.1600 358.1604 50 91 
3.65{3} 385.2073 385.2076 47 96 
3.65{4} 418.1964 418.1966 46 100 
3.65{5} 391.1603 391.1600 43 91 
3.65{6} 392.1556 392.1558 47 100 
3.65{7} 398.2277 398.2278 51 98 
3.65{8} 408.1393 408.1388 46 98 
3.65{9} 411.2229 411.2231 35 100 
3.65{10} 3681807 368.1811 49 99 
3.65{11} 313.1385 313.1386 50 100 
3.65{12} 403.1855 403.1858 42 100 
3.65{13} 389.1699 389.1703 53 99 
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3.65{14} 371.1440 371.1441 51 99 
3.65{15} 330.1651 330.1653 35 100 
3.65{16} 299.1229 229.1234 46 99 
3.65{17} 297.1072 297.1072 40 91 
3.66{1} 355.1439 355.1442 40 99 
3.66{2} 385.1545 385.1543 45 100 
3.66{3} 412.2018 412.2019 18 93 
3.66{4} 445.1909 445.1906 52 100 
3.66{7} 425.2222 425.2225 50 100 
3.66{8} 435.1338 435.1333 40 96 
3.66{9} 438.2174 438.2173 50 96 
3.66{10} 395.1752 395.1754 46 99 
3.66{11} 340.1330 340.1327 70 100 
3.66{12} 430.1800 430.1797 50 99 
3.66{13} 416.1643 416.1646 56 100 
3.66{14} 398.1385 398.1382 83 98 
3.66{15} 357.1596 357.1598 32 96 
3.66{16} 326.1174 326.1176 48 100 
3.66{17} 324.1017 324.1013 50 96 
3.67{1} 324.1745 324.1749 49 99 
3.67{2} 354.1851 354.1854 56 100 
3.67{3} 381.2323 381.2324 33 96 
3.67{4} 414.2214 414.2218 46 100 
3.67{7} 394.2527 394.2528 50 100 
3.67{8} 404.1643 404.1643 38 90 
3.67{9} 407.2480 407.2483 28 100 
3.67{10} 364.2058 364.2061 52 99 
3.67{11} 309.1636 309.1637 51 100 
3.67{12} 399.2105 399.2106 50 100 
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3.67{15} 326.1901 326.1905 36 100 
3.67{16} 295.1479 295.1482 46 99 
3.67{17} 293.1323 293.1327 44 89 
3.68{1} 324.1745 324.1765 40 100 
3.68{2} 354.1851 354.1864 52 100 
3.68{3} 381.2323 381.2313 5 100 
3.68{4} 414.2215 414.2222 52 100 
3.68{5} 387.1854 387.1872 52 99 
3.68{7} 394.2527 394.2498 54 100 
3.68{9} 407.2480 407.2472 35 100 
3.68{10} 364.2058 364.2080 54 98 
3.68{11} 309.1636 309.1641 55 100 
3.68{12} 399.2105 399.2096 53 93 
3.68{13} 385.1949 385.1961 58 99 
3.68{14} 367.1691 367.1719 57 98 
3.68{15} 326.1901 326.1933 2 100 
3.68{16} 295.1479 295.1506 60 99 
3.68{17} 293.1323 293.1329 47 97 
3.69{1} 302.1901 302.1912 48 100 
3.69{2} 332.2007 332.2004 51 92 
3.69{3} 359.2480 359.2497 16 100 
3.69{4} 392.2371 392.2408 48 99 
3.69{5} 365.2010 365.2017 43 100 
3.69{7} 372.2684 372.2688 54 100 
3.69{8} 382.1800 382.1860 22 99 
3.69{9} 385.2636 385.2644 23 100 
3.69{10} 342.2214 342.2231 45 100 
3.69{11} 287.1792 287.1787 53 100 
3.69{12} 377.2262 377.2288 56 100 
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3.69{13} 363.2105 363.2101 61 100 
3.69{14} 345.1847 345.1880 50 93 




3.69{16} 273.1636 273.1641 53 100 
3.69{17} 271.1479 271.1490 45 100 
(R)-3.3{1} 340.1694 340.1720 20 100 
(R)-3.3{2} 370.1800 370.1821 30 100 
(R)-3.3{3} 367.2273 397.2275 10 100 
(R)-3.3{4} 430.2164 430.2155 25 96 
(R)-3.3{5} 403.1803 403.1800 23 95 
(R)-3.3{7} 410.2477 410.2478 5 100 
(R)-3.3{10} 380.2007 380.2029 15 100 
(R)-3.3{12} 415.2055 415.2054 41 99 
(R)-3.3{16} 311.1429 311.1428 50 99 
(R)-3.3{18} 325.1585 325.1611 25 100 
(R)-3.3{19} 327.1378 327.1403 53 100 
(R)-3.3{20} 355.1691 355.1685 19 97 
(R)-3.3{21} 355.1691 355.1706 8 100 
(R)-3.3{22} 341.1534 341.1550 9 95 
(R)-3.3{23} 354.1851 354.1869 19 100 
(S)-3.3{1} 340.1695 340.1719 8 100 
(S)-3.3{2} 370.1800 370.1811 28 96 
(S)-3.3{3} 397.2273 397.2290 11 95 
(S)-3.3{4} 430.2164 430.2154 20 95 
(S)-3.3{10} 380.2007 380.2042 20 97 
(S)-3.3{12} 415.2055 415.2068 26 100 
(S)-3.3{16} 311.1429 311.1453 47 100 
(S)-3.3{18} 325.1585 325.1593 15 100 
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(S)-3.3{19} 327.1378 327.1395 47 99 
(S)-3.3{20} 355.1691 355.1722 7 100 
(S)-3.3{21} 355.1691 355.1722 19 96 
(S)-3.3{22} 341.1534 341.1541 19 100 
(S)-3.3{23} 354.1851 354.1852 18 100 
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5.4 Experimental Data for Chapter 4 
General procedure for preparation of tertiary 2-bromobenzenesulfonamides 
To an r. b. flask containing a solution of primary amine (2.2 mmol, 1.1 eq) in dry 
CH2Cl2 (0.1 M), was added Et3N (3.9 mmol, 2.0 eq). The reaction mixture was cooled 
to 0 ºC, stirred for 5 minutes, after which benzenesulfonyl chloride (2.0 mmol, 1.0 eq) 
was added to the reaction mixture, warmed to rt for 12 h. The reaction was quenched 
with water, the organic layer was separated and the aqueous layer extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layers were washed with brine (10 mL), 
dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford the 
desired secondary 2-bromobenzenesulfonamide.  
The crude secondary 2-bromobenzenesulfonamide (2.4 mmol, 1 eq) was added to a 
flame-dried flask, to which Cs2CO3 (4.1 mmol, 1.2 eq) and dry CH3CN (0.2 M) were 
added. After stirring for 5 min, propargyl bromide (4.1 mmol, 1.2 eq) was added and 
the reaction mixture was stirred at 60 ºC until completion of reaction (as monitored 
by TLC). The crude reaction mixture was filtered through a pad of Celite, washed 
with CH2Cl2, concentrated under reduced pressure to furnish the desired product. 
General procedure for Huisgen’s 1,3-dipolar [3+2] cycloaddition reaction 
To a flame dried r. b. flask charged with alkynyl-sulfonamide (1.4 mmol, 1 eq) was 
added tBuOH:CH2Cl2 (2.3 mL: 2.3 mL, 1:1). Benzyl azide (2.8 mmol, 2 eq) was 
added. To another flame dried round bottom flask CuSO4•5H2O (0.3 mmol, 0.2 eq) 
and (+)-sodium L-ascorbate (0.4 mmol, 0.3 eq) were added in H2O (2.3 mL) and the 
resulting solution was added into the previous flask. The reaction mixture was stirred 
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at rt for 12 h. The organic layer was separated and the aqueous layer extracted with 
CH2Cl2 (3 × 15 mL). The combined organic layers were dried over anhydrous 
Na2SO4, and concentrated under reduced pressure. The crude material was subjected 
to flash chromatography (1:1 hexane:EtOAc) to yield the desired product.  
General procedure for Mitsunobu reaction 
A portion of the secondary benzenesulfonamide (2.5 mmol, 1 eq) was added to a 
flame-dried flask under argon, to which were added PPh3 (5.3 mmol, 2 eq) and dry 
CH2Cl2 (0.5 M). After stirring for 5 min at 0 ºC, 3-butyn-1-ol (5.3 mmol, 2 equiv) 
was added followed by dropwise addition of diisopropyl azodicarboxylate (DIAD) 
(5.3 mmol, 2 eq) at 0 ºC. The reaction mixture was stirred at rt for 12 h, after which 
time the crude mixture was concentrated under reduced pressure and purified by flash 
chromatography (5:1 hexane:EtOAc) to obtain the desired product. 
General procedure for C-arylation reaction (method A) 
To an oven dried seal vial were added 1,2,3-triazole containing 2-
bromobenzenesulfonamide (0.34 mmol, 1 eq), Pd(OAc)2 ( 0.034 mmol, 10 mol%), 
and tetrabutylammonium acetate (0.683 mmol, 2 eq) under N2 atmosphere. N-
Methylpyrrolidone (0.5 M) was then added, and the reaction mixture was stirred at 
110 °C for 17 h monitoring by TLC. The reaction mixture was diluted with EtOAc 
(20 mL), washed twice with 10 mL portions of water and brine, dried over anhydrous 
Na2SO4. The solvents were removed and the residue was purified via flash 
chromatography (1:1 hexane:EtOAc) to afford tricyclic sultam compounds. 
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General procedure for C-arylation reaction (method B) 
To an oven dried seal vial were added 1,2,3-triazole containing 2-
bromobenzenesulfonamide (0.34 mmol, 1 eq), Pd(PPh3)4 (0.034 mmol, 10 mol%), 
and KOAc (0.683 mmol, 2 eq) under N2 atmosphere. Anhydrous DMF (0.5 M) was 
then added, and the reaction mixture was stirred at 110 °C for 17 h monitoring by 
TLC. The reaction mixture was diluted with EtOAc (20 mL), washed twice with 10 
mL portions of water and brine, dried over anhydrous Na2SO4. The solvents were 
removed and the residue was purified via flash chromatography (1:1 hexane:EtOAc) 
to afford tricyclic sultam compounds. 
General procedure for preparation of azides 
Caution: While synthesis of azides has become ubiquitous in the literature some are 
explosive and care should be taken when synthesizing and handling them. 
To a stirred solution of the corresponding bromide (1.0 eq) in anhydrous DMF (1 M) 
was added NaN3 (2 eq). The resulting suspension was stirred at room temperature for 
15 h. Diethyl ether and water were added to the mixture and the organic layer was 
separated. The organic layer was washed with water (4 × 20 mL) and the organic 
layers was dried over Na2SO4. Solvent was removed under reduced pressure, and the 
azide was sufficiently pure to use without further work up. 
General procedure for preparation of phenyl azide  
A mixture of aniline 1 mL (10.97 mmol), water (15.7 mL), and concd HCl (15.7 mL) 
was stirred at 0–5$°C for 30 min. The amine hydrochloride was then deazotized by the 
dropwise addition of aq NaNO2 (0.9 g, 13.04 mmol, in 13.2 mL H2O). The solution 
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was stirred at 0–5$°C and treated with aq NaN3 (1.42 g, 21.85 mmol, in 13.2 mL 
H2O). After stirring for 1 h at 0–5 ºC, the reaction mixture was extracted with CH2Cl2 
(4 × 20 mL). The combined organic layers were washed with water and brine, dried 














Yield 66%; Mp 135 ºC; 
FTIR (neat): 2987, 1319, 1101, 912 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.12 (dd, J = 7.9, 1.7 Hz, 1H), 7.82 (s, 1H), 7.74 
(dd, J = 7.8, 1.3 Hz, 1H), 7.44 (td, J = 7.5, 1.3 Hz, 1H), 7.41 – 7.33 (m, 4H), 7.26 (dd, 
J = 7.7, 2.3 Hz, 2H), 5.56 (s, 2H), 5.00 (s, 2H), 1.26 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 147.8, 143.4, 135.5, 134.8, 133.0, 131.3, 129.0, 
128.6, 127.8, 127.6, 124.0, 119.8, 60.1, 54.2, 43.0, 30,1;  













Yield 71%;  
FTIR (neat): 2985, 1326, 1153, 907 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.10 (dd, J = 7.9, 1.7 Hz, 1H) 7.77 (s, 1H), 7.72 
(dd, J = 7.8, 1.3 Hz, 1H), 7.43 (td, J = 7.5, 1.3 Hz, 1H), 7.36 (td, J = 7.7, 1.8 Hz, 7 
1H), 7.17 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 5.49 (s, 2H), 4.97 (s, 2H), 2.35 
(s, 3H), 1.27 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 147.8, 143.4, 135.5, 134.8, 133.0, 131.3, 129.0, 
128.6, 127.8, 127.6, 124.0, 119.8, 60.1, 54.2, 43.0, 30,1, 21.1;  














Yield 68%;  
FTIR (neat): 3143, 2975, 2925, 1448, 1323, 1126 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (dd, J = 7.9, 1.6 Hz, 1H) 7.80 (s, 1H), 7.82 
(s, 1H), 7.75 (dd, J = 7.8, 1.3 Hz, 1H), 7.45 (td, J = 7.5, 1.3 Hz, 1H), 7.38 (td, J = 7.7, 
1.7 Hz, 1H), 5.00 (s, 2H), 4.18 (d, J = 7.2 Hz, 2H) 1.93 – 1.88 (m, 1H) 1.75 – 1.59 
(m, 5H) 1.27 (s, 9H) 1.22 – 1.14 (m, 2H) 1.04 – 0.96 (m, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 147.1, 143.4, 135.5, 133.0, 131.3, 127.6, 124,3, 
119.9, 60.1, 56.6, 43.1, 38.7, 30.4, 30.1, 26.1, 25.5;  













Yield 77%;  
Mp 150 ºC; 
FTIR (neat): 2978, 1583, 1466, 1325, 1150 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.12 (dd, J = 8.9 Hz, 4JH-F  = 5.8 Hz, 1H), 7.78 (s, 
1H), 7.45 (dd, J = 2.6 Hz, 3JH-F = 8.0 Hz, 1H), 7.39 – 7.32 (m, 3H), 7.26 – 7.22 (m, 
2H), 7.12 (ddd, J = 9.4, 2.4 Hz, 3JH-F  = 7.5 Hz, 1H), 5.54 (s, 2H), 4.97 (s, 2H), 1.27 
(s, 9H); 
13C NMR (125 MHz, CDCl3) δ ppm 163.7 (d, 1JC-F = 259.1 Hz), 147.5, 139.7 (d, 4JC-F 
= 3.7 Hz), 134.8, 133.3 (d, 3JC-F = 10.1 Hz), 129.0, 128.6, 127.8, 124.0, 122.7 (d, 2JC-F 
= 25.2 Hz), 121.0, (d, 3JC-F = 10.1 Hz), 114.8 (d, 2JC-F = 21.4 Hz), 60.2, 54.2, 43.0, 
30.1;  













Yield 87%;  
Mp 140 ºC; 
FTIR (neat): 2977, 1583, 1325, 1150 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.11 (dd, J = 8.9 Hz, 4JH-F = 5.8 Hz, 1H), 7.75 (s, 
1H), 7.45 (dd, J = 2.5 Hz, 3JH-F = 8.0 Hz, 1H), 7.17 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 
8.5 Hz, 2H), 7.12, (ddd, J = 9.0, 2.6 Hz, 3JH-F = 7.5 Hz, 1H), 5.49 (s, 2H), 4.96 (s, 
2H), 2.35 (s, 3H), 1.27 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ ppm 163.7 (d, 1JC-F = 257.8 Hz), 147.4, 139.7 (d, 4JC-F 
= 3.7 Hz), 138.5, 133.3 (d, 3JC-F = 8.8 Hz), 131.7, 129.7, 127.8, 123.9, 122.7 (d, 2JC-F 
= 25.2 Hz), 121.0, (d, 3JC-F = 10.1 Hz), 114.8 (d, 2JC-F = 20.1 Hz), 60.2, 54.0, 43.0, 
30.1, 21.1;  













Yield 83%;  
Mp 124 ºC; 
FTIR (neat): 2926, 1734, 1583, 1464, 1325, 1150 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.15 (dd, J = 9.0 Hz, 4JH-F =  5.8 Hz, 1H), 7.78 (s, 
1H), 7.48 (dd, J = 2.6 Hz, 3JH-F = 8.0 Hz, 1H), 7.15 (ddd, J = 9.0, 2.6 Hz, 3JH-F = 7.4 
Hz, 1H), 4.99 (s, 2H), 4.18 (d, J = 7.2 Hz, 2H), 1.90 (m, 1H), 1.75 – 1.59 (m, 5H), 
1.27 (s, 9H), 1.25 – 1.10 (m, 3H), 1.03 – 0.94 (m, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 163.8 (d, 1JC-F = 259.1 Hz), 146.9, 139.8 (d, 4JC-F 
= 3.8 Hz), 133.3 (d, 3JC-F = 8.8 Hz), 124.3, 122.7 (d, 2JC-F = 23.9 Hz), 121.1 (d, 3JC-F = 
10.1 Hz), 114.8 (d, 2JC-F = 21.4 Hz), 60.2, 56.6, 43.1, 38.7, 30.4, 30.1, 26.1, 25.5;  
HRMS calculated for C20H29BrFN4O2S (M+H)+ 487.1179, found 487.1159.  
 316 
(±)-1-Benzyl-5-(tert-butyl)-4,5-dihydro-1H-benzo[f][1,2,3]triazolo[4,5-






Yield 99%;  
Mp 156 ºC; 
FTIR (neat): 2979, 1340, 1163, 912 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.14  (dd, J = 7.4, 1.5 Hz, 1H) 7.51 – 7.44 (m, 
3H) 7.41 – 7.31 (m, 3H) 7.22 (dd, J = 8.2, 1.4 Hz, 2H), 5.71 (s, 2H), 5.03 (s, 2H), 
1.18 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 144.4, 142.9, 135.3, 132.1, 131.4, 129.2, 129.1, 
128.7, 128.7, 128.3, 126.5, 124.3, 59.6, 53.4, 44.7, 29.0;  










Yield 78%;  
FTIR (neat): 2977, 1342, 1163, 912 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (d, J = 8.0 Hz, 1H), 7.56 – 7.44 (m, 3H), 
7.19 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 8.1 Hz, 2H), 5.65 (s, 2H), 5.02 (s, 2H), 2.35 (s, 
3H), 1.17 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 144.3, 142.8, 138.1, 132.3, 132.1, 131.3, 129.8, 
129.2, 128.6, 126.5, 124.3, 59.6, 53.3, 44.7, 29.0, 21.1;  










Yield 84%;  
FTIR (neat): 2975, 2927, 1479, 1342, 1190 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 7.8, 1.3 Hz, 1H), 7.69 (td, J = 7.7, 
1.4 Hz, 1H), 7.60 (dd, J = 7.8, 1.1 Hz, 1H), 7.53 (td, J = 7.7, 1.3 Hz, 1H), 4.98 (s, 
2H), 4.39 (d, J = 7.3 Hz, 2H), 1.92 – 1.84 (m, 1H), 1.68 – 1.48 (m, 6H), 1.17 (s, 9H), 
1.14 – 1.00 (m, 2H), 0.89 – 0.80 (m, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 143.9, 142.9, 132.2, 131.3, 128.8, 128.7, 128.6, 
125.0, 59.6, 56.4, 44.7, 38.7, 30.3, 29.0, 26.0, 25.4;  











Yield 99%;  
FTIR (neat): 2980, 1585, 1344, 1163 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (dd, J = 8.8 Hz, 4JH-F = 5.8 Hz, 1H), 7.42 – 
7.34 (m, 3H), 7.24 (d, J = 7.0 Hz, 2H), 7.20 (dd, J = 2.4 Hz, 3JH-F = 9.4 Hz, 1H), 7.13 
(ddd, J = 9.8, 2.5 Hz, 3JH-F = 7.4 Hz, 1H), 5.72 (s, 2H), 5.02 (s, 2H), 1.19 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 164.0 (d, 1JC-F  = 255.3 Hz), 144.9, 139.0 (d, 4JC-
F  = 3.8 Hz), 134.7, 131.2 (d, 3JC-F = 10.1 Hz), 130.4, 129.3, 128.6, 126.7 (d, 3JC-F = 
8.8 Hz), 126.6, 116.5 (d, 2JC-F = 25.2 Hz), 115.2 (d, 2JC-F  = 21.4 Hz), 59.7, 53.7, 44.7, 
29.0; 












FTIR (neat): 2980, 1585, 1344, 1190, 1163 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (dd, J = 8.7 Hz, 4JH-F = 5.6 Hz, 1H), 7.24 
(dd, J = 2.5 Hz, 3JH-F = 9.8 Hz, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 
2H), 7.12 (ddd, J = 9.0, 2.5 Hz, 3JH-F = 7.3 Hz, 1H), 5.67 (s, 2H), 5.01 (s, 2H), 2.35 (s, 
3H), 1.18 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ ppm 164.0 (d, 1JC-F  = 254.0 Hz), 144.8, 138.9 (d, 4JC-
F  = 2.5 Hz), 138.4, 131.7, 131.2 (d, 3JC-F = 8.8 Hz), 130.3, 129.9, 126.8 (d, 3JC-F = 
10.1 Hz), 126.6, 116.6 (d, 2JC-F = 26.4 Hz), 115.2 (d, 2JC-F  = 21.4 Hz), 59.7, 53.5, 
44.6, 29.0, 21.1; 











Yield 63%;  
FTIR (neat): 2928, 1583, 1344, 1190, 1163 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.18 (dd, J = 8.7 Hz, 4JH-F = 5.8 Hz, 1H), 7.31 
(dd, J = 2.5 Hz, 3JH-F = 9.5 Hz, 1H), 7.22 (ddd, J = 2.5, 8.8 Hz, 3JH-F = 7.6 Hz, 1H), 
4.96 (s, 2H), 4.39 (d, J = 7.2 Hz, 2H), 1.89 (dddt, J = 3.6, 7.1, 10.8, 14.5 Hz, 1H), 
1.68  – 1.53 (m, 6H), 1.19 (s, 9H), 1.14 – 1.08 (m, 2H), 0.92 – 0.88 (m, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 164.1 (d, 1JC-F  = 254.0 Hz), 144.4, 139.1 (d, 4JC-
F  = 2.5 Hz), 131.4 (d, 3JC-F = 8.8 Hz), 130.3, 127.5 (d, 3JC-F = 8.8 Hz), 116.0 (d, 2JC-F = 
25.2 Hz), 115.2 (d, 2JC-F  = 21.4 Hz), 59.8, 56.5, 44.7, 38.8, 30.3, 29.0, 25.9, 25.4; 














Yield 84%;  
[α]D25 = +13.43 (c = 1.40, CH2Cl2); 
FTIR (neat): 2970, 1338, 1259 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.07 (dd, J = 7.9, 1.6 Hz, 1H), 7.72 (s, 1H), 7.67 
(dd, J = 7.8, 1.2 Hz, 1H), 7.44 – 7.32 (m, 5H), 7.25 (dd, J = 7.2, 2.0 Hz, 2H), 5.52 (d, 
J = 14.9 Hz, 1H), 5.45 (d, J = 14.9 Hz, 1H), 5.08 (s, 2H), 3.86 (d, J = 10.5 Hz, 1H), 
3.44 (s, 3H), 2.40 (dqq, J = 10.5, 6.5, 6.5 Hz, 1H), 0.84 (d, J = 6.6 Hz, 3H), 0.70 (d, J 
= 6.5 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.5, 145.9, 139.0, 135.3, 134.7, 133.6, 132.8, 
129.0, 128.7, 127.9, 127.6, 124.1, 120.1, 66.0, 54.1, 51.6, 41.2, 28.5, 19.6, 19.1;  













Yield 99%;  
[α]D25 = +5.65 (c = 1.70, CH2Cl2); 
FTIR (neat): 2964, 1734, 1338, 1149 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.08 (dd, J = 7.8, 1.7 Hz, 1H), 7.70 (s, 1H), 7.68 
(dd, J = 7.8, 1.0 Hz, 1H), 7.42 (dt, J = 7.5, 1.0 Hz, 1H), 7.35 (dt, J = 7.6, 1.6 Hz, 1H), 
7.18 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 8.2 Hz, 2H), 5.48 (d, J = 14.8 Hz, 1H), 5.40 (d, J 
= 14.8 Hz, 1H), 5.07 (s, 2H), 3.86 (d, J = 10.5 Hz, 1H), 3.44 (s, 3H), 2.40 (dqq, J = 
10.5, 6.5, 6.5 Hz, 1H), 2.36 (s, 3H), 0.84 (d, J = 6.6 Hz, 3H), 0.70 (d, J = 6.5 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.5, 145.8, 139.0, 138.6, 135.3, 133.6, 132.8, 
131.7, 129.7, 127.9, 127.6, 124.0, 120.1, 66.0, 53.9, 51.6, 41.2, 28.5, 21.2, 19.6, 19.1;  














[α]D25 = +10.54 (c = 1.47, CH2Cl2); 
FTIR (neat): 2925, 1338, 1149 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.11 (dd, J = 7.9, 1.7 Hz, 1H), 7.75 (s, 1H), 7.72 
(dd, J = 7.8, 1.3 Hz, 1H), 7.45 (td, J = 7.5, 1.4 Hz, 1H), 7.39 (td, J = 7.8, 1.8 Hz, 1H), 
5.13 (d, J = 16.7 Hz, 1H), 5.08 (d, J = 16.6 Hz, 1H), 4.14 (d, J = 7.1 Hz, 2H), 3.86 (d, 
J = 10.5 Hz, 1H), 3.47 (s, 3H), 2.41 (dqq, J = 10.6, 6.6, 6.6 Hz, 1H), 1.87 (m, 1H), 
1.78 – 1.55 (m, 4H), 1.31 – 1.12 (m, 4H), 1.07 – 0.93 (m, 2H), 0.84 (d, J = 6.6 Hz, 
3H), 0.71 (d, J = 6.5 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.5, 145.4, 139.1, 135.3, 133.6, 132.8, 127.6, 
124.6, 120.1, 66.1, 56.5, 51.6, 41.4, 38.8, 30.5, 30.4, 28.5, 26.1, 25.5, 19.6, 19.1;  














Yield 85%;  
[α]D25 = –40.52 (c = 2.50, CH2Cl2); 
FTIR (neat): 2954, 1740, 1342, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.11 (dd, J = 7.9, 1.4 Hz, 1H), 7.78 (s, 1H), 7.73 
(dd, J = 7.7, 1.1 Hz, 1H), 7.46 – 7.36 (m, 5H), 7.31 – 7.28 (m, 2H), 5.51 (s, 2H), 4.93 
(d, J = 16.9 Hz, 1H), 4.72 (d, J = 16.9 Hz, 1H), 4.63 (dd, J = 10.3, 4.5 Hz, 1H), 3.50 
(s, 3H), 1.84 (ddd, J = 15.5, 11.6, 5.2 Hz, 1H), 1.59 (ddd, J = 14.3, 9.5, 4.6 Hz, 1H), 
1.30 – 1.23 (m, 1H), 0.86 (d, J = 6.5 Hz, 3H), 0.58 (d, J = 6.7 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.5, 146.1, 139.0, 135.6, 134.7, 133.6, 132.3, 
129.1, 128.7, 128.0, 127.6, 124.0, 120.2, 58.9, 54.2, 52.1, 41.7, 38.9, 24.3, 22.4, 21.1;  














Yield 85%;  
[α]D25 = –39.16 (c = 1.54, CH2Cl2); 
FTIR (neat): 2954, 1742, 1344, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.09 (dd, J = 7.8, 1.8 Hz, 1H), 7.74 (s, 1H), 7.71 
(dd, J = 7.8, 1.4 Hz, 1H), 7.42 (td, J = 7.5, 1.4 Hz, 1H), 7.36 (td, J = 7.7, 1.9 Hz, 1H), 
7.17 (s, 4H), 5.45 (s, 2H), 4.90 (d, J = 16.9 Hz, 1H), 4.69 (d, J = 16.9 Hz, 1H), 4.61 
(dd, J = 10.4, 4.6 Hz, 1H), 3.48 (s, 3H), 2.36 (s, 3H), 1.83 (ddd, J = 14.4, 10.4, 4.1 
Hz, 1H), 1.58 (ddd, J = 14.3, 9.6, 4.7 Hz, 1H), 1.30 – 1.20 (m, 1H), 0.85 (d, J = 6.5 
Hz, 3H), 0.57 (d, J = 6.7 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.4, 145.9, 139.0, 138.6, 135.6, 133.5, 132.2, 
131.7, 129.7, 128.0, 127.5, 123.9, 120.2, 58.9, 54.0, 52.1, 41.7, 38.9, 24.2, 22.4, 21.1;  














Yield 69%;  
[α]D25 = +4.69 (c = 2.45, CH2Cl2); 
FTIR (neat): 2927, 1742, 1448, 1340, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.14 (dt, J = 7.8, 1.8 Hz, 1H), 7.80 (s, 1H), 7.76 
(dt, J = 7.7, 1.5 Hz, 1H), 7.48 (tt, J = 7.6, 1.5 Hz, 1H), 7.41 (tt, J = 7.6, 1.7 Hz, 1H), 
4.96 (d, J = 16.6 Hz, 1H), 4.74 (d, J = 16.9 Hz, 1H), 4.65 (dd, J = 10.4, 4.5 Hz, 1H), 
4.19 (dd, J = 13.6, 6.8 Hz, 1H), 4.15 (dd, J = 13.6, 7.2 Hz, 1H), 3.53 (d, J = 2.0 Hz, 
3H), 1.88 (ddd, J = 14.2, 10.3, 4.1 Hz, 2H), 1.77 – 1.57 (m, 6H), 1.30 – 1.16 (m, 4H), 
1.06 – 0.97 (m, 2H), 0.89 (dd, J = 6.5, 1.1 Hz, 3H), 0.64 (dd, J = 6.6, 2.9 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.4, 145.5, 139.0, 135.6, 133.6, 132.3, 127.6, 
124.6, 120.2, 59.0, 56.6, 52.1, 41.8, 38.9, 38.8, 30.9, 30.5, 26.0, 25.5, 25.5, 24.3, 22.5, 
21.1;  














Yield 99%;  
[α]D25 = +13.19 (c = 1.35, CH2Cl2); 
FTIR (neat): 2964, 1733, 1581, 1339, 1161 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.10 (dd, J = 8.9 Hz, 4JH-F =  5.8 Hz, 1H), 7.72 (s, 
1H), 7.43 – 7.35 (m, 4H), 7.25 (m, 2H), 7.11 (ddd, J = 9.5, 2.5 Hz, 3JH-F =  7.5 Hz, 
1H), 5.54 (d, J = 14.8 Hz, 1H), 5.47 (d, J = 14.8 Hz, 1H), 5.06 (s, 2H), 3.87 (d, J = 
10.5 Hz, 1H), 3.51 (s, 3H), 2.41 (dqq, J = 10.6, 6.6, 6.4 Hz, 1H), 0.87 (d, J = 6.6 Hz, 
3H), 0.73 (d, J = 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.6, 164.1 (d, 1JC-F = 259.1 Hz), 145.6, 135.4 
(d, 4JC-F  = 3.8 Hz), 134.9 (d, 3JC-F = 10.1 Hz), 134.7, 129.1, 128.7, 127.9, 124.0, 
122.6 (d, 2JC-F = 23.9 Hz), 121.4, (d, 3JC-F = 10.1 Hz), 114.7 (d, 2JC-F = 21.4 Hz), 66.1, 
54.1, 51.7, 41.1, 28.5, 19.6, 19.1;  















Yield 77%;  
[α]D25 = +12.90 (c = 1.55, CH2Cl2); 
FTIR (neat): 2965, 1741, 1586, 1338, 1150 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.08 (dd, J = 8.9 Hz, 4JH-F =  5.8 Hz, 1H), 7.67 (s, 
1H), 7.38 (dd, J = 2.6 Hz, 3JH-F =  7.9 Hz, 1H), 7.18 (d, J = 8.2 Hz, 2H), 7.14 (d, J = 
8.3 Hz, 2H), 7.09 (ddd, J = 9.0, 2.6 Hz, 3JH-F =  7.4 Hz, 1H), 5.47 (d, J = 14.7 Hz, 
1H), 5.40 (d, J = 14.8 Hz, 1H), 5.03 (s, 2H), 3.86 (d, J = 10.5 Hz, 1H), 3.50 (s, 3H), 
2.39 (dqq, J = 10.5, 6.6, 6.6 Hz, 1H), 2.35 (s, 3H), 0.85 (d, J = 6.6 Hz, 3H), 0.71 (d, J 
= 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.6, 164.1 (d, 1JC-F = 259.1 Hz), 145.5, 138.6, 
135.4 (d, 4JC-F  = 3.8 Hz), 134.9 (d, 3JC-F  = 10.1 Hz), 131.6, 129.7, 127.9, 123.9, 122.6 
(d, 2JC-F = 25.2 Hz), 121.4 (d, 3JC-F  = 11.3 Hz), 114.7 (d, 2JC-F  = 21.4 Hz), 66.1, 53.9, 
51.7, 41.1, 28.5, 21.2, 19.6, 19.1;  













Yield 70%;  
[α]D25 = +7.13 (c = 1.94, CH2Cl2); 
FTIR (neat): 2965, 1741, 1586, 1338, 1150 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (dd, J = 9.0 Hz, 4JH-F =  5.8 Hz, 1H), 7.73 (s, 
1H), 7.45 (dd, J = 2.4 Hz, 3JH-F =  7.8 Hz, 1H), 7.14 (ddd, J = 9.4, 2.4 Hz, 3JH-F =  7.4 
Hz, 1H), 5.10 (d, J = 16.7 Hz, 1H), 5.05 (d, J = 16.7 Hz, 1H), 4.14 (d, J = 7.2 Hz, 
2H), 3.86 (d, J = 10.5 Hz, 1H), 3.52 (s, 3H), 2.41 (dqq, J = 10.6, 6.6, 6.5 Hz, 1H), 
1.86 (dtd, J = 14.9, 7.3, 3.7 Hz, 1H), 1.75 – 1.58 (m, 5H), 1.30 – 1.13 (m, 3H), 1.05 – 
0.92 (m, 2H), 0.86 (d, J = 6.6 Hz, 3H), 0.72 (d, J = 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.5, 164.1 (d, 1JC-F = 259.1 Hz), 145.1, 135.5 
(d, 4JC-F  = 3.8 Hz), 135.0 (d, 3JC-F  = 8.8 Hz), 124.5, 122.6 (d, 2JC-F = 25.2 Hz), 121.5 
(d, 3JC-F  = 10.1 Hz), 114.7 (d, 2JC-F  = 21.4 Hz), 66.2, 56.5, 51.7, 41.3, 38.8, 30.5, 
30.4, 28.5, 26.1, 25.5, 19.6, 19.1;  













Yield 94%;  
[α]D25 = –32.44 (c = 0.78, CH2Cl2); 
FTIR (neat): 2954, 1740, 1581, 1342, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.10 (dd, J = 8.9 Hz, 4JH-F = 5.8 Hz, 1H), 7.76 (s, 
1H), 7.44 (dd, J = 2.5 Hz, 3JH-F = 8.0 Hz, 1H), 7.41 – 7.36 (m, 3H), 7.30 – 7.28 (m, 
2H), 7.11 (ddd, J = 9.8, 2.5 Hz, 3JH-F = 7.4 Hz, 1H), 5.50 (s, 2H), 4.87 (d, J = 16.9 Hz, 
1H), 4.68 (d, J = 16.9 Hz, 1H), 4.61 (dd, J = 10.4, 4.6 Hz, 1H), 3.54 (s, 3H), 1.83 
(ddd, J = 14.4, 10.4, 4.0 Hz, 1H), 1.59 (ddd, J = 14.3, 9.5, 4.7 Hz, 1H), 1.29 – 1.17 
(m, 1H), 0.86 (d, J = 6.5 Hz, 3H), 0.58 (d, J = 6.7 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.4, 164.0 (d, 1JC-F = 259.1 Hz), 145.8, 135.4 
(d, 4JC-F  = 3.8 Hz), 134.7, 134.2 (d, 3JC-F  = 10.1 Hz), 129.1, 128.7, 128.0, 124.0, 
123.0 (d, 2JC-F = 25.2 Hz), 121.5 (d, 3JC-F  = 8.8 Hz), 114.7 (d, 2JC-F  = 21.4 Hz), 59.0, 
54.2, 52.2, 41.6, 38.9, 24.3, 22.4, 21.1;  













Yield 97%;  
[α]D25 = –40.29 (c = 1.72, CH2Cl2); 
FTIR (neat): 2955, 1742, 1582, 1344, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.10 (dd, J = 8.9 Hz, 4JH-F = 5.8 Hz, 1H), 7.73 (s, 
1H), 7.44 (dd, J = 2.6 Hz, 3JH-F = 8.0 Hz, 1H), 7.18 (s, 4H), 7.12 (ddd, J = 9.9, 2.6 Hz, 
3JH-F = 7.4 Hz, 1H), 5.45 (s, 2H), 4.86 (d, J = 16.9 Hz, 1H), 4.67 (d, J = 16.9 Hz, 1H), 
4.61 (dd, J = 10.4, 4.7 Hz, 1H), 3.54 (s, 3H), 2.36 (s, 3H), 1.84 (ddd, J = 14.4, 10.4, 
4.1 Hz, 1H), 1.59 (ddd, J = 14.2, 9.6, 4.7 Hz, 1H), 1.28 – 1.22 (m, 1H), 0.86 (d, J = 
6.5 Hz, 3H), 0.59 (d, J = 6.7 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.5, 164.0 (d, 1JC-F = 259.1 Hz), 145.7, 138.7, 
135.4 (d, 4JC-F  = 2.5 Hz), 134.2 (d, 3JC-F  = 10.1 Hz), 131.6, 129.7, 128.0, 123.9, 122.9 
(d, 2JC-F = 25.2 Hz), 121.5 (d, 3JC-F  = 10.1 Hz), 114.7 (d, 2JC-F  = 25.2 Hz), 59.0, 54.0, 
52.2, 41.6, 38.9, 24.3, 22.4, 21.1, 21.0;  













Yield 98%;  
[α]D25 = –36.96 (c = 0.63, CH2Cl2); 
FTIR (neat): 2928, 2853, 1742, 1582, 1344, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.15 (dd, J = 8.9 Hz, 4JH-F = 5.8 Hz, 1H), 7.78 (s, 
1H), 7.48 (dd, J = 2.5 Hz, 3JH-F = 8.0 Hz, 1H), 7.15 (ddd, J = 9.0, 2.5 Hz, 3JH-F = 7.5 
Hz 1H), 4.91 (d, J = 16.9 Hz, 1H), 4.70 (d, J = 16.9 Hz, 1H), 4.63 (dd, J = 10.4, 4.5 
Hz, 1H), 4.18 (dd, J = 13.5, 7.2 Hz, 1H), 4.13 (dd, J = 13.7, 7.3 Hz, 1H), 3.57 (s, 3H), 
1.91 – 1.84 (m, 2H), 1.77 – 1.68 (m, 3H), 1.63 – 1.58 (m, 3H), 1.33 – 1.14 (m, 4H), 
1.05 – 0.96 (m, 2H), 0.87 (d, J = 6.5 Hz, 3H), 0.64 (d, J = 6.7 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.4, 164.0 (d, 1JC-F = 259.1 Hz), 145.2, 135.4 
(d, 4JC-F  = 3.8 Hz), 134.2 (d, 3JC-F  = 10.1 Hz), 124.5, 122.5 (d, 2JC-F = 23.9 Hz), 121.6 
(d, 3JC-F  = 10.1 Hz), 114.7 (d, 2JC-F  = 21.3 Hz), 59.1, 56.6, 52.2, 41.8, 38.9, 38.8, 
30.5, 26.0, 25.5, 25.4, 24.3, 22.5, 21.1;  









Yield 67%;   
Mp 83 ºC; 
[α]D25 = +14.10 (c = 3.00, CH2Cl2); 
FTIR (neat): 2966, 2933, 1737, 1346, 1157 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.06 (dd, J = 7.6, 1.2 Hz, 1H), 7.51 (td, J = 7.6, 
1.4 Hz, 1H), 7.46 (td, J = 7.6, 1.4 Hz, 1H), 7.40 – 7.29 (m, 4H), 7.16 (d, J = 7.0 Hz, 
2H), 5.96 (d, J = 16.2 Hz, 1H), 5.81 (d, J = 16.2 Hz, 1H), 5.05 (d, J = 16.2 Hz, 1H), 
4.91 (d, J = 16.2 Hz, 1H), 3.82 (d, J = 10.5 Hz, 1H), 3.10 (s, 3H), 2.16 (dqq, J = 9.2, 
6.5, 6.2 Hz, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.3, 142.9, 140.6, 135.2, 132.3, 131.0, 129.1, 
128.9, 128.8, 128.5, 128.3, 126.4, 124.2, 65.3, 52.9, 51.7, 43.1, 28.9, 19.3, 19.1;  










Yield 54%;   
[α]D25 = +0.17 (c = 1.15, CH2Cl2); 
FTIR (neat): 2964, 2927, 1348, 1157 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.06 (d, J = 7.5 Hz, 1H), 7.52 (td, J = 7.5, 1.5 Hz, 
1H), 7.46 (t, J = 7.0 Hz, 1H), 7.40 (dd, J = 7.5, 1.3 Hz, 1H), 7.17 (d, J = 8.0 Hz, 2H), 
7.07 (d, J = 7.9 Hz, 2H), 5.78 (d, J = 16.1 Hz, 1H), 5.48 (d, J = 16.0 Hz, 1H), 5.06 (d, 
J = 16.3 Hz, 1H), 5.01(d, J = 16.4 Hz, 1H), 3.92 (d, J = 10.6 Hz, 1H), 3.10 (s, 3H), 
2.34 (s, 3H), 2.17 (dqq, J = 10.6, 6.4, 6.4 Hz, 1H), 1.05 (d, J = 6.7 Hz, 3H), 0.91 (d, J 
= 6.6 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.3, 142.8, 140.6, 138.1, 132.3, 132.2, 131.0, 
129.8, 129.0, 128.8, 128.5, 126.4, 124.3, 65.3, 52.8, 51.7, 43.1, 28.9, 21.1, 19.3, 19.1;  










Yield 66%;   
[α]D25 = +0.50 (c = 2.02, CH2Cl2); 
FTIR (neat): 2930, 1446, 1348, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.10 (dd, J = 7.8, 1.0 Hz, 1H), 7.68 (td, J = 7.7, 
1.3 Hz, 1H), 7.55 – 7.50 (m, 2H), 5.02 (d, J = 16.1 Hz, 1H), 4.94 (d, J = 16.1 Hz, 
1H), 4.41 (dd, J = 13.7, 6.9 Hz, 1H), 4.29 (dd, J = 13.7, 7.8 Hz, 1H), 3.94 (d, J = 10.5 
Hz, 1H), 3.16 (s, 3H), 2.15 (dqq, J = 10.5, 6.8, 6.6 Hz, 1H), 1.87 – 1.82 (m, 1H), 1.68 
– 1.51 (m, 5H), 1.18 – 1.06 (m, 3H), 1.04 (d, J = 6.7 Hz, 3H), 0.91 (d, J = 6.5 Hz, 
3H), 0.95 – 0.85 (m, 1H), 0.79 – 0.71 (m, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.4, 142.4, 140.8, 132.4, 131.0, 128.8, 128.7, 
128.4, 124.9, 65.3, 55.8, 51.7, 43.1, 38.7, 30.3, 30.2, 28.9, 26.0, 25.4, 25.3, 19.3, 
19.1;  









Yield 60%;  
Mp 145 ºC; 
[α]D25 = +1.08 (c = 2.69, CH2Cl2); 
FTIR (neat): 2933, 1521, 1319, 1134 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.04 (dd, J = 7.7, 1.1 Hz, 1H), 7.53 (dt, J = 7.6, 
1.4 Hz, 1H), 7.45 (dt, J = 7.7, 1.2 Hz, 1H), 7.43 – 7.33 (m, 4H), 7.21 (d, J = 7.1 Hz, 
2H), 5.82 (d, J = 16.2 Hz, 1H), 5.60 (d, J = 16.0 Hz, 1H), 4.93 (d, J = 15.7 Hz, 1H), 
4.83 (d, J = 15.7 Hz, 1H), 4.57 (dd, J = 5.4, 1.0 Hz, 1H), 3.32 (s, 3H), 1.74 – 1.65 (m, 
3H), 0.95 (d, J = 6.5 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.2, 142.6, 141.0, 135.2, 132.3, 131.7, 129.1, 
128.9, 128.6, 128.3, 128.2, 126.5, 124.5, 58.2, 52.9, 52.1, 43.1, 38.6, 24.5, 23.0, 21.0;  










Yield 33%;   
[α]D25 = +0.80 (c = 0.50, CH2Cl2); 
FTIR (neat): 2955, 1742, 1346, 1254, 1161 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.03 (dd, J = 7.6, 1.1 Hz, 1H), 7.52 (dt, J = 7.6, 
1.4 Hz, 1H), 7.44 (dt, J = 7.6, 1.3 Hz, 1H), 7.42 (m, 1H), 7.17 (d, J = 8.0 Hz, 2H), 
7.09 (d, J = 8.1 Hz, 2H), 5.75 (d, J = 16.0 Hz, 1H), 5.53 (d, J = 16.0 Hz, 1H), 4.91 (d, 
J = 15.7 Hz, 1H), 4.81 (d, J = 15.7 Hz, 1H), 4.56 (dd, J = 9.1, 5.4 Hz, 1H), 3.30 (s, 
3H), 2.34 (s, 3H), 1.70 – 1.63 (m, 3H), 0.94 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 6.7 Hz, 
3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.1, 142.5, 141.0, 138.1, 132.3, 132.2, 129.8, 
129.3, 129.0, 128.5, 128.2, 126.5, 124.5, 58.2, 52.7, 52.1, 43.1, 38.6, 24.5, 23.0, 21.1, 
21.0; 









Yield 48%;   
[α]D25 = –0.22 (c = 1.35, CH2Cl2); 
FTIR (neat): 2925, 1742, 1346, 1159 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.06 (dd, J = 7.8, 1.2 Hz, 1H), 7.68 (dt, J = 7.6, 
1.4 Hz, 1H), 7.57 (dd, J = 7.7, 1.0 Hz, 1H), 7.51 (dt, J = 7.7, 1.2 Hz, 1H), 4.84 (d, J = 
15.4 Hz, 1H), 4.74 (d, J = 15.3 Hz, 1H), 4.58 (dd, J = 8.8, 5.4 Hz, 1H), 4.40 (dd, J = 
13.7, 7.1 Hz, 1H), 4.32 (dd, J = 13.7, 7.6 Hz, 1H), 3.34 (s, 3H), 1.92 – 1.82 (m, 1H), 
1.72 – 1.53 (m, 8H), 1.17 – 1.06 (m, 3H), 0.94 (d, J = 5.8 Hz, 3H), 0.92 (d, J = 5.8 
Hz, 3H), 0.89 – 0.77 (m, 2H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.2, 142.1, 141.2, 132.4, 131.7, 128.6, 128.4, 
128.2, 125.1, 58.3, 55.7, 52.1, 43.0, 38.7, 38.5, 30.3, 30.2, 26.0, 25.4, 25.4, 24.5, 23.0, 
21.0; 










Yield 34%;   
[α]D25 = –0.92 (c = 1.52, CH2Cl2); 
FTIR (neat): 2966, 1738, 1585, 1350, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.06 (dd, J = 9.4 Hz, 4JH-F =  5.7 Hz, 1H), 7.40 – 
7.31 (m, 3H), 7.18 (d, J = 7.0 Hz, 2H) 7.13 – 7.10 (m, 2H), 5.84 (d, J = 16.2 Hz, 1H), 
5.55 (d, J = 16.2 Hz, 1H), 5.07 (d, J = 16.5 Hz, 1H), 5.02 (d, J = 16.5 Hz, 1H), 3.91 
(d, J = 10.4 Hz, 1H), 3.17 (s, 3H), 2.24 – 2.08 (m, 1H), 1.05 (d, J = 6.7 Hz, 3H), 0.92 
(d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.3, 164.2 (d, 1JC-F  = 255.3 Hz), 143.4, 136.7 
(d, 4JC-F  = 3.8 Hz), 134.7, 131.5 (d, 3JC-F = 10.1 Hz), 130.0, 129.3, 128.5, 126.9 (d, 
3JC-F = 8.8 Hz), 126.5, 116.4 (d, 2JC-F = 26.4 Hz), 114.9 (d, 2JC-F  = 21.4 Hz), 65.3, 
53.2, 51.7, 43.2, 29.0, 19.3, 19.1; 










Yield 31%;   
[α]D25 = –0.61 (c = 1.33, CH2Cl2); 
FTIR (neat): 2972, 1737, 1585, 1350, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.06 (dd, J = 8.6 Hz, 4JH-F =  5.7 Hz, 1H), 7.18 (d, 
J = 7.9 Hz, 2H), 7.15 – 7.12 (m, 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.0 Hz, 
2H), 5.80 (d, J = 16.0 Hz, 1H), 5.49 (d, J = 16.1 Hz, 1H), 5.06 (d, J = 16.3 Hz, 1H), 
5.01 (d, J = 18.1 Hz, 1H), 3.91 (d, J = 10.4 Hz, 1H), 3.17 (s, 3H), 2.35 (s, 3H), 2.18 
(dqq, J = 10.5, 6.4, 6.3 Hz, 1H), 1.05 (d, J = 6.7 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.3, 164.2 (d, 1JC-F  = 255.3 Hz), 143.3, 138.4, 
136.7 (d, 4JC-F  = 3.8 Hz), 131.7, 131.5 (d, 3JC-F = 8.8 Hz), 129.9, 128.5, 126.9 (d, 3JC-F 
= 8.8 Hz), 126.5, 116.5 (d, 2JC-F = 25.2 Hz), 114.9 (d, 2JC-F  = 21.4 Hz), 65.3, 53.1, 
51.7, 43.2, 29.0, 21.1, 19.3, 19.1; 










Yield 36%;   
[α]D25 = –0.34 (c = 1.18, CH2Cl2); 
FTIR (neat): 2927, 1737, 1585, 1350, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.11 (dd, J = 8.8 Hz, 4JH-F =  5.7 Hz, 1H), 7.24 
(dd, J = 2.5 Hz, 3JH-F =  9.2 Hz, 1H), 7.19 (ddd, J = 8.6, 2.5 Hz, 3JH-F =  7.8 Hz, 1H), 
5.02 (d, J = 16.3 Hz, 1H), 4.94 (d, J = 16.3 Hz, 1H), 4.42 (dd, J = 13.8, 6.9 Hz, 1H), 
4.26 (dd, J = 13.8, 7.8 Hz, 1H), 3.93 (d, J = 10.4 Hz, 1H), 3.25 (s, 3H), 2.26  (dqq, J = 
10.2, 6.6, 6.6 Hz, 1H), 1.90 – 1.82 (m, 1H), 1.70 – 1.51 (m, 4H), 1.22 – 1.09 (m, 4H), 
1.05 (d, J = 6.7 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.88 – 0.71 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.4, 164.3 (d, 1JC-F  = 255.3 Hz), 142.8, 137.0, 
(d, 4JC-F  = 2.5 Hz), 131.6 (d, 3JC-F  = 10.1 Hz), 130.1, 127.8 (d, 3JC-F = 8.8 Hz), 116.1 
(d, 2JC-F = 23.9 Hz), 114.9 (d, 2JC-F  = 21.4 Hz), 65.3, 55.9, 51.8, 43.2, 38.8, 30.3, 
30.2, 29.0, 26.0, 25.4, 25.3, 19.4, 19.1; 










Yield 25%;   
[α]D25 = –1.09 (c = 1.56, CH2Cl2); 
FTIR (neat): 2956, 1742, 1587, 1348, 1159 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.00 (dd, J = 8.7 Hz, 4JH-F =  5.6 Hz, 1H), 7.40 – 
7.31 (m, 3H), 7.20 (d, J = 7.2 Hz, 2H), 7.14 – 7.08 (m, 2H), 5.82 (d, J = 16.1 Hz, 1H), 
5.59 (d, J = 16.1 Hz, 1H), 4.92 (d, J = 5.8 Hz, 1H), 4.80 (d, J = 5.8 Hz, 1H), 4.55 (dd, 
J = 8.8, 5.0 Hz, 1H), 3.35 (s, 3H), 1.74 – 1.65 (m, 3H), 0.91 (d, J = 6.7 Hz, 3H), 0.94 
(d, J = 6.3 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.1, 164.2 (d, 1JC-F  = 255.3 Hz), 143.1, 137.1, 
(d, 4JC-F  = 3.8 Hz), 134.7, 130.8 (d, 3JC-F  = 8.8 Hz), 130.7, 129.3, 128.5, 127.1 (d, 3JC-
F = 8.8 Hz), 126.6, 116.4 (d, 2JC-F = 26.4 Hz), 114.9 (d, 2JC-F  = 21.4 Hz), 58.3, 53.2, 
52.2, 43.1, 38.7, 24.6, 23.0, 20.9; 










Yield 86%;   
[α]D25 = +21.92 (c = 2.29, CH2Cl2); 
FTIR (neat): 2954, 1741, 1348, 1159 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.02 (dd, J = 8.7 Hz, 4JH-F =  5.6 Hz, 1H), 7.19 (d, 
J = 8.1 Hz, 2H), 7.15 (dd, J = 2.5 Hz, 3JH-F =  9.5 Hz, 1H), 7.11 (d, J = 8.0 Hz, 2H), 
7.09 (m, 1H), 5.78 (d, J = 16.0 Hz, 1H), 5.53 (d, J = 16.0 Hz, 1H), 4.92 (d, J = 15.8 
Hz, 1H), 4.80 (d, J = 15.8 Hz, 1H), 4.55 (dd, J = 9.8, 5.2 Hz, 1H), 3.35 (s, 3H), 2.35 
(s, 3H), 1.74 – 1.65 (m, 3H), 0.95 (d, J = 6.4 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.1, 164.2 (d, 1JC-F  = 255.3 Hz), 143.1, 138.4, 
137.0 (d, 4JC-F  = 3.8 Hz), 131.7, 130.7 (d, 3JC-F  = 8.8Hz), 130.6, 129.9, 127.2 (d, 3JC-F  
= 8.8 Hz), 126.6, 116.5 (d, 2JC-F = 25.2 Hz), 114.9 (d, 2JC-F  = 21.4 Hz), 58.3, 53.0, 
52.2, 43.1, 38.7, 24.6, 23.0, 21.1, 20.9; 










Yield 51%;   
[α]D25 = +10.49 (c = 2.14, CH2Cl2); 
FTIR (neat): 2927, 1742, 1585, 1450, 1348, 1159 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.07 (dd, J = 8.8 Hz, 4JH-F =  5.6 Hz, 1H), 7.27 
(dd, J = 2.4 Hz, 3JH-F =  9.1 Hz, 1H), 7.17 (ddd, J = 8.8, 2.5 Hz, 3JH-F =  7.7 Hz, 1H), 
4.84 (d, J = 15.4 Hz, 1H), 4.73 (d, J = 15.5Hz, 1H), 4.58 (dd, J = 11.0, 5.9 Hz, 1H), 
4.41 (dd, J = 13.8, 7.1 Hz, 1H), 4.30 (dd, J = 13.7, 7.6 Hz, 1H), 3.40 (s, 3H), 1.92 – 
1.84 (m, 1H), 1.74 – 1.61 (m, 7H), 1.19 – 1.08 (m, 4H), 0.96 (d, J = 6.1 Hz, 3H), 0.95 
(d, J = 5.6 Hz, 3H), 0.92 – 0.78 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.2, 164.2 (d, 1JC-F  = 255.3 Hz), 142.5, 137.2 
(d, 4JC-F  = 3.8 Hz), 130.9 (d, 3JC-F  = 10.6 Hz), 130.8, 127.8 (d, 3JC-F = 10.1 Hz), 116.0 
(d, 2JC-F = 23.9 Hz), 115.0 (d, 2JC-F  = 21.4 Hz), 58.3, 55.7, 52.2, 42.9, 38.8, 38.5, 
30.3, 30.2, 25.9, 25.4, 25.3, 24.5, 23.1, 20.9; 











Yield 84%;  
[α]D25 = –15.93 (c = 1.53, CH2Cl2); 
FTIR (neat): 3286, 2966, 1739, 1340, 1151 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.15 (dd, J = 7.9, 1.7 Hz, 1H), 7.73 (dd, J = 7.8, 
1.3 Hz, 1H), 7.47 (td, J = 7.1, 3.5 Hz, 1H), 7.40 (td, J = 7.6, 1.7 Hz, 1H), 3.90 (d, J = 
10.3 Hz, 1H), 3.88 – 3.74 (m, 2H), 3.55 (s, 3H), 2.79 (dddd, J = 16.2, 10.6, 5.5, 2.7 
Hz, 1H), 2.49 (dddd, J = 16.4, 10.8, 5.7, 2.6 Hz, 1H), 2.21 – 2.08 (m, 1H), 2.02 (t, J = 
2.6 Hz, 1H), 1.01 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.9, 139.0, 135.5, 133.7, 132.8, 127.6, 120.3, 
81.0, 70.2, 65.7, 51.7, 44.7, 28.9, 20.8, 19.8, 19.3; 














Yield 91%;  
[α]D25 = +39.58 (c = 7.87, CH2Cl2); 
FTIR (neat): 3290, 2968, 1739, 1581, 1465, 1344, 1163 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 8.9 Hz, 4JH-F =  5.8 Hz,1H), 7.46 
(dd, J = 2.6 Hz, 3JH-F =  8.0 Hz, 1H), 7.17 (ddd, J = 9.9, 2.6 Hz, 3JH-F =  7.4 Hz, 1H), 
3.87 (d, J = 10.3 Hz, 1H), 3.90 – 3.72 (m, 2H), 3.57 (s, 3H), 2.78 (dddd, J = 16.2, 
10.5, 5.6, 2.7 Hz, 1H), 2.48 (dddd, J = 16.3, 10.8, 5.7, 2.7 Hz, 1H), 2.21 – 2.07 (m, 
1H), 2.02 (t, J = 2.7 Hz, 1H), 1.01 (d, J = 6.6 Hz, 1H), 0.91 (d, J = 6.6 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.8, 164.1 (d, 1JC-F  = 260.3 Hz), 135.3 (d, 4JC-F  
= 3.8 Hz), 134.8 (d, 3JC-F  = 8.8 Hz), 122.8 (d, 2JC-F  = 25.2 Hz), 121.7 (d, 3JC-F  = 10.1 
Hz), 114.8 (d, 2JC-F  = 21.4 Hz), 80.8, 70.3, 65.8, 51.8, 44.8, 28.9, 20.8, 19.8, 19.3; 











Yield 52%;  
[α]D25 = –45.13 (c = 1.54, CH2Cl2); 
FTIR (neat): 3285, 2955, 1742, 1344, 1155 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.15 (dd, J = 7.9, 1.7 Hz, 1H), 7.74 (dd, J = 7.8, 
1.2 Hz, 1H), 7.47 (td, J = 7.8, 1.3 Hz, 1H), 7.40 (td, J = 7.7, 1.8 Hz, 1H), 4.55 (dd, J = 
8.9, 5.6 Hz, 1H), 3.70 (ddd, J = 16.0, 11.1, 5.2 Hz, 1H), 3.57 (s, 3H), 3.51 (ddd, J = 
16.0, 11.1, 5.2 Hz, 1H), 2.78 (dddd, J = 16.3, 11.1, 5.1, 2.7 Hz, 1H), 2.46 (dddd, J = 
16.4, 11.1, 5.3, 2.7 Hz, 1H), 2.02 (t, J = 2.6 Hz, 1H), 1.81 – 1.67 (m, 2H), 1.63 (dd, J 
= 14.9, 6.1 Hz, 1H), 0.93 (d, J = 6.0 Hz, 3H), 0.80 (d, J = 6.3 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 138.8, 135.6, 133.6, 132.6, 127.6, 120.4, 
80.9, 70.3, 58.4, 52.2, 45.0, 39.5, 24.5, 22.6, 21.6, 21.0; 













Yield 78%;  
[α]D25 = –25.45 (c = 1.56, CH2Cl2); 
FTIR (neat): 2966, 1733, 1338, 1149 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.15 (dd, J = 7.9, 1.5 Hz, 1H), 7.71 (d, J = 7.8 
Hz, 1H), 7.45 (dt, J = 7.5, 1.2 Hz, 1H), 7.40 – 7.36 (m, 4H), 7.30 – 7.28 (m, 3H), 5.50 
(s, 2H), 3.99 (ddd, J = 16.6, 11.4, 5.8 Hz, 1H), 3.93 (d, J = 9.6 Hz, 1H), 3.86 (ddd, J = 
16.3, 11.6, 4.9 Hz, 1H), 3.53 (s, 3H), 3.23 (ddd, J = 14.1, 11.2, 4.8 Hz, 1H), 3.03 
(ddd, J = 14.1, 11.7, 5.8 Hz, 1H), 2.22 (dqq, J = 16.8, 6.7, 6.7 Hz, 1H), 1.02 (d, J = 
6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.0, 145.2, 139.2, 135.5, 134.7, 133.6, 132.7, 
129.1, 128.7, 128.1, 127.6, 121.3, 120.3, 65.9, 54.1, 51.7, 45.7, 28.8, 27.5, 19.9, 19.3; 












Yield 82%;  
[α]D25 = –32.80 (c = 1.63, CH2Cl2); 
FTIR (neat): 2964, 1740, 1340, 1147 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.14 (dd, J = 7.9, 1.6 Hz, 1H), 7.70 (d, J = 7.8 
Hz, 1H), 7.45 (t, J = 7.5 Hz, 1H), 7.38 (dt, J = 7.7, 1.6 Hz, 1H), 7.27 (s, 1H), 7.19 (d, 
J = 9.7 Hz, 2H), 7.17 (d, J = 8.8 Hz, 2H), 5.44 (s, 2H), 3.97 (ddd, J = 15.3, 11.4, 5.7 
Hz, 1H), 3.93 (d, J = 10.6 Hz, 1H), 3.85 (ddd, J = 15.3, 11.5, 4.9 Hz, 1H), 3.52 (s, 
3H), 3.22 (ddd, J = 14.2, 11.5, 4.8 Hz, 1H), 3.01 (ddd, J = 14.1, 11.5, 5.7 Hz, 1H), 
2.36 (s, 3H), 2.21 (ddq, J = 10.3, 6.6, 6.6 Hz, 1H), 1.02 (d, J = 6.6 Hz, 3H), 0.90 (d, J 
= 6.6 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.9, 145.1, 139.2, 138.6, 135.5, 133.6, 132.7, 
131.7, 129.7, 128.1, 127.6, 121.2, 120.3, 65.8, 53.9, 51.7, 45.7, 28.8, 27.5, 21.2, 19.9, 
19.3; 












Yield 81%;  
[α]D25 = –34.13 (c = 1.42, CH2Cl2); 
FTIR (neat): 2927, 1740, 1340, 1150 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 7.9, 1.7 Hz, 1H), 7.72 (dd, J = 7.8, 
1.2 Hz, 1H), 7.47 (dt, J = 7.6, 1.3 Hz, 1H), 7.39 (dt, J = 7.8, 1.7 Hz, 1H), 7.35 (s, 1H), 
4.14 (d, J = 7.2 Hz, 2H), 4.01 (ddd, J = 15.2, 11.2, 5.8 Hz, 1H), 3.94 (d, J = 10.3 Hz, 
1H), 3.89 (ddd, J = 15.3, 11.5, 4.9 Hz, 1H), 3.54 (s, 3H), 3.25 (ddd, J = 14.2, 11.3, 4.9 
Hz, 1H), 3.06 (ddd, J = 14.1, 11.4, 5.8 Hz, 1H), 2.24 (dqq, J = 10.4, 6.6, 6.6 Hz, 1H), 
1.91 – 1.82 (m, 1H), 1.76 – 1.64 (m, 4H), 1.28 – 1.14 (m, 3H), 1.04 (d, J = 6.6 Hz, 
3H), 0.99 – 0.97 (m, 3H), 0.92 (d, J = 6.6 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.9, 144.5, 139.2, 135.5, 133.6, 132.7, 127.6, 
121.8, 120.3, 65.9, 56.4, 51.7, 45.8, 38.8, 30.5, 28.9, 27.5, 26.1, 25.5, 19.9, 19.3; 














Yield 98%;  
[α]D25 = –50.53 (c = 1.42, CH2Cl2); 
FTIR (neat): 2954, 1742, 1433, 1340, 1153 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (dd, J = 7.8, 1.7 Hz, 1H), 7.71 (d, J = 7.8, 
1.3 Hz, 1H), 7.44 (dt, J = 7.6, 1.3 Hz, 1H), 7.41 – 7.35 (m, 4H), 7.29 – 7.27 (m, 3H), 
5.50 (s, 2H), 4.57 (dd, J = 8.7, 5.7 Hz, 1H), 3.78 (ddd, J = 15.7, 11.2, 5.0 Hz, 1H), 
3.66 (ddd, J = 15.4, 11.1, 5.8 Hz, 1H), 3.53 (s, 3H), 3.22 (ddd, J = 14.3, 11.0, 5.0 Hz, 
1H), 3.00 (ddd, J = 14.3, 11.3, 5.7 Hz, 1H), 1.79 – 1.65 (m, 3H), 0.93 (d, J = 6.0 Hz, 
3H), 0.91 (d, J = 6.2 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 145.1, 139.0, 135.6, 134.7, 133.5, 132.4, 
129.1, 128.7, 128.1, 127.6, 121.3, 120.3, 58.6, 54.1, 52.1, 46.0, 39.4, 27.7, 24.5, 22.6, 
21.7; 













Yield 98%;  
[α]D25 = –51.50 (c = 1.67, CH2Cl2); 
FTIR (neat): 2954, 1742, 1340, 1153 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.14 (dd, J = 7.9, 1.7 Hz, 1H), 7.72 (dd, J = 7.8, 
1.3 Hz, 1H), 7.45 (dt, J = 7.6, 1.3 Hz, 1H), 7.38 (dt, J = 7.7, 1.8 Hz, 1H), 7.27 (s, 1H), 
7.21 (d, J = 9.5 Hz, 2H), 7.18 (d, J = 8.9 Hz, 2H), 5.43 (s, 2H), 4.59 (dd, J = 8.7, 5.7 
Hz, 1H), 3.78 (ddd, J = 15.7, 11.3, 5.0 Hz, 1H), 3.65 (ddd, J = 15.4, 11.1, 5.7 Hz, 
1H), 3.54 (s, 3H), 3.21 (ddd, J = 14.3, 11.1, 5.0 Hz, 1H), 2.99 (ddd, J = 14.3, 11.3, 5.7 
Hz, 1H), 2.37 (s, 3H), 1.79 – 1.59 (m, 3H), 0.94 (d, J = 6.0 Hz, 3H), 0.92 (d, J = 6.2 
Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 145.0, 139.0, 138.7, 135.6, 133.5, 132.4, 
131.6, 129.8, 128.2, 127.5, 121.2, 120.3, 58.6, 53.9, 52.1, 46.0, 39.4, 27.7, 24.5, 22.6, 
21.7, 21.2; 












Yield 86%;  
[α]D25 = –55.76 (c = 1.39, CH2Cl2); 
FTIR (neat): 2928, 1742, 1342, 1153 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.16 (dd, J = 7.9, 1.7 Hz, 1H), 7.73 (dd, J = 7.8, 
1.3 Hz, 1H), 7.44 (dt, J = 7.5, 1.3 Hz, 1H), 7.39 (dt, J = 7.7, 1.8 Hz, 1H), 7.34 (s, 1H), 
5.31 (s, 2H), 4.58 (dd, J = 8.9, 5.7 Hz, 1H), 4.14 (d, J = 7.2 Hz, 2H), 3.81 (ddd, J = 
15.4, 11.2, 5.0 Hz, 1H), 3.68 (ddd, J = 15.4, 11.1, 5.8 Hz, 1H), 3.54 (s, 3H), 3.24 
(ddd, J = 14.3, 11.0, 5.0 Hz, 1H), 3.03 (ddd, J = 14.3, 11.3, 5.8 Hz, 1H), 1.92 – 1.80 
(m, 1H), 1.79 – 1.64 (m, 6H), 1.29 – 1.14 (m, 3H), 1.03 – 0.97 (m, 2H), 0.93 (d, J = 
6.7 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H);  
13C NMR (126 MHz, CDCl3) δ ppm 171.7, 144.4, 139.0, 135.6, 133.5, 132.5, 127.6, 
121.9, 120.3, 58.6, 56.4, 52.1, 46.1, 39.4, 38.7, 30.5, 27.7, 26.1, 25.5, 24.6, 22.6, 
21.7; 













Yield 98%;  
[α]D25 = –33.87 (c = 1.55, CH2Cl2); 
FTIR (neat): 2966, 1740, 1581, 1340, 1207, 1161, 1147 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.18 (dd, J = 8.9 Hz, 4JH-F =  5.8 Hz, 1H), 7.45 
(dd, J = 2.5 Hz, 3JH-F =  7.9 Hz, 1H), 7.43 – 7.37 (m, 3H), 7.31 (s, 1H), 7.30 – 7.28 
(m, 2H), 7.16 (ddd, J = 9.1, 2.6 Hz, 3JH-F =  7.5 Hz, 1H), 5.51 (s, 2H), 3.98 (ddd, J = 
15.3, 11.3, 5.7 Hz, 1H), 3.92 (d, J = 10.4 Hz, 1H), 3.85 (ddd, J = 15.4, 11.5, 4.9 Hz, 
1H), 3.57 (s, 3H), 3.23 (ddd, J = 14.2, 11.4, 4.9 Hz, 1H), 3.03 (ddd, J = 14.2, 11.5, 5.7 
Hz, 1H), 2.23 (dqq, J = 10.4, 6.6, 6.6 Hz, 1H), 1.04 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 
6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.9, 164.1 (d, 1JC-F  = 260.3 Hz), 145.1, 135.5 
(d, 4JC-F  = 3.8 Hz), 134.8 (d, 3JC-F  = 8.8 Hz), 134.7, 129.1, 128.7, 128.1, 122.8 (d, 2JC-
F  = 25.2 Hz), 121.6 (d, 3JC-F  = 10.1 Hz), 121.3, 114.8 (d, 2JC-F  = 21.4 Hz), 65.9, 54.1, 
51.7, 45.7, 28.8, 27.4, 19.9, 19.3;  














[α]D25 = –30.78 (c = 1.36, CH2Cl2); 
FTIR (neat): 2966, 1740, 1581, 1340, 1207, 1161, 1147, 1045 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 8.9 Hz, 4JH-F =  5.8 Hz, 1H), 7.44 
(dd, J = 2.6 Hz, 3JH-F =  8.0 Hz, 1H), 7.21 – 7.17 (m, 5H), 7.15 (ddd, J = 8.9, 2.5 Hz, 
3JH-F =  7.4 Hz, 1H), 5.45 (s, 2H), 3.96 (ddd, J = 15.3, 11.4, 5.7 Hz, 1H), 3.91 (d, J = 
10.3 Hz, 1H), 3.83 (ddd, J = 15.2, 11.6, 4.8 Hz, 1H), 3.56 (s, 3H), 3.21 (ddd, J = 14.2, 
11.5, 4.8 Hz, 1H), 3.01 (ddd, J = 14.2, 11.6, 5.7 Hz, 1H), 2.37 (s, 3H), 2.21 (dqq, J = 
10.3, 6.6, 6.6 Hz, 1H), 1.03 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.8, 164.1 (d, 1JC-F  = 259.1 Hz), 145.0, 135.5 
(d, 4JC-F  = 3.8 Hz), 134.8 (d, 3JC-F  = 8.8 Hz), 131.6, 130.0, 128.1, 122.8 (d, 2JC-F  = 
23.9 Hz), 121.7 (d, 3JC-F  = 10.1 Hz), 121.2, 114.8 (d, 2JC-F  = 22.6 Hz), 65.9, 53.9, 
51.7, 45.7, 30.9, 28.8, 27.5, 21.2, 19.9, 19.3; 














[α]D25 = –29.23 (c = 1.37, CH2Cl2); 
FTIR (neat): 2928, 1740, 1582, 1465, 1340, 1207, 1163, 1148, 1047 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.19 (dd, J = 8.9 Hz, 4JH-F =  5.8 Hz, 1H), 7.46 
(dd, J = 2.5 Hz, 3JH-F =  7.4 Hz, 1H), 7.34 (s, 1H), 7.17 (ddd, J = 8.9, 2.5 Hz, 3JH-F =  
7.4 Hz, 1H), 4.14 (d, J = 7.2 Hz, 2H), 4.00 (ddd, J = 15.3, 11.3, 5.8 Hz, 1H), 3.91 (d, 
J = 10.3 Hz, 1H), 3.87 (ddd, J = 15.5, 11.5, 4.9 Hz, 1H), 3.57 (s, 3H), 3.24 (ddd, J = 
14.2, 11.4, 4.9 Hz, 1H), 3.05 (ddd, J = 14.1, 11.5, 5.8 Hz, 1H), 2.37 (dqq, J = 9.6, 6.6, 
6.6 Hz, 1H), 1.91 – 1.81 (m, 1H), 1.76 – 1.61 (m, 5H), 1.28 – 1.14 (m, 3H), 1.05 (d, J 
= 6.6 Hz, 3H),1.00 – 0.95 (m, 2H), 0.92 (d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.9, 164.1 (d, 1JC-F  = 260.3 Hz), 144.4, 135.5 
(d, 4JC-F  = 3.8 Hz), 134.8 (d, 3JC-F  = 8.8 Hz), 122.8 (d, 2JC-F  = 25.2 Hz), 121.8, 121.7 
(d, 3JC-F  = 11.3 Hz), 114.8 (d, 2JC-F  = 21.4 Hz), 65.9, 56.4, 51.8, 45.9, 38.8, 30.9, 
30.5, 28.8, 27.5, 26.1, 25.5, 19.9, 19.3; 












Yield 25%;   
Mp 136 ºC; 
[α]D25 = –27.08 (c = 0.65, CH2Cl2); 
FTIR (neat): 2965, 1750, 1348, 1168 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 7.8, 1.3 Hz, 1H), 7.62 (dt, J = 7.6, 
1.3 Hz, 1H), 7.56 (dt, J = 7.5, 1.5 Hz, 2H), 7.28 – 7.26 (m, 3H), 7.20 (dd, J = 7.1, 1.3 
Hz, 1H), 7.08 (dd, J = 7.2, 3.4 Hz, 1H), 5.54 (d, J = 15.4 Hz, 1H), 5.33 (d, J = 15.4 
Hz, 1H), 4.00 (d, J = 10.9 Hz, 1H), 3.68 (dd, J = 14.9, 11.3 Hz, 1H), 3.53 (ddd, J = 
13.1, 5.3, 1.9 Hz, 1H), 3.21 (dd, J = 14.8, 4.5 Hz, 1H), 3.19 (s, 3H), 2.27 – 2.20 (m, 
2H), 1.02 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.7, 144.9, 142.4, 134.9, 132.9, 131.5, 131.3, 
130.1, 129.7, 128.7, 128.2, 127.5, 123.8, 64.8, 52.4, 51.6, 42.2, 27.4, 26.1, 19.2, 18.6; 












Yield 37%;   
[α]D25 = –50.16 (c = 1.29, CH2Cl2); 
FTIR (neat): 2966, 1740, 1342, 1160 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.18 (dd, J = 6.8, 1.2 Hz, 1H), 7.63 (dt, J = 7.7, 
1.4 Hz, 1H), 7.56 (dt, J = 7.6, 1.4 Hz, 1H), 7.21 (dd, J = 7.6, 1.2 Hz, 1H), 7.08 (d, J = 
7.9 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H), 5.51 (d, J = 15.3 Hz, 1H), 5.26 (d, J = 15.4 Hz, 
1H), 4.00 (d, J = 10.9 Hz, 1H), 3.67 (dd, J = 14.8, 11.3 Hz, 1H), 3.53 (ddd, J = 14.8, 
5.4, 1.8 Hz, 1H), 3.22 (dd, J = 15.4, 4.7 Hz, 1H), 3.18 (s, 3H), 2.30 (s, 3H), 2.25 – 
2.19 (m, 2H), 1.02 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.6, 144.8, 142.3, 138.0, 132.8, 131.9, 131.5, 
131.0, 130.1, 129.7, 129.3, 127.4, 123.8, 64.8, 52.1, 51.6, 42.2, 27.4, 26.0, 21.1, 19.2, 
18.6; 













Yield 40%;   
[α]D25 = –42.37 (c = 1.56, CH2Cl2); 
FTIR (neat): 2964, 2926, 1740, 1346, 1167 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.28 – 8.23 (m, 1H), 7.70 – 7.65 (m, 2H), 7.42 – 
7.38 (m, 1H), 4.18 (dd, J = 13.6, 8.5 Hz, 1H), 4.60 (d, J = 10.9 Hz, 1H), 4.00 (dd, J = 
13.6, 6.4 Hz, 1H), 3.69 (dd, J = 14.9, 11.2 Hz, 1H), 3.54 (ddd, J = 14.8, 5.4, 1.7 Hz, 
1H), 3.22 (s, 3H), 3.21 (dd, J = 15.4, 4.9 Hz, 1H), 2.27 – 2.17 (m, 2H), 1.70 – 1.48 
(m, 5H), 1.15 – 1.07 (m, 3H), 1.04 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.4 Hz, 3H), 0.91 
– 0.75 (m 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 170.7, 144.7, 142.2, 132.6, 131.8, 130.9, 130.3, 
129.6, 124.5, 64.9, 54.9, 51.6, 42.2, 37.8, 30.4, 30.3, 29.7, 27.4, 26.1, 25.4, 25.3, 19.3, 
18.6; 















Yield 54%;   
[α]D25 = –17.36 (c = 2.35, CH2Cl2); 
FTIR (neat): 2966, 1740, 1581, 1346, 1160, 1144 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 8.9 Hz, 4JH-F =  5.5 Hz, 1H), 7.30 – 
7.27 (m, 5H), 7.10 (dd, J = 3.5, 7.2 Hz, 1H), 6.84 (dd, J = 2.5 Hz, 3JH-F =  8.6 Hz, 1H), 
5.58 (d, J = 15.4 Hz, 1H), 5.34 (d, J = 15.5 Hz, 1H), 3.9 (d, J = 10.9 Hz, 1H), 3.66 
(dd, J = 14.9, 1.2 Hz, 1H), 3.56 – 3.51 (m, 1H), 3.27 (s, 3H), 3.23 (dd, J = 15.8, 5.0 
Hz, 1H), 2.27 – 2.21 (m, 2H), 1.02 (d, J = 6.7 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.2, 163.2 (d, 1JC-F  = 256.6 Hz), 145.1, 138.6 
(d, 4JC-F  = 3.8 Hz), 134.6, 132.8 (d, 3JC-F  = 10.1 Hz), 128.8, 128.7, 128.4 127.5, 126.6 
(d, 3JC-F = 10.1 Hz), 118.4 (d, 2JC-F = 23.9 Hz), 116.5 (d, 2JC-F  = 21.4 Hz), 64.9, 52.7, 
51.7, 42.2, 27.5, 26.0, 19.2, 18.6; 















Yield 45%;   
[a]D25 = –27.94 (c = 1.80, CH2Cl2); 
FTIR (neat): 2970, 1740, 1582, 1346, 1161 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 9.0 Hz, 4JH-F =  5.5 Hz, 1H), 7.28 
(ddd, J = 9.0, 2.6 Hz, 3JH-F =  7.6 Hz, 1H), 7.09 (d, J = 7.3 Hz, 2H), 7.00 (d, J = 8.1 
Hz, 2H), 6.84 (dd, J = 2.6 Hz, 3JH-F =  8.6 Hz, 1H), 5.54 (d, J = 15.3 Hz, 1H), 5.27 (d, 
J = 15.4 Hz, 1H), 4.00 (d, J = 10.9 Hz, 1H), 3.66 (dd, J = 14.8, 11.2 Hz, 1H), 3.54 
(ddd, J = 14.9, 7.4, 1.8 Hz, 1H), 3.27 (s, 3H), 3.23 (dd, J = 15.4, 4.6 Hz, 1H), 2.31 (s, 
3H), 2.26 – 2.20 (m, 2H), 1.02 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.4 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.6, 163.2 (d, 1JC-F = 255.3 Hz), 145.0, 138.6 
(d, 4JC-F  = 3.8 Hz), 138.2, 132.8 (d, 3JC-F  = 8.8 Hz), 131.7, 129.8, 129.5, 127.4, 126.6 
(d, 3JC-F = 10.1 Hz), 118.5 (d, 2JC-F = 23.9 Hz), 116.5 (d, 2JC-F  = 22.6 Hz), 64.9, 52.4, 
51.7, 42.3, 27.5, 26.0, 21.1, 19.2, 18.6; 














Yield 48%;   
[α]D25 = –22.39 (c = 1.80, CH2Cl2); 
FTIR (neat): 2925, 1740, 1448, 1348, 1169 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.27 (dd, J = 9.0 Hz, 4JH-F = 5.6 Hz, 1H), 7.35 
(ddd, J = 9.0, 2.6 Hz, 3JH-F =  7.7 Hz, 1H), 7.10 (dd, J = 2.7 Hz, 3JH-F =  8.5 Hz, 1H), 
4.21 (dd, J = 13.6, 8.5 Hz, 1H), 4.06 (d, J = 10.9 Hz, 1H), 4.01 (dd, J = 13.6, 6.3 Hz, 
1H), 3.67 (dd, J = 14.9, 11.0 Hz, 1H), 3.56 (ddd, J = 14.9, 5.3, 1.8 Hz, 1H), 3.31 (s, 
3H), 3.23 (dd, J = 15.4, 4.8 Hz, 1H), 2.29 – 2.18 (m, 2H), 7.71 – 1.52 (m, 7H), 1.16 – 
1.09 (m, 3H), 1.03 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.4 Hz, 3H), 0.85 – 0.78 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.6, 163.5 (d, 1JC-F = 256.6 Hz), 144.9, 138.5 
(d, 4JC-F  = 2.5 Hz), 133.1 (d, 3JC-F  = 8.8 Hz), 131.6, 127.3 (d, 3JC-F = 8.8 Hz), 117.8 
(d, 2JC-F = 23.9 Hz), 116.5 (d, 2JC-F  = 21.4 Hz), 65.0, 55.0, 51.7, 42.2, 37.9, 30.4, 
30.3, 27.5, 26.0, 25.4, 19.2, 18.6; 












Yield 50%;   
FTIR (neat): 2955, 2934, 1741, 1344, 1170, 1153 cm-1;  
HRMS calculated for C24H28N4O4SNa (M+Na)+ 491.1729, found 491.1735. 
Major Isomer 
1H NMR (400 MHz, CDCl3) δ ppm 8.12 (dd, J = 8.0, 1.5 Hz, 1H), 7.60 (dt, J = 7.7, 
1.4 Hz, 1H), 7.55 (dt, J = 7.5, 1.6 Hz, 1H), 7.27 (m, 3H), 7.21 (dd, J = 7.4, 1.5 Hz, 
1H), 7.08 (dd, J = 7.4, 3.7 Hz, 2H), 5.55 (d, J = 15.4 Hz, 1H), 5.33 (d, J = 15.4 Hz, 
1H), 4.60 (dd, J = 8.3, 6.1 Hz, 1H), 3.67 (dd, J = 15.0, 11.3 Hz, 1H), 3.49 (ddd, J = 
15.1, 5.2, 1.8 Hz, 1H), 3.25 (s, 3H), 3.22 (dd, J = 15.3, 5.0 Hz, 1H), 2.55 (ddd, J = 
15.2, 11.5, 1.9 Hz, 1H), 1.75 – 1.59 (m, 3H), 0.99 (d, J = 6.1 Hz, 3H), 0.98 (d, J = 6.3 
Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.3, 145.0, 142.2, 135.0, 132.9, 132.1, 131.4, 





1H NMR (400 MHz, CDCl3) δ ppm 8.10 (dd, J = 6.4, 1.3 Hz, 1H), 7.55 (m, 2H), 7.27 
(m, 3H), 7.22 (dd, J = 7.5, 1.4 Hz, 1H), 7.08 (m, 2H), 5.54 (d, J = 15.4 Hz, 1H), 5.30 
(d, J = 15.4 Hz, 1H), 4.52 (dd, J = 8.6, 6.4 Hz, 1H), 3.81 (dd, J = 15.3, 11.8 Hz, 1H), 
3.76 (s, 3H), 3.53 (ddd, J = 15.3, 5.0, 1.8 Hz, 1H), 3.38 (dd, J = 15.2, 4.5 Hz, 1H), 
2.36 (ddd, J = 14.9, 11.9, 1.8 Hz, 1H), 1.20 (ddd, J = 14.1, 8.7, 5.4 Hz, 1H), 0.93 – 
0.87 (m, 2H), 0.70 (d, J = 6.8 Hz, 3H), 0.69 (d, J = 6.5 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 144.4, 142.3, 134.9, 132.7, 131.7, 131.5, 


















Yield 28%;  
FTIR (neat): 2960, 1742, 1344, 1169, 1151 cm-1;   
HRMS calculated for C25H30N4O4SNa (M+Na)+ 505.1885, found 505.1880. 
Major Isomer 
1H NMR (400 MHz, CDCl3) δ ppm 8.13 (dd, J = 7.6, 1.1 Hz, 1H), 7.60 (dt, J = 7.6, 
1.5 Hz, 1H), 7.55 (dt, J = 7.5, 1.7 Hz, 1H), 7.22 (dd, J = 7.4, 1.9 Hz, 1H), 7.08 (d, J = 
8.0 Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 5.52 (d, J = 15.4 Hz, 1H), 5.26 (d, J = 15.4 Hz, 
1H), 4.60 (dd, J = 8.2, 6.2 Hz, 1H), 3.53 (ddd, J = 15.4, 5.2, 1.9 Hz, 1H), 3.66 (dd, J 
= 15.0, 11.4 Hz, 1H), 3.24 (s, 3H), 3.22 (dd, J = 15.5, 4.8 Hz, 1H), 2.54 (ddd, J = 
15.2, 11.4, 1.8 Hz, 1H), 2.31 (s, 3H), 1.73 – 1.61 (m, 3H), 0.99 (d, J = 6.3 Hz, 3H), 
0.98 (d, J = 6.5 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.3, 145.0, 142.2, 137.9, 132.9, 132.2, 131.7, 




1H NMR (400 MHz, CDCl3) δ ppm 8.12 (dd, J = 6.5, 1.5 Hz, 1H), 7.60 (dt, J = 7.6, 
1.5 Hz, 1H), 7.27 – 7.53 (m, 1H), 7.23 (dd, J = 7.4, 1.4 Hz, 1H), 7.08 (d, J = 8.0 Hz, 
2H), 6.97 (d, J = 7.9 Hz, 2H), 5.50 (d, J = 15.3 Hz, 1H), 5.23 (d, J = 15.2 Hz, 1H), 
4.53 (dd, J = 8.7, 6.5 Hz, 1H), 3.81 (dd, J = 15.6, 11.7 Hz, 1H), 3.76 (s, 3H), 3.49 
(ddd, J = 15.1, 5.3, 1.8 Hz, 1H), 3.37 (dd, J = 14.6, 4.6 Hz, 1H), 2.37 (ddd, J = 13.5, 
7.6, 1.8 Hz, 1H), 2.31 (s, 3H), 1.20 (ddd, J = 13.4, 8.7, 5.4 Hz, 1H), 0.94 – 0.87 (m, 
2H), 0.71 (d, J = 6.2 Hz, 3H), 0.69 (d, J = 6.2 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 144.3, 142.7, 138.0, 132.6, 132.0, 131.9, 

















Yield 38%;  
FTIR (neat): 2926, 2853, 1742, 1344, 1169, 1151 cm-1;   
HRMS calculated for C24H34N4O4SNa (M+Na)+ 497.2198, found 497.2195. 
Major Isomer 
1H NMR (400 MHz, CDCl3) δ ppm 8.21 (dd, J = 7.5, 1.4 Hz, 1H), 7.70 – 7.62 (m, 
2H), 7.42 (dd, J = 7.1, 1.4 Hz, 1H), 4.66 (dd, J = 8.6, 6.0 Hz, 1H), 4.18 (dd, J = 13.6, 
8.5 Hz, 1H), 4.01 (dd, J = 13.6, 6.3 Hz, 1H), 3.67 (dd, J = 14.9, 11.2 Hz, 1H), 3.53 – 
3.50 (m, 1H), 3.28 (s, 3H), 3.20 (dd, J = 15.1, 4.9 Hz, 1H), 2.53 (ddd, J = 15.2, 11.4, 
1.8 Hz, 1H), 1.73 – 1.52 (m, 7H), 1.15 – 1.05 (m, 4H), 1.01 (d, J = 6.1 Hz, 3H), 0.99 
(d, J = 6.3 Hz, 3H), 0.94 – 0.87 (m, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.4, 144.9, 142.0, 132.6, 131.8, 131.0, 129.9, 





1H NMR (400 MHz, CDCl3) δ ppm 8.20 (dd, J = 7.7, 1.4 Hz, 1H), 7.70 – 7.62 (m, 
2H), 7.44 (dd, J = 6.8, 1.4 Hz, 1H), 4.58 (dd, J = 8.6, 6.4 Hz, 1H), 4.17 (dd, J = 13.7, 
8.5 Hz, 1H), 3.98 (dd, J = 13.6, 6.3 Hz, 1H), 3.81 (dd, J = 15.4, 11.6 Hz, 1H), 3.77 (s, 
3H), 3.53 – 3.50 (m, 1H), 3.36 (dd, J = 15.3, 5.0 Hz, 1H), 2.34 (ddd, J = 15.1, 11.7, 
1.7 Hz, 1H), 1.73 – 1.52 (m, 7H), 1.15 – 1.05 (m, 4H), 0.94 – 0.87 (m, 3H), 0.73 (d, J 
= 6.6 Hz, 3H), 0.972 (d, J = 6.4 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 144.3, 142.5, 132.4, 131.9, 131.6, 129.8, 



















FTIR (neat): 3137, 2935, 1574, 1447, 1331, 1159, 913, 748 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.10 (dd, J = 7.9, 1.8 Hz, 1H), 7.70 (dd, J = 7.8, 
1.3 Hz, 1H), 7.48 (s, 1H), 7.44 (td, J = 7.7, 1.4 Hz, 1H), 7.42 – 7.35 (m, 4H), 7.29 – 
7.25 (m, 2H), 5.52 (s, 2H), 4.56 (s, 2H), 2.87 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 144.0, 138.4, 125.7, 134.4, 133.6, 132.2, 129.2, 
128.8, 128.1, 127.5, 122.9, 120.4, 54.3, 45.3, 34.5; 
















FTIR (neat): 3280, 296, 1574, 1447, 1331, 1155, 1029, 750 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.10 (dd, J = 7.8, 1.7 Hz, 1H), 7.65 (dd, J = 7.9, 
1.2 Hz, 1H), 7.42 (s, 1H), 7.43 – 7.32 (m, 5H), 7.28 – 7.23 (m, 2H), 5.50 (s, 2H), 4.65 
(s, 2H), 3.34 (q, J = 7.1 Hz, 2H), 1.07 (t, J = 7.1 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 144.6, 139.4, 135.6, 134.5, 133.5, 132.1, 129.1, 
128.8, 128.1, 128.0, 127.5, 123.0, 120.5, 54.2, 42.0, 41.8, 13.1; 
















FTIR (neat): 2980, 1448, 1329, 1153, 1047, 761 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.13 (dd, J = 7.8, 1.8 Hz, 1H), 7.70 (dd, J = 7.8, 
1.3 Hz, 1H), 7.63 (s, 1H), 7.42 (td, J = 7.6, 1.4 Hz, 1H), 7.40 – 7.34 (m, 4H), 7.26 – 
7.21 (m, 2H), 5.50 (s, 2H), 4.70 (s, 2H), 3.96 (hept, J = 6.8 Hz, 1H), 1.08 (d, J = 6.7 
Hz, 6H); 
13C NMR (125 MHz, CDCl3) δ ppm 147.1, 139.2, 135.5, 134.7, 133.5, 132.5, 129.1, 
128.7, 127.8, 127.5, 123.5, 120.2, 54.1, 49.9, 38.6, 21.0; 














FTIR (neat): 3285, 2955, 1448, 1329, 1159, 912, 744 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.16 (dd, J = 7.8, 1.8 Hz, 1H), 7.71 (dd, J = 7.8, 
1.3 Hz, 1H), 7.70 (s, 1H), 7.46 (td, J = 7.6, 1.3 Hz, 1H), 7.43 – 7.34 (m, 4H), 7.30 – 
7.26 (m, 2H), 5.55 (s, 2H), 4.79 (s, 2H), 2.52 – 2.43 (m, 1H), 0.64 – 0.53 (m, 2H), 
0.42 – 0.34 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 144.8, 139.7, 135.5, 134.6, 133.7, 132.3, 129.1, 
128.7, 128.0, 127.5, 123.3, 120.4, 54.2, 45.9, 29.3, 7.2; 











Yield 78%;   
FTIR (neat): 2934, 1697, 1454, 1343, 1166, 913 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.17 (dd, J = 7.6, 1.5 Hz, 1H), 7.55 (td, J = 7.5, 
1.7 Hz, 1H), 7.52 (td, J = 7.5, 1.6 Hz, 1H), 7.45 (dd, J = 7.3, 1.7 Hz, 1H), 7.41 – 7.36 
(m, 2H), 7.36 – 7.32 (m, 1H), 7.22 (d, J = 7.9 Hz, 2H), 5.70 (s, 2H), 4.82 (s, 2H), 2.74 
(s, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 141.9, 138.2, 135.2, 132.6, 131.3, 130.2, 129.3, 
129.2, 129.0, 128.4, 126.5, 123.7, 53.2, 49.5, 37.7; 












Yield 80%;   
FTIR (neat): 2985, 1699, 1454, 1340, 1164, 1132, 912, 752 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.13 (dt, J = 7.6, 1.7 Hz, 1H), 7.53 (td, J = 7.6, 
1.7 Hz, 1H), 7.49 (td, J = 7.6, 1.5 Hz, 1H), 7.43 (dd, J = 7.5, 1.5 Hz, 1H), 7.38 (ddd, J 
= 7.6, 6.3, 1.6 Hz, 2H), 7.36 – 7.31 (m, 1H), 7.21 (d, J = 7.8 Hz, 2H), 5.70 (s, 2H), 
4.85 (d, J = 1.2 Hz, 2H), 3.04 (q, J = 7.2 Hz, 2H), 1.10 (t, J = 7.1 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 142.3, 140.2, 135.2, 132.4, 131.5, 129.4, 129.3, 
129.2, 128.9, 128.3, 126.5, 123.7, 53.2, 46.1, 45.0, 13.5; 














Yield 88%;   
Mp 184 ºC; 
FTIR (neat): 2983, 1339, 1160, 1048, 752 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.12 (dd, J = 7.7, 1.5 Hz, 1H), 7.51 (td, J = 7.6, 
1.6 Hz, 1H), 7.46 (td, J = 7.6, 1.4 Hz, 1H), 7.42 – 7.36 (m, 3H), 7.36 – 7.31 (m, 1H), 
7.22 (d, J = 7.1 Hz, 2H), 5.69 (s, 2H), 4.82 (s, 2H), 3.98 (hept, J = 6.7 Hz, 1H), 0.95 
(d, J = 6.7 Hz, 6H); 
13C NMR (125 MHz, CDCl3) δ ppm 143.1, 141.6, 135.2, 132.3, 131.6, 129.2, 129.1, 
128.8, 128.7, 128.3, 126.5, 124.0, 53.2, 49.8, 40.4, 20.2; 











Yield 72%;   
FTIR (neat): 2979, 1454, 1346, 1172, 1135, 912, 736 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.21 (dt, J = 7.7, 1.9 Hz, 1H), 7.58 – 7.51 (m, 
2H), 7.49 (dd, J = 7.4, 1.6 Hz, 1H), 7.39 (td J = 7.7, 1.6 Hz, 2H), 7.36 – 7.31 (m, 1H), 
7.23 (d, J = 7.7 Hz, 2H), 5.72 (s, 2H), 4.93 (s, 2H), 1.81 (hept, J = 3.4 Hz, 1H), 1.00 – 
0.91 (m, 2H), 0.67 – 0.54 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ ppm 142.6, 138.4, 135.2, 132.7, 131.1, 130.5, 129.23 
129.2, 129.0, 128.3, 126.5, 123.7, 53.3, 49.8, 31.9, 7.9; 















FTIR (neat): 2955, 2927, 2856, 1464, 1335, 1256, 1157, 1099, 1053, 837 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.08 (dd, J = 7.6, 2.0 Hz, 1H), 7.70 (dd, J = 7.6, 
1.5 Hz, 1H), 7.67 (s, 1H), 7.39 – 7.30 (m, 5H), 7.26 – 7.23 (m, 2H), 5.52 – 5.41 (m, 
2H), 4.96 (d, J = 16.4 Hz, 1H), 4.85 (d, J = 16.4 Hz, 1H), 3.71 (dd, J = 11.0, 4.6 Hz, 
1H), 3.61 (dd, J = 10.9, 3.6 Hz, 1H), 3.37 (dt, J = 10.0, 4.0 Hz, 1H), 2.19 – 2.11 (m, 
1H), 0.88 (d, J = 6.6 Hz, 3H), 0.83 (s, 9H), 0.67 (d, J = 6.7 Hz, 3H), -0.06 (d, J = 5.7 
Hz, 6H); 
13C NMR (125 MHz, CDCl3) δ ppm 146.3, 140.2, 135.6, 134.7, 133.2, 132.2, 129.0, 
128.6, 127.9, 127.5, 123.8, 119.9, 65.7, 63.8, 54.1, 41.3, 27.9, 25.8, 20.4, 19.8, 18.1, -
5.7, -5.8; 













Yield 47%;   
[α]D25 = +3.14 (c = 3.19, CH2Cl2); 
FTIR (neat): 3335, 2964, 1437, 1339, 1159, 1132, 1049 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.04 (dd, J = 7.7, 1.5 Hz, 1H), 7.48 (td, J = 7.5, 
1.6 Hz, 1H), 7.44 (td, J = 7.6, 1.5 Hz, 1H), 7.41 – 7.35 (m, 3H), 7.35 – 7.30 (m, 1H), 
7.21(d, J = 7.1 Hz, 2H), 5.73 (d, J = 16.1 Hz, 1H), 5.65 (d, J = 16.1 Hz, 1H), 4.89 (d, 
J = 16.1 Hz, 1H), 4.83 (d, J = 16.0 Hz, 1H), 3.67 – 3.54 (m, 3H), 1.94 – 1.84 (m, 1H), 
1.22 (t, J = 5.1 Hz, 1H), 0.94 (d, J = 6.6 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 142.6, 142.3, 135.2, 132.0, 131.7, 129.1, 129.0, 
128.7, 128.3, 127.5, 126.5, 123.7, 66.4, 61.3, 53.0, 42.1, 27.7, 20.2, 20.0; 















Yield 21%;  
[α]D25 = +7.80 (c = 2.30, CH2Cl2); 
FTIR (neat): 3062, 2966, 1738, 1601, 1502, 1434, 1339, 1161, 1149, 1037, 760 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.19 (s, 1H), 8.10 (dd, J = 7.9, 1.7 Hz, 1H), 7.74 
– 7.68 (m, 3H), 7.53 (dd, J = 10.6, 5.0 Hz, 2H), 7.43 (m, 2H), 7.35 (td, J = 7.6, 1.7 
Hz, 1H), 5.24 – 5.10 (m, 2H), 3.98 (d, J = 10.4 Hz, 1H), 3.50 (s, 3H), 2.46 (dqq, J = 
10.5, 6.6, 6.6 Hz, 1H), 0.90 (d, J = 6.6 Hz, 3H), 0.82 (d, J = 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.8, 146.0, 139.1, 137.0, 135.3, 133.6, 132.9, 
129.7, 128.7, 127.6, 122.3, 120.5, 120.1, 66.1, 51.7, 41.2, 28.7, 19.8, 19.2; 















Yield 78%;  
[α]D25 = –55.53 (c = 1.50, CH2Cl2); 
FTIR (neat): 2955, 1742, 1599, 1501, 1448, 1344, 1155, 1040, 757 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.24 (s, 1H), 8.13 (dd, J = 7.9, 1.7 Hz, 1H), 7.77  
–7.70 (m, 3H), 7.57 – 7.52 (m, 2H), 7.49 – 7.42 (m, 2H), 7.40 – 7.35 (m, 1H), 5.02 (d, 
J = 16.8 Hz, 1H), 4.82 (d, J = 16.8 Hz, 1H), 4.69 (dd, J = 10.2, 4.8 Hz, 1H), 3.55 (s, 
3H), 1.90 (ddd, J = 14.3, 10.3, 4.2 Hz, 1H), 1.67 (ddd, J = 14.2, 9.4, 4.8 Hz, 1H), 1.47 
– 1.39 (m, 1H), 0.91 (d, J = 6.5 Hz, 3H), 0.68 (d, J = 6.7 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.5, 146.2, 139.1, 137.0, 135.6, 133.6, 132.3, 
129.7, 128.8, 127.6, 122.4, 120.6, 120.2, 58.9, 52.2, 41.6, 39.3, 24.4, 22.4, 21.3; 














Yield 90%;  
[α]D25 = –30.68 (c = 4.00, CH2Cl2); 
FTIR (neat): 2966, 2952, 1741, 1599, 1502, 1342, 1163, 1149, 1045, 757 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.18 (dd, J = 7.9, 1.7 Hz, 1H), 7.85 (s, 1H), 7.75 
– 7.70 (m, 3H), 7.55 – 7.51 (m, 2H), 7.48 (dt, J = 7.9, 1.3 Hz, 1H), 7.44 (tt, J = 7.9, 
1.0 Hz, 1H), 7.40 (td, J = 7.9, 1.7 Hz, 1H), 4.08 (ddd, J = 15.1, 11.1, 5.8 Hz, 1H), 
3.97 (d, J = 10.3 Hz, 1H), 3.96 (ddd, J = 15.1, 11.1, 5.8 Hz, 1H), 3.56 (s, 3H), 3.35 
(ddd, J = 14.3, 11.1, 4.8 Hz, 1H), 3.16 (ddd, J = 11.3, 11.2, 5.8 Hz, 1H), 2.26 (dqq, J 
= 13.1, 10.3, 6.6 Hz, 1H), 1.05 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.0, 145.5, 139.1, 137.1, 135.5, 133.7, 132.8, 
129.7, 128.6, 127.6, 120.5, 120.3, 119.8, 65.9, 51.7, 45.8, 28.9, 27.5, 19.9, 19.3; 














Yield 95%;  
[α]D25 = –60.65 (c = 5.00, CH2Cl2); 
FTIR (neat): 2955, 1740, 1500, 1344, 1153, 1045, 760 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.17 (dd, J = 7.8, 1.3 Hz, 1H), 7.85 (s, 1H), 7.76 
– 7.70 (m, 3H), 7.56 – 7.50 (m, 2H), 7.49 – 7.42 (m, 2H), 7.39 (td, J = 7.5, 1.7 Hz, 
1H), 4.60 (dd, J = 8.7, 5.5 Hz, 1H), 3.88 (ddd, J = 15.8, 10.9, 5.1 Hz, 1H), 3.76 (ddd, 
J = 15.6, 10.6, 5.9 Hz, 1H), 3.55 (s, 3H), 3.34 (ddd, J = 14.7, 10.6, 5.0 Hz, 1H), 3.14 
(ddd, J = 14.3, 10.8, 6.0 Hz, 1H), 1.84 – 1.66 (m, 3H), 0.94 (d, J = 5.9 Hz, 3H), 0.92 
(d, J = 6.0 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 145.4, 138.9, 137.1, 135.6, 133.6, 132.5, 
129.7, 128.6, 127.6, 120.5, 120.4, 119.9, 58.6, 52.2, 46.1, 39.5, 27.7, 24.6, 22.7, 21.7; 











Yield 60%;   
Mp 170 ºC; 
[α]D25 = –3.60 (c = 2.50, CH2Cl2); 
FTIR (neat): 2966, 2934, 1737, 1597, 1501, 1436, 1350, 1159, 995, 914, 764 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.08 (d, J = 7.9 Hz, 1H), 7.53 – 7.45 (m, 3H), 
7.44 – 7.34 (m, 3H), 7.31 – 7.24 (m, 1H), 6.93 (d, J = 7.8 Hz, 1H), 5.21 – 5.02 (m, 
2H), 3.93 (d, J = 10.5 Hz, 1H), 3.11 (s, 3H), 2.20 (dqq, J = 10.5, 6.6, 6.6 Hz, 1H), 
1.08 (d, J = 6.7 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.4, 143.1, 140.5, 136.9, 131.8, 130.6, 130.1, 
129.7, 129.7, 128.6, 128.2, 125.9, 123.9, 65.2, 51.8, 43.0, 29.0, 19.3, 19.1; 












Yield 46%;   
[α]D25 = +1.36 (c = 2.20, CH2Cl2); 
FTIR (neat): 2957, 2931, 1742, 1500, 1436, 1348, 1161, 995, 761 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.05 (dd, J = 7.9, 1.4 Hz, 1H), 7.53 – 7.46 (m, 
3H), 7.41 – 7.35 (m, 3H), 7.29 (dd, J = 7.7, 1.4 Hz, 1H), 6.96 (dd, J = 7.8, 1.2 Hz, 
1H), 5.01 (d, J = 16.3 Hz, 1H), 4.94 (d, J = 16.3 Hz, 1H), 4.55 (dd, J = 9.6, 5.6 Hz, 
1H), 3.32 (s, 3H), 1.74 – 1.60 (m, 2H), 0.93 (t, J = 6.0 Hz, 5H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.2, 142.9, 140.8, 136.8, 131.8, 130.7, 130.5, 
129.7, 128.2, 128.0, 125.9, 124.2, 58.1, 52.1, 43.0, 38.8, 24.6, 23.0, 21.0; 














Yield 44%;   
Mp 135 ºC; 
[α]D25 = –3.20 (c = 2.10, CH2Cl2); 
FTIR (neat): 2968, 1738, 1504, 1435, 1344, 1163, 983, 750 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.22 (dd, J = 8.1, 1.2 Hz, 1H), 7.55 (td, J = 7.8, 
1.3 Hz, 1H), 7.42 – 7.29 (m, 6H), 6.99 (dd, J = 7.7, 1.3 Hz, 1H), 4.14 (d, J = 10.9 Hz, 
1H), 3.78 (dd, J = 15.1, 11.3 Hz, 1H), 3.64 (ddd, J = 14.9, 5.6, 1.8 Hz, 1H), 3.31 (dd, 
J = 15.3, 5.5 Hz, 1H), 3.24 (s, 3H), 2.37 – 2.24 (m, 2H), 1.09 (d, J = 6.8 Hz, 3H), 0.96 
(d, J = 6.4 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 170.7, 145.1, 141.9, 136.3, 133.1, 131.8, 131.6, 
129.9, 129.4, 129.3, 129.1, 125.1, 124.4, 65.0, 51.6, 42.1, 27.5, 26.1, 19.3, 18.7; 













Yield 44%;   
FTIR (neat): 3007, 2882, 1742, 1506, 1342, 1239, 1169, 1151, 993, 917, 742 cm-1;  
HRMS calculated for C23H26N4O4SNa (M+Na)+ 477.1572, found 477.1570. 
Major Isomer 
1H NMR (500 MHz, CDCl3) δ ppm 8.19 (dd, J = 8.2, 1.2 Hz, 1H), 7.54 (dt, J = 7.7, 
1.3 Hz, 1H), 7.39 (dd, J = 3.4, 1.4 Hz, 1H), 7.43 – 7.30 (m, 5H), 7.02 (dd, J = 7.8, 1.4 
Hz, 1H), 4.72 (t, J = 7.5 Hz, 1H), 3.77 (dd, J = 15.4, 11.4 Hz, 1H), 3.61 (ddd, J = 
15.1, 5.6, 1.8 Hz, 1H), 3.33 (m, J = 15.3, 5.4 Hz, 1H), 3.30 (s, 3H), 2.65 (ddd, J = 
15.4, 11.3, 1.8 Hz, 1H), 1.80 – 1.76 (m, 2H), 1.75 – 1.66 (m, 1H), 1.05 (d, J = 6.3 Hz, 
3H), 1.03 (d, J = 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.4, 145.2, 141.8, 136.3, 133.3, 131.9, 131.6, 




1H NMR (500 MHz, CDCl3) δ ppm 8.17 (dd, J = 7.2, 1.2 Hz, 1H), 7.53 (dt, J = 8.0, 
1.3 Hz, 1H), 7.41 (dd, J = 3.2, 1.3 Hz, 1H), 7.39 – 7.30 (m, 5H), 7.04 (dd, J = 7.8, 1.3 
Hz, 1H), 4.66 (dd, J = 8.5, 6.5 Hz, 1H), 3.92 (dd, J = 15.4, 11.0 Hz, 1H), 3.81 (s, 3H), 
3.66 (ddd, J = 15.5, 5.4, 1.8 Hz, 1H), 3.48 (ddd, J = 15.2, 5.4, 1.0 Hz, 1H), 2.46 (ddd, 
J = 15.2, 11.6, 1.8 Hz, 1H), 1.76 – 1.72 (m, 2H), 1.29 (ddd, J = 14.1, 8.5, 5.6 Hz, 1H), 
0.76 (d, J = 3.8 Hz, 3H), 0.75 (d, J = 3.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ ppm 171.7, 144.6, 142.3, 136.2, 133.0, 132.6, 131.8, 


















FTIR (neat): 2968, 1740, 1434, 1340, 1163, 1043, 912, 742 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.83 – 7.79 (m, 1H), 7.68 – 7.65 (m, 1H), 7.56 (s, 
1H), 7.39 – 7.30 (m, 5H), 7.21 (dd, J = 7.7, 1.8 Hz, 2H), 5.70 (d, J = 15.6 Hz, 1H), 
5.60 (d, J = 15.6 Hz, 1H), 4.89 (dd, J = 16.3, 0.8 Hz, 1H), 4.71 (d, J = 16.3 Hz, 1H), 
4.21 (d, J = 10.4 Hz, 1H), 3.56 (s, 3H), 1.84 (dp, J = 10.4, 6.6 Hz, 1H), 0.92 (d, J = 
6.7 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H); 
 13C NMR (125 MHz, CDCl3) δ ppm 171.1, 139.0, 135.5, 135.3, 134.9, 133.9, 132.9, 
132.1, 129.0, 128.4, 127.7, 127.3, 119.7, 65.8, 51.8, 51.7, 38.0, 29.2, 19.8, 19.3; 












Yield 13%;   
Mp 140 ºC; 
[α]D25 = –1.94 (c = 0.52, CH2Cl2); 
FTIR (neat): 2966, 1378, 1434, 1342, 1161, 1045, 706 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 8.65 (dd, J = 8.0, 1.2 Hz, 1H), 8.03 (dd, J = 8.0, 
1.4 Hz, 1H), 7.67 (td, J = 8.0, 1.4 Hz, 1H), 7.49 – 7.31 (m, 4H), 7.26 – 7.21 (m, 2H), 
5.61 (d, J = 15.9 Hz, 1H), 5.53 (d, J = 15.8 Hz, 1H), 4.73 (d, J = 17.3 Hz, 1H), 4.53 
(d, J = 17.4 Hz, 1H), 3.77 (d, J = 10.7 Hz, 1H), 3.01 (s, 3H), 1.87 – 1.77 (m, 1H), 
0.97 – 0.88 (m, 3H), 0.79 (d, J = 6.5 Hz, 3H); 
 13C NMR (125 MHz, CDCl3) δ ppm 169.9, 141.7, 137.9, 133.3, 133.1, 133.0, 129.3, 
128.8, 128.6, 128.0, 127.9, 127.5, 127.2, 64.3, 52.7, 51.6, 39.9, 28.6, 18.9, 18.8; 
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Single-Crystal X-ray Structural Studies for Compounds 2.27, 2.47 and 2.55. 
 Colorless crystals of C11H12N2O3S (2.27) are, at 100(2) K, triclinic, space 
group P1 – Ci1  (No. 2) [1] with a = 6.2228(4) Å, b = 8.5044(5) Å, c = 10.5418(6) Å, 
α  = 95.101(1)°, β  = 105.391(1)°, γ  = 93.264(1)° ,V = 533.86(6) Å3 and Z =  2 
molecules {dcalcd = 1.569 g/cm3; µa(MoKα) = 0.301 mm-1}.   Colorless crystals of 
C15H17NO4S (2.47) are, at 100(2) K, orthorhombic, space group P212121 – D24 (No. 
19) [1] with a = 7.0472(3) Å, b = 16.252(1) Å, c = 25.172(1) Å, V = 2883.0(2) Å3 
and Z = 8 molecules {dcalcd = 1.416 g/cm3; µa(MoKα) = 0.240 mm-1}.   Colorless 
crystals of C13H17NO5S (2.55) are, at 100(2) K, triclinic, space group P1 – Ci1  (No. 
2) [1] with a =7.0534(5) Å, b = 10.0416(7) Å, c = 10.7686(7) Å, α  = 72.391(1)°, β  = 
86.267(1)°, γ  = 71.551(1)° ,V = 689.22(8) Å3 and Z =  2 molecules {dcalcd = 1.442 
g/cm3; µa(MoKα) = 0.254 mm-1}.   Full hemispheres of diffracted intensities (1850 
10-second frames with a ω scan width of 0.30°) were measured for all three 
compounds using graphite-monochromated MoKα radiation (λ= 0.71073 Å) on a 
Bruker SMART APEX CCD Single Crystal Diffraction System [2].  X-rays were 
provided by a fine-focus sealed x-ray tube operated at 50kV and 30mA.  Lattice 
constants were determined with the Bruker SAINT software package using peak 
centers for 5323 (2.27), 9162 (2.47) and 5465 (2.55) reflections.  Totals of 6327 
(2.27), 34818 (2.47) and 8274 (2.55) integrated reflection intensities having 
2θ((MoKα)< 60.95° (2.27), 2θ((MoKα)< 61.11° (2.47) and  2θ((MoKα)< 60.99° 
(2.55) were produced using the Bruker program SAINT[3]; 3103 (2.27), 8614 (2.47) 
and 4040 (2.55) of these were unique and gave Rint = 0.029 (2.27), Rint = 0.051 (2.47)  
and Rint = 0.032 (2.55) with a coverage which was at least 95.6% complete. The data 
were corrected empirically for variable absorption effects using equivalent 
reflections.  The relative transmission factors ranged from 0.925 to 1.000 for (2.27), 
from 0.919 to 1.000 for (2.47) and from 0.851 to 1.000 for (2.55).  The Bruker 
software package SHELXTL was used to solve all three structures using “direct 
methods” techniques.  All stages of weighted full-matrix least-squares refinement 
were conducted using Fo2 data with the SHELXTL Version 6.10 software package 
 426 
[4].  
 All hydrogen atoms for all three structures were located from difference 
Fouriers and included in the structural model as independent isotropic atoms whose 
parameters were allowed to vary in least-squares refinement cycles.  The final 
structural models for all three compounds incorporated anisotropic thermal 
parameters for all nonhydrogen atoms and isotropic thermal parameters for all 
hydrogen atoms.   
 A total of 202 parameters were refined for 2.27 using no restraints, 3103 data 




) + (0.0552 P)
2 




] / 3.  
Final agreement factors at convergence for 2.27 are:  R1(unweighted, based on F) = 
0.032 for 2991 independent absorption-corrected “observed” reflections having 
2θ(MoKα)<  60.95° and I>2σ(I);  R1(unweighted, based on F) = 0.033 and 
wR2(weighted, based on F2) = 0.089 for all 3103 independent absorption-corrected 
reflections having 2θ(MoKα)< 60.95°.  The largest shift/s.u. was 0.001 in the final 
refinement cycle.  The final difference Fourier for 5 had maxima and minima of 0.49 
e-/Å
3
 and -0.39 e-/Å
3
, respectively.   
 A total of 515 parameters were refined for 2.47 using no restraints, 8614 data 




) + (0.0377 P)
2 




] / 3.  Final 
agreement factors at convergence for 2.47 are:  R1(unweighted, based on F) = 0.040 
for 7746 independent absorption-corrected “observed” reflections having 
2θ(MoKα)<  61.11° and I>2σ(I);  R1(unweighted, based on F) = 0.045 and 
wR2(weighted, based on F2) = 0.080 for all 8614 independent absorption-corrected 
reflections having 2θ(MoKα)< 61.11°.  The largest shift/s.u. was 0.001 in the final 
refinement cycle.  The final difference Fourier for 2.47 had maxima and minima of 
0.51 e-/Å
3
 and -0.34 e-/Å
3
, respectively.  The absolute configuration for 2.47 was 
determined experimentally using anomalous dispersion of the x-rays; the “Flack 
absolute structure” parameter refined to a final value of  0.03(4). 
 A total of 249 parameters were refined for 2.55 using no restraints, 4040 data 
 427 




) + (0.0651 P)
2 




] / 3.  
Final agreement factors at convergence for 2.55 are:  R1(unweighted, based on F) = 
0.038 for 3724 independent absorption-corrected “observed” reflections having 
2θ(MoKα)<  60.99° and I>2σ(I);  R1(unweighted, based on F) = 0.041 and 
wR2(weighted, based on F2) = 0.105 for all 4040 independent absorption-corrected 
reflections having 2θ(MoKα)< 60.99°.  The largest shift/s.u. was 0.000 in the final 
refinement cycle.  The final difference Fourier for 2.55 had maxima and minima of 
0.63 e-/Å
3
 and -0.32 e-/Å
3
, respectively.   
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Table 1.  Crystal data and structure refinement for C20H22N4O2S.  
Empirical formula  C20 H22 N4 O2 S 
Formula weight  382.48 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.1667(8) Å α= 94.567(3)°. 
 b = 10.7670(11) Å β= 91.652(3)°. 





Density (calculated) 1.333 Mg/m
3
 
Absorption coefficient 1.696 mm-1 
F(000) 404 
Crystal size 0.23 x 0.20 x 0.17 mm
3
 
Theta range for data collection 4.06 to 69.08°. 
Index ranges -9<=h<=9, -12<=k<=12, -12<=l<=13 
Reflections collected 13615 
Independent reflections 3319 [R(int) = 0.0342] 
Completeness to theta = 66.00° 95.5 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.742 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2sigma(I)] R1 = 0.0369, wR2 = 0.0952 
R indices (all data) R1 = 0.0370, wR2 = 0.0954 




Table 2.  Atomic coordinates  ( x 10
4





)for C20H22N4O2S.  U(eq) is defined as one third of  the trace of theorthogonalized 
Uij tensor. 
___________________________________________________________________________
 x y z U(eq) 
___________________________________________________________________________  
S 7036(1) 8267(1) 8085(1) 22(1) 
O(1) 8361(1) 9235(1) 8360(1) 29(1) 
O(2) 6906(1) 7215(1) 8821(1) 27(1) 
N(1) 7124(2) 7675(1) 6671(1) 23(1) 
N(2) 3812(2) 4973(1) 6586(1) 27(1) 
N(3) 2355(2) 4918(1) 7083(1) 28(1) 
N(4) 2160(2) 6067(1) 7585(1) 24(1) 
C(1) 6336(2) 6379(2) 6440(2) 24(1) 
C(2) 4573(2) 6161(1) 6799(1) 22(1) 
C(3) 3528(2) 6901(1) 7432(1) 21(1) 
C(4) 3652(2) 8241(1) 7842(1) 21(1) 
C(5) 5172(2) 8970(1) 8167(1) 20(1) 
C(6) 5258(2) 10231(2) 8536(1) 23(1) 
C(7) 3824(2) 10828(2) 8613(1) 24(1) 
C(8) 2323(2) 10135(2) 8291(2) 26(1) 
C(9) 2242(2) 8876(2) 7896(1) 25(1) 
C(10) 7292(2) 8432(2) 5562(1) 27(1) 
C(11) 5637(2) 8334(2) 4850(2) 34(1) 
C(12) 8587(2) 7867(2) 4766(2) 38(1) 
C(13) 7892(2) 9810(2) 5904(2) 32(1) 
C(14) 794(2) 6147(2) 8429(1) 24(1) 
C(15) 1404(2) 6417(1) 9750(1) 23(1) 
C(16) 2813(2) 5951(2) 10184(2) 32(1) 
C(17) 3314(2) 6170(2) 11410(2) 35(1) 
C(18) 2403(2) 6843(2) 12219(2) 33(1) 
C(19) 996(2) 7306(2) 11796(2) 33(1) 




Table 3.   Bond lengths [Å] and angles [°] for  C20H22N4O2S. 
_____________________________________________________  
S-O(1)  1.4286(12) 
S-O(2)  1.4378(12) 
S-N(1)  1.6324(13) 
S-C(5)  1.7724(15) 
N(1)-C(1)  1.474(2) 
N(1)-C(10)  1.516(2) 
N(2)-N(3)  1.3194(19) 
N(2)-C(2)  1.361(2) 
N(3)-N(4)  1.340(2) 
N(4)-C(3)  1.3798(19) 
N(4)-C(14)  1.4740(19) 
C(1)-C(2)  1.503(2) 
C(1)-H(1A)  0.965(19) 
C(1)-H(1B)  0.96(2) 
C(2)-C(3)  1.390(2) 
C(3)-C(4)  1.469(2) 
C(4)-C(9)  1.400(2) 
C(4)-C(5)  1.416(2) 
C(5)-C(6)  1.380(2) 
C(6)-C(7)  1.395(2) 
C(6)-H(6)  0.94(2) 
C(7)-C(8)  1.387(2) 
C(7)-H(7)  0.95(2) 
C(8)-C(9)  1.384(2) 
C(8)-H(8)  0.98(2) 
C(9)-H(9A)  0.97(2) 
C(10)-C(13)  1.526(2) 
C(10)-C(11)  1.530(2) 
C(10)-C(12)  1.534(2) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(11)-H(11C)  0.9800 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(13)-H(13A)  0.9800 
 593 
C(13)-H(13B)  0.9800 
C(13)-H(13C)  0.9800 
C(14)-C(15)  1.511(2) 
C(14)-H(14A)  0.94(2) 
C(14)-H(14B)  0.949(19) 
C(15)-C(16)  1.389(2) 
C(15)-C(20)  1.390(2) 
C(16)-C(17)  1.387(3) 
C(16)-H(16)  0.93(2) 
C(17)-C(18)  1.382(3) 
C(17)-H(17)  0.95(2) 
C(18)-C(19)  1.382(3) 
C(18)-H(18)  0.95(2) 
C(19)-C(20)  1.390(2) 
C(19)-H(19)  0.93(2) 

































































































Symmetry transformations used to generate equivalent atoms:  
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) for C20H22N4O2S.  The 
























S 17(1)  26(1) 24(1)  0(1) 3(1)  1(1) 
O(1) 18(1)  34(1) 32(1)  -4(1) 2(1)  -2(1) 
O(2) 26(1)  31(1) 26(1)  5(1) 2(1)  6(1) 
N(1) 21(1)  23(1) 25(1)  1(1) 7(1)  -2(1) 
N(2) 26(1)  25(1) 28(1)  1(1) 8(1)  -2(1) 
N(3) 28(1)  24(1) 30(1)  -1(1) 9(1)  -4(1) 
N(4) 21(1)  22(1) 25(1)  0(1) 6(1)  -4(1) 
C(1) 23(1)  22(1) 27(1)  1(1) 8(1)  0(1) 
C(2) 23(1)  23(1) 21(1)  2(1) 4(1)  -1(1) 
C(3) 18(1)  23(1) 22(1)  3(1) 3(1)  -2(1) 
C(4) 20(1)  23(1) 20(1)  4(1) 5(1)  0(1) 
C(5) 18(1)  24(1) 18(1)  3(1) 5(1)  0(1) 
C(6) 22(1)  25(1) 21(1)  2(1) 4(1)  -2(1) 
C(7) 28(1)  21(1) 24(1)  2(1) 7(1)  2(1) 
C(8) 23(1)  27(1) 30(1)  6(1) 7(1)  5(1) 
C(9) 19(1)  27(1) 28(1)  4(1) 4(1)  0(1) 
C(10) 29(1)  28(1) 25(1)  3(1) 9(1)  -6(1) 
C(11) 40(1)  33(1) 27(1)  8(1) 1(1)  -6(1) 
C(12) 41(1)  32(1) 38(1)  -5(1) 22(1)  -10(1) 
C(13) 35(1)  27(1) 31(1)  2(1) 12(1)  -6(1) 
C(14) 19(1)  26(1) 28(1)  2(1) 8(1)  -3(1) 
C(15) 20(1)  20(1) 28(1)  5(1) 6(1)  -4(1) 
C(16) 28(1)  35(1) 34(1)  8(1) 9(1)  6(1) 
C(17) 26(1)  42(1) 39(1)  16(1) 0(1)  2(1) 
C(18) 34(1)  33(1) 29(1)  7(1) -2(1)  -10(1) 
C(19) 39(1)  30(1) 29(1)  -2(1) 5(1)  2(1) 




Table 5.   Hydrogen coordinates ( x 10
4







 x  y  z  U(eq) 
___________________________________________________________________________ 
H(1A) 6960(20) 5824(17) 6870(16) 21(4) 
H(1B) 6400(20) 6100(18) 5588(18) 25(4) 
H(6) 6290(20) 10683(19) 8722(17) 29(5) 
H(7) 3900(20) 11692(19) 8875(17) 23(4) 
H(8) 1300(30) 10550(20) 8323(19) 35(5) 
H(9A) 1190(30) 8419(19) 7616(18) 32(5) 
H(11A) 5285 7454 4581 51 
H(11B) 5756 8821 4133 51 
H(11C) 4811 8664 5381 51 
H(12A) 9630 7915 5241 57 
H(12B) 8750 8338 4041 57 
H(12C) 8207 6989 4508 57 
H(13A) 7101 10184 6438 47 
H(13B) 7991 10254 5158 47 
H(13C) 8969 9877 6337 47 
H(14A) 190(20) 5347(19) 8315(17) 25(4) 
H(14B) 120(20) 6757(18) 8180(16) 22(4) 
H(16) 3410(30) 5480(20) 9650(20) 40(6) 
H(17) 4280(30) 5860(20) 11700(20) 40(6) 
H(18) 2740(30) 7000(20) 13060(20) 45(6) 
H(19) 400(30) 7780(20) 12330(20) 43(6) 
H(20) -460(30) 7430(20) 10260(19) 37(5) 
___________________________________________________________________________
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Table 1.  Crystal data and structure refinement for C22H24N4O4S. 
Empirical formula  C22 H24 N4 O4 S 
Formula weight  440.51 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 8.3353(5) Å α= 90°. 
 b = 15.2338(9) Å β= 113.4630(10)°. 





Density (calculated) 1.361 Mg/m
3
 
Absorption coefficient 1.651 mm-1 
F(000) 464 
Crystal size 0.18 x 0.14 x 0.11 mm
3
 
Theta range for data collection 5.23 to 69.31°. 
Index ranges -9<=h<=9, -17<=k<=14, -11<=l<=10 
Reflections collected 8997 
Independent reflections 3039 [R(int) = 0.0258] 
Completeness to theta = 66.00° 98.0 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.910 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2sigma(I)] R1 = 0.0256, wR2 = 0.0627 
R indices (all data) R1 = 0.0256, wR2 = 0.0627 
Absolute structure parameter 0.094(13) 
Extinction coefficient 0.0077(9) 
Largest diff. peak and hole 0.223 and -0.225 e.Å-
3 
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Table 2.  Atomic coordinates  ( x 10
4





) for C22H24N4O4S.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) 
___________________________________________________________________________ 
S -2521(1) 3681(1) 2601(1) 18(1) 
O(1) -2899(2) 4448(1) 1622(2) 23(1) 
O(2) -3314(2) 3586(1) 3718(1) 22(1) 
O(3) -727(2) 1210(1) 4085(2) 33(1) 
O(4) -422(2) 1531(1) 1840(2) 38(1) 
N(1) -3089(2) 2832(1) 1425(2) 20(1) 
N(2) -1305(2) 3637(1) -1470(2) 27(1) 
N(3) 177(2) 4036(1) -1205(2) 28(1) 
N(4) 1128(2) 4027(1) 369(2) 23(1) 
C(1) -2917(3) 2906(2) -104(2) 24(1) 
C(2) -1328(2) 3373(1) -73(2) 22(1) 
C(3) 229(2) 3619(1) 1135(2) 20(1) 
C(4) 892(2) 3543(1) 2870(2) 20(1) 
C(5) -233(2) 3583(1) 3673(2) 18(1) 
C(6) 388(2) 3522(1) 5305(2) 20(1) 
C(7) 2167(3) 3430(1) 6186(2) 25(1) 
C(8) 3307(2) 3384(1) 5425(2) 27(1) 
C(9) 2666(3) 3425(1) 3789(2) 25(1) 
C(10) -3063(2) 1967(1) 2138(2) 21(1) 
C(11) -4521(3) 1351(2) 1055(2) 27(1) 
C(12) -4522(3) 494(2) 1922(3) 33(1) 
C(13) -6294(3) 1790(2) 496(3) 43(1) 
C(14) 2745(3) 4538(2) 956(2) 27(1) 
C(15) 2675(3) 5323(1) 1926(2) 22(1) 
C(16) 4204(3) 5613(2) 3132(2) 30(1) 
C(17) 4193(3) 6369(2) 3956(2) 30(1) 
C(18) 2673(3) 6842(1) 3601(2) 27(1) 
C(19) 1135(3) 6543(2) 2425(2) 29(1) 
C(20) 1143(3) 5791(2) 1589(2) 26(1) 
C(21) -1257(3) 1541(1) 2640(2) 25(1) 
C(22) 978(3) 797(2) 4684(3) 45(1) 
___________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for  C22H24N4O4S. 
_____________________________________________________  
S-O(1)  1.4329(15) 
S-O(2)  1.4367(12) 
S-N(1)  1.6322(17) 
S-C(5)  1.7708(16) 
O(3)-C(21)  1.326(2) 
O(3)-C(22)  1.448(3) 
O(4)-C(21)  1.199(3) 
N(1)-C(10)  1.469(3) 
N(1)-C(1)  1.477(2) 
N(2)-N(3)  1.309(2) 
N(2)-C(2)  1.358(2) 
N(3)-N(4)  1.349(2) 
N(4)-C(3)  1.367(2) 
N(4)-C(14)  1.461(3) 
C(1)-C(2)  1.494(3) 
C(1)-H(1A)  0.99(3) 
C(1)-H(1B)  0.94(3) 
C(2)-C(3)  1.384(3) 
C(3)-C(4)  1.476(2) 
C(4)-C(9)  1.392(3) 
C(4)-C(5)  1.409(2) 
C(5)-C(6)  1.387(2) 
C(6)-C(7)  1.385(3) 
C(6)-H(6)  0.93(2) 
C(7)-C(8)  1.391(3) 
C(7)-H(7)  0.98(2) 
C(8)-C(9)  1.387(3) 
C(8)-H(8)  1.03(2) 
C(9)-H(9)  0.90(3) 
C(10)-C(21)  1.532(3) 
C(10)-C(11)  1.546(3) 
C(10)-H(10)  0.97(2) 
C(11)-C(13)  1.514(3) 
C(11)-C(12)  1.531(3) 
C(11)-H(11)  0.97(2) 
C(12)-H(12A)  1.00(3) 
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C(12)-H(12B)  1.03(3) 
C(12)-H(12C)  0.93(4) 
C(13)-H(13A)  0.98(3) 
C(13)-H(13B)  0.94(4) 
C(13)-H(13C)  1.04(4) 
C(14)-C(15)  1.508(3) 
C(14)-H(14A)  0.99(3) 
C(14)-H(14B)  0.95(3) 
C(15)-C(20)  1.386(3) 
C(15)-C(16)  1.389(3) 
C(16)-C(17)  1.383(3) 
C(16)-H(16)  0.99(3) 
C(17)-C(18)  1.378(3) 
C(17)-H(17)  0.89(3) 
C(18)-C(19)  1.386(3) 
C(18)-H(18)  0.93(3) 
C(19)-C(20)  1.383(3) 
C(19)-H(19)  0.99(3) 
C(20)-H(20)  0.93(2) 
C(22)-H(22A)  1.03(3) 
C(22)-H(22B)  1.01(4) 












































































































Symmetry transformations used to generate equivalent atoms:  
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) for C22H24N4O4S.  The aniso- 










 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________ 
S 16(1)  20(1) 17(1)  1(1) 7(1)  2(1) 
O(1) 23(1)  23(1) 22(1)  3(1) 8(1)  2(1) 
O(2) 21(1)  24(1) 22(1)  -1(1) 12(1)  1(1) 
O(3) 28(1)  38(1) 27(1)  9(1) 5(1)  2(1) 
O(4) 36(1)  43(1) 40(1)  5(1) 21(1)  11(1) 
N(1) 24(1)  22(1) 15(1)  0(1) 7(1)  -1(1) 
N(2) 41(1)  25(1) 17(1)  -2(1) 13(1)  -6(1) 
N(3) 43(1)  27(1) 19(1)  -3(1) 18(1)  -5(1) 
N(4) 28(1)  25(1) 21(1)  -4(1) 16(1)  -3(1) 
C(1) 27(1)  28(1) 15(1)  0(1) 6(1)  -3(1) 
C(2) 29(1)  21(1) 15(1)  0(1) 10(1)  0(1) 
C(3) 23(1)  21(1) 19(1)  -1(1) 13(1)  1(1) 
C(4) 23(1)  19(1) 18(1)  -3(1) 9(1)  0(1) 
C(5) 18(1)  18(1) 18(1)  -2(1) 7(1)  0(1) 
C(6) 25(1)  19(1) 19(1)  -1(1) 10(1)  0(1) 
C(7) 28(1)  28(1) 17(1)  0(1) 6(1)  2(1) 
C(8) 18(1)  32(1) 26(1)  -3(1) 3(1)  3(1) 
C(9) 22(1)  30(1) 26(1)  -3(1) 12(1)  3(1) 
C(10) 23(1)  23(1) 17(1)  0(1) 8(1)  -1(1) 
C(11) 29(1)  29(1) 23(1)  -5(1) 8(1)  -9(1) 
C(12) 41(1)  28(1) 29(1)  -5(1) 13(1)  -11(1) 
C(13) 26(1)  40(2) 52(1)  0(1) 2(1)  -10(1) 
C(14) 31(1)  29(1) 32(1)  -6(1) 22(1)  -7(1) 
C(15) 28(1)  21(1) 23(1)  1(1) 16(1)  -2(1) 
C(16) 24(1)  30(1) 35(1)  -3(1) 11(1)  3(1) 
C(17) 27(1)  30(1) 28(1)  -5(1) 6(1)  -2(1) 
C(18) 38(1)  23(1) 23(1)  0(1) 15(1)  2(1) 
C(19) 28(1)  28(1) 32(1)  1(1) 14(1)  5(1) 
C(20) 24(1)  29(1) 26(1)  -2(1) 9(1)  -1(1) 
C(21) 28(1)  21(1) 26(1)  -1(1) 8(1)  -2(1) 
C(22) 28(1)  45(2) 50(2)  17(1) 4(1)  7(1) 
___________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 10
4







 x  y  z  U(eq) 
___________________________________________________________________________ 
H(1A) -3980(30) 3200(17) -880(30) 28(6) 
H(1B) -2990(30) 2326(18) -470(30) 27(6) 
H(6) -380(30) 3593(18) 5810(20) 21(5) 
H(7) 2590(30) 3373(16) 7340(30) 26(6) 
H(8) 4640(30) 3347(17) 6080(30) 29(6) 
H(9) 3420(30) 3402(17) 3310(30) 32(6) 
H(10) -3320(30) 2086(16) 3060(30) 22(5) 
H(11) -4220(30) 1229(16) 160(30) 19(5) 
H(12A) -5370(40) 50(20) 1250(30) 40(7) 
H(12B) -3300(40) 200(18) 2360(30) 34(6) 
H(12C) -4800(40) 590(30) 2800(40) 64(9) 
H(13A) -6210(40) 2310(20) -100(30) 40(7) 
H(13B) -7190(50) 1430(20) -190(40) 62(9) 
H(13C) -6620(50) 1930(30) 1450(50) 83(12) 
H(14A) 3730(30) 4137(17) 1510(30) 26(6) 
H(14B) 2890(30) 4744(17) 40(30) 27(6) 
H(16) 5330(40) 5310(20) 3360(30) 37(7) 
H(17) 5190(40) 6561(18) 4690(30) 30(6) 
H(18) 2680(30) 7358(18) 4150(30) 27(6) 
H(19) 40(40) 6887(19) 2130(30) 35(7) 
H(20) 70(30) 5636(17) 810(30) 28(6) 
H(22A) 1160(40) 550(20) 5780(30) 44(8) 
H(22B) 1900(50) 1220(30) 4660(40) 68(10) 
H(22C) 1090(40) 350(20) 3930(40) 47(8) 
___________________________________________________________________________
 609 















































































Table 1.  Crystal data and structure refinement for C23H26N4O4S. 
Empirical formula  C23 H26 N4 O4 S 
Formula weight  454.54 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 13.0665(5) Å α= 90°. 
 b = 9.2804(3) Å β= 97.2240(10)°. 





Density (calculated) 1.371 Mg/m
3
 
Absorption coefficient 1.628 mm-1 
F(000) 960 
Crystal size 0.23 x 0.16 x 0.09 mm
3
 
Theta range for data collection 3.41 to 69.17°. 
Index ranges -13<=h<=15, -11<=k<=11, -17<=l<=21 
Reflections collected 20135 
Independent reflections 3874 [R(int) = 0.0196] 
Completeness to theta = 66.00° 96.7 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.778 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2sigma(I)] R1 = 0.0321, wR2 = 0.0795 
R indices (all data) R1 = 0.0322, wR2 = 0.0796 
Extinction coefficient 0.00154(19) 
Largest diff. peak and hole 0.327 and -0.380 e.Å-
3 
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Table 2. Atomic coordinates ( x 10
4





) for C23H26N4O4S.U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
___________________________________________________________________________ 
 x y z U(eq) 
___________________________________________________________________________  
S 2124(1) 3819(1) 5982(1) 18(1) 
O(1) 1986(1) 2314(1) 5830(1) 23(1) 
O(2) 1766(1) 4408(1) 6628(1) 24(1) 
O(3) 3326(1) 7939(1) 5682(1) 26(1) 
O(4) 3845(1) 6252(1) 4926(1) 23(1) 
N(1) 3357(1) 4152(1) 6019(1) 19(1) 
N(2) 3886(1) 1954(1) 4381(1) 23(1) 
N(3) 3332(1) 1827(1) 3734(1) 25(1) 
N(4) 2539(1) 2759(1) 3711(1) 20(1) 
C(1) 3943(1) 3248(2) 5553(1) 21(1) 
C(2) 3444(1) 2962(2) 4780(1) 19(1) 
C(3) 2574(1) 3499(2) 4362(1) 18(1) 
C(4) 1842(1) 4633(2) 4511(1) 17(1) 
C(5) 1574(1) 4874(2) 5223(1) 17(1) 
C(6) 955(1) 6022(2) 5373(1) 19(1) 
C(7) 560(1) 6948(2) 4810(1) 22(1) 
C(8) 802(1) 6719(2) 4106(1) 24(1) 
C(9) 1439(1) 5587(2) 3960(1) 21(1) 
C(10) 3668(1) 5654(2) 6199(1) 21(1) 
C(11) 4748(1) 5757(2) 6630(1) 25(1) 
C(12) 4841(1) 5145(2) 7412(1) 28(1) 
C(13) 4213(2) 5993(2) 7910(1) 35(1) 
C(14) 5981(2) 5144(2) 7728(1) 41(1) 
C(15) 1768(1) 2704(2) 3054(1) 24(1) 
C(16) 724(1) 2156(2) 3202(1) 21(1) 
C(17) -162(1) 2764(2) 2825(1) 26(1) 
C(18) -1127(1) 2191(2) 2899(1) 30(1) 
C(19) -1217(1) 1026(2) 3356(1) 29(1) 
C(20) -337(1) 435(2) 3746(1) 28(1) 
C(21) 630(1) 988(2) 3667(1) 24(1) 
C(22) 3626(1) 6616(2) 5517(1) 20(1) 
C(23) 3341(2) 9008(2) 5105(1) 33(1) 
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Table 3.   Bond lengths [Å] and angles [°] for  C23H26N4O4S. 
_____________________________________________________  
S-O(1)  1.4317(11) 
S-O(2)  1.4329(11) 
S-N(1)  1.6337(13) 
S-C(5)  1.7762(14) 
O(3)-C(22)  1.3350(18) 
O(3)-C(23)  1.4503(19) 
O(4)-C(22)  1.2021(18) 
N(1)-C(1)  1.4760(19) 
N(1)-C(10)  1.4780(18) 
N(2)-N(3)  1.3137(19) 
N(2)-C(2)  1.3603(19) 
N(3)-N(4)  1.3469(18) 
N(4)-C(3)  1.3710(18) 
N(4)-C(15)  1.4692(19) 
C(1)-C(2)  1.505(2) 
C(1)-H(1A)  0.96(2) 
C(1)-H(1B)  0.989(18) 
C(2)-C(3)  1.381(2) 
C(3)-C(4)  1.470(2) 
C(4)-C(9)  1.395(2) 
C(4)-C(5)  1.4100(19) 
C(5)-C(6)  1.386(2) 
C(6)-C(7)  1.390(2) 
C(6)-H(6)  0.973(18) 
C(7)-C(8)  1.383(2) 
C(7)-H(7)  0.954(18) 
C(8)-C(9)  1.386(2) 
C(8)-H(8)  0.97(2) 
C(9)-H(9)  0.980(18) 
C(10)-C(11)  1.531(2) 
C(10)-C(22)  1.531(2) 
C(10)-H(10)  1.007(18) 
C(11)-C(12)  1.530(2) 
C(11)-H(11A)  1.004(19) 
C(11)-H(11B)  1.005(19) 
C(12)-C(13)  1.522(3) 
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C(12)-C(14)  1.529(2) 
C(12)-H(12)  0.965(19) 
C(13)-H(13A)  1.00(2) 
C(13)-H(13B)  0.96(2) 
C(13)-H(13C)  0.99(2) 
C(14)-H(14A)  1.00(2) 
C(14)-H(14B)  0.99(2) 
C(14)-H(14C)  0.98(3) 
C(15)-C(16)  1.511(2) 
C(15)-H(15A)  0.934(19) 
C(15)-H(15B)  0.998(19) 
C(16)-C(17)  1.391(2) 
C(16)-C(21)  1.394(2) 
C(17)-C(18)  1.391(3) 
C(17)-H(17)  0.94(2) 
C(18)-C(19)  1.381(3) 
C(18)-H(18)  0.97(2) 
C(19)-C(20)  1.388(2) 
C(19)-H(19)  0.95(2) 
C(20)-C(21)  1.388(2) 
C(20)-H(20)  0.96(2) 
C(21)-H(21)  0.958(19) 
C(23)-H(23A)  0.96(2) 
C(23)-H(23B)  0.97(2) 


















































































































Symmetry transformations used to generate equivalent atoms:  
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) for C23H26N4O4S. The anisotropic 












 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________ 
S 20(1)  18(1) 15(1)  4(1) 1(1)  0(1) 
O(1) 23(1)  18(1) 27(1)  5(1) 2(1)  -2(1) 
O(2) 27(1)  29(1) 16(1)  4(1) 3(1)  1(1) 
O(3) 34(1)  17(1) 26(1)  4(1) 4(1)  1(1) 
O(4) 24(1)  23(1) 23(1)  1(1) 3(1)  -3(1) 
N(1) 21(1)  17(1) 18(1)  2(1) -1(1)  -1(1) 
N(2) 25(1)  17(1) 29(1)  0(1) 7(1)  1(1) 
N(3) 28(1)  19(1) 28(1)  -4(1) 9(1)  1(1) 
N(4) 23(1)  19(1) 20(1)  -3(1) 5(1)  -1(1) 
C(1) 18(1)  21(1) 24(1)  2(1) 1(1)  2(1) 
C(2) 20(1)  15(1) 23(1)  2(1) 6(1)  -2(1) 
C(3) 22(1)  16(1) 16(1)  -1(1) 5(1)  -3(1) 
C(4) 18(1)  16(1) 17(1)  -2(1) 1(1)  -3(1) 
C(5) 18(1)  17(1) 16(1)  1(1) 0(1)  -3(1) 
C(6) 20(1)  21(1) 16(1)  -2(1) 2(1)  -1(1) 
C(7) 23(1)  20(1) 23(1)  -2(1) 1(1)  4(1) 
C(8) 29(1)  23(1) 18(1)  3(1) -2(1)  4(1) 
C(9) 26(1)  23(1) 15(1)  -1(1) 1(1)  0(1) 
C(10) 24(1)  19(1) 20(1)  1(1) 0(1)  -2(1) 
C(11) 24(1)  24(1) 24(1)  1(1) -1(1)  -3(1) 
C(12) 34(1)  22(1) 26(1)  5(1) -7(1)  -8(1) 
C(13) 47(1)  32(1) 26(1)  3(1) 3(1)  -11(1) 
C(14) 38(1)  41(1) 41(1)  10(1) -11(1)  -5(1) 
C(15) 30(1)  24(1) 16(1)  -5(1) 4(1)  -3(1) 
C(16) 28(1)  20(1) 16(1)  -7(1) 2(1)  0(1) 
C(17) 36(1)  25(1) 16(1)  -4(1) 0(1)  4(1) 
C(18) 28(1)  37(1) 24(1)  -12(1) -3(1)  6(1) 
C(19) 25(1)  32(1) 31(1)  -15(1) 6(1)  -4(1) 
C(20) 33(1)  21(1) 30(1)  -4(1) 7(1)  -3(1) 
C(21) 27(1)  20(1) 25(1)  -3(1) 2(1)  2(1) 
C(22) 17(1)  18(1) 23(1)  1(1) -1(1)  -4(1) 
C(23) 45(1)  21(1) 34(1)  10(1) 5(1)  2(1) 
___________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 10
4







 x  y  z  U(eq) 
___________________________________________________________________________ 
H(1A) 4592(15) 3715(19) 5529(9) 25(4) 
H(1B) 4066(13) 2305(19) 5801(10) 23(4) 
H(6) 787(14) 6158(18) 5872(10) 25(4) 
H(7) 120(14) 7724(19) 4911(10) 24(4) 
H(8) 548(15) 7370(20) 3708(11) 33(5) 
H(9) 1627(13) 5481(18) 3461(10) 22(4) 
H(10) 3149(14) 6022(18) 6518(9) 22(4) 
H(11A) 5246(14) 5260(20) 6338(10) 27(4) 
H(11B) 4935(14) 6810(20) 6674(10) 26(4) 
H(12) 4602(14) 4160(20) 7365(10) 26(4) 
H(13A) 3455(17) 5910(20) 7757(11) 33(5) 
H(13B) 4351(16) 5690(20) 8415(12) 40(5) 
H(13C) 4394(17) 7030(30) 7912(12) 46(6) 
H(14A) 6378(15) 4590(20) 7386(11) 32(5) 
H(14B) 6238(15) 6140(20) 7768(11) 34(5) 
H(14C) 6058(19) 4710(30) 8222(14) 62(7) 
H(15A) 2043(14) 2072(19) 2733(10) 23(4) 
H(15B) 1711(14) 3670(20) 2811(10) 25(4) 
H(17) -96(15) 3590(20) 2536(11) 30(5) 
H(18) -1741(16) 2620(20) 2633(11) 34(5) 
H(19) -1875(16) 650(20) 3419(10) 30(5) 
H(20) -406(15) -360(20) 4069(11) 35(5) 
H(21) 1236(15) 560(20) 3927(10) 27(4) 
H(23A) 4044(18) 9200(20) 5044(11) 40(6) 
H(23B) 3019(16) 9850(20) 5289(11) 40(5) 
H(23C) 2954(17) 8660(20) 4655(13) 43(6) 
___________________________________________________________________________
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Table 1.  Crystal data and structure refinement for C23H26N4O4S. 
Empirical formula  C23 H26 N4 O4 S 
Formula weight  454.54 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.3721(2) Å α= 90°. 
 b = 13.0470(3) Å β= 100.8540(10)°. 





Density (calculated) 1.312 Mg/m
3
 




Crystal size 0.22 x 0.02 x 0.02 mm
3
 
Theta range for data collection 3.99 to 69.32°. 
Index ranges -10<=h<=9, -15<=k<=14, -21<=l<=26 
Reflections collected 23825 
Independent reflections 4227 [R(int) = 0.0224] 
Completeness to theta = 69.32° 98.2 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.880 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2sigma(I)] R1 = 0.0333, wR2 = 0.0852 
R indices (all data) R1 = 0.0352, wR2 = 0.0865 




Table 2.  Atomic coordinates  ( x 10
4





)for C23H26N4O4S.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) 
___________________________________________________________________________ 
S 230(1) 2774(1) 1853(1) 19(1) 
O(1) 1715(1) 2219(1) 1872(1) 22(1) 
O(2) -50(1) 3284(1) 2414(1) 24(1) 
O(3) -3488(1) 3604(1) 764(1) 32(1) 
O(4) -2394(1) 4681(1) 147(1) 34(1) 
N(1) 151(1) 3646(1) 1299(1) 21(1) 
N(2) 1866(1) 1122(1) 226(1) 22(1) 
N(3) 1963(1) 192(1) 468(1) 22(1) 
N(4) 827(1) 122(1) 835(1) 20(1) 
C(1) 1053(2) 3516(1) 777(1) 23(1) 
C(2) 328(2) 2742(1) 260(1) 24(1) 
C(3) 674(2) 1649(1) 441(1) 21(1) 
C(4) -5(2) 1015(1) 834(1) 20(1) 
C(5) -1394(2) 1161(1) 1159(1) 20(1) 
C(6) -1434(2) 1934(1) 1610(1) 20(1) 
C(7) -2819(2) 2092(1) 1872(1) 23(1) 
C(8) -4171(2) 1474(1) 1688(1) 26(1) 
C(9) -4136(2) 690(1) 1254(1) 28(1) 
C(10) -2761(2) 533(1) 992(1) 25(1) 
C(11) -1090(2) 4458(1) 1252(1) 23(1) 
C(12) -2388(2) 4284(1) 654(1) 25(1) 
C(13) -377(2) 5542(1) 1265(1) 29(1) 
C(14) -1700(2) 6320(1) 1342(1) 36(1) 
C(15) 1099(2) 5662(1) 1792(1) 39(1) 
C(16) -4703(2) 3288(2) 224(1) 39(1) 
C(17) 782(2) -811(1) 1216(1) 24(1) 
C(18) 2397(2) -969(1) 1654(1) 25(1) 
C(19) 2855(2) -300(1) 2166(1) 28(1) 
C(20) 4342(2) -404(1) 2574(1) 36(1) 
C(21) 5388(2) -1173(2) 2473(1) 43(1) 
C(22) 4981(2) -1839(2) 1975(1) 43(1) 
C(23) 3464(2) -1737(1) 1560(1) 36(1)
 624 
Table 3.   Bond lengths [Å] and angles [°] for  C23H26N4O4S. 
_____________________________________________________  
S-O(2)  1.4317(10) 
S-O(1)  1.4326(10) 
S-N(1)  1.6374(12) 
S-C(6)  1.7719(14) 
O(3)-C(12)  1.3313(19) 
O(3)-C(16)  1.451(2) 
O(4)-C(12)  1.2040(19) 
N(1)-C(1)  1.4734(18) 
N(1)-C(11)  1.4747(18) 
N(2)-N(3)  1.3162(18) 
N(2)-C(3)  1.3617(18) 
N(3)-N(4)  1.3477(16) 
N(4)-C(4)  1.3585(19) 
N(4)-C(17)  1.4697(18) 
C(1)-C(2)  1.539(2) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-C(3)  1.493(2) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.377(2) 
C(4)-C(5)  1.4757(19) 
C(5)-C(10)  1.398(2) 
C(5)-C(6)  1.403(2) 
C(6)-C(7)  1.396(2) 
C(7)-C(8)  1.385(2) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.387(2) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.388(2) 
C(9)-H(9)  0.9500 
C(10)-H(10)  0.9500 
C(11)-C(13)  1.533(2) 
C(11)-C(12)  1.534(2) 
C(11)-H(11)  1.0000 
C(13)-C(15)  1.518(2) 
 625 
C(13)-C(14)  1.534(2) 
C(13)-H(13)  1.0000 
C(14)-H(14A)  0.9800 
C(14)-H(14B)  0.9800 
C(14)-H(14C)  0.9800 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
C(17)-C(18)  1.507(2) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-C(23)  1.382(2) 
C(18)-C(19)  1.398(2) 
C(19)-C(20)  1.387(2) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.374(3) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.370(3) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.414(3) 
C(22)-H(22)  0.9500 


















































































































Symmetry transformations used to generate equivalent atoms:  
  
 629 




) for C23H26N4O4S. The aniso-












 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________ 
S 18(1)  19(1) 19(1)  1(1) 3(1)  -1(1) 
O(1) 19(1)  23(1) 25(1)  0(1) 2(1)  0(1) 
O(2) 28(1)  25(1) 20(1)  -1(1) 5(1)  0(1) 
O(3) 24(1)  37(1) 33(1)  9(1) 0(1)  -4(1) 
O(4) 33(1)  39(1) 28(1)  9(1) 4(1)  -1(1) 
N(1) 21(1)  20(1) 22(1)  2(1) 6(1)  0(1) 
N(2) 21(1)  24(1) 21(1)  0(1) 5(1)  -1(1) 
N(3) 20(1)  26(1) 21(1)  0(1) 6(1)  -1(1) 
N(4) 18(1)  23(1) 19(1)  -1(1) 3(1)  -3(1) 
C(1) 23(1)  22(1) 25(1)  2(1) 9(1)  -2(1) 
C(2) 27(1)  24(1) 21(1)  2(1) 7(1)  1(1) 
C(3) 19(1)  25(1) 18(1)  -2(1) 4(1)  -2(1) 
C(4) 18(1)  22(1) 19(1)  -2(1) 2(1)  -2(1) 
C(5) 18(1)  23(1) 20(1)  3(1) 4(1)  -1(1) 
C(6) 19(1)  20(1) 20(1)  4(1) 4(1)  -1(1) 
C(7) 23(1)  22(1) 24(1)  4(1) 8(1)  2(1) 
C(8) 20(1)  28(1) 33(1)  7(1) 11(1)  1(1) 
C(9) 19(1)  29(1) 34(1)  4(1) 5(1)  -5(1) 
C(10) 24(1)  26(1) 25(1)  -1(1) 5(1)  -4(1) 
C(11) 24(1)  22(1) 24(1)  3(1) 6(1)  3(1) 
C(12) 23(1)  24(1) 28(1)  4(1) 7(1)  5(1) 
C(13) 38(1)  21(1) 28(1)  2(1) 7(1)  0(1) 
C(14) 51(1)  25(1) 35(1)  3(1) 12(1)  7(1) 
C(15) 45(1)  26(1) 42(1)  -2(1) -1(1)  -10(1) 
C(16) 26(1)  45(1) 41(1)  5(1) -6(1)  -6(1) 
C(17) 25(1)  22(1) 24(1)  1(1) 4(1)  -5(1) 
C(18) 22(1)  24(1) 30(1)  9(1) 10(1)  1(1) 
C(19) 24(1)  28(1) 30(1)  7(1) 3(1)  -2(1) 
C(20) 30(1)  36(1) 39(1)  10(1) -2(1)  -6(1) 
C(21) 25(1)  44(1) 60(1)  20(1) 5(1)  1(1) 
C(22) 32(1)  38(1) 64(1)  21(1) 22(1)  14(1) 
C(23) 40(1)  29(1) 45(1)  6(1) 21(1)  6(1) 
___________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 10
4







 x  y  z  U(eq) 
___________________________________________________________________________ 
  
H(1A) 2176 3298 961 27 
H(1B) 1125 4191 574 27 
H(2A) -866 2841 156 28 
H(2B) 765 2890 -129 28 
H(7) -2835 2621 2175 27 
H(8) -5123 1587 1859 31 
H(9) -5058 259 1135 33 
H(10) -2749 -6 695 30 
H(11) -1633 4390 1627 28 
H(13) -35 5673 850 35 
H(14A) -1280 7017 1317 54 
H(14B) -2016 6221 1755 54 
H(14C) -2650 6219 1003 54 
H(15A) 1985 5230 1702 59 
H(15B) 816 5454 2197 59 
H(15C) 1447 6381 1819 59 
H(16A) -5314 2703 344 59 
H(16B) -4167 3090 -127 59 
H(16C) -5451 3858 89 59 
H(17A) 533 -1410 932 28 
H(17B) -88 -749 1469 28 
H(19) 2136 233 2235 33 
H(20) 4636 54 2921 44 
H(21) 6407 -1242 2753 52 
H(22) 5713 -2367 1910 52 
H(23) 3177 -2198 1214 43 
___________________________________________________________________________
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Table 1.  Crystal data and structure refinement for C21H22N4O4S. 
Empirical formula  C21 H22 N4 O4 S 
Formula weight  426.49 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 10.3318(6) Å α= 90°. 
 b = 14.0777(8) Å β= 90°. 





Density (calculated) 1.367 Mg/m
3
 




Crystal size 0.07 x 0.05 x 0.03 mm
3
 
Theta range for data collection 4.42 to 69.46°. 
Index ranges -9<=h<=12, -17<=k<=14, -16<=l<=17 
Reflections collected 16995 
Independent reflections 3766 [R(int) = 0.0295] 
Completeness to theta = 66.00° 99.9 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.928 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3766 / 0 / 359 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0228, wR2 = 0.0606 
R indices (all data) R1 = 0.0238, wR2 = 0.0611 
Absolute structure parameter 0.043(10) 




Table 2.  Atomic coordinates  ( x 10
4





) for C21H22N4O4S.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) 
___________________________________________________________________________ 
S 3608(1) 1209(1) 1933(1) 14(1) 
O(1) 3075(1) 589(1) 2634(1) 18(1) 
O(2) 4921(1) 1075(1) 1643(1) 19(1) 
O(3) 1228(1) 2714(1) 182(1) 29(1) 
O(4) 3199(1) 3312(1) -102(1) 22(1) 
N(1) 2664(1) 1137(1) 1017(1) 15(1) 
N(2) -487(1) 1086(1) 2330(1) 18(1) 
N(3) -797(1) 1584(1) 3077(1) 18(1) 
N(4) 151(1) 2233(1) 3210(1) 16(1) 
C(1) 1282(1) 906(1) 1172(1) 16(1) 
C(2) 664(1) 1406(1) 1987(1) 16(1) 
C(3) 1085(1) 2149(1) 2539(1) 15(1) 
C(4) 2220(1) 2777(1) 2482(1) 16(1) 
C(5) 3453(1) 2415(1) 2276(1) 16(1) 
C(6) 4527(2) 2998(1) 2231(1) 21(1) 
C(7) 4392(2) 3968(1) 2395(1) 25(1) 
C(8) 3175(2) 4344(1) 2574(1) 23(1) 
C(9) 2099(1) 3759(1) 2616(1) 19(1) 
C(10) 3088(1) 1663(1) 174(1) 15(1) 
C(11) 2949(1) 1038(1) -714(1) 18(1) 
C(12) 3251(2) 1614(1) -1601(1) 27(1) 
C(13) 3862(2) 189(1) -637(1) 24(1) 
C(14) 183(1) 2776(1) 4064(1) 16(1) 
C(15) 1308(2) 2786(1) 4596(1) 21(1) 
C(16) 1345(2) 3308(1) 5423(1) 24(1) 
C(17) 256(2) 3794(1) 5723(1) 23(1) 
C(18) -866(2) 3770(1) 5193(1) 22(1) 
C(19) -911(2) 3266(1) 4350(1) 18(1) 
C(20) 2378(1) 2610(1) 89(1) 18(1) 
C(21) 2618(2) 4244(1) -220(1) 24(1) 
___________________________________________________________________________
 635 
Table 3.   Bond lengths [Å] and angles [°] for  C21H22N4O4S. 
_____________________________________________________  
S-O(2)  1.4315(10) 
S-O(1)  1.4360(10) 
S-N(1)  1.6325(11) 
S-C(5)  1.7741(13) 
O(3)-C(20)  1.2045(18) 
O(4)-C(20)  1.3295(17) 
O(4)-C(21)  1.4531(17) 
N(1)-C(10)  1.4781(16) 
N(1)-C(1)  1.4801(18) 
N(2)-N(3)  1.3139(17) 
N(2)-C(2)  1.3625(18) 
N(3)-N(4)  1.3534(16) 
N(4)-C(3)  1.3645(18) 
N(4)-C(14)  1.4374(17) 
C(1)-C(2)  1.5014(19) 
C(1)-H(1A)  0.944(18) 
C(1)-H(1B)  0.919(19) 
C(2)-C(3)  1.3779(19) 
C(3)-C(4)  1.4708(19) 
C(4)-C(9)  1.4016(19) 
C(4)-C(5)  1.4022(19) 
C(5)-C(6)  1.382(2) 
C(6)-C(7)  1.392(2) 
C(6)-H(6)  0.933(19) 
C(7)-C(8)  1.388(2) 
C(7)-H(7)  1.02(2) 
C(8)-C(9)  1.384(2) 
C(8)-H(8)  0.96(2) 
C(9)-H(9)  0.968(18) 
C(10)-C(20)  1.5272(18) 
C(10)-C(11)  1.5473(18) 
C(10)-H(10)  0.951(17) 
C(11)-C(13)  1.527(2) 
C(11)-C(12)  1.5329(19) 
C(11)-H(11)  0.994(17) 
C(12)-H(12A)  1.03(2) 
 636 
C(12)-H(12B)  0.971(19) 
C(12)-H(12C)  0.99(2) 
C(13)-H(13A)  0.955(19) 
C(13)-H(13B)  0.99(2) 
C(13)-H(13C)  0.94(2) 
C(14)-C(19)  1.385(2) 
C(14)-C(15)  1.388(2) 
C(15)-C(16)  1.390(2) 
C(15)-H(15)  0.959(19) 
C(16)-C(17)  1.384(2) 
C(16)-H(16)  0.989(18) 
C(17)-C(18)  1.385(2) 
C(17)-H(17)  1.008(17) 
C(18)-C(19)  1.396(2) 
C(18)-H(18)  0.95(2) 
C(19)-H(19)  0.935(19) 
C(21)-H(21A)  0.959(18) 
C(21)-H(21B)  0.98(2) 






































































































Symmetry transformations used to generate equivalent atoms:  
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) for C21H22N4O4S.  The 











 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________ 
S 14(1)  14(1) 14(1)  0(1) 0(1)  1(1) 
O(1) 20(1)  17(1) 17(1)  2(1) 0(1)  2(1) 
O(2) 16(1)  22(1) 19(1)  1(1) 0(1)  4(1) 
O(3) 17(1)  27(1) 44(1)  14(1) 1(1)  1(1) 
O(4) 19(1)  16(1) 29(1)  4(1) -1(1)  -1(1) 
N(1) 15(1)  16(1) 13(1)  0(1) 2(1)  -1(1) 
N(2) 16(1)  20(1) 18(1)  0(1) 1(1)  -2(1) 
N(3) 15(1)  21(1) 17(1)  0(1) 1(1)  -2(1) 
N(4) 16(1)  17(1) 16(1)  0(1) 2(1)  2(1) 
C(1) 16(1)  15(1) 16(1)  -1(1) 1(1)  -2(1) 
C(2) 16(1)  15(1) 16(1)  2(1) 0(1)  0(1) 
C(3) 15(1)  17(1) 14(1)  1(1) 0(1)  2(1) 
C(4) 19(1)  18(1) 12(1)  -1(1) 1(1)  0(1) 
C(5) 18(1)  17(1) 12(1)  0(1) -2(1)  0(1) 
C(6) 19(1)  24(1) 20(1)  -2(1) 0(1)  -3(1) 
C(7) 26(1)  23(1) 26(1)  -4(1) 1(1)  -8(1) 
C(8) 31(1)  16(1) 22(1)  -3(1) 2(1)  -4(1) 
C(9) 23(1)  18(1) 16(1)  -2(1) 1(1)  1(1) 
C(10) 15(1)  18(1) 14(1)  2(1) 1(1)  -2(1) 
C(11) 18(1)  23(1) 15(1)  -1(1) 1(1)  -5(1) 
C(12) 32(1)  34(1) 14(1)  0(1) 2(1)  -10(1) 
C(13) 22(1)  26(1) 23(1)  -9(1) 0(1)  0(1) 
C(14) 20(1)  16(1) 14(1)  1(1) 3(1)  1(1) 
C(15) 20(1)  24(1) 20(1)  -1(1) 1(1)  4(1) 
C(16) 27(1)  26(1) 19(1)  -1(1) -1(1)  -1(1) 
C(17) 30(1)  20(1) 18(1)  -2(1) 5(1)  -4(1) 
C(18) 24(1)  17(1) 23(1)  -1(1) 9(1)  3(1) 
C(19) 18(1)  18(1) 19(1)  2(1) 2(1)  1(1) 
C(20) 18(1)  20(1) 15(1)  3(1) -2(1)  -2(1) 
C(21) 25(1)  16(1) 31(1)  4(1) -2(1)  2(1) 
___________________________________________________________________________ 
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Table 5.   Hydrogen coordinates ( x 10
4







 x  y  z  U(eq) 
___________________________________________________________________________ 
 
H(1A) 1205(17) 246(13) 1275(11) 15(4) 
H(1B) 818(17) 1049(12) 641(13) 16(4) 
H(6) 5331(18) 2727(13) 2101(13) 24(4) 
H(7) 5190(20) 4391(15) 2394(15) 35(5) 
H(8) 3044(18) 5016(14) 2656(13) 27(5) 
H(9) 1250(17) 4026(11) 2729(11) 14(4) 
H(10) 3975(16) 1808(11) 283(11) 7(3) 
H(11) 2037(16) 817(11) -740(11) 10(4) 
H(12A) 2630(20) 2186(16) -1676(15) 40(5) 
H(12B) 3148(18) 1207(13) -2145(13) 25(4) 
H(12C) 4170(20) 1824(15) -1553(15) 35(5) 
H(13A) 3735(18) -162(13) -71(13) 24(4) 
H(13B) 4760(20) 426(15) -629(14) 34(5) 
H(13C) 3730(20) -216(15) -1152(15) 37(5) 
H(15) 2066(18) 2464(13) 4372(13) 26(5) 
H(16) 2160(18) 3338(12) 5785(12) 18(4) 
H(17) 295(16) 4143(12) 6341(12) 15(4) 
H(18) -1623(19) 4096(14) 5391(13) 26(5) 
H(19) -1641(18) 3245(12) 3961(12) 18(4) 
H(21A) 2357(17) 4485(12) 381(13) 15(4) 
H(21B) 1870(20) 4240(14) -646(15) 36(5) 
H(21C) 3300(20) 4619(16) -464(15) 37(5) 
___________________________________________________________________________
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Table 1.  Crystal data and structure refinement for C22H24N4O4S. 
Empirical formula  C44 H48 N8 O8 S2 
Formula weight  881.02 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 15.0364(3) Å α= 90°. 
 b = 8.2478(2) Å β= 94.0360(10)°. 





Density (calculated) 1.333 Mg/m
3
 




Crystal size 0.16 x 0.07 x 0.05 mm
3
 
Theta range for data collection 5.00 to 69.32°. 
Index ranges -17<=h<=17, -8<=k<=9, -20<=l<=21 
Reflections collected 16054 
Independent reflections 3935 [R(int) = 0.0171] 
Completeness to theta = 66.00° 98.6 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.893 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2sigma(I)] R1 = 0.0309, wR2 = 0.0822 
R indices (all data) R1 = 0.0321, wR2 = 0.0832 
Largest diff. peak and hole 0.352 and -0.339 e.Å-3 
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Table 2.  Atomic coordinates  ( x 10
4





) for C22H24N4O4S.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) 
___________________________________________________________________________ 
S 2683(1) 3738(1) 965(1) 21(1) 
O(1) 2237(1) 4886(1) 1414(1) 27(1) 
O(2) 3006(1) 4244(1) 262(1) 29(1) 
O(3) 3482(1) -438(1) 930(1) 30(1) 
O(4) 4504(1) -340(1) 1910(1) 40(1) 
N(1) 3539(1) 3058(1) 1494(1) 22(1) 
N(2) 1620(1) 2974(1) 3246(1) 26(1) 
N(3) 775(1) 3228(2) 3051(1) 27(1) 
N(4) 625(1) 2705(1) 2329(1) 22(1) 
C(1) 3564(1) 3154(2) 2326(1) 26(1) 
C(2) 2989(1) 1913(2) 2714(1) 25(1) 
C(3) 2016(1) 2296(2) 2656(1) 22(1) 
C(4) 1388(1) 2122(2) 2061(1) 20(1) 
C(5) 1426(1) 1425(2) 1300(1) 19(1) 
C(6) 1961(1) 2071(1) 755(1) 19(1) 
C(7) 1957(1) 1399(2) 36(1) 23(1) 
C(8) 1439(1) 43(2) -144(1) 26(1) 
C(9) 925(1) -630(2) 395(1) 26(1) 
C(10) 907(1) 65(2) 1105(1) 23(1) 
C(11) 4205(1) 2056(2) 1133(1) 24(1) 
C(12) 5168(1) 2653(2) 1284(1) 33(1) 
C(13) 5748(1) 1693(3) 767(1) 53(1) 
C(14) 5233(1) 4470(2) 1144(1) 41(1) 
C(15) -225(1) 3021(2) 1932(1) 23(1) 
C(16) -253(1) 4007(2) 1299(1) 28(1) 
C(17) -1074(1) 4376(2) 931(1) 33(1) 
C(18) -1851(1) 3767(2) 1200(1) 32(1) 
C(19) -1810(1) 2783(2) 1833(1) 32(1) 
C(20) -993(1) 2394(2) 2207(1) 27(1) 
C(21) 4104(1) 291(2) 1377(1) 25(1) 
C(22) 3230(1) -2065(2) 1141(1) 39(1) 
___________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for  C22H24N4O4S. 
_____________________________________________________  
S-O(2)  1.4328(9) 
S-O(1)  1.4330(10) 
S-N(1)  1.6378(10) 
S-C(6)  1.7748(12) 
O(3)-C(21)  1.3265(16) 
O(3)-C(22)  1.4506(17) 
O(4)-C(21)  1.2029(16) 
N(1)-C(1)  1.4758(16) 
N(1)-C(11)  1.4790(16) 
N(2)-N(3)  1.3102(16) 
N(2)-C(3)  1.3610(16) 
N(3)-N(4)  1.3552(15) 
N(4)-C(4)  1.3596(16) 
N(4)-C(15)  1.4396(16) 
C(1)-C(2)  1.5341(19) 
C(1)-H(1A)  0.982(16) 
C(1)-H(1B)  0.980(17) 
C(2)-C(3)  1.4930(17) 
C(2)-H(2A)  0.968(16) 
C(2)-H(2B)  0.975(17) 
C(3)-C(4)  1.3730(18) 
C(4)-C(5)  1.4736(16) 
C(5)-C(10)  1.3960(18) 
C(5)-C(6)  1.4047(17) 
C(6)-C(7)  1.3902(17) 
C(7)-C(8)  1.3878(19) 
C(7)-H(7)  0.930(16) 
C(8)-C(9)  1.3864(19) 
C(8)-H(8)  0.967(16) 
C(9)-C(10)  1.3861(18) 
C(9)-H(9)  0.971(18) 
C(10)-H(10)  0.958(15) 
C(11)-C(21)  1.5287(19) 
C(11)-C(12)  1.5348(17) 
C(11)-H(11)  0.977(14) 
C(12)-C(14)  1.523(2) 
 647 
C(12)-C(13)  1.531(2) 
C(12)-H(12)  1.004(18) 
C(13)-H(13A)  0.98(2) 
C(13)-H(13B)  0.96(2) 
C(13)-H(13C)  0.99(2) 
C(14)-H(14A)  0.981(18) 
C(14)-H(14B)  0.99(2) 
C(14)-H(14C)  0.96(2) 
C(15)-C(20)  1.3850(19) 
C(15)-C(16)  1.3854(19) 
C(16)-C(17)  1.390(2) 
C(16)-H(16)  0.957(18) 
C(17)-C(18)  1.387(2) 
C(17)-H(17)  0.969(19) 
C(18)-C(19)  1.383(2) 
C(18)-H(18)  0.977(18) 
C(19)-C(20)  1.392(2) 
C(19)-H(19)  0.969(18) 
C(20)-H(20)  0.951(17) 
C(22)-H(22A)  0.97(2) 
C(22)-H(22B)  0.94(2) 












































































































Symmetry transformations used to generate equivalent atoms:  
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) for C22H24N4O4S. The aniso- 










 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________ 
S 23(1)  17(1) 24(1)  3(1) 1(1)  -3(1) 
O(1) 29(1)  18(1) 34(1)  0(1) 1(1)  0(1) 
O(2) 30(1)  26(1) 30(1)  8(1) 2(1)  -5(1) 
O(3) 32(1)  18(1) 38(1)  2(1) -4(1)  -3(1) 
O(4) 45(1)  36(1) 38(1)  2(1) -10(1)  12(1) 
N(1) 21(1)  21(1) 24(1)  -2(1) 0(1)  -2(1) 
N(2) 28(1)  30(1) 21(1)  -2(1) 2(1)  5(1) 
N(3) 28(1)  31(1) 21(1)  -4(1) 3(1)  6(1) 
N(4) 23(1)  23(1) 21(1)  -1(1) 3(1)  3(1) 
C(1) 24(1)  28(1) 25(1)  -5(1) -2(1)  0(1) 
C(2) 25(1)  29(1) 21(1)  0(1) 0(1)  6(1) 
C(3) 25(1)  21(1) 19(1)  1(1) 2(1)  3(1) 
C(4) 22(1)  17(1) 22(1)  2(1) 4(1)  2(1) 
C(5) 19(1)  18(1) 19(1)  1(1) 0(1)  3(1) 
C(6) 18(1)  18(1) 21(1)  1(1) -1(1)  0(1) 
C(7) 23(1)  27(1) 20(1)  2(1) 2(1)  1(1) 
C(8) 28(1)  28(1) 21(1)  -5(1) -1(1)  1(1) 
C(9) 26(1)  22(1) 29(1)  -3(1) -3(1)  -4(1) 
C(10) 21(1)  22(1) 25(1)  2(1) 2(1)  -1(1) 
C(11) 22(1)  25(1) 25(1)  -4(1) 2(1)  -2(1) 
C(12) 22(1)  42(1) 37(1)  -11(1) 3(1)  -6(1) 
C(13) 26(1)  67(1) 67(1)  -29(1) 15(1)  -10(1) 
C(14) 34(1)  46(1) 42(1)  -8(1) 6(1)  -21(1) 
C(15) 23(1)  22(1) 25(1)  -5(1) 2(1)  5(1) 
C(16) 26(1)  26(1) 32(1)  1(1) 2(1)  3(1) 
C(17) 34(1)  28(1) 35(1)  1(1) -3(1)  7(1) 
C(18) 25(1)  32(1) 39(1)  -8(1) -5(1)  6(1) 
C(19) 24(1)  34(1) 39(1)  -11(1) 5(1)  -2(1) 
C(20) 28(1)  26(1) 28(1)  -5(1) 5(1)  1(1) 
C(21) 22(1)  27(1) 25(1)  -3(1) 3(1)  5(1) 
C(22) 43(1)  19(1) 56(1)  5(1) 5(1)  -2(1) 
___________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 10
4







 x  y  z  U(eq) 
___________________________________________________________________________ 
  
H(1A) 4194(11) 3010(20) 2499(9) 29(4) 
H(1B) 3382(10) 4250(20) 2469(8) 26(4) 
H(2A) 3182(10) 1910(20) 3246(9) 28(4) 
H(2B) 3101(10) 830(20) 2517(9) 27(4) 
H(7) 2281(10) 1870(20) -333(9) 26(4) 
H(8) 1419(10) -440(20) -641(9) 27(4) 
H(9) 569(11) -1590(20) 281(9) 34(4) 
H(10) 539(10) -373(19) 1475(8) 23(4) 
H(11) 4049(9) 2103(17) 590(8) 15(3) 
H(12) 5337(11) 2420(20) 1831(10) 39(4) 
H(13A) 6376(15) 1980(30) 867(12) 63(6) 
H(13B) 5709(14) 550(30) 869(11) 53(6) 
H(13C) 5570(14) 1920(30) 232(13) 58(6) 
H(14A) 4961(11) 5090(20) 1541(10) 38(4) 
H(14B) 4930(14) 4810(30) 654(12) 53(5) 
H(14C) 5850(15) 4740(30) 1137(12) 60(6) 
H(16) 275(12) 4460(20) 1114(9) 34(4) 
H(17) -1101(12) 5060(20) 486(10) 40(5) 
H(18) -2429(12) 4000(20) 936(10) 39(5) 
H(19) -2352(12) 2360(20) 2023(10) 42(5) 
H(20) -952(10) 1720(20) 2641(9) 29(4) 
H(22A) 3741(13) -2780(30) 1155(11) 48(5) 
H(22B) 2964(15) -2040(30) 1604(13) 66(6) 
H(22C) 2813(15) -2410(30) 706(13) 69(7) 
___________________________________________________________________________
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Symmetry transformations used to generate equivalent atoms:  
 
